Targeted Therapy for Chordoma by Jorgensen, M
1 
  
 
 
 
Targeted Therapy for Chordoma 
 
 
 
 
 
A thesis submitted to University College London (UCL) for 
the degree of Doctor of Philosophy 
 
 
 
 
 
Dr Mette Jorgensen 
2016 
 
 
UCL Cancer Institute, London UK 
  
Targeted therapy for chordoma 
 2 
  
Targeted therapy for chordoma   
 3 
 
Declaration 
I, Mette Jorgensen, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated 
in the thesis.  
 
The high-throughput compound screening described in chapter 3 was conducted in 
conjunction with Cancer Research Technologies (CRT), Dr S. Scheipl and Dr L. 
Cottone.  
  
Targeted therapy for chordoma 
 4 
  
Targeted therapy for chordoma   
 5 
Abstract 
Chordoma is a rare and slow growing but locally aggressive bone tumour with a poor 
prognosis and limited treatment options. Current treatment strategies include surgical 
resection and radiotherapy.  There are no approved drugs for the treatment of 
chordoma. The aim of this thesis was to explore novel therapeutics approaches. 
 
Work presented within the thesis includes: 
A high throughput screen of more than 1100 compounds in three chordoma cell lines. 
This work identified 27 compounds selective for chordoma; 78% were EGFR/ErbB 
inhibitors. These data adds to existing evidence that EGFR inhibitors are potential 
therapeutic agents for treatment of chordoma.  
 
A gene therapy approach, using an Adeno-associated viral  (AAV) vector for the 
delivery of RNAi targeting brachyury in vitro and in a xenograft model generated as 
part of the project. Chordoma cells were found to be permissive to AAV. Treatment 
with the brachyury-silencing vector resulted in tumour cell growth arrest.  
 
In addition, two biomarkers were assessed to establish the potential to monitor for 
disease and disease response to treatment in chordoma patients. Detection of a 
protein biomarker AKR1B10, which has shown promise in breast cancer, was 
assessed but was not detectable in plasma from chordoma patients. Circulating tumour 
DNA (ctDNA) has shown great promise in high grade and advanced cancer. The 
potential to detect ctDNA in plasma from patients with chordoma was assessed 
following genomic profiling for tumour specific mutations. Digital PCR was used for 
detection of tumour DNA from 4 chordoma patients. Low levels of ctDNA were 
detected in 3 patients, establishing proof of concept that with further optimisation this 
method can potentially be used for detection of disease recurrence and monitoring 
response to treatment. 
 
This work signposts the way towards further research into novel techniques to improve 
patient outcome for chordoma. 
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1.1 Background 
Chordomas are rare malignant bone tumours which almost exclusively affect the axial 
skeleton. They are slow growing, locally destructive tumours with a high local 
recurrence rate and the potential to metastasise. Chordomas are thought to arise from 
cellular remnants of the notochord. They are characterised by their expression of the 
transcription factor T, brachyury homolog (mouse) commonly referred to as brachyury. 
1.1.1 Incidence and epidemiology  
Chordoma represents between 1 and 6% of primary malignant bone tumours(1,2), 20% 
of primary spinal tumours(3,4) and 50% of malignant sacral tumours(5). The incidence 
of chordoma is reported as 0.08 per 100,000 translating to an estimated 300 new 
cases in the United States(6-9) and approximately 50 cases in the UK per year. 
However, reported cases of chordoma in the UK amount to an average of 22 new 
cases per year over the past 10 years(1) suggesting a lower incidence or under-
reporting of these tumours in the UK. Chordomas can present at any age though they 
are extremely rare under the age of 25. The incidence increases with age and nearly 
80% of diagnoses are made in patients over the age of 50 years, with a peak incidence 
between 50-60 years of age(6). 
 
Most chordomas arise in the axial skeletal with a few chordomas reported arising in 
extra-axial locations. These extra-skeletal chordomas have been described in different 
anatomical sites, including soft tissue(10) in the lung(11,12), and in a wide variety of 
bones including the thumb, ankle, shoulder and chest wall with no predilection for 
specific bones or sites within the bone(10-15). The extra-skeletal chordomas resemble 
the axial chordoma in histology and brachyury expression(10,13-16).  
 
The reported distribution of axial chordomas, along the base of the skull to the coccyx, 
varies in different studies. A recent review of all malignant bone sarcomas registered in 
England between 1979 and 2007 found approximately 45% of chordomas arose from 
the pelvis, 23% arose from the vertebral bodies and 26% from the bones of the 
skull(1), aligning with historical data(17). A much larger cohort of 490 patients in a 
recent review of the California Cancer Registry identified 49% of chordomas arising in 
the skull, with approximately 25% arising in the spine or pelvis(18). Other studies have 
described an almost equal anatomical distribution between the base of skull, the 
mobile spine and the sacrococcygeal region(4,6). The location of chordoma varies with 
age at diagnosis. In patients under the age of 20, 70% of tumours occur at the base of 
skull compared with 21% of patients over the age of 50. In patients over the age of 50, 
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80% of tumours occur in the lower vertebral bodies, sacrum and coccyx(1,6,18). 
Chordoma occurs more frequently in males (ratio 1.6:1), especially for pelvic chordoma 
with a 3:1 male to female ratio(19). Cranial tumours occur more frequently in 
females(18).  
 
Median survival for patients with chordoma is 7.7 years. Younger patients (aged <40 
years) survive longer compared to older patients (10-year relative survival 68% vs 
43%), excluding the very young children who have a dismal prognosis(20). The 5-year, 
10-year, and 20-year survival rate across all age groups have recently been reported 
as 72%, 48%, and 31% respectively(7).  
1.1.2 History and origin of chordoma 
Chordomas were first characterised microscopically in 1857 by Virchow(21), who 
described the distinguishing feature of the cells of a clivus tumour as “ecchondrosis 
physaliferous” (Greek for “bubble-bearing”), due to the foamy appearance of the 
cytoplasm which contains multiple vacuoles. In 1858 Müller described chordoma 
dorsalis as “ecchordosis physaliphora”, thereby being the first to consider it of 
notochordal origin(22). Ribbert supported this in 1894 when he produced proliferative 
lesions resembling chordoma by releasing tissue of notochordal origin from the nucleus 
pulposus(23).  
 
Examination of human embryos and fetuses(24,25) and cell-fate tracking experiments 
in mice(26) have shown that notochordal cell nests correspond topographically with the 
anatomic distribution of chordoma(25). Rare benign intra-osseous notochordal tumours 
(BNCT) have been described(27) as a possible precursor for conventional chordoma. 
These benign tumours were identified in 20% of 100 vertebral autopsy specimens in 
patients ranging in age from 7 to 82, with a distribution of 11.5% of the clival region, 5% 
of cervical vertebrae, 2% of lumbar vertebrae, 12% of sacrococcygeal vertebrae and 
none in the thoracic vertebrae(28). This distribution is similar for the anatomical sites of 
chordoma previously described, supporting the concept that the persistent notochord is 
the precursor of chordoma. The low incidence of chordoma suggests that 
transformation into a malignant tumour is a rare occurrence(29,30). Conclusive 
evidence supporting notochordal remnant cells as the origin of chordoma was 
confirmed when molecular phenotyping identified brachyury as a specific marker for 
chordoma(31-33).  
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1.1.3 Etiology 
The vast majority of chordoma arise sporadically. Very occasionally it occurs in a 
familial setting with inheritance compatible with an autosomal dominant trait.  In some 
families the inherited disease is associated with duplication of brachyury(19,34,35) 
(detailed below). Patients with familial chordoma are younger at presentation than 
those presenting with sporadic disease and the majority of patients present with a clival 
tumour(19,36). There is also a recognised, though rare, association of chordoma with 
tuberous sclerosis complex (TSC) - an autosomal neuro-cutaneous syndrome, 
characterised by abnormal tissue growth in multiple organ systems. TSC is caused by 
inactivation or loss of TSC1/TSC2 where loss of function results in phosphorylation of 
the mTOR pathway, leading to enhanced cell growth and proliferation(37-39). 
Chordomas associated with TSC have mainly been described in children, is found 
more frequently in the sacrum and has a better outcome(39). The 
PI3K/AKT/TSC1/TSC2/mTOR pathway is activated in approximately 65% of sporadic 
chordoma, suggesting involvement in the pathogenesis of chordoma(40). 
1.1.4 Histology 
Chordomas not otherwise classified (NOS) were previously categorised as classical (or 
conventional) chordomas. Specific subtypes haven been categorised as chondroid or 
dedifferentiated(3,41). Chordomas generally have a homogenous histological 
appearance composed of large cells with clear to eosinophilic cytoplasm separated into 
lobules by fibrous septa. The tumour cells have round nuclei and copious vacuolated 
‘bubbly’ cytoplasm, referred to as “physaliphorous cells”, that are characteristic of 
classical chordomas. Cells are arranged as small cords embedded in abundant 
extracellular myxoid matrix, or as more densely arranged epithelioid tumours. Nuclear 
atypia and mitotic figures are not commonly seen except for in tumours with spindled 
sarcomatoid appearance where nuclear atypia and pleomorphism may be prominent. 
Necrosis is frequently present and may be extensive(41). Chondroid chordoma refers 
to chordoma in which the matrix mimics hyaline cartilaginous tumours. This component 
can be focal or extensive. The chondroid histological subtype accounts for 5-15% of all 
chordomas and up to 33% of all cranial chordomas(3). The outcome for the chondroid 
subtype is similar to classical chordoma(42). Dedifferentiated chordoma accounts for 
less than 10% of chordomas, characterised by being biphasic, comprised of classical 
chordoma with sarcoma-like regions with undifferentiated spindle-cell tumours(43-45). 
The dedifferentiated variant tends to be more aggressive and is associated with loss of 
brachyury expression(46). 
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1.1.5 Clinical presentation  
Chordomas are indolent and slow growing, therefore often diagnosed late, presenting 
with large locally invasive and destructive lesions. The clinical manifestations vary 
depending on location, though pain and neurologic symptoms from local compression 
are the main presenting symptoms. Skull-base chordomas often grow from the clivus, 
and present with cranial nerve palsies. Patients often complain of headache and visual 
disturbances with diplopia, due to raised intracranial pressure(2). The skull-based 
tumours may erode distally and obstruct nasal passages with the potential to cause 
breathing difficulties(17). Clinical manifestations of vertebral column-based chordoma 
are a result of pressure on nerve roots, with the earliest presenting symptoms being 
paraesthesia in an upper or lower limb(2,47). Sacrococcygeal chordoma often presents 
late, as symptoms are often non-specific with initial symptoms of mild perianal pain and 
numbness. Patients present with urinary symptoms and/or constipation and go on to 
develop paraesthesia due to nerve compression(2,47,48).  
 
Chordomas are locally invasive and typically have not metastasised at presentation. 
Distant metastases occur late in the course of the disease in 30-40% of patients(49-52) 
with metastases to lymph nodes, lungs, bone, skin and brain(52-54). Patient survival is 
less affected by distant metastases than by local progression(55-58). Local recurrence 
has been described in up to 66% of cases(50,59-61) emphasising the difficulties in 
obtaining clear resection margins, due to the infiltrative nature of the tumour, and the 
anatomical location. The disease can have a very protracted course often with multiple 
recurrences(1,6).  
1.1.5.1 Chordoma in children and young adults 
Chordoma in children and young adults (under the age of 20) is very rare, representing 
less than 5% of all chordomas(7,62,63) with equal incidence between male and 
female(20).  
Sphenooccipital lesions are most frequent in children and adolescents (~64%), whilst 
sacrococcygeal tumours (~9%) are less common(20,39,63). The majority of chordomas 
in childhood are classical (58%) or chondroid variants (23%) while the poorly 
differentiated subtype is found in 8% of cases(20). The poorly differentiated subtype 
occurs mostly in very young children, its behaviour is aggressive and associated with a 
higher rate of metastases(20,63-67). Recently, a subset of early childhood chordoma 
was found to have SMARCB1/INI1 loss, which was found to be associated with poorly 
differentiated chordoma and poor prognosis(68-70). SMARCB1/INI1 loss is a rare 
finding in adult chordoma(71).  In a recent systematic review comprising an analysis of 
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560 patients diagnosed with intracranial chordoma including children and adults, the 
only predictor of survival was age. Patients under the age of 5 were found to have 
worse outcomes, with an overall survival of 14% compared to patients over the age of 
5, with an overall survival of 66%(72). Hoch et al. reported their experience, treating 
base of skull chordoma in children and young adults, from a single treatment centre. 73 
children under the age of 18 were included, all treated with partial or gross surgical 
excision and post-operative proton beam irradiation. The overall survival rate was 81% 
with no difference noted in survival between patients with classical versus chondroid 
chordoma. However, of a subset of patients under the age of 5 with poorly 
differentiated chordoma, 83% died (5 of 6 patients). The survivor had metastatic 
disease and a short follow up period(20). In children with classical chordoma the 5-year 
overall survival of 81% is comparable with current data for adult patients treated with 
surgery and proton irradiation or carbon ion irradiation(73,74). 
1.2 Brachyury  
Brachyury is a member of the T-box family of transcription factors, characterised by a 
conserved DNA-binding domain called the T-box(75). The human ortholog of brachyury 
has been mapped to the conserved linkage group on chromosome 6q27(76). T-box 
transcription factors are vital to the development of the vertebrate embryo, playing 
essential roles in the control of morphogenesis and cell fate decisions(77,78). In the 
developing embryo, brachyury is expressed within the notochord, which forms the 
central axial skeletal element of the developing embryo. Brachyury expression from the 
notochord is essential for mesoderm formation and differentiation, and is involved in 
the control of early embryonal development (gastrulation) (79,80). Loss   of brachyury 
expression leads to failure of notochord formation with homozygous loss being 
associated with embryonic lethality(79). Heterozygosity of the gene has been shown to 
cause skeletal abnormalities. This was first described by Dr Zavadskaia in 1927, as a 
mutation affecting tail length and sacral vertebrae in mice(81). Molecularly 
characterisation of the brachyury gene was first described in 1990(79). Recently a 
homozygous missense mutation in brachyury was identified within a consanguineous 
family, suggesting a causal effect in the development of sacral agenesis(82). A 
different missense mutation in brachyury has previously been associated with vertebral 
malformations(83), and a single nucleotide polymorphism in intron 7 has been found to 
be associated with an increased risk of spina bifida(84).  
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1.2.1 Brachyury implication on pathogenesis of chordoma 
Brachyury expression was identified as the diagnostic hallmark of chordoma in a gene 
expression microarray study of 96 mesenchymal tumours identifying a gene-specific 
signature for chordoma, compared to 18 different mesenchymal tumours(33). Further 
studies using a polyclonal antibody confirmed that brachyury was expressed in all 53 
chordomas tested, as well as in the embryonic notochord, but not in 300 other 
neoplasms tested(31). Brachyury has since become the diagnostic marker for 
chordoma(46), though the level of expression has not been found to be a prognostic 
indicator(85).  It remains to be determined whether or how brachyury-expressing 
notochord cells turn into the brachyury expressing cells found in chordoma, though little 
doubt remain of brachyury’s involvement in the pathogenesis of chordoma(86). The 
basis of this statement is presented below.  
1.2.2 Brachyury Amplification 
Familial chordoma has been described in 8 families including 24 cases of 
chordoma(19,87). Germline duplication of brachyury was found in 7 affected individuals 
in 4 of the families representing a major susceptibility mechanism in some chordoma 
families(87,88). In a study of 98 chordoma samples, non-germline amplification of 
brachyury was identified in 7% of sporadic cases, while 52% of tumours showed copy 
number gain (CNG) of brachyury and within these tumours 39% were polysomic for 
chromosome 6(89).  
1.2.3 Single-nucleotide variant confer risk of chordoma 
Recently a common single-nucleotide polymorphism (SNP) was identified in brachyury 
(rs2305089) which was found to be significantly associated with the risk of sporadic 
chordoma(90). The non-synonymous SNP was found in more than 95% of patients 
with chordoma with approximately 75% of patients being homozygous. Patients with 
homozygous alteration had relative higher expression of brachyury and downstream 
targets compared to heterozygous patients.  The association has been confirmed in 
familial chordoma identifying the SNP in all 24 cases within the 8 families. A second 
common variant, rs1056048 was identified as strongly associated with chordoma in 
familial cases(87). These findings further highlight the importance of brachyury in the 
pathogenesis of both familial and sporadic chordoma. 
1.2.4 Silencing of brachyury leads to cell senescence in vitro 
In vitro silencing of brachyury, using RNA interference delivered by lenti-viral vectors, 
has been shown to lead to cell senescence and apoptosis in two different chordoma 
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cell lines: UCH1 and JHC7, thereby supporting the involvement of brachyury in the 
pathogenesis of chordoma(89,91). 
1.2.5 Brachyury and epithelial mesenchymal transition 
Brachyury has recently been identified as a major driver of epithelial to mesenchymal 
transition (EMT) in cancer progression(92,93). In normal development EMT plays a 
crucial role in the formation and differentiation of multiple tissues and organs, and is 
essential for numerous developmental processes including mesodermal formation and 
neural tube formation(94). EMT is a process where epithelial cells lose their cell 
polarity and cell-to-cell adhesion and gain migratory and invasive properties by 
becoming multi-potent stromal cells with stem cell properties. The transition, involving 
loss of E-cadherin expression, is considered a crucial step in the progression of 
epithelial tumours, during which the cells undergo a phenotypic conversion into 
mesenchymal cells. This progression enables them to metastasise and prevents 
apoptosis and senescence, an important mechanism leading to chemo- and 
radiotherapy resistance(93,95,96). Brachyury expression has been identified in many 
carcinomas, including breast (primary and metastatic), lung, hepato-cell-carcinoma, 
colorectal and adenoid cystic carcinoma. Expression of brachyury has been correlated 
with metastatic disease and poor outcome(96-105). Silencing of brachyury using RNAi 
in carcinoma cell lines and xenografts reversed the epithelial-mesenchymal transition 
with down-regulation of mesenchymal markers, reducing the ability of cell invasion and 
migration(102,106-109).  
1.2.6 EMT and chordoma 
The role of brachyury-mediated EMT in chordoma pathophysiology is unclear and the 
EMT signalling pathway is not fully understood but involves down-regulation of 
epithelial proteins such as E-cadherin and cytokeratins and the induction of 
mesenchymal proteins including fibronectin, N-cadherin, vimentin and matrix 
metalloproteinases (MMPs)(94,110-112). MMP expression levels have been linked 
with outcome in patients with chordoma, with increased levels associated with worse 
outcome(113,114).  Histologically chordomas have epithelial features such as cell 
cohesiveness, a cord like structure and lobulation(115). The tumour cells are 
immunoreactive for epithelial markers including cytokeratin 8, 18 and 19, and epithelial 
membrane antigen (EMA)(13,115,116). Membrane expression for E-cadherin has been 
reported in 14-18% of chordoma, describing weak and focal expression(115,117). One 
study found no E-cadherin expression in 11 chordomas but all were immunoreactive 
for N-cadherin(118). Following gene silencing of brachyury in the chordoma cell lines 
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JHC7, U-CH1 and U-CH2, an increase in E-cadherin, a reduction in N-cadherin, and 
the mesenchymal transcription factors Snail and Slug were seen(119). Snail and Slug 
belong to a superfamily of zinc finger transcriptional repressors that participates in 
EMT, with Snail acting as a repressor of E-cadherin(92,120,121). There are two main 
Snail genes in vertebrates, Snail1 and Snail2 (called SNAI1 and SNAI2 or Slug). Snail 
genes represent a convergence point in EMT induction. Numerous signalling pathways 
induce EMT and all have been shown to activate the expression of these genes(122). 
The regulation is complex but includes transforming growth factor beta (TGFβ) 
superfamily of cytokines, and fibroblast growth factor (FGF), signalling(122,123). FGF 
as well as TGFβ have been implicated in the pathogenesis of chordoma and the 
control of brachyury(124-127). Findings in a recent study supported brachyury’s 
involvement in EMT in chordoma, demonstrated interactions between brachyury and 
FGF/FGFR signalling via the MAPK pathway. FGF-activated 
FGFR/MEK/ERK/brachyury pathway was found to actively control cell growth, survival 
and EMT in chordoma(91,119).  
1.3 Somatic mutations in chordoma 
To date, no single recurrent somatic driver mutation has been identified in chordoma. A 
study of somatic point mutations in common cancer genes (TP53, PTEN, BRAF, 
CTNNB1, FLT3, JAK2, APC, KIT, KRAS, NOTCH1 and PIK3CA) in 21 chordomas 
found no recurrent mutations(128). Choy et al. performed mutational analysis, 
genotyping 45 chordoma samples using focused genetic analysis, screening hotspot 
mutations in 111 oncogenes and selected tumour suppressor genes. Six mutations 
were identified in ALK, CTNNB1, NRAS, PIK3CA, PTEN, CDKN2A and SMARCB1. 
The mutations in CDKN2A and PTEN occurred in areas of chromosomal loss(129) 
Direct sequencing of mutational hotspots in the MAPK signalling pathway, including 
EGFR, KRAS, NRAS, HRAS, BRAF and FGFR1-4, have not identified any recurrent 
mutations in over 100 cases(119,130). Recently, exome or whole genome sequencing 
of 32 chordomas has not found a single unifying recurrent mutation (personal 
communication Professor A. Flanagan).  Most chordomas have a bland genomic 
landscape harbouring only a few mutations although some cases have been described 
with chromothripsis(131,132). Chromothripsis, a recently reported cancer-initiating 
event, describing a phenomenon whereby tens to hundreds of genomic 
rearrangements occur in a one-off cellular crisis(133). This has been found in 2-3% of 
all cancers but in up to 25% of bone tumours and in 20% of chordomas. This was 
observed in a chordoma cell line where chromothripsis was reported to have 
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simultaneously affected the cancer-associated genes CDKN2A, Werner syndrome ATP 
dependent helicase (WRN) and Fbox and WD40 domain containing 7 (FBXW7)(133). 
 
Other molecular profiling studies have shown chordomas are characterised by non-
random genomic copy number alterations, with copy number losses being more 
frequent than copy number gains. The most common cytogenetic abnormality is 
monosomy 1 and gain of chromosome 7(125,126,128,134,135).  Genomic 
homozygous and heterozygous loss of the tumour suppressors such as cyclin-
dependent kinase inhibitor 2A (CDKN2A), CDKN2B (9p21) and PTEN has been 
reported to occur in up to 80% of chordomas(125,128).  
1.4 Therapeutic options 
1.4.1 Surgery and radiotherapy 
The treatment option for chordoma is primarily surgical with complete resection being 
crucial for long-term event-free survival(56,136). The long-term survival after local 
relapse is low, and local control is rarely achieved(57,60,137-139). En bloc resection 
should be performed where possible with the aim of maximum tumour resection 
combined with preservation of neurological function and quality of life(140-142). 
Adjuvant radiotherapy is recommended following complete macroscopic resection and, 
for unresectable tumours, radiotherapy is given following biopsy. Chordomas are 
radiotherapy resistant requiring a high dose of at least 70-74Gy(143-145), which can 
be challenging to deliver due to toxicity to the surrounding tissue. Proton therapy has 
improved outcome for patients(143,144,146-148), achieving superior local control if 
radiotherapy is given as adjuvant therapy with surgery(74,146). Newer radiation 
therapies with carbon ion has shown promising results(73,149-151). 
1.4.2 Chemotherapy  
Chordoma has been shown to be chemo-resistant and at present there are no 
approved drug treatments for advanced chordoma(56). The experience with 
chemotherapy largely derives from case-reports(152-155). In a phase II trial utilising 9-
nitroocamptothecin (9-NC), a topoisomerase I inhibitor to treat 15 patients with 
chordomas, one (7%) objective response was observed. The 6-month progression-free 
survival was 33%(156). The study was halted due to toxicity and inconsistent clinical 
activity(157). Patients with chordoma treated with chemotherapy have generally had a 
clinically aggressive tumour with metastatic or progressive disease(58,158,159). 
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Chemotherapy has shown initial response in dedifferentiated chordoma(160) but 
disease control has not been maintained.  
1.4.3 Targetable tyrosine kinase receptors in chordoma 
The first tyrosine kinase inhibitor used for treatment of chordoma was Imatinib, a 
kinase inhibitor developed to treat chronic lymphoblastic leukaemia (CLL) by blocking 
the BCR-Abl enzyme(161). Imatinib is a small molecule inhibitor of several tyrosine 
kinases including platelet-derived growth factor receptor (PDGFR) and cKIT(162). 
Subsequent work has shown that PDGFR is expressed in virtually all chordomas(163-
165) and cKIT is expressed in 33-77% of chordomas(164,166). This provided the basis 
for further studies using Imatinib in patients with chordoma(167-169). The results of a 
multicentre, non-randomised, phase II study of Imatinib in patients with advanced 
chordoma showed an objective response in one (2%) of 50 patients assessed 
according to the Response Evaluation Criteria in Solid Tumours (RECIST)(170), 
whereas a minor response was seen in 20% of patients. Functional imaging using PET 
showed a 39% response rate which correlated with reported clinical symptomatic 
relief(171). Stabilisation of disease was achieved in 70% of patients with mean 
progression-free-survival (PFS) of 9.9 months in a patient group with active 
progressive disease, supporting activity of Imatinib in advanced stage 
chordoma(171,172).  
 
The use of EGFR inhibitors for treatment in chordoma was reported in 2006 in a patient 
with progressive disease treated with the EGFR inhibitor Gefitinib, and a monoclonal 
antibody (Cetuximab) targeting EGFR. A degree of disease regression was observed, 
suggesting anti-tumour effect(173). Further pre-clinical studies and several case 
reports have reported activity of EGFR inhibitors including Gefitinib, Cetuximab, and 
Erlotinib in patients with chordoma(173-178). However, a recent phase II study testing 
efficacy of Lapatinib (EGFR and HER2 dual inhibitor) reported minimal activity(179). 
EGFR has been reported to be expressed in 24-100% of 
chordomas(165,166,180,181), with EGFR polysomy and gene amplification reported in 
17-52% of tumours(164,180,182-184). No mutations have been detected in EGFR in 
chordoma(40,164).  
 
Imatinib and EGFR inhibitors are amongst the most commonly tested drugs in 
chordoma patients totalling approximately 120 patients identified in the literature (Table 
1.2). Imatinib efficacy in chordoma was only investigated in a preclinical setting in 
2013, following nearly 9 years of clinical use. Imatinib was included in a large 
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compound high throughput drug screen and found to exert only a moderate inhibitory 
effect(185). EGFR inhibitors (Erlotinib and Gefitinib) were found to exert a modest 
growth inhibitor activity on the U-CH1 and U-CH2 cell lines, whilst Erlotinib 
demonstrated a significant inhibitory effect in a primary cell culture C24(185). This 
observation correlated with data testing Erlotinib and Gefitinib in a newly established 
patient derived xenograft model(178). 
 
Expression of other potentially targetable tyrosine kinase receptors include the proto-
oncogene Mesenchymal Epithelial Transition factor (MET) or (c-MET) also known as 
the hepatocyte growth factor receptor (HGFR) found in 60-100% of 
chordomas(181,186). The level of c-MET expression was found to be a prognostic 
factor in recurrent lesions, with low levels being associated with a worse outcome in 
spinal (vertebra) and skull-based chordoma(187). HGF/c-MET interacts with both the 
PI3K/AKT/mTOR and RAS/RAF/MEK/MAPK pathways(188), which are often 
dysregulated in cancer(189-191), and have been found to be dysregulated in 
chordoma(40,119,192). Active phosphorylated forms of the transduction molecules ERK 
and AKT were expressed in 86% and 76-92% respectively of chordomas(40,165). 
Mammalian target of rapamycin (mTOR) expression has been reported in 24-56% of 
chordomas(40,166). Rapamycin, an mTOR inhibitor has been tested in preclinical 
studies and treatment response has been reported in one patient describing reduced 
tumour growth rate and clinical improvement(193). A phase II study of imatinib plus 
everolimus (mTOR inhibitor) is in progress(56). 
 
Vascular endothelial growth factor receptor 2 (VEGFR2) and inducible nitric oxide 
(iNOS) are involved in the angiogenesis and recurrence of chordoma, and have been 
associated with poorer outcome in spinal(194) and in sacral chordoma(195). However, 
the expression of VEGFR2 in chordoma has not been observed in all studies(194) 
indicating that further work is required to clarify the expression pattern of this receptor 
in chordoma. The combination of Bevacizumab  (VEGFR2 inhibitor) and Erlotinib or 
Cetuximab (EGFR inhibitor) was reported in three patients with chordoma, leading to 
symptom relief and stable disease(176,196). None of the genes coding for the proteins 
aberrantly expressed in chordoma have been found to have activating 
mutations(40,163-165,180).
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Table 1.1 Preclinical drug screening in chordoma cell lines and xenografts  
Year Drug Target Cell lines Effect Reference 
2014 FGFR inhibitor (VEGFR) (PD173074), MEK 
inhibitor (MAPK/ERK kinase)(PD 0325901 
and PD 184352) 
FGF2, MEK, 
ERK 
JHC7, UCH1, UCH2 Decreased brachyury expression, 
induced apoptosis, and inhibited cell 
growth and EMT  
(119) 
2014 Lapatinib EGFR/Her2/Neu Xenograft (PDX) Minimal effect (177) 
2013 SAHA (Vorinostat; Suberoylanilide 
hydroxyamic acid), LBH-589 
(Panobinostat), PXD101 (Belinostat)  
HDAC UCH1, MUG Apoptosis & cell cycle arrest (198)  
2014 Erlotinib and Gefitinib EGFR UCH1 and patient-
derived xenograft  
Reduced proliferation in cell line, 
reduced tumour growth in xenograft 
(178)  
2013 NCGC Pharmaceutical collection (NPC)   UCH1, UCH2, CCL4 
control (+3 primary 
chordoma cell cultures 
Inhibition of cell growth, Apoptosis 
(UCH1) 
(185) 
2012 Methotrexate, Doxorubicin, Cisplatin, 
Paclitaxel 
  CH22 (new chordoma 
cell line) 
Chemo-resistance (199) 
2011 Doxorubicin, Vincristine, Etoposide, 
Cisplatin, Fludarabine, Methotrexate, 
Nilotinib and Imatinib. Trans-retinoic acid 
(ATRA)   
UCH1 High doses used for effect. The 
addition of ATRA improved cell kill. 
Imatinib no effect. Doxorubicin killed 
all cells at 10uM 
(200) 
2011 Tyrphostin (AG1478) EGFR  UCH1 Inhibition of proliferation (180) 
2010 CDDO-Me (synergistic effect with Cisplatin 
and Doxorubicin) 
STAT3, Src  UCH1, CH8 (GB60) Inhibition of proliferation and 
apoptosis 
(201)  
2010 Doxorubicin, Cisplatin, Methotrexate, 
Zalypsis, Paclitaxel, Yondelis 
  UCH1, CH8, (GB60) MTT assay, reduced proliferation (202) 
2009 SD-1029 (+Cisplatin or Doxorubicin) STAT3 inhibition 
(JAK2 inhibition)  
UCH1, CH8 (GB60) MTT assay, reduced proliferation (88) 
2009 PI-103 (+/- Cisplatin or Doxorubicin) PI3K/mTOR 
inhibition 
UCH1 Reduced proliferation and induction 
of apoptosis 
(192) 
2009 Rapamycin mTOR UCH1 Reduced proliferation  (203) 
Some of the cell lines described as generated from chordomas has not been fully characterised, and have not become part of the ATCC repository.  Indeed 
the GB60 cell line has been shown not to represent chordoma(197). U-CH1, U-CH2, MUG and JHC7 are all well characterised (www.chordomafoundation) 
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Table 1.2 Overview of targeted therapy used in the treatment of chordoma  
Year Drug Target Number of 
patients 
treated 
Effect Adjuvant 
therapy 
Additional details Reference 
2014 Bevacizumab 
& Erlotinib 
VEGF-A & 
EGFR  
3 Stable disease Surgery & 
radiotherapy 
All three patients had progressive disease and 
all achieved long term stable disease (2-4 
years follow up). 
(176) 
2013 Rapamycin  mTOR 
(mTORC1) 
1 Reduced growth 
rate, clinical 
improvement 
Surgery & 
radiotherapy 
Patient-derived sample used: Rapamycin 
tested in cell line generated from patient 
tumour sample. Cell line used to generate 
xenograft, treated with Rapamycin (reduced 
growth/histological changes). The patient 
responded with reduced tumour growth rate. 
Tumour genome showed PTEN loss & KRAS 
mutation. 
(193) 
2013 Imatinib & 
metronomic 
cyclophos-
phamide 
PDGFR,  
c-Kit  
7 Symptomatic relief, 
stable disease. 
 
Surgery & 
radiotherapy
.  
All had progressive disease prior to treatment, 
all achieved SD with 42% PFS at 12 months. 2 
of 7 patients previously treated with Imatinib 
as single therapy. 
(204) 
2013 Lapatinib 
(phase II) 
EGFR/ 
ErbB2 
18 PR 6 patients (33%), 
SD 7 patients 
(38.9%). Clinical 
benefit reported by 
22% of patients. 
Surgery & 
radiotherapy 
Phase II study;18 patients with metastatic or 
locally advanced EGFR-positive chordoma 
treated with lapatinib. 16 of the 18 patients had 
prior therapy with imatinib  
(179) 
2012 Imatinib 
(phase II) 
PGDFR 50 1 PR (RECIST) 
13/26 (Choi), 35 SD, 
14 PD, 9 SD. 64% 
reported clinical 
benefit. 
Surgery & 
radiotherapy 
Phase II study involving 50 patients with 
locally advanced or metastatic chordoma 
expressing PDGFR, 1 PR (by RESIST), 35 
SD. 64% reported clinical response. Minor 
dimensional response was detected in <20% 
of patients. Median PFS 9 months. 
(171) 
2011 Imatinib PDGFR 1 PD Surgery Sacral tumour with lung and brain metastases. 
Progression of metastases on Imatinib. 
(205) 
2011 Erlotinib 
(Imatinib) 
EGFR 1 Regression of 
thoracic lesion 
(12months). 
Symptomatic relief. 
Surgery Pelvic tumour, lung metastases, disease 
progression on Imatinib. Relapse tumour 
biopsy with > 90% of tumour cells showing 
strong staining for EGFR.  
(206) 
2010 Imatinib  PDGFR 16 Pain relief (54%), 5- 
and 10 year survival 
76% and 59%) 
3/22 
patients 
received 
adjuvant 
radiotherapy 
Progressive disease, local and/or metastatic 
disease.  
(207) 
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2009 Imatinib PDGFR, 
KIT 
3 1x SD, 2xPD 
Single agent not 
found to have 
efficacy 
Not 
recorded 
Target driven study of imatinib in paediatric 
solid tumours. The patient with initial SD 
subsequently had progressive disease and 
died. 
(208) 
2009 Erlotinib EGFR 1 Partial responds 
(11months) 
Sacral, 
relapse LN 
involvement 
Progressive disease, refractory to radiotherapy 
and imatinib. 
(209) 
2009 Sunitinib VEGFR, 
PDGFR, 
KIT, FLT3 
9 44% SD (RECIST) Surgery & 
radiotherapy 
Qualitative decrease in tumour density was 
observed 
(174) 
2009 Cetuximab & 
Gefitinib 
EGFR 1 PR with clinical 
improvement 
Cervical 
lesion, local 
relapse 
Symptoms of cord compression relieved by 
treatment. Reduction of tumour size. 
(175) 
2009 Imatinib & 
Sirolimus 
PDGFR-β, 
mTOR 
10 1 PR (RECIST) 7 
PR (Choi) 1PD, 89% 
clinical improvement 
6/10 
previously 
received 
adjuvant 
radiotherapy 
Patients progressing on Imatinib (+/- cisplatin). 
50% (5 patients continuing treatment for 
regressive disease)  
50% came off treatment as disease 
progression on treatment 
(169) 
2007 Imatinib & 
Cisplatin 
PDGFR-β 6 PET response and 
clinical 
improvement, 4 
patients had SD on 
CT/MRI 
Surgery & 
radiotherapy
Progression 
on Imatinib 
Addition of low dose cisplatin (25mg/m2/week) 
showed synergistic effect and restored 
response to Imatinib. 
(168) 
2006 Cetuximab & 
Gefitinib 
EGFR 1 PR; regression of all 
lesions (9 months) 
Surgery  Sacral, local relapse with LN and pulmonary 
disease 
(173) 
2005 Imatinib PDGFR,   
c-KIT, 
BCR-ABL 
18 11% dimensional 
response, 61% 
radiological signs of 
tissue response 
Surgery Follow-on reporting of patients from 2004 
paper (ASCO meeting) 
(167) 
2004 Imatinib  PDGFR,  
c-KIT, 
BCR-ABL 
6 Symptomatic relief Surgery Anti-tumour effect, all patients +ve for 
PDGFRb. 2005 update of data now a total of 
18 patients with continued effect. 
(210) 
PR: partial response, SD: stable disease, PD: progressive disease 
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1.5 Novel therapies 
With the lack of treatment options and minimal effect of current therapies for the 
treatment of chordoma, alternative approaches are needed. One such approach could 
be gene therapy, which is currently undergoing a renaissance in the field of cancer 
treatment. A gene therapy approach is reported as part of this thesis (Chapter 3) 
involving preclinical studies utilising an Adeno-Associated viral vector delivering RNA 
interference (RNAi) targeting brachyury. 
1.5.1 Gene therapy 
Gene therapy was conceptualised in the 1970s and refers to the transfer of genetic 
material, using a vector, with the intention of altering gene expression to prevent, halt 
or reverse a pathological process(211). The European Medicines Agency (EMA) 
defines a gene therapy medicinal product as a biological medicinal product with the 
following characteristics: (A) it contains an active substance which contains a 
recombinant nucleic acid administered to human beings with a view to regulating, 
repairing, replacing, adding or deleting a genetic sequence; (B) its therapeutic, 
prophylactic or diagnostic effect relates directly to the recombinant nucleic acid 
sequence it contains, or to the product of genetic expression of this sequence(212).  
1.5.2  History of gene therapy 
Frederick Griffith, a British bacteriologist researching the epidemiology and pathology 
of bacterial pneumonia, published a report in 1928 describing transformation of one 
pneumococcal type to another in vivo. By observing that mice infected with a living 
bacteria of the non-virulent R form of Type I pneumococcus, and co-infected with heat-
inactivated bacteria of the virulent S form of Type II pneumococcus, developed 
pneumonia and died, he developed the idea that a virulence factor or information 
determining virulence could be transferred from one bacteria to another. The 
transformation of bacteria was subsequently observed in vitro by Dawson and Sia in 
1931(213,214) and in 1944 the transforming substance was identified to be 
deoxyribonucleic acid (DNA)(215). 
 
Key research in the development of gene therapy was performed by Joshua 
Lederberg, a geneticist and microbiologist, who received the Nobel Prize in 1958 for 
his work on bacterial genetics. He introduced the term “transduction” following the 
discovery of bacteriophages, and uncovered their ability to transfer DNA from one 
bacterium to another. This discovery was significant as it explained how bacteria of 
Targeted therapy for chordoma 
 48 
different species could gain resistance to the same antibiotic very quickly. The 
understanding that phages transfer genetic material brought about their development 
as gene transfer tools and further extended research to eukaryotic viruses(216,217). 
Initial proof-of-concept studies demonstrating that viruses were capable of mediating 
gene transfer(218) led to the first human gene therapy trial for arginase deficiency in 
1973(219,220). This first attempt at human gene transfer with therapeutic intent 
involved a wild-type virus with no added recombinant DNA. The aim was to transfer a 
functional arginase gene from the virus itself. The attempts were unsuccessful, and 
later it was discovered that the Shope Papilloma virus used did not encode for 
arginase(221). 
 
While the emergence of recombinant DNA technology(222-224) brought about the 
development of functional gene-expressing units, major challenges remain. In 
particular the most efficient and safe way to deliver these therapeutic agents to patients 
still requires optimisation. Many mammalian viruses have been explored as gene 
delivery vectors, with adenoviral and retroviral vectors amongst the most commonly 
used gene transfer vectors in clinical trials (Figure 1.4). The first trial using a 
therapeutic gene involved two children suffering from adenosine deaminase deficiency 
(ADA-SCID)(225). The study did not demonstrate therapeutic benefit, yet generated 
great enthusiasm for the potential of gene therapy. In 1999 a major setback occurred 
when a young man died following a high dose of adenovirus in a trial for ornithine 
transcarbamylase (OTC) deficiency(226).  
 
The first successful cure using gene therapy came in 2000. Autologous bone marrow 
cells were transduced with Moloney retrovirus expressing the cytokine receptor 
interleukin-2 receptor gamma (IL2RG) and transplanted into patients, resulting in the 
development of a functional immune system in children with X-linked severe combined 
immune deficiency (SCID)(227). The success was tempered by the fact that 5 of the 20 
patients treated developed leukaemia due to the clonal expansion of T-lymphocytes 
derived from the modified haematopoietic stem cells. This transformation was driven by 
aberrant expression of the LIM domain only 2 (LMO2) proto-oncogene as a result of 
transcriptional read-through from the viral promoter of the integrated retroviral 
cassette(228,229). The safety of Moloney retroviruses remains a cause for concern 
although clinical efficacy and safety has been reported following the development of a 
self-inactivating retrovirus(230). Further safety measures have included the use of 
lentiviral vectors, which has substantially increased in recent years. Whilst lentivirus 
also integrates into the host cell genome, the frequency of integration at promoter sites 
Targeted therapy for chordoma   
 49 
is substantially lower than that seen with retrovirus(231). Consequently the risk of 
insertional mutagenesis is lowered and, to date, no patients have developed 
malignancy(211,232). Despite such improvements, further assessment of these 
vectors is required, if they are to be used widely in the clinic(233,234). 
 
Another class of viral vectors are those that remain predominantly episomal and at the 
forefront of these is the Adeno-Associated Virus (AAV). Recent years have seen a 
dramatic success using AAV vectors for the treatment of monogenic disorders with 
specific protein deficiencies such as haemophilia B(235), Lebers congenital 
amaurosis(236), Parkinson disease(237) and α-1 anti-trypsin deficiency(238). Two 
gene therapy therapeutics utilising AAV vectors have been licensed for use. The first 
gene therapy product to be licensed in Europe was Glybera, utilising an AAV vector for 
delivery of the human lipoprotein lipase (LPL) gene by intramuscular injection in 
patients with lipoprotein lipase deficiency (LPLD)(239-244). The US Food and Drug 
Agency (FDA) has not yet approved Glybera. The FDA has not yet approved a gene 
therapy product but in 2014 the gene therapy product MYDICAR was granted 
designation by the FDA. MYDICAR utilises an AAV vector for delivery of a copy of 
SERCA2a gene, linked with systolic dysfunction, into the patient’s cardiac muscle in 
order to restore the SERCA2a enzyme in patients with heart failure(245,246). 
 
While replacement gene therapy is the basis for the majority of gene therapy clinical 
trials for inherited disorders, these represent less than 8% of all gene therapy clinical 
trials conducted(247). Since 1989 more than 1800 gene therapy clinical trials have 
been conducted. More than 60% of these trials have been against cancer and have 
accounted for more than 80% of patients entered into gene therapy clinical 
trial(248,249) (Figure 1.1). The majority are phase I and phase II trials (Figure 1.2). 
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Figure 1.1 Review of indications for the use of gene therapy 
Indications addressed by gene therapy in clinical trials. Initial studies were on monogenetic 
diseases, but cancer soon became the major interest. Source: The Journal of Gene Medicine, 
Wiley and Sons. Accessed February 2015. 
 
 
Figure 1.2 Review of the current trial phases for gene therapy 
Source: The Journal of Gene Medicine, Wiley and son. Accessed February 2015. 
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1.5.3 Gene therapy’s potential applications for cancer therapy 
Numerous potential therapeutic targets involved in the regulation of pathogenic 
processes of tumours are amenable to gene transfer. These include genes involved in 
angiogenesis, tumour growth, invasion, metastasis, and immune response against 
tumours(250,251). Inter-tumour heterogeneity and treatment resistance has led to a 
range of strategies for targeting cancer using gene therapy, including: (a) inserting a 
wild-type tumour suppressor gene to compensate for its loss/deregulation; (b) 
enhancing tumour sensitivity to conventional drug/radiation therapy using an oncolytic 
virus carrying a suicide gene, and inducing apoptosis; (c) enhancing immunogenicity of 
the tumour to stimulate immune cell recognition; (d) blocking expression of an 
oncogene by using an antisense (RNAi) approach(252).  
1.5.3.1 Regulation of tumour suppressor gene (a)  
Tumour suppressors act as “cellular guardians” by inhibiting cell growth pathways 
and/or by inducing cellular apoptosis, consequently preventing cancer formation. One 
of the most important tumour suppressors is TP53, which functions as a sensor of DNA 
damage and other cellular and metabolic stresses including hypoxia(253). In response 
to stress, TP53 induces cell cycle arrest and subsequent DNA repair, senescence or 
apoptosis, depending on the level of cellular compromise(254,255). Many types of 
cancer show a high incidence of TP53 mutations and disturbance of the TP53 
signalling pathway is believed to be required for the development of most cancers(256-
258). Evidence suggests that restoration or activation of TP53 function will have 
significant therapeutic benefit(257). Strategies targeting TP53 have been developed 
including gene therapy to restore TP53 function, inhibition of TP53-MDM2 interaction, 
as well as TP53-based vaccines(257,259,260). Some of these TP53-targeted therapies 
have entered clinical trials(253). TP53 gene therapy using an adenoviral vector Ad-p53 
(Gendicine) was approved in China in 2003 without data from a standard phase III 
clinical trial(261,262). Subsequent publications have reported a good safety profile and 
efficacy in combination with radiotherapy in hepatocellular carcinoma(263) and 
advanced nasopharyngeal carcinoma(264). This is in contrast to a study in ovarian 
cancer which did not reveal any therapeutic benefit(265). Nearly 2500 patients have 
received treatment in China(266). Two years after the approval of Gendicine the 
Chinese State Food & Drug Administration (SFDA) granted approval of another gene 
therapy product, Oncorine. The gene therapy products have not been approved in the 
US or Europe as efficacy has not yet been established(260). TP53 vaccine-based 
studies have also entered early phase clinical trials. Phase I/II clinical trials of a TP53 
synthetic vaccine for the treatment of metastatic colorectal cancer(267) and small lung 
Targeted therapy for chordoma 
 52 
cell cancer(268) found it to be well tolerated and generating a specific anti-TP53 
immune response. MDM2 small molecule inhibitors of the MDM2-TP53 protein-protein 
interaction are currently being evaluated in human clinical trials for cancer 
treatment(260,269). 
1.5.3.2 Oncolytic virus (b) 
Gene therapy strategies involving oncolytic virus therapy were first introduced in the 
1950s but the field has been slow to develop(270,271). Oncolytic viruses selectively 
replicate in tumour cells with the burden of viral progeny eventually resulting in lysis of 
the malignant cell. In addition to mediating direct destruction of the host cell, it also 
results in the release of tumour-derived antigens, providing relevant antigenic targets 
for T-cell activation(272) and stimulation of a system-wide anti-tumour immune 
response(273). Oncolytic Herpes Simplex Virus (HSV) vectors expressing immune 
stimulatory genes such as granulocyte-macrophage colony-stimulating factor (GM-
CSF) or suicide genes such as thymidine-kinase (tk) or cytosine deaminase (CD), have 
been developed to maximise tumour destruction(274). So-called ‘suicide genes’ are 
enzymes that mediate the conversion of a pro-drug into a cytotoxic product. In addition 
to inducing apoptosis of the malignant cell, it can increase the cells susceptibility to 
chemotherapy and radiotherapy(249,275-278). Viral thymidine kinase (HSV-tk) 
mediates the conversion of the inert pro-drug Ganciclovir into Ganciclovir 
monophosphate, which is then rapidly converted into the toxic purine analogue 
Ganciclovir triphosphate. Incorporation of this molecule inhibits DNA synthesis, 
resulting in the apoptosis of the malignant cell(279,280). In a similar manner, the 
suicide gene CD converts the relatively non-toxic 5-fluorocytosine (5-FC) molecule into 
5-fluorouracil (5FU), a known anti-cancer drug(276,281,282). In a phase II study for 
prostate cancer, the utility of an oncolytic adenovirus with two cytotoxic gene systems 
CD/5-FC and HSV-1 tk/ganciclovir demonstrated clinical benefit when combined with 
radiotherapy(283). The first oncolytic virus approved for a phase III clinical trial was an 
oncolytic HSV vector encoding human GM-CSF for treatment of metastatic melanoma. 
The data demonstrated durable tumour response with reduction in size in 
approximately two-thirds of the tumours injected. The therapeutic product, Talimogene 
Laherparepvec (T-vec) is being considered for approval by the FDA(284-286).  
1.5.3.3 Immunotherapy (cancer vaccines) (c) 
Different types of immunotherapy strategies have been applied for cancer treatment. 
Some of these approaches currently in trial include the development of vaccination 
using tumour cells or antigen presenting cells (APCs), engineered to express immune-
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stimulatory GM-CSF to elicit an immune response against the cancer 
cells(248,287,288). Tumour-associated antigens can be recognised by the immune 
system, however these antigens often evoke only weak immune responses, as they 
are usually ‘self’ antigens(289). To prevent autoimmunity, immune cells capable of 
targeting such antigens with high affinity have been purged or suppressed through 
central and peripheral tolerance mechanisms(287,289). In addition many cancers have 
developed a range of immune evading mechanisms to avoid eradication(290). To 
overcome the immune-suppression and to develop a successful vaccine, the vaccine 
must induce a cytotoxic T-lymphocyte (CTL) response rather than rely on an innate 
antibody response(291). Various approaches for generating cancer vaccines have 
been developed over the past 20 years with more than 175 reported clinical trials, with 
less than 10% of recipients of cancer vaccines demonstrating clinical 
response(248,289,292,293).  
 
Of specific interest for the treatment of chordoma is a phase I/II clinical trial conducted 
under the National Cancer Institute (NCI) (NCT01519817) using a yeast-brachyury 
vaccine (GI-6301) in patients with advanced solid tumours including chordoma(294). 
Brachyury, like other transcription factors, is localised to the nucleus; however, 
brachyury peptides have been found to be expressed on the surface of some 
carcinomas in the context of major histocompatibility complex (MHC) class I 
molecules(103). Preclinical studies have demonstrated that brachyury-specific T-cells 
can lyse human chordoma cells expressing brachyury in an MHC restricted 
fashion(294). In this vaccine-study the yeast Saccharomyces cerevisiae has been 
genetically modified to express the full-length brachyury gene to stimulate an antigen 
specific T-cell response. The vaccine was tested in xenografts (carcinoma murine 
models) where the vaccine elicited a CD4+ and CD8+ T-cell response capable of 
reducing tumour burden. In view of involvement of brachyury in EMT, toxicity was 
assessed through monitoring wound healing and embryonic development. No toxicity 
was observed(295,296). Early clinical data has been encouraging, suggesting that 
patients with chordoma can elicit a brachyury specific T-cell immune response(297). 
Disease assessment has shown evidence of clinical benefit with stable disease or 
partial response. The early phase trial demonstrated safety and immunogenicity of the 
vaccine and has lead to a phase II clinical trial enrolling patients for a randomised trial 
receiving radiotherapy with or without the GI-6031(298). It will be of interest to discover 
if this approach improves local control. 
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The first FDA-approved immunotherapy product was the therapeutic vaccine 
Sipuleucel-T, for treatment of metastatic prostate cancer, approved in 2010, and 
subsequently by the EMA under Advanced Therapy Medicinal Product (ATMP) or gene 
therapy in 2013. This therapeutic vaccine involves the harvesting of individual patients’ 
white blood cells, primarily APCs (dendritic cells), by leukapheresis. Harvested cells 
are incubated with a fusion protein consisting of antigen prostatic acid phosphatase 
(PAP), which is present in 95% of prostate cells and GM-CSF to enhance immune 
response. Cells are reinfused into the same patient to stimulate a T-cell response 
against PAP-GM-CSF and consequently against cancerous prostatic cells. The overall 
survival was prolonged for men with metastatic prostate cancer, though disease-free 
interval was not increased(299-303). The product is considered too expensive for the 
NHS and has not been introduced in the UK. A recent phase I trial for patients with 
metastatic prostate cancer has shown tolerability and early data suggest response 
when combining Sipuleucel-T with Ipilimumab(301,304).  
 
Additional T cell-based immunotherapy such as chimeric antigen receptors (CARs) and 
engineered tumour specific T-cells (CAR-T cells) developed to confer specificity to 
tumour-associated antigens is a rapidly developing field(305). Application has mainly 
been in haematologic malignancies(306), although preclinical studies and early phase 
clinical trials exploring the potential application in targeting solid tumour antigens with 
CAR-T cells are on-going(307).  
1.5.3.4 RNA interference (d)  
RNA interference (RNAi) is a naturally occurring endogenous, evolutionary conserved 
and sequence-specific post-transcriptional mechanism of gene silencing. The 
technique exploits mechanisms that repress protein expression by degradation of 
mRNA thereby effectively resulting in silencing gene expression. In primitive 
organisms, RNAi is involved in several processes such as cell growth, tissue 
differentiation, hetero-chromatin formation and cell proliferation(308). RNAi also 
protects the genome from viruses by suppressing active replication of the virus-like 
transposable element, likely to be fossilised remnants, present in the human 
genome(309-312), and regulates gene expression during development(313-315). 
Dysfunction in the RNAi pathway is linked to cardiovascular diseases(316), 
neurological disorders(317), and cancer(318,319). 
  
The discovery of RNAi followed observations that the introduction of the chalcone 
synthase gene into petunias to increase the intensity of their purple colour 
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paradoxically resulted in areas of hypopigmentation(320,321). Further work by Fire and 
colleagues in C. elegans, demonstrated that introducing long double-stranded RNA 
(dsRNA) led to targeted degradation of homologous RNA(322,323). Subsequently, 
RNAi was found to be a highly conserved mechanism in eukaryotic cells(324) and 
interest in the technology increased when observed that RNAi provided a tool for 
studying gene function in mammalian cells(325-328).  
 
The spectrum of gene therapy applications has further increased with the use of small 
nucleic acids(247,329). The ability of small interfering RNA (siRNA) to silence target 
genes with high efficiency and specificity has stimulated efforts to develop these 
molecules as therapeutic agents. This approach is of interest for cancer therapy where 
many key therapeutic targets remain beyond current treatment options(330,331).  
Transcription factors are known to be non-targetable and brachyury is such a target. 
Silencing of brachyury in two different chordoma cell lines using short hairpin RNA 
(shRNA) delivered by lentiviral vectors, resulted in cell death and cell senescence, 
emphasising brachyury’s role in the pathogenesis of chordoma. This work provided the 
rationale for developing a gene therapy approach for the treatment of 
chordoma(89,91). 
1.5.4 The mechanism of RNAi 
RNAi is the process of sequence-specific post-transcriptional gene silencing triggered 
by double-stranded RNA(327,332).  The actions of RNAi can be mediated either 
through the chemically synthesised siRNA or the shRNA transcribed from a DNA 
expression vector(333,334).  
 
When double-stranded RNA (dsRNA) composed of a passenger (sense) strand and a 
guide (antisense) strand is imported into the cytoplasm, it is cleaved into short 
fragments by the ATP-dependent ribonuclease (RNase III) enzyme Dicer(335,336). 
Dicer cleaves the long dsRNA, molecules into short double stranded fragments of ~22 
nucleotides of mature microRNA (miRNA) or siRNAs(337). With the assistance of 
Dicer, miRNA is loaded onto the intracellular Argonaute protein containing RNA 
interfering silencing complex (RISC). One strand of the siRNA, the sense strand, is 
degraded(338). RISC loaded with the anti-sense strand attaches with the 
complimentary base pairs in a messenger RNA molecule inducing cleavage, 
degradation, and sequestration. Endonucleolytic cleavage of the target mRNA is 
mediated by Argonaute, the catalytic component of the RISC complex, leading to post-
transcriptional gene silencing(327,328,339).  
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Unlike siRNA, vector-driven-expression of shRNA needs to be transcribed in the 
nucleus. ShRNA can be transcribed from the RNA polymerase III or modified 
polymerase II promoter, following a plasmid transfection or delivery through infection 
(transduction) using virally produced vectors, some of which facilitate DNA integration 
and long term stable expression, compared to the short-term silencing achieved by 
siRNA(340-342).  
 
Transcribed shRNA consists of two complementary 19–22 base pairs (bp) RNA 
sequences linked by a short loop of 4–11 unpaired nucleotides (nt) similar to the 
hairpin found in naturally occurring pre-miRNA(343). This structure is processed in the 
nucleus by a microprocessor complex containing the RNase III enzyme Drosha, and 
the double-stranded RNA-binding domain protein DGCR8(344,345). The processed 
primary transcript is the pre-shRNA molecule, which is transported to the cytoplasm by 
Exportin 5(345,346). In the cytoplasm the pre-shRNA is loaded onto the complex 
containing the RNase III enzyme Dicer and the double-stranded Tat-RNA binding 
protein (TRBP) or the RNA-dependent protein kinase activating protein (PACT) where 
the transcript is processed, removing the loop, to form a double-stranded 
siRNA(341,343,347,348). The Dicer containing complex coordinates loading onto the 
Argonaute (Ago2) protein containing the RISC. The Ago2 protein contains the 
endonuclease activity necessary to cleave and release the passenger strand of the 
double stranded stem(338,349,350). Ago2 protein complex loaded with guide-strand 
siRNA seeks out complimentary target sites in mRNAs where endonucleolytically 
active Ago2 cleaves mRNA to initiate mRNA degradation and post-transcriptional gene 
silencing(332,341). 
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Figure 1.3 Vectors and RNAi construct processing in target cells  
Naked RNAi constructs can be introduced to target cells in forms of siRNA or long dsRNA using 
a variety of transfection protocols such as lipid-based transfection reagents or electroporation, 
or active uptake by target cells through receptor-mediated endocytosis. Once inside the 
cytoplasm, RNAi constructs can be further processed by host endonucleases or directly loaded 
into RISC to facilitate gene expression knock down. Alternatively, RNAi can be introduced using 
viral vectors, such as lentiviral-, adenoviral- or AAV vectors carrying siRNA or shRNA 
expression cassettes. Once transcribed, shRNA can be processed and exported to cell 
cytoplasm for silencing gene expression. Figure used with permission from Professor 
Tripp(351). 
 
Alternative methods for gene silencing include gene-editing technologies using 
programmable nucleases include zinc-finger nucleases (ZFNs), transcription activator-
like effector nucleases (TALENs), and RNA-guided engineered nucleases (RGENs) 
from the type II clustered regularly interspaced short palindromic repeats (CRISPR) 
CRISPR-associated protein 9 (Cas9) system. These methods are now widely used for 
genome editing in higher eukaryotic cells and whole organisms(352,353) and have 
revolutionised almost every discipline in biological research, medicine and 
biotechnology. Each of these nucleases have their advantages and disadvantages, 
including specificity with off-target mutations at sites similar in sequence to on-target 
sites, limiting their utility in many applications including gene or cell therapy(354-356). 
These methods have not been utilised for the work presented in my thesis. 
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1.5.4.1 Clinical application of RNAi 
The first clinical data on RNAi-based therapy was reported in 2005 from a phase I trial 
using siRNA targeting Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1), a 
receptor in the pathway mediating blood vessel growth, for the treatment of age-related 
macular degeneration (AMD)(357). The single intravitreal siRNA dosing was well 
tolerated and resulted in stabilisation or improvement of visual acuity(358). The number 
of RNAi-based pre-clinical and clinical trials have grown over the last few years and 
have included studies focussed on viral infections, respiratory disorders, haemophilia, 
cardiovascular diseases, metabolic diseases and cancer(330,359).   
1.5.5 RNAi in cancer therapy 
The ability of RNAi to silence target genes has stimulated efforts to develop molecules 
for use as therapeutic agents. Cancer cell survival, unlike normal cellular survival, is 
dependent on a limited subset of signalling interactions through mutated or 
dysregulated genes(256,360).  
 
SiRNA and shRNA have been used in high throughput screens for studying gene 
function in mammalian cancer cell lines(361-368). A number of preclinical studies 
targeting genes critical for tumour cell growth, metastasis, angiogenesis and 
chemotherapy resistance have identified key regulators in diverse biological 
pathways(290,359,369-372). Potentially, all identifiable genes can be targeted for gene 
silencing(341,373) however, careful selection of the target gene is critical to 
minimise/circumvent any effects upon healthy tissue. Consequently, for selective 
treatment of tumour cells, RNAi must be selected to target genes specifically involved 
in the growth and survival of the malignant cell. Targeting a driver of the disease may 
have the added benefit of reducing the ability of the tumour cells to acquire resistance. 
An additional strategy to minimise the impact of gene silencing in healthy tissues is to 
achieve targeted delivery and selective expression of shRNA to the tumour 
cells(211,374,375).  
 
The first proof-of-concept study in man utilising systemic siRNA, delivered by targeted 
nano-particles, was undertaken on patients with metastatic melanoma. The predicted 
cleavage product of Ribonucleotide reductase M2 (RRM2) mRNA was detected from 
one patient who received the highest dose of nanoparticles. Therapy was well tolerated 
and no dose-limiting toxicities were observed. The effect on tumour reduction and 
clinical phenotypes were not reported(376). A small number of early phase clinical 
trials using siRNA in cancer have been reported. One: ALN-VSP trial, used lipid 
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nanoparticles (LNP)-formulated siRNA dual targeting VEGF and Kinesin spindle protein 
(KSP), formulated for intravenous administration to patients with solid tumours. A total 
of 41 patients were included: 3 patients showed a partial response or stable disease 
maintained after 19 months of treatment, and one patient with metastatic endometrial 
cancer demonstrated a complete response according to the RECIST criteria. 
Treatment consisting of twice weekly infusions was generally well tolerated. Toxicity 
included dose-dependent pro-inflammatory cytokine induction(377). Another early 
phase trial targeting polo-like kinase 1 (PLK-1), a protein involved in tumour cell 
proliferation, confirmed tolerability and in some cases tumour response(378). In a study 
for patients with Glioblastoma multiforme (GBM) 46 patients received treatment 
delivered as naked RNAi, administered as double stranded RNA, targeting tenascin-C 
mRNA (ATN-RNA). The molecule of ATN-RNA was injected into the postoperative area 
resulting in improvement in progression free and overall survival, supporting site-
specific delivery of therapy to achieve higher effective concentration in the tumour 
bypassing the blood-brain barrier while limiting the potential system exposure to drug 
degradation(379-381). These early phase trials have highlighted the feasibility of 
delivering siRNAs into tumours, demonstrating a good safety profile and an on-target 
effect(377,382). Current early phase cancer trials using RNAi are summarised in Table 
1.3 
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Table 1.3 RNAi-based therapeutics in clinical cancer trials  
LNP (lipid nano-particles), LODER polymer, NP (nano-particles) LNA (locked nucleic acid); BCL-2, B-cell CLL/lymphoma; LMP2, also known as proteasome 
subunit beta type 9 (PSMB9); LMP7, also known as proteasome subunit beta type 8 (PSMB8); MECL1, also known as proteasome subunit beta type 10 
(PSMB10); PKN3, protein kinase N3; PLK1, polo-like kinase 1; RRM2, ribonucleoside-diphosphate reductase subunit M2; VEGF, vascular endothelial growth 
factor, FANG vaccine (GM-CSF, bi-shRNAi targeting Furin convertase with then down regulation of TGF). Table adapted from Sherry Y. Wu 2014 and 
Beverley Davidson 2011(330,359) 
RNAi therapeutics in clinical trials for cancer 
DISEASE TRIAL TARGET CARRIERS TRIAL STATUS AND 
REMARKS 
CLINICAL 
TRIAL ID 
REF 
Solid tumours CALAA-01 RRM2 Cyclodextrin 
NP 
Phase I; terminated; details 
pending. First study using NP 
to target solid tumours 
NCT00689065 (376)  
Solid tumours ALN-VSP2 VEGF/KSP LNP  NCT01158079 (377) 
Neuroendocrine tumours 
Adrenocortical carcinoma 
TKM-PLK1 PLK1 LNP Phase I/II; recruiting NCT01262235 (378) 
Pancreatic cancer SIG12D 
LODER 
KRAS-
G12D 
mutant 
LODER 
polymer 
Phase II; not yet recruiting. 
First to target undruggable 
mutation in cancer 
NCT01676259 (383) 
Advanced, recurrent or 
metastatic solid 
malignancies 
EPHARNA EphA2 LNP Phase I; start March 2015 NCT01591356 (384) 
Metastatic melanoma iPsiRNA LMP2, 
LMP7, 
MECI1 
Ex-vivo 
transfection 
Phase I; completed NCT 00672542 (385) 
Advanced, recurrent or 
metastatic solid 
malignancies 
Atu027 PKN3 LNP Phase I; completed. First 
siRNA trial aimed at inhibiting 
metastasis 
NCT00938574 (386) 
Chronic lymphocytic 
leukaemia 
SPC2296 BCL-2 LNA Phase I/II Not registered (387) 
Advanced, recurrent or 
metastatic solid 
malignancies 
FANG Furin  Autologous 
tumour cell 
vaccine  
Phase II NCT01309230 (388) 
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1.5.6 Factors influencing activity of RNAi-based therapies 
1.5.6.1 siRNA 
There are many challenges to overcome in the process of moving RNAi-based 
therapies from the laboratory to the clinic. The major barrier facing siRNA therapeutics 
is the delivery to the desired cell type, tissue, or organ. siRNAs do not readily pass 
through the cell membrane due to their size and negative charge(359). Post-injection, 
the siRNA complex must navigate the circulatory system of the body avoiding kidney 
filtration, uptake by phagocytes, aggregation with serum proteins and enzymatic 
degradation by endogenous nucleases(389).  Effective delivery also includes 
avoidance of host defence mechanisms(390). siRNA can induce non-specific activation 
of the immune system through the toll-like receptor (TLR) 7/8 pathway(391-393). TLR 
protect the host from pathogens by detecting infectious non-self agents including 
double-stranded RNA. Activation of TLR results in production of interferon and 
inflammatory cytokines, thereby inducing an innate immune response(391,393,394). 
Identification of immune stimulatory motifs have allowed chemical modifications of 
siRNAs thereby inducing minimal immune response(391,395).  
1.5.6.2 shRNA 
An additional limitation of siRNA mediated RNAi is that target repression is transient. 
Although this may be sufficient in some situations, stable integration of shRNA 
expression vectors overcomes this limitation(396). Considerable research into the 
delivery of shRNA and the factors that govern efficacy of shRNA have resulted in the 
development of variations in shRNA design and promoter sequences(364,397,398). 
Appropriate choice of promoter for shRNA transcription is vital for effective vector 
delivered RNAi(399). An additional benefit using shRNA is the ability to control 
expression by the use of inducible promoters, thereby increasing the control over gene 
knockdown studies(400,401). Viral vectors contain potential immune-stimulators, 
including CpG DNA in the plasmid from bacterial DNA or the viral genome. The viral 
protein from viral particles, transferred into targeted cells or tissues, may induce not 
only T cell-mediated immune responses to transduced cells, but also humoral immune 
responses by generating antibodies to viral proteins and transgene products. These 
immune responses against vectors, transgene products and transduced cells can lead 
to transient expression of the therapeutic genes and re-administration inhibition of the 
recombinant vectors(231,402-404).  
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1.5.6.3 Toxicity of RNAi 
Specificity of RNAi and careful selection of targets also needs to be considered for 
development of a therapy for cancer. RNAi techniques were initially believed to be 
highly specific, however several studies have shown that RNAi can cause silencing of 
other genes in addition to the gene intended(405,406). ‘Off target’ activity can 
complicate interpretation of phenotypic effects in gene-silencing experiments and can 
potentially lead to unexpected toxicity(407). Much effort has been put into the design of 
shRNAs to increase specificity and reduce off-target effects(408-411). Another factor to 
consider regarding safety and specificity of RNAi is the level of shRNA expression. 
Dose dependent liver toxicity and fatality was observed in mice transduced with 
AAV/shRNA(412). Cytotoxicity was thought to be due to saturation of the endogenous 
miRNA pathways as a result of high levels of exogenous siRNA and shRNA(412-414). 
More recently, the cellular toxicity of shRNAs in the nervous systems of animals 
injected with AAV vectors has been described - in particular, high-level expression of 
shRNAs in the dorsal root ganglia of rats(415) and in mouse striatum(416). Numerous 
factors influencing activity have been identified, including the loop sequence, 
thermodynamic properties of the hairpin, secondary structure, and the surrounding 
sequences(396). By altering the design of the shRNA structure toxicity can be reduced 
without compromising targeted gene silencing(414,417,418).  
1.6 Vectors for gene therapy 
The success of RNAi therapeutics relies heavily on the ability to deliver the RNAi in an 
efficient and safe manner to the intended target cells. Delivery systems can be 
categorised into physical methods, conjugation methods (transfection), natural carrier 
(viruses and bacteria) and non-viral carrier methods(419-421). Non-viral delivery 
vectors can be classified as organic systems such as lipid complexes and conjugated 
polymers, and inorganic systems such as magnetic nanoparticles and gold 
nanoparticles(422,423).  
1.6.1  Nano-particles 
Nano-medicine is an emerging multi-disciplinary field exploring avenues for cancer 
detection and therapy, with more than 30 nano-carries currently approved for clinical 
use(424). Nanocarrier-based approaches include a carrier, a targeting moiety that is 
bound to the carrier via specific conjugation chemistry, and a therapeutic effector such 
as chemotherapy compound or RNAi. Carriers may be composed of lipids, polymeric 
nanoparticles, or inorganic nanoparticles. Targeting moieties conjugated to the carrier 
include either include high affinity ligands, antibodies or nucleic acids(424).  
Targeted therapy for chordoma   
 63 
 
Nanoparticles have been investigated extensively for siRNA delivery(389,425). Current 
delivery approaches of siRNAs include the use of stable nucleic acid lipid particles 
(SNALP), applied as liposomes, or LNP. The LNPs are uniform lipid bilayers or solid 
cores which can entrap various cytotoxic drugs: hydrophilic drugs will be trapped in the 
aqueous region while a lipophilic drug will be captured in the lipid leaflets(424). The 
combination of LNPs and siRNAs have been applied successfully in studies for gene-
silencing in tumors and viral infections(369,376,426-428)  and utilised in early phase 
clinical trials(330,377,429,430) (Table 1.3) These studies indicate nanoparticles are 
well tolerated when administered systemically by intra-venous, or intra-peritoneal 
injection or by intranasal route, and have demonstrated effective uptake into tumour 
cells(376,424).  
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1.6.2 Viral vectors for gene therapy 
Viruses have evolved over millions of years to infect human cells efficiently, resulting in 
the transfer of their genetic material into the host cell as part of their replication 
process. These systems have been exploited in the development of viral-mediated 
gene therapy, replacing the pathogenic sequences from the viral genome with a DNA 
sequence of therapeutic interest. Currently several classes of viral vector are under 
investigation in the development of gene therapy for clinical use, including retroviruses 
and lentiviruses (both members of the Retroviridae family), adenoviruses, AAV and 
HSV (Figure 1.4). The choice of vector depends largely on the application. Desirable 
properties such as high titre production, efficient delivery, transgene expression, cell 
specificity and toxicity vary between viral vectors.  A comparison of vectors can be 
found in Table 1.4.  
 
 
Figure 1.4 Vectors used for gene therapy  
Overview of different gene transfer vectors used in clinical trials. Source: The Journal of Gene 
Medicine, Wiley and Sons (http://www.abedia.com/wiley/index.html).  13 of 89 trials utilised in 
vivo therapy. Database accessed April 2015. 
 
23% 
19% 
18% 
7% 
6% 
5% 
5% 
4% 
3% 
7% 
3% Adenovirus (488) 
Retrovirus (409) 
Naked/Plasmid DNA (379) 
vaccinia virus (162) 
Adeno-associated virus (117) 
Lipofection (113) 
Poxvirus (100) 
Lentivirus (89) 
Herpes simples virus (63) 
Other vectors (150) 
Unknown (71) 
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Table 1.4 Properties of commonly used viral vectors 
Adapted from Bouard et al. and Thomas et al. 2003. (431,432) and www.abedia.com.Wiley/vectors  
AAV, Adeno-associated virus; dsDNA, double stranded DNA; ssDNA single stranded DNA 
Vector Genetic 
material 
Transgene 
capacity 
Tropism Vector 
genome 
forms  
Length of 
transgene 
expression 
Main limitations Main advantages Use in 
clinical trials 
to date 
Retrovirus RNA ~9Kb Broad 
Dividing 
cells only 
Integrated Long term Only transduces 
dividing cells; 
Integration may 
induce 
oncogenesis 
Persistent gene 
transfer in 
dividing cells 
20.3% 
(362) 
Lentivirus RNA ~10Kb Broad Integrated Long term Integration might 
induce 
oncogenesis 
Persistent gene 
transfer in most 
tissue 
3.3% 
(67) 
Herpes virus 
(HSV-1) 
dsDNA >30Kb Broad, 
strong for 
neurons 
Episomal Transient  Inflammatory; 
transient gene 
expression in cells 
other than neurons 
Large packaging 
capacity; strong 
tropism for neurons 
3.1% 
(62) 
Adenovirus dsDNA ~30Kb Broad  Episomal Short term 
(weeks) 
Capsid mediates a 
potent 
inflammatory 
response 
Extremely efficient 
transduction of 
most tissue 
23.5% 
(476) 
AAV ssDNA <5Kb Broad >90% 
episomal 
<10% 
integrated 
Medium to 
long term 
(years) 
Small packaging 
capacity 
Non-inflammatory; 
non-pathogenic 
5.2% 
(105) 
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1.6.2.1 Integrating and non-integrating vectors 
The main aim of gene therapy for genetic disease is to provide long-term therapeutic 
levels of gene transfer, to ameliorate or cure the clinical phenotype of the disease. The 
approach taken to achieve persistent expression of the therapeutic gene is often 
dependent upon the target cell. In cells that undergo regular division, integrating 
vectors, such as retrovirus or lentivirus, are necessary. Integration of the therapeutic 
gene into the host cell genome ensures it is copied during each mitotic event, providing 
stable, persistent expression of the therapeutic gene within the target cell population. In 
long-lived post-mitotic cells such as skeletal muscle(238), cardiac muscle(423,433),  
central nervous system(434) and liver cells(435), cell proliferation/turnover is minimal 
and the use of an integrating vector is less important. Consequently, non-integrating 
vectors such as AAV are commonly used to transduce such tissues as they ensure 
sufficient levels of gene expression whilst precluding the safety concerns associated 
with insertional mutagenesis(436). Lentiviral vectors have most frequently been used 
for gene transfer ex vivo in haematopoietic stem cells. In contrast AAV has, in the 
majority of trials, been used for in vivo transduction of post-mitotic cells(211). AAV has 
however also been used for the treatment of solid tumours in early phase clinical trials, 
underpinning the choice for using this vector for delivery of RNAi in chordoma, as 
reported in this thesis. 
1.6.3 Adeno-associated viral vector 
Vectors based on AAV are currently showing exceptional promise for gene therapy in 
the clinic(235,243,437). These vectors present an attractive gene therapy tool due to 
lack of pathogenicity and toxicity associated with wild type virus. More than 70% of 
adults are sero-positive for antibodies for one or more AAV serotypes(438), yet 
infection has not been associated with any symptoms or disease(439). AAV vectors 
are able to infect dividing and non-dividing cells of various tissue origins, thereby 
allowing efficient targeting of post-mitotic tissues while eliciting a low host immune 
response(439-441). The use of Recombinant AAV (rAAV) vectors in clinical trials 
started in the mid-1990s and present a proven safety profile with over 300 subjects 
enrolled in studies without any serious adverse events(437,441,442).  
1.6.3.1 Adeno-associated virus biology 
AAV was discovered in 1965 as a contaminant of adenovirus preparation(443). AAV is 
a non-enveloped virus with an icosahedral capsid of approximately 22nm which 
surrounds a single stranded DNA (ssDNA) genome of 4.7kb(444). Belonging to the 
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Parvoviridae family, AAV is classed as a Dependovirus as it requires a helper virus, 
such as adenovirus or herpes virus(445), to complete its replicative cycle(446,447). In 
the absence of a helper virus AAV establishes a latent infection within the cells, either 
by site-specific integration into the host genome(448-450) or by persisting in episomal 
form(451). 
 
The AAV genome consists of a 145 nucleotide-long inverted terminal repeats (ITRs) 
that, due to the multipalindromic nature of its terminal 125 bases, can fold on itself and 
form a characteristic T-shaped hairpin structure(452) (Figure 1.5) The virus does not 
encode a polymerase but relies on host cell polymerase for DNA replication(453). The 
ITRs flank the two viral genes rep (replication) and cap (capsid). The rep gene encodes 
four regulatory proteins required for replication: Rep 78, Rep 68, Rep 52, and Rep 40. 
The two larger proteins (Rep 78 and Rep 68) are required for AAV DNA 
replication(454,455). The two smaller Rep proteins (Rep52 and Rep40) are required for 
packaging DNA into capsids(456). The cap gene encodes three structural proteins: 
VP1 (68kDa), VP2 (72kDa) and VP3 (62kDa), which interact together to form a capsid 
of an icosahedral structure(457). The capsid proteins VP1, VP2, VP3 are present in a 
1:1:10 molar ratio. VP3, the most abundant subunit in the virion, is used for receptor 
recognition at the surface of cells, defining the tropism of AAV(458). The three proteins 
VP1, VP2, and VP3 share a common C-terminal region, but have different N-termini 
resulting from alternative start codon usage. As a result the entire sequence of VP3 is 
present in VP2, which in turn is entirely contained within VP1. Differences in the protein 
structures lead to differences in topology which defines the different 
serotypes(444,459), and are instrumental for virus infectivity, cellular tropism and 
genome packaging(460,461). Recently, a non-structural viral protein encoded by an 
alternative open reading frame (ORF) within the cap gene was identified and termed 
assembly-activating protein (AAP) for its role in capsid formation(462-464). There are 
three viral promoters within the viral genome: promoter 5 (p5), promoter 19 (p19), and 
promoter 40 (p40). The rep gene is transcribed from p5 and p19, whereas the cap 
gene is prescribed from p40(465) (Figure 1.5).  
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Figure 1.5 AAV genetic map 
The ∼5-kb AAV genome contains the rep and cap genes. Asterisk* indicates a weak CTG start 
codon for AAP. Also shown are the 145-base (not to scale) T-shaped AAV inverted terminal 
repeats (ITRs). Adapted from Jude Samulski et al. 2014(439). 
 
1.6.3.2 Recombinant AAV vectors 
The rAAV vectors are generated by replacing the AAV genome with the gene of 
interest, leaving no viral coding sequences except the viral ITRs. The ITRs contain all 
the cis-acting elements required for genome rescue, replication and 
packaging(466,467). All other viral sequences required for viral production are supplied 
in trans(468). The recombinant single stranded AAV relies on de novo synthesis of the 
complementary DNA strand, or base pairing of complementary strands. This is 
possible as AAV packages the plus or minus DNA strand with equal 
efficiency(469,470). The ITRs serve as primers for cellular DNA polymerase to 
synthesise the complementary strand after uncoating in the host cell(471). The 
requirement for complementary-strand synthesis, or recruitment for self annealing, is 
considered to be a limiting factor in the efficiency of rAAV vectors(472).   
1.6.3.3 Self-complementary AAV vector 
To avoid the rate-limiting step of second strand synthesis self-complementary vectors 
have been developed. Self-complementary AAV (scAAV) vectors allow the vector to 
package two complementary ssDNA strands, with the ability to fold to generate dsDNA 
thus circumventing the need for second strand synthesis(471). A deletion in the 
terminal resolution site of one of the ITRs allows replication to continue through the ITR 
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into the displaced strand generating the dsDNA template. The self-complementary 
form can promote faster onset and higher levels of transgene expression, however 
packaging capacity is reduced by half(471,473-475). 
1.6.3.4 AAV serotypes and tissue tropism  
Most of the rAAV characterisation studies have been performed using vectors of capsid 
serotype 2. A key finding in the development of rAAV as a gene therapy vector was the 
identification that vector genome containing ITRs of one serotype could be “cross-
packaged” or pseudo-serotyped into the capsid of another serotype(476). Currently 
there are approximately twelve human serotypes of AAV and more than 100 variant 
capsid sequences. The identification of novel capsids and the ability to pseudo-
serotype has dramatically expanded the potential of rAAV as a gene transfer vector. 
Each serotype has a distinct tissue tropism and receptor binding specificity (Table 1.5). 
Different serotypes exhibit variation in their immunologic profile(459,477-479). Specific 
gene delivery to the desired target cell type is key to gene therapy success. Targeted 
delivery has the potential to prevent adverse effects that may arise from off-targeting, 
allow reduction in therapeutic dose, and increase gene transfer efficiency(459,480-
483). In vitro studies have demonstrated different cancer cell lines to be permissive to 
different serotypes of AAV(484)  and evaluation of tissue tropism and bio-distribution of 
AAV serotypes have been characterised in pre-clinical animal models, unraveling 
vectors’ suitability for specific clinical applications(482) (Table 1.6). 
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Table 1.5 Receptors for common AAV serotypes 
Capsid 
Serotype 
Primary 
receptor Co-receptor References 
1 Sialic acid - (486) 
2 Heparan 
sulphate 
Proteoglycan 
(HSPG) 
Fibroblast growth factor 
receptor (FGFR), Hepatocyte 
growth factor receptor 
(HGFR), Laminin receptor 
(LamR), αVβ5 and αVβ1 
integrin 
(476,487,488) 
3 HSPG HGFR, LamR (476,488) 
4 Sialic acid -  (486,489) 
5 Sialic acid Platelet derived growth factor 
receptor 
(490,491) 
6 Sialic 
acid/HSPG 
EGFR  (476,492) 
7 - -  
8 - LamR  (488) 
9 Galactose LamR (488,493) 
Rh10 - -   
 
 
 
Table 1.6 AAV serotype and tissue tropism 
 
AAV1 Skeletal muscle, CNS, pancreas 
AAV2 Skeletal muscle, CNS, liver, kidney 
AAV3 Skeletal muscle 
AAV4 CNS, retina 
AAV5 Skeletal muscle, CNS, eye,  
AAV6 Skeletal muscle, heart, lung, liver 
AAV7 Skeletal muscle, CNS, retina 
AAV8 Skeletal muscle, liver, heart, pancreas 
AAV9 Skeletal muscle, liver, heart, CNS, lung, kidney 
AAV10 Heart, lung, liver, kidney, uterus 
AAV11 Skeletal muscle, liver, kidney, heart 
AAV12 Muscle, saliva glands 
Adapted from Wu et al. (459), Asokan et al. (485) and Luo et al. (251). 
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1.6.3.5 Cellular processing of AAV vector 
Transduction by AAV is a multistep process beginning with the virus binding to the cell 
surface, followed by viral uptake, intracellular trafficking, nuclear localisation, uncoating 
and second strand DNA synthesis. Most knowledge about this process is based on 
AAV2 transduction. After binding to its receptor, heparan sulfate proteoglycan(487) 
AAV2 is rapidly endocytosed via clathrin-coated pits(494). More than 60% of bound 
virus is internalised within the first 10 minutes of incubation at 370C. Following release 
into the cytosol, AAV accumulates in the peri-nuclear region and slowly penetrates 
through the nuclear membrane. The events and processes that regulate the trafficking 
of AAV particles into the nucleus are still not fully understood(457). Once in the nucleus 
the uncoated ssDNA from rAAV must become transcriptionally active by conversion to 
dsDNA. This occurs, as previously mentioned, by either second strand synthesis or 
annealing of complementary strands. Transgene expression can be detected within 3-4 
hours post transduction(494). 
 
Genomic studies of rAAV in vivo have shown that rAAV DNA molecules in non-dividing 
cells in the muscle, liver, heart, brain and lung are converted to circular constructs and 
persist predominantly as extra-chromosomal episomes, containing multiple copies of 
the transgene cassette, usually in a head-to-tail configuration(495-501). Stable 
transgene expression mediated by rAAV vectors without integration can persist for 
months and up to several years in vivo(235,502-506). However in dividing cells, AAV 
DNA is lost through cell division, as episomal DNA is not replicated along with the host 
cell DNA(451,507,508). It has been shown that one or two cell divisions can result in 
the loss of 90-95% of rAAV genomes(495).  
1.6.3.6 AAV Immunogenicity  
Immunogenicity of rAAV is very low, yet, in mice, it elicits a mild, innate immune 
response due to activation of Toll-like receptor 9 (TLR9), when rAAV infects APC(509). 
Activation of the TLR9 pathway induces the production of pro-inflammatory cytokines 
by activating the NF-κB pathway and inducing type I interferon response. This 
generates a CTL response, which activates B-cell lymphocyte, thereby stimulating 
production of neutralising antibodies (NAb)(510). In humans the immune response 
appears to be restricted to the generation of NAb as no clearly defined cytotoxic 
response has been identified(235,511-514). The generated immune response can be 
directed against the AAV vector component, the transgene product, or both, by pre-
existing and/or recall responses to the wild-type virus from which the vector is 
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engineered(436). This response can dramatically interfere with therapeutic efficacy.   
Humoral immunity to wild-type AAV represents one of the most effective barriers to 
successful systemic gene delivery with AAV vectors. In the first clinical trial for 
haemophilia B, using an AAV2 vector delivered systemically, NAb titers were 
measured in recipients but were not used to exclude subjects from the trial, as it was 
unclear what level of titers would affect transduction. The study showed that relatively 
low NAb titers completely neutralised the vector(515). In a subsequent clinical trial for 
haemophilia B, utilising an AAV8 vector with a liver specific promoter, a transient 
elevation of capsid specific CTL was observed and was associated with liver toxicity. A 
short course of glucocorticoid therapy resolved the immune response without loss of 
transgene expression(235).   
 
Animal models have predicted many aspects of the human immune response to 
transgene products, but have largely failed to predict responses to AAV capsids(516-
520). The immune responses against AAV vectors can shorten or even prevent 
transgene expression, which is a major concern for the treatment of disease in which 
life-long gene expression is required(436,521-523). Switching serotype to one less 
prevalent in the human population, or inducing immunosuppression, are utilised to 
overcome these problems(235,404,515,524). However, a high degree of conservation 
in the amino acid sequence among AAV capsids(525) causes anti-AAV antibodies to 
have cross-reactivity over a wide range of serotypes(526-529). Strategies to map 
neutralising antibody epitopes on the serotypes are currently being explored for pre-
clinical and clinical trials(479,529,530). 
 
AAV2 is a common virus in the human population and most people have detectable 
antibodies against one or more AAV serotypes(438,531,532). Characterisation of the 
IgG subclass response to AAV, and the prevalence of both IgG and NAb to AAV 
serotypes 1, 2, 5, 6, 8, and 9 in the human population, revealed that the highest sero-
prevalence neutralising factors were observed for AAV2 (59%) and AAV1 (50.5%). The 
lowest were observed for AAV8 (19%) and AAV5 (3.2%)(480). AAV4 and AAV5 are the 
most divergent, carrying one of the least conserved capsid sequences(533). 
1.6.3.7 AAV integration and genotoxicity 
Wild-type AAV has the ability to integrate stably into the host cell genome at a specific 
site on the human chromosome 19q13.3(449,450,534).   Site-specific integration is 
mediated by AAV Rep proteins, which are absent from recombinant AAV vectors. 
Integration of rAAV DNA into the host genome occurs at a low but measurable rate 
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(0.1-1% of transduction events). The integration has not been found to be 
chromosome- or site-specific, though it has been shown that rAAV proviral genome 
preferentially integrates within or near transcriptionally active genes and double-
stranded breaks(535-540). Latent AAV infection is common in the human population 
and yet AAV has never been associated with any human malignancy(532).   
 
The safety of AAV as a vector has been challenged by a single study documenting the 
development of hepatocellular carcinoma (HCC) after AAV gene delivery in mice. This 
study was undertaken in a mouse (C3H/HeJ) liver model, prone to hepatocyte tumour 
formation, and HCC developed following exposure to a self-complementary AAV 
vector. This was not reproduced in the severe combined immune-deficient (SCID) 
mice(541). In a recent study in neonates (mice) a dose-dependent increase in HCC 
was observed, and this appeared to be independent of murine genotype or viral 
transgene. Factors that seem to influence HCC incidence were vector dose, promoter 
selection and timing of gene transfer. In addition AAV integration into the site of RNA 
Imprinted and Accumulated in Nucleus (Rian) locus was associated with an increased 
incidence of HCC(542). Tumour development has also been reported in a knockout 
mouse model, following liver transduction with single-stranded rAAV expressing β-
glucuronidase. Correlation between integration of rAAV and the development of 
tumours was not observed(543,544). Two studies, one where expression of the LacZ 
transgene was associated with an increased incidence of tumour development(545), 
and another where overexpression of Tcf12, produced glioblastoma-like proliferation at 
the site of injection in rat brains(546), suggest that overexpression of a gene may lead 
to tumour formation even if the rAAV vector genome does not integrate. Most studies 
have not shown an increased incidence of liver tumours following exposure to 
AAV(547,548). The importance of this small number of studies is still uncertain, as the 
tumour formation has only been observed in small rodents. However, the risk of 
inducing tumours in man can not be excluded and each gene cassette may have to be 
monitored separately for potential oncogenic effects(439,542).  
1.6.3.8 AAV in clinical trials for cancer gene therapy 
AAV vectors have been successfully used to deliver and transfer a variety of 
therapeutic genes to cancer cells, including suicide genes, anti-angiogenic genes and 
immune-related genes, inhibiting tumour growth and metastasis(251). Preclinical use of 
AAV in xenograft cancer models has shown promising effect, in particular using AAV 
based immune gene therapy(549-558). There are currently 16 phase I-III clinical trials 
open, utilising an AAV vector for cancer therapy (Table 1.7). Preliminary data from 
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early phase clinical trials has shown tolerability and no severe adverse reaction. One 
trial involved AAV-based immunotherapy, with rAAV transduced dendritic cells (DCs), 
for expression of cancer embryonic antigen (CEA) to elicit CTL in patients with 
advanced stage IV gastric cancer(559).  Other examples include the GVAX cancer 
vaccine-study with autologous or allogeneic tumour cells engineered by AAV (ex vivo) 
mediated gene transfer to secrete GM-CSF. The GVAX vaccine initiates a potent CTL 
response, thereby generating a pool of T-cells capable of recognising the tumour. The 
vaccine has been used for targeting various malignant solid tumours such as pancreas, 
prostate, melanoma and non-small lung cell carcinoma(560-565)  
www.wiley.co.uk/genetherapy/clinical. 
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Table 1.7 Gene therapy trials in cancer therapy utilising AAV vector 
Trial ID AAV vectors used in Cancer Gene therapy 
CH-0025 Gene therapy for patients with malignant melanoma. AAV/GM-CSF (IT) 
CN-0020 
Adoptive T cell treatment of CTL generated from autologous dendritic cells 
transfected with rAAV virus containing tumour antigen gene 
CN-0028 
Phase I Study of Antigen-specific CTL Induced by Dendritic Cells Infected 
by rAAV with CEA Gene in Stage IV Gastric Cancer 
ES-0021 
A phase I, multi centre, open label, dose escalation study of intra-tumoural 
injection of VCN 01 oncolytic adenovirus in combination with intravenous 
gemcitabine in advanced pancreatic cancer 
JP-0014 
Phase I/II clinical trial of gene therapy for hormone refractory metastatic 
prostate cancer. IT injection of AAV/HSV-tk 
NL-0012 
GVAX immunotherapy in combination with Ipilimumab (MDX-010) in 
Hormone Refractory Prostate Cancer 
NL-0013 
Phase III studies in advanced metastatic prostate cancer patients using 
immunotherapy with an allogeneic prostate tumour cell vaccine, stably 
transduced with the human GM-CSF gene by non-pathogenic, replication 
defective, recombinant adeno-associated viral vector. 
NL-0014 
A Phase III Randomized, Open-Label Study of CG1940/CG8711 Versus 
Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory 
Prostate Cancer who are Chemotherapy-naïve (GM-CSF) 
NL-0015 
A Phase III Randomized, Open-Label Study of Docetaxel in Combination 
with CG1940/CG8711 versus Docetaxel and Prednisone in Taxane-Naive 
Patients with Metastatic Hormone-Refractory Prostate Cancer with Pain 
(GM-CSF) 
NL-016 
A Phase 1 Dose Escalation Trial of MDX-010 in Combination with CG1940 
and CG8711 in Patients with Metastatic Hormone-Refractory Prostate 
Cancer (GM-CSF) 
NL-0021 
Adjuvant IL-12 immunotherapy prior to radical prostatectomy in patients with 
prostate cancer  
UK-0133 
A Phase III Randomized, Open-Label Study of Docetaxel in Combination 
with CG1940 and CG8711 versus Docetaxel and Prednisone in Taxane-
Naive Patients with Metastatic Hormone-Refractory Prostate Cancer 
EudraCT: 2005-003275-20 (GM-CSF) 
UK-0134 
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus 
Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory 
Prostate Cancer who are Chemotherapy-Naive.EudraCT: 2005-002738-36 
US-0675 
Development of Effective Immunotherapy for Prostate Cancer Patients: 
Phase I/II Study of Human GM-CSF Gene Transduced Irradiated Prostate 
Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX) in Advanced 
Prostate Cancer Patients lympho-depleted by Chemotherapy and Infused 
with Autologous Peripheral Blood Mononuclear Cells 
US-0834 
Administration of LMP1- and LMP2-Specific CTL to Patients with EBV-
Positive Nasopharyngeal Carcinoma 
US-1165 
A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy 
Combined with a GM-CSF Secreting Allogeneic Prostate Cancer Vaccine 
and Low-dose Cyclophosphamide in Men with High-risk Localised Prostate 
Cancer Undergoing Radical Prostatectomy 
CG1940 and CG8711 represent two prostate cancer cell lines (GVAX). IT: Intratumoral. LPM1 
and LPM2: Latent membrane proteins encoded by EBV involved in pathogenesis for EBV(566-
568). EudraCT: European Medicines Agency Clinical trials Database.  Table adapted from data 
from www.wiley.co.uk/genetherapy/clinical (Accessed October 2015). 
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1.7 Pre-clinical models  
Drug discovery and development for anti-cancer compounds is an inexact and 
inefficient process, as a large proportion of drugs entering preclinical testing fail to 
achieve FDA approval since a majority of phase III trials fail to meet their primary 
endpoint(569,570). The lack of preclinical models that closely recapitulate the 
heterogeneity of human tumours, with predictive value for therapeutic evaluation, 
represents one of the main reasons for the failure of successful development of new 
agents in oncology(571). This has been true for chordoma, as well as other cancers. 
However, through sheer determination by researchers and patients, an increasing 
number of cell lines for preclinical studies are being generated. 
1.7.1 Human cancer cell lines 
Since 1952 when the first human cell line HeLa was established(572,573) there has 
been an increase in the use of human cell lines as models for human diseases, 
particularly in cancer.  Human cancer cell lines are widely used in in vitro models for 
studying cancer and its biology, including regulation of cell proliferation and gene 
expression(574,575). They have also proven a valuable tool for identifying biomarkers 
and genetic variants(576). Genome sciences, combined with bioinformatics, have 
allowed dissection of the genetic basis of diseases and from this identified the most 
suitable points of attack for future medicines(574,577). An example of this is the 
discovery of the somatic missense mutation (V600E) in the BRAF gene in multiple 
cancer cell lines(578). This discovery subsequently led to the development of 
Vemurafenib (PLX4032), a potent inhibitor of mutated BRAF(579,580) with antitumor 
effect against melanoma cell lines harbouring the BRAF V600E mutation, but not 
against cell lines with wild-type BRAF. The introduction of Vemurafenib has led to 
prolonged event-free and overall survival for patients with metastatic malignant 
melanoma(581). Cancer cell lines play a pivotal role in the early stages of drug 
discovery(582), facilitating screening of hundreds of potential drugs before translating 
into in vivo models and clinical trials(583). High-throughput screening of cancer cell 
lines for drug-sensitivity patterns provides a strategy to identify appropriate cancer 
subtypes and biomarkers that may guide the early-phase clinical trials of novel 
compounds(574). However the use of tumour-derived cell lines grown in two-
dimensional culture has its limitations. Experimental models are needed that resemble 
the tumour microenvironment to increase our understanding of drug 
sensitivity(566,568). For this purpose various 3D culture models have been developed 
to simulate the growth environment taking into account the spatial organisation of the 
cells mimicking the native tissue(566,584,585). 
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1.7.2 Mouse models 
Numerous mouse models have been developed to study human cancer; the pattern of 
invasion, metastasis and malignant transformation, as well as the response to anti-
cancer therapy(586). The predictive value of tumour models relies on how closely they 
recapitulate the underlying genetic aberrations, tumour growth and metastatic potential 
as well as the surrounding neoplastic stromal and immune microenvironment(256,587).  
 
The most widely used model is the human tumour-derived xenograft. Tumour can be 
generated following intravenous injection, or by subcutaneous, intra-peritoneal and 
orthotopic inoculation, using immune-deficient mice such as the athymic nude mouse 
or the SCID mouse(588,589). The lack of a functional immune system in mice appears 
to play an important role in the success of xenograft formation.  However such models 
are compromised by this lack of immunity as it prevents the interactions between the 
tumour and the endogenous immune system. This is a particular limitation for the use 
of xenograft models in assessing efficacy of immunotherapies(568,590). 
 
Tumours generated in vivo using cell lines established in vitro often lack the distinct 
histological features characteristic of tumours seen in patients, but instead appear 
more homogeneous due to the clonal selection of cells grown in culture(568,591). 
Patient-derived xenograft (PDX) models, where patient tumour is transplanted into 
immunodeficient mice, often retain the principal histologic and genetic characteristics of 
patients’ tumours.  They are biologically stable, in terms of global gene-expression 
patterns, mutational status, metastatic potential and drug responsiveness, across 
passages(589,592). The intratumoral heterogeneity, including genetic and non-genetic 
mechanisms, refers to biological differences amongst malignant cells originated within 
the same tumour. Through accumulated genetic changes several cellular subclones 
with significant biological differences can be identified(593). Different cancer cell clones 
display distinct behaviour and may contribute to the phenotypic variability of tumour 
cells(594). Clonal diversities have been found to correlate between the patient and the 
PDX(590,594-596). These models have been shown to be predictive of clinical 
outcomes and are being used for preclinical drug evaluation, biomarker identification, 
biologic studies, and personalised medicine strategies(597-600). The xenografts 
generated from patient-derived tumours may however not fully represent the inter-
tumour heterogeneity as the tumours which are able to engraft and generate a 
xenograft have been shown to be biased towards the more aggressive tumours(590).  
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The genetically engineered mouse (GEM) model represents another method for 
studying human cancer and plays an increasingly important role in the development of 
novel therapeutics targeted at specific oncogenes and signalling pathways(601,602). In 
these mice the genetic profile has been changed by mutation of cancer genes in order 
to observe tumour development and response to therapy related to specific 
mutations(586). One of the benefits of using this model is the opportunity to observe 
the influence of the tumour microenvironment as immunocompetent mice can be 
used(603). Some of the weaknesses with the GEM model is that the tumour is a 
mouse tumour rather than a human tumour and that there is a limited number of target 
or mutated genes, which is not usually reflective of the complex heterogeneity of 
particularly adult human tumour cells(586,604,605). In contrast, transformation in many 
paediatric cancers is initiated by comparably few “driver” mutations that occur during a 
short window of programmed differentiation(602,606,607), providing an opportunity to 
develop GEM models to enhance the understanding of tumour development and 
improve therapy for some childhood cancers(601). 
1.7.3 Chordoma preclinical models 
The first chordoma cell line, U-CH1, was established in 2001(134) from a locally 
recurrent sacral chordoma. This was the only chordoma cell line until 2010 since when 
~6 more cell lines have been established and characterised, which are available 
through the Chordoma Foundation and/or the American Type Culture Collection 
(ATCC). The first chordoma xenograft was generated following subcutaneous injection 
of U-CH1 cells in the NOD/SCID/interleukin 2 receptor [IL2r]γ null (NSG) mouse after 
10 weeks. No xenografts were generated in CD1 mice(89). UCH2 and JHC7 cell lines 
have since been used to generate a xenograft in NSG mice. The xenograft histology 
resembled chordoma in all cases(89,91,608). In 2012 the first successful PDX in an 
athymic nude mouse was reported, derived from a recurrent clival chordoma. Genomic 
analysis confirmed that the xenograft was more than 99% genetically identical to the 
primary tumour(609). This PDX was treated with the EGFR inhibitor Erlotinib(178) 
which  reduced tumour growth and phosphorylation of EGFR, demonstrating an on-
target effect(178). A second study reported successful engraftment by 4 of 8 sacral 
chordomas in CD-1nu/nu mice. One PDX expressed EGFR and was treated with the 
EGFR inhibitor, Lapatinib. No reduction in tumour growth was observed, though MRI 
imaging showed a change in contrast enhancement and biochemical analysis 
demonstrated switching off of EGFR, AKT and MEK 1/2(610). Of note is a phase II 
study testing Lapatinib in advanced chordoma that showed only a slight effect(179).  
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This decrease in growth rate often viewed as positive in mouse xenograft may not 
register in standard clinical testing. RECIST criteria for evaluating efficacy in human 
clinical trials require >50% tumour reduction in two planes to be considered a 
response(170). Different methods for assessing tumour response to target therapies 
are being investigated as changes may be non-dimensional requiring functional 
imaging to assess tumour response(611-613). A consensus is being compiled for how 
to best validate response of chordoma to therapy, as overall survival is not an ideal 
endpoint due to slow disease progression, and to date no reliable tumour biomarker 
has been identified for chordoma. Consequently other measures such as clinical 
benefit, shrinkage or arrested disease progression may be used as surrogate markers 
for disease response (http://www.chordomafoundation.org/latest-updates/clinical-trials-
roundtable-clarifies-path-get-drugs-approved-chordoma). 
1.8 Biomarkers and response assessment 
With cancer treatment moving towards personalised targeted therapy, it is becoming 
increasingly important to have biomarkers tracking tumour dynamics in real time for 
monitoring treatment response and early detection of disease progression or 
recurrence. Sampling of tumour tissue has its limitations due to the invasiveness of the 
procedure, and the tissue represents a single snapshot in time of the molecular profile 
of the tumour. Many cancers continue to be treated according to histology, 
immunohistochemistry and tissue origin of the primary tumour and, to a lesser extent, 
according to molecular markers. The importance of interpatient tumour genetic 
heterogeneity and intratumour genetic heterogeneity is recognised(614,615), and 
poses a challenge to personalised cancer treatment, as a single biopsy or surgical 
excision of the primary tumour is unlikely to capture the complete genomic landscape 
of a patient’s cancer(616). 
1.8.1 Cell-free DNA  
A new generation of biomarkers has become available with the discovery of genetic 
alterations in solid tumours and the detection of cancer specific cell-free DNA (cfDNA) 
in the blood of cancer patients(617,618).  
 
The most successful application for the utility of evaluating cfDNA has been the 
investigating of fetal DNA in the circulation of expectant mothers(619,620). Detection of 
fetal DNA by a maternal blood test for trisomy 13, 18 and 21 has become standard 
care(621,622). 
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Fragmented cfDNA deriving from tumours, also known as circulating tumour DNA 
(ctDNA), is shed into the bloodstream by cells undergoing apoptosis or necrosis(623). 
Necrotic and apoptotic cells are usually phagocytosed by macrophages or other 
scavenger cells(624). The proportion of ctDNA detectable in blood is influenced by 
clearance, degradation and other physiological filtering events of the blood and 
lymphatic circulation. Nucleic acid is cleared from the blood by the liver and kidney(s) 
and has a half-life in the circulation ranging from 15 minutes to several hours(625). 
Healthy patients have cfDNA concentration between 0 and 100ng/mL, cancer patients 
by comparison, have increased levels of cfDNA(625-632), with levels reported up to 
1200ng/mL(632,633). The quantity of ctDNA can vary between 0.01% to more than 
90% of the overall circulating DNA(618). The proportion of ctDNA has been found to be 
related to tumour burden and prognosis(634-636).  
1.8.1.1 Detection of ctDNA 
Discriminating ctDNA from normal cfDNA has been challenging due to issues with 
sensitivity and specificity. However, with increasing ability to detect single base-pair 
mutations present only in the genome of the cancer cells, specificity of ctDNA as a 
biomarker has been confirmed(623). Early efforts at detecting ctDNA focused on the 
application of allele-specific real-time quantitative polymerase chain reaction (RT 
qPCR) assays(623). The assays, which utilised TaqMan technology, were limited in 
their applicability to patients with high tumour burden due to their analytical sensitivity 
and specificity. Within the past decade, several methods have been developed 
allowing for ultrasensitive detection of ctDNA. These methods fall into two categories; 
next generation sequencing (NGS)(637-639), and digital PCR (dPCR)(634,635,640). 
These methods have detection thresholds between 0.001 and 0.1% for mutant 
alleles(641,642), which is 1000 times lower than RT qPCR.  dPCR is a refinement of 
conventional PCR methods that can be used to directly quantify and clonally amplify 
nucleic acids including DNA, cDNA and RNA. The key difference between dPCR and 
traditional RT PCR lies in the method of measuring nucleic acids amounts. PCR carries 
out one reaction per single sample whereas dPCR also carries out a single reaction 
within a sample, but the sample is separated into a large number of partitions(640). 
Raindance® digital droplet technology generates up to 10 million picolitre-sized 
droplets whereas the BioRad platform partitions into approximately 20,000 droplets. 
Each droplet encapsulates a single nucleotide, enabling quantification of the number of 
droplets containing specific target DNA and comparing that to the number of droplets 
with background wild-type DNA. This separation allows a more reliable and sensitive 
measurement of nucleic acid amounts. Limitations of dPCR include the ability to 
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interrogate only one or a few genomic positions simultaneously and assays require 
optimisation for each mutation of interest, complicating clinical implementation. NGS-
based methods for ctDNA detection can detect multiple somatic alterations 
simultaneously(643), but optimisation has been required to improve detection of ctDNA 
as this often represents a small fraction (<1.0%) of total cfDNA(617,618). 
 
The different processes for detection of ctDNA have been applied for detection of 
tumour specific mutation, identified by sequencing of the primary tumour DNA. An 
alternative approach has been to scan regions of DNA extracted from plasma or serum 
for mutations of interest in a blinded manner when the tumour tissue has not been 
assessed(634,637,639). This method has been used for detecting the presence of 
specific but commonly observed mutations of known oncogenes, such as KRAS, 
PIK3CA and EGFR in hot spot locations(644-647). 
 
In addition to ctDNA, circulating tumour cells (CTC) can be non-invasively assessed as 
a source of tumour DNA in the circulation(634,648). While ctDNA is composed of small 
fragments (70-200 base pairs) of nucleic acid(632) CTCs represent intact, often viable, 
tumour cells that can be isolated from blood by cell surface molecules, distinguishing 
them from normal blood cells. The basis of the validated CTC detection test has been 
based on the expression of epithelial markers(649). Limited sensitivity has been an 
issue using CTCs and recent reports suggest the difficulties may be due to incomplete 
characterisation of the CTCs as some of these cells have been found to undergo EMT 
and express mesenchymal markers(650). Few studies have compared the amounts of 
ctDNA and CTC and conclusions are mixed(634,648). Recent studies suggest ctDNA 
levels are higher than CTC levels(634,635,641),  supporting ctDNA as the preferred 
biomarker to prognosticate survival, monitor for response to specific therapeutics and 
for detection of recurrence and progression in the metastatic phase(651,652). 
1.8.1.2 Monitoring or molecular resistance 
Acquired mutations leading to drug resistance can be detected using 
ctDNA(637,639,653,654). This has been shown by detection of a well characterised 
secondary resistant mutation (T790M) appearing during treatment, leading to 
resistance to the EGFR inhibitor Gefitinib in patients with colorectal cancer(655,656). 
Secondary resistance to EGFR inhibition has also been associated with the emergence 
of KRAS mutations or MET amplification. Detection of KRAS variants in ctDNA in 
patients receiving therapy with EGFR-inhibitors have identified relapse months before 
clinical and radiologic changes(655,657,658). Similarly, ctDNA has also been used for 
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detection of HER2 amplification in patients with metastatic breast cancer which were 
not detected at primary diagnoses but present at time of recurrence, thereby changing 
the options for therapy(659).  
 
CtDNA has prognostic significance and reflects the dynamics changes in the mutation 
profile that occur during therapy as well as the heterogeneity that emerges as a result 
of the therapeutic selection pressure(634,635,651), supporting the use of ctDNA as a 
‘liquid biopsy’ to guide therapy(660). 
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1.9 Aims 
This thesis covers the identification of targeted therapy for chordoma, the evaluation of 
potential biomarkers in plasma and the generation of new disease models.  
 
Chordoma is a rare malignant tumour of bone. It is slow growing and often presents 
with a large tumour which impacts on the likelihood of successful treatment. Current 
standard therapy is en-bloc surgical resection followed by radiation therapy. No drugs 
have been approved for the treatment of chordoma and indeed no phase III trial has 
ever been conducted for this disease. Chordoma is resistant to chemotherapy leaving 
an unmet need for the treatment of residual and recurrent disease. 
 
The transcription factor brachyury has been identified to play a role in the pathogenesis 
of chordoma, and silencing of brachyury in vitro results in apoptosis and cell 
senescence in chordoma cell lines. The hypothesis was that by using a viral vector for 
delivery of RNA interference to silence brachyury in vivo, at time of tumour resection 
for recurrent disease, this could possibly further reduce tumour burden and improve 
event free survival?  
 
The AAV vector was chosen for delivery due to its safety profile and tolerability 
demonstrated in clinical trials. Local treatment was considered the most appropriate 
application to ensure adequate tumour dosing and the knowledge that local recurrence 
represents the biggest challenge in the treatment of chordoma.  
 
To aim was to establish the suitability of the AAV vector and to identify a serotype for 
efficient transduction of chordoma cells. It was not known if silencing of brachyury in 
vivo could be maintained and if this would lead to tumour regression. A xenograft 
model was to be generated and intra-tumoural injection was to be performed to 
establish response. This would be assessed by xenograft tumour size and metabolic 
response as a measure of cell viability in the tumour.  
 
To achieve cure of most cancers multimodality therapy and combination of compounds 
is required. Limited pre-clinical data is available for the treatment of chordoma. A high 
throughput compound screen of more than 1100 compounds was to be undertaken in 
three chordoma cell lines. The aim was that by performing a phenotypic screen and 
investigation the mechanism of death to potentially identify effective compounds for the 
treatment of chordoma. By testing multiple kinase inhibitors would it be possible to 
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identify important pathways involved in the pathogenesis of chordoma? Adding 
informed guidance on therapy and help identify compounds with synergistic effect 
suitable for screening in combination to improve therapeutic efficacy?  By screening 
the compounds in multiple chordoma cell lines, would this demonstrate a 
homogeneous response to treatment? Or if heterogeneous response was observed 
would this add insight into inter-tumour heterogeneity and aid patient selection for 
guidance of future clinical trials? 
 
Biomarkers play and important role in the assessment of response to therapy. 
Currently no tumour marker is available for chordoma. The protein marker, AKR1B10 is 
expressed on all chordoma tumour samples. The relevance of this protein in the 
pathogenesis of chordoma is still to be established. AKR1B10 levels in plasma have 
been shown to have prognostic implications in breast cancer patients. The aim was 
therefore to test if levels could be assessed in plasma from chordoma patients and if so 
to consider the potential of AKR1B10 as a tumour marker to assess response to 
therapy in patients with chordoma. More recently ctDNA has been shown to be a 
sensitive marker for persistent or recurrent disease in solid tumours, as well as a 
method for assessing response to therapy. Detection of ctDNA has been established in 
high-grade tumours where as in most CNS tumours and low grade tumours the 
evidence remains sparse. The aim was to establish if ctDNA can be detected in the 
plasma of chordoma patients and if proof of concept were established would this 
represent a potential marker for detection of recurrence in patients enabling early 
diagnosis of relapse. 
 
Lack of disease models in chordoma has impact on the opportunities for scientific 
discoveries. To enable the work presented in this thesis two xenograft models were 
generated. A patient derived xenograft model to establish the persistence of 
morphology and assess genetic stability across multiple passages. This model was to 
be shared within the chordoma scientific community for compound screening. The 2nd 
xenograft was generated from the U-CH1 chordoma cell line. The U-CH1 cell line has 
previously been used to generate a xenograft. The aim was to generate a modified U-
CH1 cell line expressing luciferase and to utilise this for the xenograft model to 
establish, if luciferase expression could be serially quantified and used as a method for 
assessing tumour response to gene therapy.  
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2 MATERIAL AND METHODS 
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2.1 Cell lines 
2.1.1 Authentication of cell lines with DNA fingerprinting 
DDC Medical, a division of DNA Diagnostics Center (DDC)(London, UK) was used for 
cell line authentication. DDC Medical’s DNA STR analysis examines 17 highly 
polymorphic genetic markers, generating a DNA profile, which uniquely identifies the 
cell line. DNA was extracted from the three chordoma cell lines and sent for STR 
testing, confirming authenticity of the cell lines. Results are compared to the DSZM 
STR profile database, which include 2455 cell lines from ATCC, SMZX, JCRB and 
RilKEN databases. STR data represent allelic size and determinations performed by 
capillary electrophoresis of PCR products using primers mapping to a number of 
genetic loci 
2.1.2 Chordoma cell lines 
U-CH1 chordoma cell line 
Provided by Dr David Alcorta, Duke University, Durham, NC, USA through the 
Chordoma Foundation. This cell line was established, from 56-year old male patient 
with a recurrent sacral chordoma. The cells morphology demonstrated physalipherous 
features. Brachyury expression approximately has been assessed as 10x of U-CH2 
with no amplification of brachyury. Multiple chromosomal abnormalities including 
biallelic loss of 9q21 (CDKN2A and CDKN2B loci)(134).  
 
U-CH2 chordoma cell line 
Generated and provided by Silke Bruderlein, University of Ulm, Germany through the 
Chordoma Foundation. This cell line was established from a 72-year old female with 
recurrent sacral chordoma. The cell morphology is physalipherous, brachyury 
expression is positive (weaker than other cell lines). Chromosomal abnormalities are 
multiple, and including amplification of T/brachyury and biallelic loss at 9p21 (CDKN2A 
and CDKN2B loci)(197). 
 
MUG-Chor chordoma cell line 
Generated and provided by Dr Beate Rinner, University of Graz, Austria through the 
Chordoma Foundation. This cell line was established, from a 57-year old female 
patient with primary sacral chordoma. The cell morphology is physalipherous, 
brachyury expression is positive (10x that of U-CH1). Chromosomal abnormalities are 
multiple, including gain at 6q27 (T/brachyury), loss at 9p21 (CDKN2A and CDKN2B 
loci), loss at 10p (PTEN) and 10q (PDCD4 loci)(661). 
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2.1.3 Other cell lines 
HEK 293T cells 
HEK 293T cells were purchased from ATCC (LGC Standards, Middlesex UK). This cell 
line is a human embryonic kidney adenoviral 5-transformed cell line(662,663). HEK 
293T cell line was cultured in Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO® 
Invitrogen) with 10% Fetal bovine serum (FBS) (GIBCO®, Invitrogen) and Penicillin G 
100U/mL and streptomycin 100µg/mL (Invitrogen). 
 
Three breast cancer cell lines: MDA_MB_231, MDA_MB_435 and MCF7, three 
glioblastoma cell lines: U87, A172, U 251, two liver carcinoma cell lines: Sk.Hep.1 and 
HUH1 (kindly provided from Amit Nathwani’s lab UCL Cancer institute) were used for 
control of experiments. These cell lines were all cultured in DMEM with 10% FBS and 
Penicillin G 100U/mL and streptomycin 100µg/mL. 
2.1.4 Passaging of adherent cell lines 
All cell lines were incubated at 37°C with 5% CO2. Tissue culture flasks and plates 
were from TPP (TPP, Trasadingen Switzerland) unless otherwise stated. 
 
U-CH1, U-CH2 and Mug-Chor cell lines were cultured as a monolayer in Iscove’s 
Modified Dulbecco’s medium (IMDM) (GIBCO® Invitrogen, Paisley, UK) and RPMI-
1640 (GIBCO® Invitrogen) in a 4:1 ration of IMDM:RPMI medium (GIBCO®, 
Invitrogen) supplemented with 10% FBS (Reserved: South American FBS, catalogue 
number 10270106, Lot # 41A1241K, and previously Lot # 41F6034K) (Life 
technologies, UK) and 5 mL penicillin-streptomycin. Cells were grown in T175 (175cm2) 
tissue culture flasks (Thermo scientific, Loughborough, UK) in incubators at 37°C with 
5% CO2 atmosphere. Cells were passaged when 75-80% confluent. Medium was 
removed, cells were washed using Dulbecco’s phosphate buffered saline (PBS) 
(Sigma), and then incubated in trypsin/EDTA (Invitrogen) (5mL) for 5 minutes at 37°C 
and detached by tapping the flask. The trypsin/EDTA reaction was quenched using 
serum. The cell suspension was centrifuged at 400x g for 5 minutes. The supernatant 
was discarded, the cell pellet disrupted and resuspended in fresh medium before 
transferring to new flasks. U-CH1 cell line was maintained in collagen-coated flasks 
(Collagen solution Type 1 from rat tail product #C3867 Sigma Aldrich). 
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2.1.4.1 Cell count calculations 
Cells were counted using a Neubauer Haemocytometer (Weber Scientific International 
Ltd. Middlesex, UK). Tryphan blue solution (Sigma Aldrich) was added to the cell 
suspension to identify dead cells. 
2.1.4.2 Thawing of cells 
Frozen vials of cells were removed from liquid nitrogen and thawed in warm water at 
37°C. The cell suspension was transferred to a 50mL falcon tube containing 20mL of 
cold complete medium. The suspension was centrifuged at 50 × g at 4°C for 3 minutes. 
The supernatant was gently aspirated without disturbing the pellet. The cell pellet was 
resuspended in 10mL IMDM:RPMI with FBS and an aliquot set aside to determine cell 
number and viability using tryphan blue. After re-suspension cells were transferred to a 
new flask containing complete medium at a final volume of 5mL/25 cm2, 10mL/75 cm2, 
20mL/150 cm2 flask or 10mL/10 cm2 dish. 
2.1.4.3 Freezing cell lines in liquid nitrogen 
Cell cultures were harvested as described in Section 1.1.3. After centrifugation they 
were resuspended in freezing medium (DMEM plus 20% (v/v) FBS and 10% (v/v) 
DMSO) for a cell density of 1-5×106/mL. The cell suspension was quickly aliquoted into 
cryo-vials (Corning), rested on ice briefly before storing overnight at -80°C prior to long-
term storage in liquid nitrogen. 
2.2 Generation of new cell lines 
2.2.1 Puromycin Dose-Response 
To select for transduced cell to generate a uniform cell population, a dose-titration was 
performed, to establish the correct dose of Puromycin required to cause 100% cell 
death within 48 hours. The cell lines were plated at 50% confluency in 6 well plates. 
The following day the medium was replaced with medium containing a range of 
concentrations (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10µg/mL) of Puromycin: this was done in 
duplicate. Cells were monitored daily by microscopy, and the minimum amount of 
Puromycin required to kill 100% of non-transfected cells was determined at 3-7 days. 
For U-CH1 the dose required was 5µg/mL, and for HEK 293T the dose required to kill 
100% of the cells was 2µg/mL. 
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2.2.2 U-CH1 luciferase cell line 
The U-CH1 cell line was modified using a plasmid supplied by Addgene (Cambridge, 
MA, USA) (plasmid 17477): Lenti_CMV_Luciferase_Puromycin(664) to express 
luciferase.  
 
From the bacterial stab, provided by Addgene, colonies were generated on an agar 
plate (ampicillin 100µg/mL) from which individual colonies were picked and grown 
overnight in 3mL Luria Broth (LB). Following plasmid purification the colonies were 
checked by restriction digest. 1mL of fresh LB were used in 300mL LB for large scale 
DNA preparation.  Lentivirus was produced using 293T cells for packaging, and the 
supernatant was collected at two time points as described in the section on lentivirus 
production (section 2.6.1). The titre was determined using Lentivirus qPCR Titre kit 
from Gentaur catalogue # LV900 (Gentaur Ltd, London UK) viral titre as determined by 
qPCR was 5x1010 viral particles per mL.  U-CH1 cells were transduced twice within 24 
hours using a Multiplicity of infection (MOI) of 10. The cells underwent Puromycin 
(5µg/mL) (Sigma-Aldrich, Ayrshire, UK) selection 72 hours after the initial transduction.  
 
Following Puromycin selection the cells were checked for luciferase expression. Cells 
were washed with PBS, and passive lysis buffer (Promega, WI, USA) was added to the 
plate to lyse the cells. A cell scraper was used to detach the cells, and the cells and 
solution was transferred to a micro-centrifuge tube. Debris was pelleted by 
centrifugation and the supernatant was transferred to a separate tube. Cell lysate was 
mixed with D-luciferin (Melford, Chelsworth, Ipswich, Suffolk, UK). Adding D-luciferin 
produces bioluminescence when oxidized by firefly luciferase there by confirming 
luciferase expression in the cell line. The luminescence was measured by a 
luminometer (Turner Biosystems Model TD 20/20; Promega).  
2.2.3 293T_Brachyury-expressing cell line 
Brachyury is expressed mainly in chordoma cell lines and these cells have proven 
notoriously difficult to transfect (personal experience) and evident by a small number of 
recent publications(119,665,666). Expression has also been documented in a colon 
cancer cell line SW480, however the expression in this cell line varies at different levels 
of cell confluency, making it a sub-optimal model for gene-silencing experiment. We 
therefore generated a HEK 293T cell line stably expressing brachyury for testing of 
gene-silencing constructs. This was achieved by generating cDNA from U-CH1 cell 
lines following RNA extraction (QIAzol) (section 2.72). Primers were designed for PCR 
amplification of the brachyury gene. Restriction enzyme sites (RE) were added to the 5’ 
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of the primers for subsequent cloning, using restriction digest for insertion of the 
brachyury transcript into a vector. 
 
Table 2.1 Primers for Brachyury transcript amplification 
Brachyury forward 5’CAATTCCATGGATTATGAGCTCCCCTGGCACCGA 3’ 
Brachyury reverse 5’ CGATCCTCGAGTCACATGGAAGGTGGCGACAC 3’ 
Primers for Brachyury transcript amplification for cloning into a vector for expression. Restriction 
enzyme sites: Forward: NcoI (5’CCATGG 3’) / Reverse: XhoI 5’ CTCGAG 3’ 
 
The PCR product was separated on an agarose gel, and the correct size band was 
visualised. The band was excised and isolated by gel-extraction (QIAGEN, GmBH, 
Hilden, Germany) as per manufactures recommendation. The PCR product was then 
digested with Nco1/Xho1 to create appropriate overhang for cloning into the receiving 
vector. This was followed by PCR clean-up to remove the enzymes as per 
manufactures recommendation (QIAGEN). 
 
The PCR product was cloned into the entry vector: PENTR4_flag in which it was 
sequenced and subsequently gated into the lentiviral destination vector 
(pLenti_PGK_Puromycin) using the Gateway LR Clonase Enzyme Mix (Invitrogen) as 
described in section 2.5.3.2 
 
Lentivirus was generated as described 2.6.1 and Lentivirus qPCR Titre kit previously 
described (section 2.6.2) was used to establish the titre. HEK 293T cells were 
transduced with an MOI of 10. The transduction was repeated within 24 hours and after 
further 48 hours cells Puromycin collection was commenced. The expression of 
brachyury was checked by RT qPCR. 
2.3 Methods for Patient derived xenograft  
The use of patient material was approved by the Cambridgeshire Research Ethics 
committee (REC reference 10/H1107/36).  
 
Animal work was performed under the authority of UK Home Office Project and 
Personal License regulations (PPL 70/7511 & PIL 70/24801) and was compliant with 
University College London ethical re-view committee guidelines. Mice were obtained 
from Charles River Laboratories (Charles River UK, Kent, UK), and were housed in a 
pathogen-free room controlled for temperature and humidity. NOD/SCID/interleukin 2 
receptor [IL2r]γ-null mice and Balb/C nude mice (athymic) were used.  
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For generating the patient derived xenograft, a freshly obtained tumour sample was 
transferred from the operating theatre to the laboratory, the sample was diced under 
sterile conditions into 2mm square fragments and placed directly into transport medium 
containing antibiotics (Penicillin and Streptomycin) and an antifungal agent 
(Amphotericin, GIBCO Invitrogen) and held at room temperature over night. The 
following morning, the tumour sample was mixed in a 1:1 ratio with growth factor–
reduced Matrigel (BD Biosciences CA), and injected subcutaneously into both flanks of 
two 5-6-week-old female NOD/SCID/interleukin 2 receptor [IL2r]γ null mice. During the 
engraftment phase, tumours are allowed to establish and grow and then harvested 
upon reaching a size of 1-1.5cm3 (P1). The tumour was subsequently expanded into 2-
3 BalbC/nude mice (P2). Over a period of 14 months the tumours were passaged 
every 8-10 weeks into nude mice, though one additional passage went through 
NOD/SCID mice as the BalbC/nude mice growing the tumour became unwell and in 
the interest of time we used the mice available. Once the tumours had reached a 
volume of 1-1.5 cm3 the mouse was sacrificed according the guidelines, and the tumour 
removed. The tumour was dissected as described into smaller sections; one small 
piece was sent for histology to monitor for histological resemblance to the primary 
tumour (10% formalin), at least one piece was frozen in freezing medium (for re-
implantation at a later date, see below) or snap-frozen for histology review or DNA 
extraction. The remaining tumour was divided into small pieces for re-implantation into 
the flank of new mice by inoculation following a small incision. Over a period of 14 
months the tumours were passaged every 8-10 weeks into nude mice, though one 
additional passage went through NOD/SCID mice. The treatment cohort (P6) was 
transferred to John Hopkins University, Baltimore, USA for further expansion and drug 
testing. 
 
The mice were anaesthetised using isofluorane for inhalation, and placed on a heating 
mat to maintain a temperature of 37°C. The small incision was glued using surgical 
glue, in the nude mice, but for the NOD/SCID mice the incision was stitched as these 
mice have hair. They also have a much more inquisitive and aggressive behaviour, and 
the glue was found not to be sufficient for maintaining the wound. 
2.3.1 Freezing xenograft tissue: 
Multiple cuts were made in, but not through, the tissue using two scalpels to obtain the 
equivalent of tenderised meat, and the tissue was then placed in freezing medium:  
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Freezing Media for re-engraftment 
50mL FBS 
15mL DMSO 
85mL of appropriate cell culture media according to tumour type/cell line 
Total volume = 150mL  
2.4 Luciferase expression chordoma xenograft 
The U-CH1_luciferase cell line was engineered as described in section 2.2.2. The cells 
were intermittently put under Puromycin selection to maintain 100% pure population of 
cells. The U-CH1 luciferase expression cell line was subsequently expanded and 
stored in liquid nitrogen.  
 
For injection into the mice, the cells were expanded, collected (disrupted by trypsin) 
and counted as previously described. The cells were pelleted, re-suspended in medium 
and pelleted again before they were mixed with matrigel on ice (BD Matrigel™ 
Basement Membrane, Scientific laboratory supplies, UK). 
 
Matrigel solidifies at room temperature and therefore has to be kept on ice right to the 
point of injection. The matrigel was put in aliquots of 150µL and stored at -20°C. The 
night before the injection, the aliquots were thawed on ice in the fridge, and then kept 
on ice when mixing with the cells. The syringes and needles were also kept cool in an 
icebox. For injection a total of 200µL containing the cells and the matrigel was 
aspirated into 1mL syringes with a 26-gauge needle. The mice were manually 
immobilised in a prone position and the animals were injected subcutaneously in the 
flank and monitored periodically for tumour formation. 1x107 cells were 
injected/xenograft. Assessment of the tumours were performed weekly by 
measurement of size using an external caliper(667). 
2.4.1 Treatment of the xenograft 
The mice were subsequently injected intraperitoneal with D-luciferin substrate, and 
intratumoral injection was done using the AAV vector  (or PBS). The latter procedure 
was done under general anaesthetic in order to achieve accurate injection. 50µL (vg 
1x1012) was injected in total using 3 different sites within each tumour.  
2.4.2 In vivo imaging 
The animals were image using the IVIS spectrum in vivo imaging system for non-
invasive longitudinal monitoring of bioluminescence. The machine was set up with 
anaesthetic equipment to be used while obtaining the images and the measurement, 
as well as a temperature control to keep the animals comfortable.  
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Luciferase expression was detected using D-Luciferin (Melford Laboratories, Cat # 
L1350), which was injected intraperitoneal (IP) at a dose of 200µg/mouse, as 
substrate, using the IVIS Imaging System 100 Series (Perkin Elmer). The images were 
analysed using the Living Image software 3.1, by grouping the images from different 
time points the relative light units (photons) can be directly compared. Following 
intraperitoneal injection of D-luciferin, the luciferase enzyme catalyse the substrate into 
oxyluciferin, requiring the presence of oxygen, and cofactors such as adenosine 
triphosphate (ATP) and mg2 ions(668). The resulting light photons generated by this 
reaction are captured non-invasively with a charge-coupled device (CCD) camera 
mounted within the BLI system(669).  
 
Bioluminescence imaging (BLI) was used to quantitatively assess tumour growth by 
correlating this to the intensity of luciferase expression. After injection of the D-luciferin 
the signal increases gradually, reaching a peak 10-20 minutes after injection. The 
signal intensity at the peak, is often used as a quantitative indicator of the luciferase 
activity and, consequently, of the tumour burden(670). A single predetermined time 
point for imaging after D-luciferin injection was used based on preliminary experiments, 
a method which has been shown to similarly represent tumour burden(671-673). The 
protocol was to image the mice 3 minutes after D-luciferin injection, with 45 seconds 
exposure time, delay in imaging meant saturation and inability to analyse the data. 
 
Baseline luciferase expression in the tumour was determined using bioluminescent 
imaging to establishing level of expression on “day 0” (week 1). Assessment of the 
tumours was performed weekly by bioluminescence in vivo imaging measuring 
luciferase activity following inter-peritoneal injection of D-luciferin. 
2.4.3 Viral genome distribution in xenograft 
On termination of the experiment, 21 days after intra-tumoural administration of 
1x1011PCR-vg/mouse, the tumour from each mouse was harvested.  A small biopsy 
from the tumour was used for DNA extraction to assess copy number of the virus per 
cell by qPCR.  
2.4.4 Antibody staining of paraffin sections for immunohistochemistry  
Antibody staining of paraffin sections for brachyury was performed on the xenograft 
tumours. Brachyury (H-210); sc20109 antibody (Santa Cruz Biotechnology Inc. Santa 
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Cruz, CA, USA) is a rabbit polyclonal antibody against amino acids 226-435 of 
brachyury of human origin.  Immunohistochemistry was carried out as follows: 
After fixation of xenograft tumours in 10% neutral buffered formalin (Sigma) tissue was 
prepared, paraffin-embedded, and cut into 3µm thick sections. These sections were 
dewaxed through two changes of xylene and rehydrated through a series of graded 
ethanols (100% (v/v) to 50% (v/v)). Antigen retrieval was carried out by heating the 
sections, using a pressure cooker for two minutes in an antigen-unmasking solution 
(Vector Laboratories, Peterborough, UK).  The iVIEW DAB Detection Kit and NexES 
immunohistochemistry system (Ventana Medical Systems Inc. Tucson, AR, USA) was 
used according to the manufacturer’s instructions. Briefly, the endogenous peroxidase 
activity was inhibited and the sections incubated with the primary brachyury antibody 
(diluted 1:50) for 30 minutes. After washing the secondary antibody, a biotinylated Ig 
rabbit antibody (Ventana Medical Systems Inc.) was applied to facilitate visualization of 
the primary antibody, and a streptavidin-horseradish peroxidase conjugate (Ventana 
Medical Systems Inc.) was applied. Diaminobenzidine (DAB)(Sigma) substrate solution 
was used for visualising positive staining.  The slides were counterstained with 
haematoxylin, dehydrated and mounted with a glass cover slip.  
 
2.4 Fluorescent in situ hybridisation (FISH) analysis  
FISH was performed on TMAs using probes from the bacterial artificial chromosomes 
(BACs) from the RP-BACs library (BAC/PAC resources centre, Oakland, CA, USA). 
The details of the BACs used are shown below. Chromosome enumeration probes 
(CEP) were used as references and obtained from alpha satellite DNA for 
chromosomes 6 and 7 (Resources for Molecular Cytogenetics, Bari, Italy) labeled in 
green with Vysis reagents. Details of chromosome enumeration markers are listed 
below.  
TMA sections were cut at 4µm thickness, de-paraffinised in xylene and rehydrated in 
ethanol. Sections were pre-treated using the Paraffin Pretreatment Reagent Kit II 
(Vysis). Briefly, the slides were placed in the pre-treatment solution at 80°C for 50 -70 
minutes, and in pepsin solution 0.05% at 37°C 20 to 25 minutes. The probes were 
applied to the slides and co-denatured for 5 min at 73°C and hybridised for at least 16 
hours at 37°C in a Thermo-Brite hybridizer (Iris, Westwood, MA, USA). The slides were 
washed in formamide-free solutions: 2XSCC/0.3% Igepal CA-630 (Sigma-Aldrich 
Company Ltd, Gillingham, Dorset, UK) at room temperature for 5 min, at 73°C for 2 
minutes and at room temperature for 1 minute, and then counter-stained with 4',6’-
diamidino-2-phenylindole (DAPI) and analysed under a fluorescent microscope 
(Olympus, Watford, Hertfordshire, UK) using AnalySIS software (Olympus). The 
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chromosome localisation of all BAC clones was confirmed on normal metaphase 
spread slides (Vysis). Fifty non-overlapping nuclei that contained unequivocal signals 
were counted for each case. For the probes used, amplification was defined by a ratio 
of more than 2 for the gene-specific probe compared to the chromosome-specific 
reference probe.  FISH analysis for EGFR comprises two groups; FISH positive (EGFR 
genomic gain) and FISH negative (no or low EGFR genomic gain) according to the 
Colardo criteria developed or non small cell lung carcinoma, The former included high 
level polysomy (≥ 4 copies/cell in ≥ 40% of cells) and amplification (defined by the 
presence of tight gene clusters, or ratio EGFR gene signals/CEP7 signals ≥ 2, or ≥ 15 
copies of the gene per cell in ≥ 10% of analysed cells). The latter included two 
subgroups; low level polysomy (> 2 copies/cell in ≤ 40% of cells or 3 copies/cell in ≥ 
40% of cells) and diosomy (≤ 2 copies in > 90% of the cells)  
 
Details of BACs used to generate FISH probes 
BAC reference Gene covered Chromosome 
location 
Type of aberration Labeling 
colour 
RP11-235F13 Brachyury 6q27 Amplification Orange 
RP11-381G5 EGFR 7p11.2 Amplification Orange 
Details of probes used as chromosome enumeration markers 
 Location Labeling colour 
Chromosome 6 
alpha satellite 
DNA (CEP6)  Chromosome 6 Green 
Chromosome 7 
alpha satellite 
DNA (CEP7)  Chromosome 7  Green 
 
2.5 Molecular biology techniques 
2.5.1 Generation of Adeno-associated viral vector for RNAi delivery 
The previous work within the lab had been undertaken using the GIPZ construct (GIPZ 
Lentivirus shRNA from Thermo Scientific Open Biosystems, Chesterville, AI, USA) 
Clone ID: V2LHS_153725. Within the GIPZ construct the shRNA are expressed as 
human microRNA-30 (miR-30) primary transcripts. This design adds a Drosha 
processing site to the hairpin construct and has been shown to greatly increase gene 
silencing efficiency(674). The hairpin stem consists of 22 nucleotides (nt) of dsRNA 
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and a 19 nucleotides loop from human miR-30. The addition of the miR-30 loop and a 
miR-30 flanking sequence (125 nucleotides) on either side of the hairpin, results in 
greater than 10-fold increase in Drosha and Dicer processing, of the expressed 
hairpins when compared with conventional shRNA designs(364). Increased Drosha 
and Dicer processing translates into greater shRNA production and greater potency for 
expressed hairpins. 
http://www.thermoscientificbio.com/uploadedFiles/Resources/GIPZ%20Lentiviral%20s
hRNA%20Technical%20Manual.pdf 
 
Cloning of the shRNA with the miR-30 flanking sequences was undertaken, using PCR 
amplification, amplifying the sequence of interest having designed the primers to add 
restriction sites to the sequence, for cloning into the viral vector plasmid. A scAAV 
vector with a CMV promoter and green fluorescent protein (GFP) expression cassette 
was used. Generating a AAV_CMV_shRNA_GFP plasmid. Methods detailed below.  
Subsequently a different donor vector was used to test a different expression cassette 
for generating an AAV vector. This vector was a pLKO.1 vector containing a U6 
promoter expressing the shRNA and a PGK promoter for expression of Puromycin. 
The cloning strategy and methods used were similar for the different constructs used. 
2.5.1.1  Plasmids 
Self-complimentary AAV: pAAV sc_CMV_GFP  (Amit Nathwani, UCL Cancer Institute) 
Gateway cloning entry vector: PENTR4_flag; Invitrogen (Addgene 17423) 
Lentiviral vector: pLenti PGK_Puro_DEST (Addgene 19068/pRRL vector) 
Lentiviral vector: pLenti_CMV_Luciferase_Puromycin (Addgene 17477) 
GIPZ Lentivirus shRNA from Thermo Scientific Open Biosystems, Chesterville, AI, 
USA) Clone ID: V2LHS_153725.  
 
Table 2.2 GIPZ brachyury targeting clone 
Clone ID 
Target region 
Mature sense Mature anti-sense 
V2LHS_153725 
Exon 4/exon 5 
GAGGAGATCACAGCTCTTAA TAAGAGCTGTGATCTCCTC 
 
Gene silencing construct: pLKO.1 Lentivirus shRNA from Thermo Scientific Open 
Biosystems (RNAi consortium). Clone ID:  TRCN0000005481-TRCN000005484. The 
pLKO.1 vectors hairpin stem consists of 21 nucleotides of dsRNA and a 6 nucleotides 
loop and short flanking sequence of 4-5 nucleotides.  
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Table 2.3 pLKO.1 Brachyury targeting clone 
Clone ID 
Target region 
Mature sense Mature anti-sense 
TRCN0000005481 
Exon 4 
CGAATCCACATAGTGAGAGTT AACTCTCACTATGTGGATTCG 
TRCN0000005482 
Exon 8 
GCATGTTTATCCATGCTGCAA TTGCAGCATGGATAAACATGC 
TRCN0000005483 
Exon 4 
GCATAAGTATGAGCCTCGAAT ATTCGAGGCTCATACTTATGC 
TRCN0000005484 
Exon 4/exon 5 
CGAGGAGATCACAGCTCTTAA TTAAGAGCTGTGATCTCCTCG 
Non-targeting 
SHC002 
CAACAAGATGAAGAGCACCAA TTGGTGCTCTTCATCTTGTTG 
 
The different short hairpins targeting brachyury were purchased from Open Biosystems 
Thermo scientific as glycerol stocks. Each clone was streaked using a sterile loop 
transferring the frozen bacteria from the top of the glycerol stock to an agar plate, and 
grown overnight in an incubator at 37°C. Colonies were picked the following day and 
grown in 3mL of Luria Broth (LB) overnight: The following day, plasmid DNA was 
prepared as described in section 2.7.1. Clones were tested with restriction digest using 
the enzymes BamH1/Nde1 as per recommendation by Open Biosystems protocol. 
2.5.2 Cloning of vectors  
2.5.2.1 PCR amplification  
Primers were designed manually and checked using clone manager. Restriction sites 
for cloning were added, and the primers were checked for primer dimers (NCBI BLAST 
web tools for alignment of two sequences). DNA sequences were generated using 
DYAD Peltier Thermal cycler (BioRad Laboratories Ltd, Hemel Hempstead, UK).  
Phusion® High-Fidelity DNA Polymerase (New England Biolabs UK Ltd. Hitchin, UK) 
were used for the amplification according to manufactures recommendations. A 
temperature gradient was used to find the optimal annealing temperature for each 
template-primer pair combination. 
Table 2.4 Phusion PCR reaction 
Component 20 µL reaction 50uL reaction Final concentration 
Nuclease-free water To 20 µL To 50 µL  
5X Phusion HF or GC Buffer 4 µL 10 µL 1X 
10mM dNTPs 0.4 µL 1 µL 200 µM 
10µM Forward primer 1 µL 2.5 µL 0.5 µM 
10µM Reverse primer 1 µL 2.5 µL 0.5 µM 
Template DNA variable variable < 250 ng 
DMSO (optional) (0.6 µL) (1.5µL) 3% 
Phusion DNA polymerase 0.2 µL 0.5 µL 1.0 units/50 µL 
PCR 
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DNA template: Genomic DNA (50-250ng), cDNA or plasmid (1pg-10ng)  
 
Table 2.5 Thermo cycling conditions for PCR 
Step Temperature Time 
Initial denaturation 98°C 30 seconds 
25-35 cycles 98°C 
45-72°C 
72°C 
5 seconds 
30 seconds 
15 seconds 
Final extension 72°C 10 minutes 
Hold 4-10°C  
 
2.5.2.2 Restriction enzyme digest 
The production of adeno-associated viral (AAV) vectors relied on DNA digestion with 
restriction enzymes. Restriction sites were also used to accurately verify plasmid 
inserts. Digestion was performed in the presence of buffers designed to optimise 
enzyme efficiency. All restriction enzymes and buffers were supplied by New England 
Biolabs UK Ltd (Hitchin, UK). In brief the vector backbone was digested by the 
restriction enzymes added to the insert using specific primers, the linearised plasmid 
was then visualised on an agarose gel and the DNA was extracted from the gel. The 
linearised plasmid was de-phosphorylated using calf intestinal alkaline phosphatase 
(CIP) to prevent the exposed ends to re-ligate. A PCR clean up reaction was 
undertaken prior to ligation with the insert amplified by PCR, details below. 
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2.5.2.3 Material and reagents for cloning 
Table 2.6 Restriction digest reagents 
Restriction enzymes New England Biolabs 
(NEB) 
10X Enzyme buffer NEB 
100X Bovine Serum Albumin (BSA)  NEB 
Ultrapure water HyClone Laboratories, 
Utah, USA 
DNA template  
Eppendorf Mastercycler Gradient PCR machine Eppendorf 
DNA loading buffer NEB 
2.5.2.4 Protocol for restriction digest reaction 
Table 2.7 Restriction digest reaction 
Plasmid DNA (0.2-5µg) x µL 
10X NEB Buffer 2 µL 
100X NEB BSA solution 1 µL 
Enzyme 1U 1 µL 
Distilled water to final volume x µL 
Total volume 20 µL 
 
Digests were carried out at 37°C for 1-3 hours, or as specified for optimal enzyme 
activity. Double digests were performed when required and buffer were compatible. 
When double digests with incompatible enzymes, a sequential digest was set up. The 
initial digest with the first enzyme was set up as a 20µL reaction. The second enzyme 
(1.2µL) and buffer (3µL) were added after completion of the first incubation. When 
performing these sequential digests, the enzyme requiring the buffer containing a lower 
salt concentration was used in the first reaction. For very dilute DNA samples, 50µL 
reaction volumes were used with the volume of individual components adjusted 
accordingly. Following incubation DNA loading buffer was added (3-5µL) to the 
reaction and run on an agarose gel. 
2.5.2.5 Isolation of DNA fragments using agarose gel electrophoresis 
Separation of DNA fragments was achieved using agarose gel electrophoresis. The 
constant mass to charge ratio of DNA molecules means that separation is determined 
by fragment size. Migration rates are therefore influenced by the pore size of the gel, 
which is determined by the agarose concentration (Table 2.8). Consequently, careful 
selection of the percentage of agarose used ensured optimal resolution of the 
fragments of interest. 
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Table 2.8 Agarose concentrations for separation of different size DNA fragments 
Agarose (%w/v) Range of separation (Kb) 
0.5 0.7 - 25 
0.8 0.5 - 15 
1.0 0.25 -12 
1.2 0.15 - 6 
1.5 0.08 - 4 
Agarose concentrations required for achieving separation of specific DNA fragments. 
Adapted from Sambrook J. & Russell DW (675). 
 
Buffers and solutions; 
10x TBE = 108g Tris-base, 55g boric acid, 9.3g EDTA in 1L deionised water  
6x DNA Loading Buffer = Distilled water, 40% (w/v) sucrose, 0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol. 
 
Protocol 
The protocol given below is for the production of a 1% 100mL agarose gel. The weight 
of agarose used and the volume of TBE into which it was dissolved differed depending 
upon the size and percentage of the gel required. 
 
• One gram of agarose was mixed with 100mL 1x TBE and heated in a microwave 
oven (with regular agitation) until completely dissolved. 
• After cooling 0.30µg/mL ethidium bromide was added and the mixture swirled 
vigorously to ensure even distribution.  
• The gel was poured into a pre-cast mould, a comb inserted and the mixture was 
left to set at room temperature. 
• Prior to loading, samples were mixed 5:1 with 6x DNA loading buffer. In addition 
to the samples, a 1kb DNA ladder was loaded to allow the size of migrating DNA 
fragments to be estimated. 
• Once loaded, the gel was run at 5-8 V/cm until sufficient migration (as visualised 
by the loading dye) had occurred.  
• The DNA was visualised with UV light at 254nm using a UV trans-illuminator. 
Images were taken using a TV zoom lens and thermal monochrome printer or the 
Universal Hood II Chemidoc system. 
In instances when the DNA was required for further manipulation, the level of UV 
exposure was minimised to reduce the risk of mutagenesis.  
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2.5.2.6  Retrieval of DNA from agarose gels 
Retrieval of DNA fragments from agarose gels enabled insertion into new vectors. 
Isolation of DNA from the agarose gel relies on the ability of the DNA to bind the silica 
membrane of a purification column in the presence of chaotropic salt. The DNA was 
subsequently eluted following the replenishment of the hydration shell upon the 
addition of water. Purification of the DNA from the agarose gel was achieved using the 
protocol for the QIAquick
 
Gel Extraction Kit (QIAGEN, Crawley, UK) according to 
manufacture’s recommendation. 
2.5.2.7  Alkaline phosphatase treatment of digested plasmid DNA termini 
Alkaline phosphatase enzyme was used to remove 5’ phosphate groups from vector 
backbone DNA in order to prevent self-ligation. When digested DNA fragments had 
compatible or blunt ends, DNA was treated with calf intestinal alkaline phosphatase 
(CIP) (New England Biolabs, Ipswich, MA, USA) to dephosphorylate the ends prior to 
ligation. De-phosphorylation reactions were performed in restriction enzyme buffers 
immediately after digestion. 5U of CIP was added to the digestion reaction as well as 
5µL 10X NEB Buffer 3, and incubated at 37°C for 1 hour. This step was always 
followed by PCR clean up to remove remaining reagent before proceeding with ligation 
(QIAGEN PCR clean up kit). 
2.5.2.8  Fragment insertion using DNA ligation 
The plasmid preparation for cloning included a restriction digest with the enzymes 
generated on the insert with the use of specific primers. DNA was quantified using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Inc. Wilmington, DE, 
USA. Insertion of DNA fragments into a plasmid was performed using T4 DNA ligase 
(New England Biolabs) according to the manufacturer’s instructions. Briefly, ligations 
were undertaken with 1:2 and 1:5 ratio of DNA concentration (vector:insert). A control 
was added using vector only (1:0). Reactions were incubated overnight at 16°C. The 
following day One Shot® Stbl3 or DH5α chemically competent Escherichia coli (E. Coli) 
cells (Invitrogen) were transformed using sterile technique with 10µl ligation mix by 
heat shock.  
2.5.3 Additional cloning methods used: 
2.5.3.1  TOPO® TA cloning 
Once amplified, insertion of PCR fragments into the vector of choice was achieved 
using a four-step process. Firstly, the fragments required ‘A-tailing’ in order to facilitate 
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their introduction into a subcloning (TOPO) vector (step two). Bacterial colonies 
containing the fragment of interest was identified by restriction digest and sequencing 
(step three), the fragment was cloned into the vector of choice (step four).  
 
Step One; A-tailing 
The subcloning vector TOPO vector (Invitrogen) was used. For cloning the PCR 
product into the TOPO vector, a-tailing of the PCR product was performed according to 
manufacture’s recommendation, briefly described below. TA cloning is a method of 
cloning PCR products that utilizes stabilisation of the single-base extension 
(adenosine) adding a 3’ adenosine overhang produced by Taq polymerase to the 
complementary T (thymidine) of the T-vector (TOPO) where the insertion site is defined 
by the presence of single 3’ thymidine overhangs. PCR products can be used directly 
without modification.  
 
Following PCR clean of the PCR amplified DNA 2µL 100mM dATP (Invitrogen), 0.2 µL 
Taqman Polymerase (NEB), 5µL Buffer (NEB) and water was added to the completed 
PCR reaction mixture to a total volume of 50 µL. The reaction was incubated at 72°C 
for 30 minutes. An aliquot was subcloned into the TOPO vector (see below). 
  
Step two; Sub-cloning into the TOPO vector 
The following reaction mixture was produced: 
3µL A-tailed PCR reaction; 1µL salt solution; 1µL water; 1µL TOPO vector 
The mixture was incubated for 15 minutes at room temperature.  
 
Step three; Screening for successful transformants  
Blue/white screening was used to select bacterial clones transformed with the TOPO 
vector containing the desired insert. This technique harnesses the natural ability of the 
β-galactosidase enzyme to hydrolyse the β(1-4) glycosidic bond found in lactose. In the 
lactose analogue, X-gal, a galactose sugar is bound via a β(1-4) glycosidic bond to a 
chromophore. Hydrolysis of this glycosidic linkage by β-galactosidase releases the 
chromophore, which forms a blue product upon oxidation. Consequently, as the TOPO 
vector contains the coding region for the β-galactosidase enzyme, those bacteria 
transformed with this vector turn blue when supplied with X-gal. This process is 
optimised by also providing the E.coli with the allolactose analogue isopropyl-β-D-
thiogalactopyranoside (IPTG). The IPTG binds to and releases an inhibitor bound to 
the β-galactosidase promoter, thereby maximising the transcription of this enzyme. 
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However, as the site of DNA fragment insertion in the TOPO vector is situated within 
the β-galactosidase coding region, ligation of a DNA fragment into this site disrupts β-
galactosidase expression, thereby ensuring that the E.coli remain white.   
 
Protocol 
The reaction mixture was transformed into DH5α E.coli as previously described 
(Section 2.5.3.3). One notable exception is that prior to drying, plates were spread with 
β-galactosides (Invitrogen) to enable blue/white screening. 
Following overnight incubation at 37°C, white colonies were picked and grown in liquid 
culture overnight in the presence of antibiotics. 
 
Step four: Transfer of the DNA fragment into the vector of choice 
The colonies generated overnight, were pelleted and plasmid DNA isolated. The DNA 
was subjected to an appropriate restriction digest to verify fragment insertion. The DNA 
from the miniprep was used for sequencing if the yield (concentration of DNA) was 
satisfactory, otherwise the colony was expanded and DNA was isolated by maxiprep. 
Sequencing within TOPO was done using standard primers as directed by the protocol. 
Subsequently those DNA preparations containing the correct fragment were ligated 
into the pre-digested backbone of the vector of interest as previously described 
(section 2.5.2.8) 
 
The determine quickly and precisely DNA sequences was achieved using a technique 
based on the chain termination method originally described by Sanger et al., (593,662) 
and utilised Big Dye Terminator chemistry. In this, the dideoxynucleotides (ddNTP) 
responsible for chain termination are fluorescently labelled (a different fluorophore for 
each base), thereby enabling their incorporation into DNA fragments to be easily 
distinguished. Sequencing of the DNA was achieved using capillary zone 
electrophoresis and was performed by the scientific support services at UCL Cancer 
Institute, using an Applied Biosystems 3730 DNA Analyser. Sequencing was analysed 
using Sequencing Scanner v1.0 and NCBI BLAST web tool for alignment of 
sequences. Subsequently those DNA preparations containing the correct fragment 
were ligated into the pre-digested backbone of the vector of interest as previously 
described (section 2.5.2.8) 
2.5.3.2  Gateway cloning 
The Gateway cloning system exploits the site-specific recombination system utilised by 
bacteriophage lambda to shuttle sequences between plasmids bearing flanking 
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compatible recombination attachment (att) sites(248,676). Once the sequence for 
expression has been captured within an entry clone, this DNA fragment can be 
recombined into a variety of destination vectors resulting in expression clones geared 
to specific applications. The recombination reactions are driven by two enzyme blends 
known by their commercial names: BP Clonase and LR Clonase(677,678).  
 
Gateway® Technology was performed with a PENTR4_Flag (entry clone) and the 
Destination vector: pLenti_PGK_Puromycin (Addgene 19068)(664). The cloning 
reaction was performed according to the protocol from Invitrogen for the LR Clonase™ 
reaction. http://tools.lifetechnologies.com/content/sfs/manuals/pentr_man.pdf 
 
LR Recombination reaction was performed. The reaction between an attL-containing 
entry clone and an attR-containing destination vector generate an expression clone 
with the gene of interest. 
The following components were added to a 1.5 mL microcentrifuge tube at room 
temperature: 
• Entry clone (supercoiled, 100-300 ng) 1-10µL  
• Destination vector (supercoiled, 150 ng/µL) 2µL  
• 5X LR Clonase™ reaction buffer 4µL  
• 16µL TE Buffer, pH 8.0 (10mM Tris-HCl, pH 8.0, 1mM EDTA)   
• Vortex LR Clonase™ enzyme-mix briefly. Add 4µL to the components above 
and mix well by vortexing briefly twice. 
The reaction was incubated at 25°C for 1 hour. 
• 2µL of 2µg/µL Proteinase K solution were added and incubated at 37°C for 10 
minutes. 
Competent E. coli were transformed and selected for the appropriate antibiotic-
resistant expression clones (note the vector changes from kanamycin resistance to 
ampicillin resistance). Transformation described below. 
 
Note: For propagation of the pENTR™ vector, Library Efficiency® DB3.1™ Competent 
Cells (Catalogue no. 11782-018) from Invitrogen for transformation are required. The 
DB3.1™ E. coli strain is resistant to CcdB effects and can support the propagation of 
plasmids containing the ccdB gene. 
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2.5.3.3 Transformation of One Shot® Stbl3 or DH5α  
Replenishment of plasmid stocks and selection of newly produced vectors was 
achieved by introducing the plasmid into chemically competent Escherichia coli (E.coli). 
In general, the DH5α E.coli strain was used, however for amplification of lentiviral 
plasmids the DNA was introduced into the One Shot® Stbl3 strain of E.coli to reduce 
risk of inducing mutations. All steps followed common microbiological practice, using a 
Bunsen burner to provide the sterile vacuum. 
 
Protocol 
1. One vial of E.coli was thawed on ice prior to being incubated for 30 minutes on ice 
with 1µg plasmid DNA.  
2. Bacteria were heat-shocked at 42°C for 90 seconds and subsequently incubated on 
ice for 5 minutes. 
3. Following addition of 300µL SOC media, samples were shaken at 220rpm for one 
hour at 37°C. During this, agar plates containing the required antibiotic were dried 
in an oven at 37°C.  
4. The E.coli were subsequently centrifuged at 4000g for 5 minutes and 150µL of 
supernatant removed.  
5. Once resuspended in the remaining 150µL SOC media, bacteria were spread onto 
the pre-dried plate and incubated either at 37°C overnight, or at room temperature 
for 72 hours.  
6. The antibiotic used for selection was dependent upon the plasmid being amplified.  
2.5.3.4  Luria broth and Agar plates 
Luria broth (LB-medium) (1L): 
1. Dissolve 10g tryptone, 5g yeast extract, and 10g NaCl in 950mL deionised water. 
2. Adjust the pH of the medium to 7.0 using 1N NaOH and bring volume up to 1 liter. 
3. Autoclave on liquid cycle for 20 minutes at 15 psi. Allow solution to cool to 55°C, and 
add antibiotic if needed (100µg/mL of Ampicillin or 50µg/mL Kanamycin). 
4. Store at room temperature or +4°C. 
LB agar-plates: 
1. Prepare LB medium as above, but add 15 g/L agar before autoclaving. 
2. After autoclaving cool to approx. 40°C, add antibiotic (if needed), and pour into petri 
dishes. 
3. Let solidify, then invert and store at 4°C in the dark. 
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2.5.3.5 Colony Analysis 
Single bacterial colonies were selected using a sterile 200µL pipette tip and submerged 
in 3mL Luria Broth (LB) media containing 100µg/mL Ampicillin. The tubes were shaken 
at 220rpm for 16 hours at 37°C. The following day 2mL of the medium was centrifuged 
at 400xg for 10 minutes to pellet the bacteria. The supernatant was discarded and the 
pellet used for plasmid isolation. Retrieval of plasmid DNA was achieved using 
QIAquick Plasmid MiniPrep Kit (Qiagen GmBH, Hilden, Germany) according to the 
manufacturer’s guidelines. Colonies were subsequently analysed using restriction 
digest with suitable enzymes generating differential sized bands to be visualised using 
gel-electrophoresis and UV exposure. 
2.5.4  Large scale plasmid DNA preparation 
Maxipreps were used for the production of concentrated DNA preparations. 300mL of 
LB was transferred to a 2L conical flask and inoculated with 1mL of fresh culture and 
incubated overnight at 37°C with agitation (220 rpm). Plasmid DNA was extracted 
using Macherey-Nagel NucleoBond Xtra Maxi kit (Macherey-Nagel (GmbH, Hilden, 
Germany) in accordance with manufactures recommendations. The DNA concentration 
following extraction was quantified using Nanodrop spectrophotometry (Thermo 
Scientific, Wilmington, DE, USA). 
2.5.5   Cloning of the AVV knockdown construct 
2.5.5.1 Generation of rAAV vector (GIPZ_ V2LHS_153725 construct) 
A self-complimentary AAV (scAAV) plasmid was used to generate our vector, for 
expressing the shRNA sequence from the GIPZ_ V2LHS_153725 construct. The 
shRNA sequence was generated by PCR amplification, with restriction sites added with 
designing them into the primer sequence. The PCR product of the hairpin was initially 
cloned into the TOPO vector. The sequence was checked within the TOPO vector, 
using standard primers as per manufacture’s recommendations, and the sequence was 
aligned manually using BLAST web based aligning tool to confirm the amplified 
sequence. The insert (shRNA) was subsequently cloned into the scAAV plasmid using 
restriction digest as described in section 2.5.2.2 and cloned using T4 DNA ligase. Two 
different knock down constructs were generated to establish if the miR30 scaffolding, 
and flanking sequence were needed for efficient processing of the shRNA. Control 
constructs were also generated consisting of an empty vector (scAAV_CMV_GFP) and 
a non-silencing (scrambled shRNA) with and without the miR30 regulatory region. The 
shRNA was inserted between the CMV promoter and the GFP (green fluorescent 
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protein) the generated expression cassette is illustrated below. Two control vectors 
were generated; one containing a non-silencing shRNA, and one empty vector 
containing only the CMV promoter and the gene sequence for GFP. All constructs were 
checked by restriction digests and sequenced to confirm insertion of the shRNA. 
 
 
Figure 2.1 Expression cassette for rAAV CMV shRNA GFP 
 
 
Figure 2.1 Examples of mammalian shRNA Lentiviral vectors  
Two of the most commonly used mammalian shRNA expression vectors: the pGIPZ and the 
pLKO.1 construct. Available with a genome-wide shRNA collections and individual clones from 
Sigma (pKL0.1-puro) and Open Biosystems (pGIPZ). pGIPZ carries shRNAs with mir30 flanking 
sequences, whereas pLKO.1-puro carries simple snapback hairpins. A key difference is that 
pGIPZ uses a RNA polymerase II promoter (CMV) for shRNA expression, offering the potential 
for inducible and tissue-specific expression. The pLKO.1 uses a RNA polymerase III promoter 
(U6 promoter), less subject to cell-type-specific variation in its expression(343). Adapted from 
Chang et al. Cold Spring Harbor protocol(679). 
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2.5.5.2 Generation of rAAV vector (pLKO.1) 
Primers were designed to amplify the hairpin with the whole expression cassette 
including the U6 promoter as well as the Puromycin-resistance selection cassette as 
illustrated below including the sequence amplified annotated with primers and genes. 
 
 
Table 2.9 Primers for pLKO.1 expression cassette 
Forward primer 5’ ctaGCGGCCGCaatCCTTCACCGAGGGCCTATTTC  3’ 
Reverse primer 5’ ctaCTGCAGcgtTGGCTAAGATCTACAGCTGCC 3’ 
RE sites added: forward RE: Not1 5’ GCGGCCGC 3’ Reverse RE: Pst1 5’ CTGCAG 3’ (All 
primers purchased from Invitrogen, Paisley, UK). 
 
PCR amplification of the expression cassette from the pLKO.1 vector was performed, 
using Phusion® High-Fidelity DNA Polymerase.  The PCR product was identified on an 
agarose gel detected by fluorescence of intercalated ethidium bromide under UV 
illumination. The PCR product was cut from the gel and cleaned up using Qiagen gel 
extraction kit. The PCR product was subsequently A-tailed and cloned into TOPO TA. 
The constructs were verified by sequencing using primers: M13 reverse and M13-20 
according to protocol. Following restriction digest the correct bands where visualized 
on the agarose gel and DNA was extracted from the gel. Generation of the rAAV vector 
constructs, were made using self-complimentary recombinant AAV plasmids. The 
expression cassette contained a CMV promoter and luciferase which was removed by 
restriction digest using Not1 and Pst1 restriction enzymes in a double digest. These 
restriction enzymes were also used to digest the expression cassette (insert) 
(U6_shRNA_PGK_Puromycin) from the TOPO vector. The scAAV backbone was 
dephosphorylated using Calf Intestine phosphorylation (CIP) before the insert was 
ligated into the vector using T4 DNA ligase. The AAV vector 
(pAAV_U6_shRNA_PGK_puro) was digested to confirm insert. Not1/Pst1 enzymes 
confirmed the presence of the insert, and DraIII/Xmn1 enzymes cut within the insert 
and the backbone respectively (right). Not1/Pst1 digest, expected bands: 1834 & 3166. 
Control: pAAV_CMV_Luciferase (bands: 2400 and 3169 bp). DraIII/Xmn1 digest 
expected bands of 1292 & 3708 bp.  pAAV_CMV_Luciferase, contains only the Xmn1 
site linearised by double digest.  
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Transformation of competent cells was undertaken and confirmation of ligation was 
demonstrated by the presence of colonies.  The colonies were picked and grown in LB 
overnight.  Restriction digest was performed on the mini-preps, the size of the insert 
was confirmed and an additional digest was done using restriction enzymes cutting 
within the insert as well as the backbone for further confirmation of successful ligation. 
The ITRs were checked using restriction enzymes Ahd1 or Bgl1 prior to producing 
large-scale plasmid DNA. 
2.5.6 AAV5 production and transduction 
2.5.6.1 Transient transfection 
Transient transfection using PEI and HEK 293T cells for rAAV production: 
PEI (polyethyleneimine, Polysciences cat. 24765 Polysciences Inc, Northampton, UK) 
of which 1g was dissolved in 900mL of water and the pH adjusted with sodium 
hydroxide to pH 7.2 and made up to 1L with water. This was filter sterilised and 
aliquoted for short-term storage at 4°C, and -20°C for long-term storage.  
 
HEK 293T cells (1.5x107 cells/150mm plates, Greiner Bio-One GmbH) were seeded the 
day before transfection. 
 
Table 2.10 Assays for AAV production (40 plates) 
 Mix 1 Mix 2 
DMEM (Serum free) 54mL 64mL 
PEI 3mL - 
HGTI  1.8mg 
Capsid  0.6mg 
Transgene  0.6mg 
 
In preparation for virus production from 40 plates, 6mL of PEI was added to 54mL of 
serum-free medium. In a separate tube, three plasmids were added (1.8mg HGTI, 
0.6mg capsid, 0.6mg transgene) to 64mL of serum free medium. The mixture 
containing plasmid was filtered through a sterile filter (0.2µm) into the PEI mixture, and 
incubated at room temperature for 15 minutes before adding 3mL/plate.  The following 
day the medium was changed to serum-free medium (SFM) and the cells were 
incubated for another 48 hours(680). The virus was harvested by collecting 
supernatant and cells using a cell scraper and then centrifuged at 500g for 10 minutes, 
the supernatant was stored at 4°C until purification was done.  The pellet was 
resuspended in PBS, and following another centrifugation resuspended in 10mL TD 
buffer (100mM NaCl, 2mM MgCl2, 10mM Tris.HCl pH8). The lysate was stored at -
Targeted therapy for chordoma   
 111 
80°C. For the virus to be released from the cells, the cell lysate was freeze/thawed 5 
times using liquid nitrogen and a water bath at 37°C. The cells were vortexed between 
each freeze/thaw cycle. 
2.5.7 Purification of AAV5 with AVB Sepharose column 
The cell lysate was thawed at 37°C and the supernatant, was placed in the water bath 
before adding MgCl2 (1M) and benzonase (Sigma Aldrich)(50units/mL or 2units/10µL) 
and incubated for 30 minutes at 37°C.  The solutions were then centrifuged at 3000g 
for 30 minutes at 4°C, the supernatant was gently removed from both cell lysate and 
supernatant, and filtered through a 0.2µm sterile filter before mixing prior to purification.  
The AVB Sepharose column (GE Healthcare UK Ltd, Buckinghamshire, UK) was set 
up according to protocol. Collecting tubes were prepared by adding 30µl Tris pH 8.8 to 
each tube to neutralise the glycine elution buffer. The sample was run through the AVB 
Sepharose column and eluted into the collecting tubes. Tubes from the second peak 
on the 260 and 280 graphs, were collected and pooled together, the waste from the run 
through was collected and run through the AVB Sepharose column a second time to 
collect as much virus as possible. Slide-A-Lyzer™ dialysis cassette (Life technologies), 
which facilitates effective dialysis, was briefly immersed in PBS, before injecting the 
virus into the cassette. The virus was then dialysed in 2 litres of PBS at 4°C stirring for 
12-16 hours. The dialysed virus was sterilised by filtration through a 0.2µm filter and 
stored at 4°C. 
2.5.7.1 Alkaline gel electrophoresis titration 
For quantifying viral DNA viruses were run on denaturing alkaline gels and the band 
intensity was quantified by comparison against a standard DNA ladder I (Bioline, 
London, UK). Gels were made by dissolving 1g of agarose in 98mL water heated in a 
microwave, when cooled below 50°C 2mL of alkaline buffer (2.5M NaOH (50g), 50mL 
0.5M EDTA (pH8.0) made up to 500mL of deionised water) was added. The gels were 
then cast and cooled further. 
 
Alkaline sample loading buffer made from 200µL glycerol, 80µL 50X alkaline running 
buffer, 60µL 20% Ficoll (GE Healthcare UK Ltd, Buckinghamshire, UK), and xylene 
cyanol (enough to colour- dip pipette tip in powder)(Sigma) made up to 1mL of water 
8.5µL of loading buffer was added to 25µL of sample (virus). Samples were mixed and 
placed on ice. The samples were then loaded onto the gel and run at 20V overnight in 
a cold room (4°C).  
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The next day the gel was washed for one hour in 300mL 1M Tris pH 8.0 with agitation. 
Gels were then transferred to 100mL of 4X Gelred (Cambridge Bioscience, Cambridge, 
UK) solution (prepared in 0.1M NaCl) and left for 2 hours in darkness with agitation. 
After rinsing twice with tap water the gel was imaged for quantification of viral DNA 
using Genesnap (Syngene) software. Output raw volume and background values for 
the intensity of each band were exported into an excel file. To calculate viral titre, 
background was subtracted from raw volume to obtain net volume values and a 
standard curve was generated by plotting ng of DNA in the Hyperladder against 
corresponding net volumes. The equation from the chart was used to calculate ng of 
DNA in each sample. To derive at a DNA concentration in ng/mL values were 
multiplied by 40. Viral titre was then calculated determining the number of AAV 
genomes in the given amount of DNA (based on the length of the viral genome in 
question). 
2.5.7.2 Quantification of AAV titre by qPCR 
The titre was determined against a standard curve generated from the plasmid used for 
virus production. The plasmid was linearised by a single cutter restriction enzyme and 
nano-dropped in order to calculate copy number. Serial dilutions (1:10) were made to 
generate the standard curve (1x109-1x103). Each virus was quantified in three dilutions 
(1:100, 1:1000 and 1:10000). 
 
Table 2.11 Primers for RT qPCR viral titration 
Forward GFP GACGGCAACATCCTGGGGCACAAG 
Reverse GFP CGGCGGCGGTCACGAACTC 
Forward U6 ACGATACAAGGCTGTTAGAGAGA 
Reverse U6 AAAACTGCAAACTACCCAAGAAA 
Forward U6_2 ATCCTTCACCGAGGGCCTAT 
Reverse U6_2 TCTCTCTAACAGCCTTGTATCGT 
All primers were purchase from Invitrogen, Paisley, UK. 
 
 
Table 2.12 Assay for SYBR green RT qPCR viral titration 
SYBR green master mix 12.5µL  
Forward primer (2.5 µM) 1µL  
Reverse primer (2.5 µM) 1µL  
Water 0.5µL  
Total (master mix)  15µL 
Sample or standard  10µL 
  
Samples and standards were run in triplicate. Water was used as a negative control. 
Cycle conditions used: 95°C for 5 minutes, 95°C for 10 seconds and 60°C for 30 
seconds. A melting curve was inserted in order to review the reaction and the accuracy 
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of the primers. Viral particles per mL was calculated as average of the diluted samples 
(1:100, 1:1000 and 1:10000) multiplying by dilution factor and 100 to obtain titre/mL.  
2.5.7.3 AAV5 transduction of U-CH1 
Cells were washed with PBS prior to transduction and serum-free medium was used 
for transduction. A Multiplicity of Infection (MOI) of 1x105 (multiplicity of infection) was 
used after optimisation confirmed that increasing the MOI did not improve transduction 
efficiency. Virus was added to serum-free medium and applied drop-wise to the cells. 
The plate was gently shaken at regular intervals over the following 6-7 hours at which 
point the medium was topped up with serum containing medium. Calculation for 
determining the amount of virus to be added:  ((number of cells x MOI) / titre) x1000 = 
µL virus.  
2.5.7.4 WST-1 proliferation assay  
Water Soluble Tetrazolium Salt (WST1) assay (Roche), a cell proliferation reagent is a 
colourimetric assay designed to measure the relative proliferation rates of cells in 
culture. The assay principle is based on the conversion of the tetrazolium salt WST-1 
into a coloured dye by mitochondrial dehydrogenase enzymes. The soluble salt is 
released into the media. Within a given time period, the reaction produces a colour 
change, which is directly proportional to the amount of mitochondrial dehydrogenase in 
a given culture. As a result, the assay actually measures the net metabolic activity of 
cells which is reflective of cell number i.e. the more cells, the more dehydrogenase 
available to reduce the reagent. By the same reasoning, cell viability can be measured. 
 
Cells were seeded 5x104 in 96 well plates, 3 plates were seeded for end-point assays 
for 3 different time points (24 hours, 48 hours and 72 hours) the assay was read at time 
30 minutes only on day 1 (24 hours) to have a starting point for the readout. The end 
point readout was then done at 4 hours for time point 24, 48 and 72 hours. Each 
condition was seeded in triplicates and the average was used for generating the data. 
Puromycin selection was commenced 48 hours after transduction and maintained for 
72 hours. The end point readout was then done at 4 hours for time point 24, 48 and 72 
hours. Each condition was seeded in triplicates. The average was used for generating 
the data. 
2.6 Lentivirus production and transduction 
2.6.1 Transient transfection 
Transient transfection using PEI and HEK 293T cells for lentiviral production: 
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PEI (polyethyleneimine, Polysciences cat. 24765) of which 1g was dissolved in 900mL 
of water and the pH adjusted with sodium hydroxide to pH 7.2 and made up to 1L with 
water. This was filter sterilised and aliquoted for short-term storage at 4°C and -20°C 
for long-term storage. Third-generation VSV-G pseudo-typed high titres lenti viruses 
were generated by transient co-transfection of 293T cells with a three-plasmid 
combination. 
 
Plasmid: DNA (2 plates) 
KGP3R 4.6µg 
RTR2 2.4µg 
VSVG 5µg 
Transgene 48µg 
 
HEK 293T cells (1x107) were seeded into 15cm plates (Greiner Bio-One, GmbH) the 
day before transfection in 15mL of DMEM medium. For a small preparation of 
Lentivirus, 2 plates were used. 
Preparation for 2 plates included: 3mL of serum-free medium mixed with 120µL of PEI. 
In a separate falcon DNA (as above) was added to 3mL of serum-free medium. The 
mix with DNA was then filtered (0.2µm sterile filter) into the serum-free medium 
containing PEI, mixed well and incubated at room temperature for 20 minutes. 
Following incubation 3mL were added drop-wise to each plate. After 12-16 hours the 
medium was replaced by fresh medium, as the PEI is toxic to the cells. Supernatant 
was harvested at 36 and 48 hours post transfection. The supernatant from the 1st 
harvest was spun at 1500rpm for 10 minutes, filtered and stored on ice at 4°C until 
after the 2nd harvest when the supernatant was mixed and ultra-centrifuged at 25000 
rpm for 90 minutes at 4°C (Beckman ultra-centrifuge, Beckman Coulter Life Sciences, 
High Wycombe, UK). The supernatant was discarded and the virus (pellet) was 
resuspended in 200µL of serum-free medium, kept on ice for the pellet to dissolve for 
an hour, and then put in 20µL aliquots before storing at -80°C. 
2.6.2 Titration of lentivirus 
The viral titre was determined using a “Lentivirus qPCR Titre kit” from Gentaur Ltd 
London, UK. (Cat. Number LV900). This one step lentiviral vector titration employs a 
quick RNA extraction step, which is followed by a qRT-PCR assay.  The viral RNA was 
extracted using a virus lysis buffer. The viral RNA was then mixed with reagent 
containing primers and Reverse Transcriptase (RT). The qPCR-RT program used: 
42°C for 20 minutes, 95°C for 10 minutes, 95°C for 15 seconds and 60°C for 1 minute 
the last two steps are repeated x40. Standards were provided with the kit. 
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2.6.3 Lentivirus transduction of U-CH1 
U-CH1 cells (5x105 cells/dish) were seeded in a 10 cm tissue culture dish the day 
before transduction. Cells were transduced with MOI of 10. Viral titres attained were: 
Lenti_pLKO.1_5484 (7.5x109 viral particles/mL), Lenti_pLKO.1_NS (1.76x109 viral 
particles/mL), Lenti_GIPZ_V2LHS_15327 (1.01x109 viral particles per mL).   Virus was 
thawed and then kept on ice. The required amount of virus was added to 100µL of 
serum-free medium before being put onto the cells in their medium (without antibiotics). 
Polybrene was not used on the U-CH1 cell line, as this was found to be toxic to the 
cells. 
 
72 hours following transduction Puromycin (5µg/mL) was added for selection, un-
transduced U-CH cells were used as a control for the Puromycin selection. After 96 
hours of Puromycin selection, when all un-transduced control cells had been killed by 
the Puromycin, the transduced cells were harvested for RNA extraction (QIAzol), cDNA 
was generated (GoScript Promega) for quantification of RNA expression by qRT-PCR 
as described in methods. U-CH1 cells were also transduced with a lentiviral vector 
expressing luciferase and Puromycin in order to generate a U-CH1 cell line, which 
stably express luciferase. 
2.6.4 Lentiviral transduction  
Polybrene (hexadimethrine bromide, Sigma-Aldrich, St. Louis, MO, USA) was used at 
8µL/mL for transduction of HEK 293T cells. This was added to serum-free medium and 
virus mix prior to infection of the cells. Transduction was performed as described for U-
CH1 except cells were grown in 6 well plates. 
 
For assessment of toxicity of the silencing construct in multiple control cell lines 5x105 
cells were seeded in 6-well-plates and transduced the following day with the lentiviral 
vector pLKO.1_5484 targeting brachyury and the pLKO.1_non-silencing vector using 
an MOI of 10. Puromycin selection was commenced 48 hours post-transduction and 
maintained for 72 hours.  
2.6.5 Transfection of U-CH1 cell line 
Transfection of UCH-1 cells has been optimised using different transfection reagents, 
as well as testing transfection by nucleofector technology (Lonza Cologne GmbH). 
XtremeGene HP (Roche, Diagnostics Ltd. Burgess Hill, West Sussex, UL) was the 
reagent, which gave the best result in the U-CH1 cell line. Transfection was performed 
using 1µg DNA to 3µL of XtremeGene HP. DNA was diluted in 100µL of serum-free 
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medium and XtremeGene HP was added directly in to the serum-free medium with the 
DNA mix and incubated for 15 minutes. Following incubation the mix was added drop-
wise to the cells in their normal medium without antibiotics. The transfected cells were 
then left in the incubator for 24-72 hours depending on the experiment and the time 
required to generate the results. For GFP expression cells were harvested at 24 and 
48 hours. For the shRNA knockdown experiment cells were left for 72 hours at which 
point Puromycin selection was initiated. Transfections were done in duplicate or 
triplicate. 
2.6.6 Transfection of HEK 293T cells 
Fugene transfection reagent (Roche diagnostics Ltd) was used for transfection of HEK 
293T cells, and HEK 293T_brachuyry-expressing cells. Transfection was performed 
using 1µg DNA to 3µL of Fugene. DNA was diluted in 96µL of serum-free medium. 
Fugene was added directly in to the serum-free medium/DNA mix and incubated for 15 
minutes. Following incubation the mix was added drop-wise to the cells in their normal 
medium (no antibiotics). The cells were then monitored for 24-72 hours depending on 
the experimental end-point. 
2.6.7 GFP quantification 
Efficiency transduction and transfection was assessed by quantification of GFP 
2.6.7.1 CYAN flow cytometry analysis 
Cells were prepared by trypsinising and pellets were resuspended in PBS with 1% 
Bovine Serum Albumin (BSA) and filtered through a cell strainer. Samples were 
analysed using a CyAn ADP flow cytometry analyser and Summit v4.3 Software 
(DakoCytomation, Redwood City, CA. USA).  
2.6.7.2 IncuCyte, kinetic imaging system 
The IncuCyte (Essen BioScience, Inc. Michigan USA) is an imaging system that allows 
long-term, live-cell imaging. It can be utilised for documenting cellular proliferation, 
behaviour, and morphology. This was used to monitor GFP expression in U-CH1 cells 
transduced with AAV5 vector-expressing GFP. Cells were placed in the Incucyte 
imaging system in a 6 well plate and were monitored using a computer software 
program (Incucyte Zoom, Essen BioScience) downloaded to the desktop. The setting 
options allow monitoring and imaging of the cells at various time-intervals. 
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2.7 Molecular biology: Nucleic acid 
2.7.1 DNA extraction 
Cells were trypsinised, pelleted and resuspended in 200µl PBS. Genomic DNA was 
extracted using proteinase K (Qiagen, GmBH, Hilden, Germany) according to the 
manufacturer’s protocol for “DNA purification from Blood or Body fluids”. Briefly, 200µL 
of Buffer AL was added and sample was pulse-vortexed and subsequently incubated at 
560C for 10 min. After brief centrifugation 200µL of 100% ethanol was added and 
samples were applied to separate QIAamp spin columns. Washing steps with buffers 
AW1 and AW2 were performed and DNA was eluted in 50-100µL of buffer AE. DNA 
was stored at -200C 
2.7.2 RNA extraction 
Total RNA was extracted from cell lines using miRNeasy Mini Kit (Qiagen). Cells grown 
in 175T flasks were trypsinised and collected as a cell pellet prior to lysis. Cells grown 
in wells were lysed directly in the plate. Medium was aspirated and cells were washed 
with PBS. Cells were lysed adding QIAzol lysis reagent (QIAGEN). RNA was extracted 
according to protocol “Purification of Total RNA from Animal cells”. Briefly, 140µL of 
chloroform (Sigma-Aldrich) was added for phase separation and following 
centrifugation the aqueous phase was carefully removed and mixed with 1.5 times the 
volume of 100% ethanol (VWR International Ltd, Lutterworth, UK). Samples were 
centrifuged in RNeasy mini spin columns (Qiagen). On-column DNase digestion was 
performed and multiple washing steps were performed using RWT and RPE buffer. 
RNA was eluted in 30-50µL of RNase-free water and frozen at -800C. 
2.7.3 cDNA synthesis 
Reverse transcription of RNA to cDNA was performed according to the manufacture’s 
instruction using GoScriptTM Reverse Transcription system; First-strand cDNA 
synthesis (Promega, Madison, WI, USA) utilising equivalent amount (up to 5µg) of 
RNA. 
2.8 RT qPCR 
Brachyury expression at RNA level was assessed using RT qPCR. Total RNA was 
isolated from cells using the QIAzol Lysis Reagent (QIAGEN) with miRNeasy Mini Kit 
according to the manufacturer’s protocol. Total RNA was reverse transcribed using 
GoScript reverse Transcription system (Promega). Quantitative PCR was performed 
using Taqman Universal Master Mix II no UNG (Applied Biosystems, Invitrogen).  
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100ng cDNA were amplified as follows: 95°C for 10 minutes, 95°C for 15 seconds, 
60°C for 30 seconds, 60°C for 30 seconds. Steps 2 through 4 were repeated for 40 
cycles. Each reaction was performed in triplicate. Results were normalised to those for 
PGK. The comparative threshold cycle (Ct) method with the calculation of 2-
[delta][delta]Ct was used to assess the relative level of expression of brachyury. 
 
Table 2.13 Primers for Taqman assays and SYBR green assays 
Primer Brachyury TQM probe (FAM) 5’ CTCACCAACAAGCTCAACGGAGGG 3’ 
Endogenous PGK TQM probe (VIC) 5’ CCTTGGAGAGCCCACAGCGACCCT 3’ 
  
Brachyury (3BF) forward primer 5’ CCCGTCTCCTTCAGCAAAGTC 3’ 
Brachyury (4BR) reverse primer 5’ TGGATTCGAGGCTCATACTTATGC 3’ 
PGK forward primer 5’ GAAGAAGGAGCTGAACTACTTTGC 3’ 
PGK reverse primer 5’ TGATGAGCTGGATCTTGTCTG C 3’ 
 
GAPDH (cDNA) forward primer 5’ GGAGTCAACGGATTTGGTCGTA 3’ 
GAPDH (cDNA) reverse primer 5’ GGCAACAATATCCACTTTACCAGAGT 
GAPDH (gDNA) forward primer 5’ GAGGTAGAGGGGTGATGTGGGGAG 
GAPDH (gDNA) reverse primer 5’ GTGGCAGTGATGGCATGGACTGTGG 
TENM3 forward primer (exon 24/25) 5’ GTGTCTCGGGTCTTTGCTGA 3’ 
TENM3 reverse primer (exon 24/25) 5’ GATGTACTGCCGCTGGCTAT 3’ 
 
2.9 Compound screen 
2.9.1 Control cell line  
Normal adult human dermal fibroblasts: NAHDF 
Order from LGC (ATCC UK distribution) 
Queens Road, Teddington, Middlesex, TW11 0LY UK 
 
Dermal fibroblast, human adult product: PCS-301-012  
Fibroblast basal medium: PCS-201-030  
Fibroblast growth kit, low serum: PCS-201-041    
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2.9.2 Materials 
Table 2.14 Materials for compound screen 
 
2.9.3 Quality control criteria  
Quality control criteria in this study included the effect on cell viability and morphology: 
using the multi-drop combi (MDC) for seeding cells, viability and signal stability of 
WST1 assay determining timing of read out of the end-point assay, and the optimum 
number of cells to seed for each cell line was established, and the time-point for the 
cells reaching 90% confluency. In addition the tolerance for DMSO (dimethyl sulfoxide) 
was established to assess the effect as the assays needed to be configured according 
to the cell lines sensitivity to the concentrations of the solvent, as this was used for the 
initial dilution of the compounds.  
2.9.4 Assay performance and optimisation 
The signal window for each assay plate was defined by the controls (cells + 0.25% 
DMSO) and blanks (cells + 30µM Staurosporine) for which there were eight replicates 
of each. Robust Z factors were calculated using robust controls and robust blanks to 
measure signal window range and variance. The acceptance threshold of >0.4 was 
implemented due to inherent variability of the signal window for each cell line. All assay 
plates for each cell line came back with Z Factors >0.4. The Z-factor is defined in term 
of four parameters: the means and standard deviations of both the positive and 
negative control. In high-throughput screens, a large number of single measurements 
of unknown samples are compared to positive and negative control samples. The Z-
factor is an attempt to quantify the suitability of a particular assay for use in a full-scale, 
Reagent/Consumable Supplier Catalogue number 
Cell Lines Flanagan lab  
Media Flanagan lab  
Staurosporine Sigma S4400 
White Walled 96 Clear Bottom TC 
Plates, Lid, Sterile (Corning) 
Sigma CLS3610 
CellTiter-Glo Assay (100mL) Promega G7572 
Caspase-Glo 3/7 Assay (100mL) Promega G8092 
384LDV ECHO Compatible Plates Labcyte LP-0200 
384PP Plates Matrix 
Technologies 
4314-11 
ECHO 550 LabCyte  
Multidrop Combi (MDC) Thermofisher  
Multidrop Standard Cassette Thermofisher  
Pherastar BMG Labtech  
Biomek FX Beckman  
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high-throughput screen. Zhang and colleagues developed a method to quantify the 
quality of an assay(681). 
 
 
Z-factor is defined as the result of the following calculations.  
1.  Compute the threshold value for negative controls as the mean signal of the 
negative controls plus three times their standard deviation. 
2. Compute the threshold value for positive controls as the mean signal of the 
positive controls minus three times their standard deviation. 
3. Compute the difference between the two thresholds and call it the 'separation 
band' of the assay, S. If the threshold computed in step 1 is less than the one 
computed in step 2, then this difference is positive. Otherwise, this difference 
will have a negative value. 
4. Compute the absolute value of the difference between the two means and call it 
the 'dynamic range' of the assay, R. 
5. Compute the Z as S/R 
 
To interpret the Z-factor, use these guidelines (direct from Zhang's paper). 
 
A Z-factor of 1  
An assay can never have a Z-factor of 1.0.  This value is approached when you 
have a huge dynamic range with tiny standard deviations.  
Z-factors can never be greater than 1.0. 
A Z-factor between 0.5 and 1.0 is an excellent assay. 
A Z-factor between 0 and 0.5 is marginal. 
A Z-factor less than 0 means that the signal from the positive and negative controls 
could overlap, making the assay not very useful or screening purposes. 
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2.9.4.1 Effect of multi-drop combi on cell viability  
The effect on cell viability, following cell seeding by Multi-Drop Combi (MDC) (Thermo 
Fisher Scientific) used for equal automated distribution of cells, was done by 
assessment of morphology and use of the viability assays: WST-1 and Cell Titre glow 
(CTG). Viability was compared with previous data on manual (pipette) seeding of cells.  
2.9.4.2 Evaluation of WST-1 assay 
WST previously discussed in section 2.5.7.4. WST-1, cell viability and proliferation 
assay was used to determine cell survival. The WST-1 assay signal stability was 
assessed as part of the optimisation and quality control. Cells were seeded using the 
MDC and treated the following day with Staurosporine in a 10 point IC50 format (10 
doses across the plate), to establish the robustness of the assay format and 
reproducibility with automation (n=2). A 96-well absorbance assay was set up using 
three Chordoma cell lines, MUG Chor, U-CH1 and U-CH2. Assay technology used was 
the WST-1 cell viability kit from Roche. Method used was as stated by the 
manufacturer. The WST-1 assay was measured at regular interval to monitor if the 
signal was stable to determine the optimal time point for reading the assay. Importantly 
this had to be done before the point of saturation was reached.  
 
WST-1 cell proliferation reagent is a colourimetric assay designed to measure the 
relative proliferation rates of cells in culture. The assay principle is based on the 
conversion of the tetrazolium salt WST-1 into a coloured dye by mitochondrial 
dehydrogenase enzymes. The soluble salt is released into the media. Within a given 
time period, the reaction produces a colour change, which is directly proportional to the 
amount of mitochondrial dehydrogenase in a given culture. As a result, the assay 
actually measures the net metabolic activity of cells. Theoretically, this is reflective of 
cell number – the more cells, the more dehydrogenase available to reduce the reagent. 
By the same reasoning, cell viability can be measured. 
2.9.4.3 Optimisation of cell density 
Cell proliferation and optimum numbers of cells for seeding were assessed in the 
planning process. Cells were seeded manually in densities of 6x103, 5x103, 3x103 and 
2x103 cells per well in 90µL medium, in a 96 well plate. The confluency was assessed 
by light microscopy aiming for cells to be at 90% confluency at 120 hours. 
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2.9.4.4 Cell tolerance of DMSO 
Cells were seeded by MDC. DMSO was tested in a dilutional format in a 96 well plated. 
WST-1 assay was used to assess the effect on proliferation.  
2.9.5 Overview of compound screening 
 
2.9.5.1 Single point screening 
The compound screen was done using two kinase libraries, which were, screened 
‘blind’ (PKIS1 and PKIS2) provided by GlaxoSmithKline (GSK). The screen was 
performed against pharmacologically active libraries held at CRT, namely the 
Calbiochem and Anti-Cancer libraries. The initial screening consisted of a high 
through-put screen (HTS), performing a single-point screen of approximately 1100 
compounds using a cell viability endpoint assay. The compounds were tested in three 
well-characterised chordoma cell lines as models of disease. The compounds were 
screened at a concentration of 1µM based on experience gained from the collaboration 
with CRT and information provided by GSK regarding the potency of individual 
compounds in vitro for cell-based assays(682). The experiments in the screen were 
done in duplicate and in replicates using an automated screening format.  Compounds 
causing a decrease in viability of more than 2 standard deviations (CI 95%) compared 
to the DMSO-controls (negative control) were regarded as hits. Staurosporine (SSP, 
1µM, Calbiochem, Nottingham, Nottinghamshire) at 1µM concentration was used as 
positive control. Common and selective hits of each cell line was taken forward for IC50 
profiling.  
SP#Screen##
! UCH1&Cells&
! &UCH2&Cells&
! &MUG.Chor1&Cells&
IC50#Conﬁrma0on#of#Hits#
! UCH1&Cells&
! &UCH2&Cells&
! &MUG.Chor1&Cells&
Counter#Screen##
!&Normal&Human&Adult&Dermal&
Fibroblasts&(Primary&Cells)&
Mechanism#of#Cell#Death#(IC50#)#
! !&UCH1&Cells&
! !&UCH2&Cells&
! &!&MUG.Chor1&Cells&
1153#Compounds#
227#Hits##
227#Hits##
28#
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Compounds were screened in parallel in the single point screen with all compounds 
run in separate experiments (n=3). For each run of a total of 30 plates/run with10 
plates/cell line, with a total of ~5 x T150 flasks for each cell line per was needed per 
run. 
 
Protocol: 
Day 1: 5x103 cells/ well of U-CH1 and MUG Chor, and 2.5x103 cells/well for U-CH2 
cells were seeded by multi-drop combi (MDC) into 96 well plates 90µL/well. 
Day 2: The compounds were aliquoted in 382 well mother plates at either 10 or 12mM 
concentration. Pre-dispensed daughter plates were generated with 100x the final 
concentration (1µM for single-point screening) in 2.5% DMSO. The plates were 
prepared by ECHO 550 and frozen in 384-format. Daughter plates were thawed for one 
hour at room temperature and sterile PBS was added to all wells at the required 
volume to dilute compounds to 10x the final concentration. 10µL of compound was 
then transferred from daughter cell to assay plate using the Biomek FX automated drug 
dispenser (96 head) (Beckman Coulter). DMSO (0.1%) was used as a negative control, 
and Staurosporine was used as a positive control. The compound-treated cells were 
incubated for 96 hours at 37ºC.  
Day 6: WST1 assay was used to determine cell survival after 96 hours (the time point 
had been established in our optimisation experiments, aiming for a >90% confluence of 
control). 10µL of WST1 assay was dispensed using the Multi Drop Combi. The assay 
was incubated for 3 hours at 37ºC. Absorbance was read using a read-out at 440nm 
(maximum absorbance-spectrum of the dye) using a PHERAstar FS plate reader (BMG 
Labtech). Media controls containing the same amount of WST1 served as blanks. The 
raw data files were imported into the software programme: ActivityBase Visualisation 
by Vortex (Dotmatics) and analysed. CRT automated equipment was used.  
 
Frequent calibration of equipment was undertaken to ensure minimal variation in the 
low-volume liquid dispensing. In addition the signal window for each assay plate was 
defined by the controls (cells + 0.25% DMSO) and blanks (cells + 30µM Staurosporine) 
for which there were eight replicates of each. Robust Z’ Comparison of data was done 
between different runs to ensure comparability between experiments. 
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Automation pipeline for compound screening; MDC = multidrop combi, Cpd = 
compounds. 
 
2.9.5.2 IC50 point compound screen 
Confirmation of hits identified by the single-point screen was done using the IC50 
format, with compound screening done in a 10-point dose response format with a top 
concentration of 20-30µM for all compounds, and a final DMSO concentration of 0.25% 
n=2. The % inhibition documented from the single-point screen was compared with the 
nearest equivalent dose (750nM) from the IC50 screen. 
 
Day 1: Decontamination of the MDC cassette was performed with 50mL of 70% IMS, 
followed by 50mL of sterile PBS and then priming the cassette with 50mL of complete 
media. Cells were seeded (90µL/well) at defined cell density (5x103 cells/well U-CH1 
and MUG Chor, 2.5x103 cells/well UCH-2) into 96 well plates in columns 1-11. Cells 
were added to wells 12A-D (Staurosporine control) and medium only (background) to 
12E-H manually. MDC speed setting: Medium. Two plates were seeded for each time 
point, per cell line. The MDC cassette was decontaminated MDC between cell lines as 
aforementioned, and cells were incubated o/n at 37ºC, 5% CO2, 80% humidity. When 
the seeding was completed, the MDC cassette was decontaminate with 50mL 70% 
IMS. 
Day 2: Compound treatment of plates (10-point IC50 format) was prepared 24 hours in 
advance at a 100x final assay concentration from 12mM/10mM compound stocks using 
the ECHO 550 (ECHO dispenses required dilution of compound, but 10x the final 
assay concentration was achieved when PBS was added on day 2). The ‘mother’ 
plates were in a 384 well format with compounds from which ‘daughter’ plates were 
generated by serial dilution at 1:3 from a top concentration of 300µM (100x) (for a final 
top concentration of 20-30µM). Staurosporine was the reference compound at one 
concentration and located in all wells of columns 23 and 24 at 300µM. DMSO was 
used as the control and was located in all wells of columns 21 and 22. Once prepared, 
100x daughter plates was sealed (DMSO resistant foil seal) and frozen at minus 20ºC 
for 24 hours. Daughter plates were removed from the freezer and allowed to defrost at 
room temperature (RT) for 1.5 hour. Sterile PBS was equilibrated to RT. The MDC 
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cassette was decontaminated as described, but only primed with sterile PBS. The 
required volume of sterile PBS was added to all wells to bring the plates to the 10x 
concentration. Plates were sealed and left at RT for 15 minutes. The Biomek FX was 
decontaminated using Azowipes. The program was set up according to programme 
’96x4_Transfer_from_384_Version 16’. Assay plates were placed in the required 
spaces according to the programme. Sterile p20 96 well tips were placed in tip loader 
in between cell lines/mother plates. Lids were removed from assay plates. It was then 
indicated in the programme to transfer 10µL (diluted 10µL into 90µL to final 
concentration 1x) from relevant wells in daughter plate to assay plate. The programme 
stamped out each assay plate in duplicate. Eight plates per cell line were compound 
treated with the same compounds (e.g. from red locations in Figure 8) transferred to 8 
x 96 well plates). The assay plates were placed back in the incubator at 37ºC, 5% CO2, 
80% humidity until assay end point. The MDC was decontaminated with 50mL 70% 
IMS. 
Day 6: WST-1 reagent was defrosted at RT. The MDC was decontaminated with 50mL 
70% IMS followed by 50mL PBS. The MDC cassette was then primed with WST-1 
reagent. 10µL of WST-1 reagent was added to all wells of each assay plate and 
incubated at 37ºC, 5% CO2, 80% humidity between 2 to 3 hours before reading on 
Pherastar FS using ‘Chordoma Abs 96’ protocol. The MDC was decontaminated as 
before with 50mL 70% IMS. 
2.9.6 Summary of analysis  
EC50 values were used as a measure of potency for the effect of a compound 
exerted on molecular targets. Values were determined from graphical plots of 
percentage inhibition vs. log [µM]. IC50 and EC50 can both be used as a measure of 
potency, however for using IC50, a classic sigmoidal graphical profile would be 
expected spanning between 0 to 100% inhibition. EC50 is defined as the 
effective concentration, which elicits a half-maximal response (e.g. half way between 
the baseline and maximum response). In order to compare a compound that 
demonstrated heterogeneity, EC50 is the preferred measure of potency. In regard to 
this project, EC50 was used due to the nature of the data (baseline/maximum response 
was different between cell lines and did not always span 0 to 100% inhibition). 
 
Raw data was converted to % inhibition and was plotted against [Log]. % Inhibition = 
100*(1-(Sample – Mean Blank)/(Mean Positive – Mean Blank)). Potency was 
calculated by method of EC50 (due to the biased of Max/Min % Inhibition of the 
graphical profiles). Max % Inhibition was used as a tool to characterise compound 
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activity in conjunction with the EC50 (concentration of the compound which elicited 50% 
growth inhibition of the maximal response). EC50 values [µM] were converted to pEC50 
values (-Log) to allow for easy comparison. pEC50 scale equals the inverse of molarity 
(pEC50 of 6 = 1µM or 9=1nM).  
 
Compounds with a Max Inhibition (Maximal Response) of less than 40% were classed 
as inactive and were reported as 30µM (or >30µM). Compounds, which were 
potentially biphasic, were given an artificial potency of 100µM (pEC50 = 4) as EC50 
cannot be calculated accurately on these types of curves. 
  
Hit Confirmation Rate  (HCR) characterises ability of a compound to reproduce activity 
over several experiments. 
 
Hit confirmation rate (%) = (Number of confirmed compounds/Total Hits)*100 
 
 
Figure 2.2 Illustration of IC50 in EC50 confirmation of hits 
EC50 indicates 50% efficacy in a dose-response-profile, IC50 indicates 50% inhibition in dose-
response-profiling, the latter being most informative in a setting where the sigmoidal graphical 
profiles span between 0 to 100% inhibition. EC50 values are more informative for comparison 
between heterogeneous profiles. 
2.9.7 Hit selection criteria and calculations of EC50 
Three runs of experiments were performed in four replicates for each cell line (U-CH1, 
U-CH2, MUG-Chor). Raw data were converted to percentage inhibition and Z-scores 
were calculated.  The signal window for each assay plate was defined by the controls 
(cells + 0.25% DMSO) and blanks (cells + 30µM Staurosporine) for which there were 
eight replicates of each. Robust Z Factors were calculated using controls and blanks to 
measure signal window range and variance. Common hits across all cell lines as well 
as cell line specific selective hits above a threshold of 2 standard deviations (CI 95%) 
were selected unless otherwise stated. The half-maximal inhibitory concentration 
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(EC50) was generated by testing a range of 10 concentrations from 1nM to 30µM in an 
automated format (IC50). WST1 was used as an endpoint assay.  
 
Within each run (n number) a standard compound, Staurosporine, was also tested in a 
10-point dose response format at random alongside the test compounds. The pEC50 
of each dose response was tracked to ensure reproducibility between each run. A 
potency acceptance range for each cell line measured reproducibility: Geomean ± 0.3 
(equivalent to a 4-fold acceptance range of the mean pEC50 value). 
2.9.8 Mechanism of cell death assay 
The inhibition of cell growth may be brought about by a combination of mechanisms 
including apoptosis, alterations in cell cycle progression, cell senescence, autophagy, 
and increased toxicity leading to cell necrosis. Markers for apoptosis and cell viability 
were assessed.  
 
Two 96-well luminescent assays were used to determine induction of apoptosis and 
cell viability, Caspase-Glo 3/7 (CG)(Promega) and CellTiter-Glo (CTG) (Promega) 
respectively. Each assay was performed on separate plates (at each time point) as 
both were lytic based. Method used was as stated by the manufacturer. Time points 
tested were 6, 24, 48 and 72 hours. 
 
Caspase-Glo 3/7 assay provides a proluminescent caspase-3/7 DEVD-aminoluciferin 
substrate and a proprietary thermostable luciferase in a reagent optimized for caspase-
3/7 activity, luciferase activity and cell lysis. Adding the single Caspase-Glo 3/7 
Reagent in an "add-mix-measure" format results in cell lysis, followed by caspase 
cleavage of the substrate. This liberates free aminoluciferin, which is consumed by the 
luciferase, generating a "glow-type" luminescent signal. The signal is proportional to 
caspase-3/7 activity. 
 
The CellTiter-Glo Luminescent Cell Viability Assay is a homogeneous method to 
determine the number of viable cells in culture based on quantification of the ATP 
present, which signals the presence of metabolically active cells. The homogeneous 
"add-mix-measure" format results in cell lysis and generation of a luminescent signal 
proportional to the amount of ATP present. The amount of ATP is directly proportional 
to the number of cells present in culture. 
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Compounds were tested using a non-randomised plate layout in a 96-well plate format 
(8 compounds per plate in a 10-point dose response). Profiling was conducted at a top 
concentration of 20-30µM with a 1:3 serial dilution for each test compound in two 
independent experiments. Data analysis was carried out using XLFit (IDBS). Raw data 
files were placed into a dose response template and for cell viability (CellTiter-Glo), 
percentage inhibition was calculated for each well from the raw data using positive 
(Staurosporine treated cells) and negative (DMSO treated cells) controls on each 
assay plate. For caspase-3/7 induction, percentage induction was calculated for each 
well from the raw data using the negative controls (i.e. percentage increase of 
compound treated cells vs. DMSO). All raw data was corrected for background (media 
only) in the first instance.  
 
Time Points 6, 24, 48 and 72 Hours: 
CTG and CG reagent were defrosted at RT, and reconstituted according to 
manufacturer’s protocol. Two plates per cell line were equilibrated in the dark at RT for 
30 minutes. One plate was used for the CG assay and the other CTG assay 
(decontaminate MDC with 50mL 70% IMS followed by 50mL PBS). 
The MDC cassette was primed with CG reagent and 50µL of CG reagent were added 
to all wells of the assay plate. The plates were shaken gently at RT (protected from 
light with a cover plate) for 30 minutes and read on Pherastar FS using ‘Chordoma CG 
96’ protocol (decontaminate MDC with 50mL 70% IMS, followed by 50mL PBS). Next 
the MDC cassette was primed with CTG reagent and 50µL CTG reagent were added to 
all wells of the assay plate. The plates were gently shaken at RT (protected from light 
with a cover plate) for 20 minutes and read on Pherastar FS.  
2.9.9 Data Analysis 
QC metrics were assessed for each assay plate, for each cell line, for both assays (Z 
Factor, percentage Coefficient Variation (CV) of controls/reference compound at one 
concentration). The curves were analysed for each time point.  Caspase Glo calculated 
data was either the fold induction of caspase-3/7 or percentage induction of caspase-
3/7 (treatment well increase in signal relative to DMSO control corrected for 
background). CTG calculated data as percentage inhibition (treatment well within the 
plate, decrease in signal relative to DMSO control, corrected for background). 
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Figure 2.3 Mother Plate and Assay Plate Layout 
(Grey indicates media only in 12E-H). 
2.9.10  Western Blot 
Reagents: 
RIPA Buffer  
Ingredients 
Stock used Total volume (10mL) 
20mM TRIS, pH 7.4   1M pH 7.4 200µL 
150mM NaCl  5M 300µL 
3mM EDTA 500mM pH 8 20µL 
1mM EGTA 250mM pH 8 40µL 
50mM NaF 1M  500µL 
60.5% Sodium Deoxycholate 
(Sigma-S6750) 
100% 50µL 
0.1% SDS 20% 50µL 
1% Nonidet P-40 Igepal® CA630-
I3021 (Sigma) 
100% 100µL 
Fill up to 10mL with dH2O 8.790mL. Keep it at 4o C 
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Add fresh before use: 
Protease inhibitor cocktail (Complete, Roche, 04693116001), 25X stock 
(dissolving one tablet in 2mL water)  
Phosphatase inhibitor Cocktail 2 (Sigma, P5726), use 1:100 
 
Running Buffer 10X (1000mL) 
30g TRIZMA BASE  
144g Glycine  
0.5% SDS  
 
Transfer Buffer 10X (1000mL) 
30g TRIZMA BASE  
Glycine 144g 
 
Transfer Buffer 1X (1000mL) 
200mL Transfer Buffer 10X  
20% Methanol 
 
Blocking Buffer  
PBS-T (Phosphate Buffered Saline with Tween® 20)  
10X Concentration is 80mM Na2HPO4, 1.5M NaCl, 20mM KH2PO4, 30mM KCl, 
0.5% Tween® 20, pH 7.4). 
 
or TBS-T (Tris Buffered Saline with Tween®20) 
For 1L TBS: 24g Tris-HCl (formula weight: 157.6g) 5.6g Tris base (formula 
weight: 121.1g) 88g NaCl (formula weight: 58.4g). 
Dissolve in 900mL distilled water. 
For 1L TBS-T: 100mL of TBS 10x, 900mL distilled water, 1mL Tween® 20 
Bovine Serum Albumin (BSA) / Non-fat dried milk (Milk) 5% (5g) 
 
5X Laemmli Buffer (50mL) 
10% w/v SDS (5g) 
50% w/v glycerol (25mL) 
0,125% w/v bromophenol blue (5mL) 
250mM Tris pH 6.8 (12.5mL of a 1M stock Tris pH 6.8) 
2mM 2-mercaptoethanol (7.5mL) 
 
20X TBS (2000mL) 
30mL HCl 37% Anolar Normapur 20252.290 (under hood) 
Targeted therapy for chordoma   
 131 
48g Trisma Base (Sigma, T1503) (MW 121.14) 
152g NaCl S7653 Sigma Aldrich (MW 58.44) 
Initially add 700mL H2O and solubilise the powder. pH adjusted to 7.4 using 
NaOH 1M. Add H2O to total 2000mL. 
 
TBS-T (1000mL) 
20X TBS 50mL  
0.1% Tween20 (1mL) 
PBS-T (1000mL) 
1X PBS 1000ml  
0.1% Tween20 (1mL) 
 
Protocol: 
Lyse the samples: 
1.  RIPA Buffer was added (with freshly added Protease Inhibitor and Phosphatase 
Inhibitor) to the cell pellet and kept on ice for 15 minutes. The cell solution was 
then centrifuged for 15 minutes at 5000g, and the lysate was transferred to new 
clear Eppendorf and stored at -20oC or protein concentration was determined 
by Pierce™ Bicinchoninic Acid Solution assay (BCA). 
2.  Protein concentration quantification was performed using Pierce™ BCA Protein 
Assay Kit (#23225, Thermo Scientific) according to manufacture’s instructions. 
3.  The appropriate volume of RIPA-lysate was used to achieve 30µg of protein 
extract. 
a.  A volume of 5X Laemmli loading buffer was added to all samples. The 
sample was boiled (in loading buffer) at 100oC for 3–5 minutes. 
4.  Samples were loaded for electrophoresis on precast gels Criterion TGX Stain 
Free Gel and run at 150 volts until the bromophenol blue reached the bottom of 
the gel. 
5.  To transfer proteins, gels were placed on top of three pieces of 1mm filter paper 
soaked in transfer buffer. A piece of Whatman™ Protran nitrocellulose 
membrane standard pore size 45um (#10087970, GE Healthcare Life 
Sciences) soaked in transfer buffer was then placed on top of the gel followed 
by another 3 pieces of wet filter paper. To remove air bubbles a 5mL plastic 
pipette was rolled over the top of the gel stack. The stack was then placed in a 
transfer cassette on top of two sponges soaked in transfer buffer. Remaining 
space in the cassette was filled with more soaked sponges before clamping the 
cassette into an electrophoresis tank. Inside the tank, the cassette was filled 
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with transfer buffer and the outer chamber was filled with tap water to cool the 
transfer system. The transfer was then run at 70 volts for 2.5 hours at room 
temperature or at 30 volts overnight in a cold room (4oC). 
6.  Efficiency of the transfer was checked by briefly incubating the nitrocellulose 
with Ponceau S Solution (P7170-1L, Sigma).  
7.  After transfer membranes were blocked with blocking buffer for 1 hour at room 
temperature with gentle agitation on a platform shaker.  
8.  Membranes were then washed with TBS-T 4 times over a period of 30 minutes 
at room temperature.  
9.  The filter was then incubated with primary antibody (see table 2.15) at 4oC 
overnight with gentle agitation on a platform shaker. 
10.  The blocking solution was discarded and the filter was washed 3 times (10 
minutes each time) with TBS-T. 
11.  Following this the filter was immediately incubated with the secondary antibody.  
a.  IRDye 800CW Goat anti-Rabbit IgG (Thermo Scientific, #35571), 1:5000 
in 5% milk in PBS-T. 
b.  IRDye 680CW Goat anti-Mouse IgG (Thermo Scientific, #35518), 
1:5000 in 5% milk in PBS-T. 
12.  The filter was incubated 1 hour at room temperature with gentle agitation.  
13.  The secondary antibody was discarded and washed with TBS-T 3 times for 10 
minutes each time followed by one wash with PBS. 
14.  Protein bands were visualised using Li-Cor Odyssey scanner (Li-COR 
Biosciences, Ltd UK). 
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Table 2.15 Antibodies for Western blot analysis 
Protein KDa Brand Cat. Number Species Clonality Washes Dilution Buffer Store 
EGFR 180 Cell Signalling 2232 Rabbit   TBS-T 1:500 5% 
BSA 
4oC fridge 
pEGFR-
Y1068 
180 Cell Signalling 2234 Rabbit   TBS-T 1:500 5% 
BSA 
4oC fridge 
AKR1B10 36/40 AbNova H00057016-
M01 
Mouse (M01), clone 
1A6 
PBS-T 1:1000 5% 
Milk 
-20oC  
PTEN 54 Millipore 04-035 Mouse IgG, clone 
6H2.1 
TBS-T 1:1000 5% 
BSA 
-20oC  
B-actin 42 Sigma A5441 Mouse Monoclonal PBS-T 1:5000 5% 
Milk 
4oC fridge 
Brachyury 47 Santa Cruz 
Biotechnology 
sc-20109 Rabbit Polyclonal PBS-T 1:15000 5% 
BSA 
4oC fridge 
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2.10 Circulation tumour DNA   
Table 2.16 Kits for isolation of DNA and ctDNA 
QIAamp DNA Mini kit (cat # 51304) Qiagen 
Qiagen FFPE Tissue Kit (cat #56404) Qiagen 
QIAamp Circulating Nucleic Acid kit (cat# 55114) Qiagen 
2.10.1 Patient samples 
Consent was obtained for all samples, and collection of patient data under compliance 
with the Royal National Orthopaedic Hospital and University College London Hospital 
Biobank UK consent, approved by the Cambridgeshire Research Ethics committee 
(REC reference 10/H1107/36). Tumours were either frozen at a minimum of -80°C, or 
formalin-fixed paraffin-embedded (FFPE) according to histopathologic procedures. 
Tumours were dissected under a dissecting microscope to ensure a neoplastic 
cellularity of >60%. DNA was purified from the macro-dissected frozen tumours using 
QIAamp DNA Mini kit (Qiagen cat # 51304) and from macro-dissected FFPE tumours 
with a Qiagen FFPE Tissue Kit (Qiagen cat #56404) according to manufactures 
instruction. Exome and whole genome sequencing was done at the Sanger Institute 
Wellcome Trust as part of the International Cancer Genome Consortium (ICGC) project 
for bone tumours. Whole blood for isolation of white blood cells for DNA extraction 
(QiaAMP DNA mini kit) was used as normal tissue (constitutional DNA) for comparison 
and identification of somatic mutations.  
 
Plasma was generated according to standard of procedures, from peripheral blood 
collected from patients into EDTA tubes, which was kept on ice until processed (max 2 
hours). The tubes underwent centrifugation at 1200g for 10 minutes at 4°C and then 
1mL of supernatant was transferred in aliquots to 1.5mL ml tubes and centrifuged at 
14,000g for 10 minutes at 4°C to pellet any remaining cellular debris(683,684). The 
supernatant was transferred to fresh 1.5mL tubes and stored at −80°C.  
 
Total genomic DNA was purified using QIAamp Circulating Nucleic Acid kit (Qiagen 
cat# 55114) according to manufacture’s recommendation. 4mL of plasma was 
available from each patient. The plasma samples were in aliquots of 1mL each, DNA 
was extracted from each individual aliquot, but prior to DNA extraction samples were 
spiked with frog DNA (XENT) approximately 20,000 molecules in each sample in order 
to assess the extraction efficiency, and consistency of DNA extraction, as described in 
reference(685). 
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Patients were selected according to availability of plasma and mutations for which it 
was deemed possible to design Taqman probes. 
2.10.2 Primer design 
Primers were designed using BeaconDesigner software. Primer3 software was used 
and primers were checked using NCBI BLAST engine for nucleotide BLAST and 
Primer BLAST to align primers against the genome to confirm specificity and to check 
for primer dimer effect with complement sequences between the primers. The 
programs could not generate a Taqman assay for the GENE X deletion as the 
sequence was extremely AT rich. It was also not possible to design a SYBR assay on 
the BeaconDesigner as an appropriate sequence was not found. Attempts were made 
to manually design primers based on putting the deletion/normal sequence at the 3-
prime-end and adding bases until a sensible melting temperature (TM) was reached. A 
common reverse primer was generated. 20 random bases were added to the mutant 
specific primer (in green).  
 
GENE X mutation and primer design: 
c.8894_8898delGTTAT 
chr1:235894380 AATAAC>A 
range=chr1:235894281-235894480 strand=+  
 
WT 
GACCATAGTTCTCTGCTATATTTATATGTTGAGTCAAGAAGCCACTATTACCTTCTGATTTCT
GTCTATCCCTAAGGAGATACTTATTTGGAATAGTTAAATAACATCTCTGTAAACGTCTCCTC
TCTCGATTTGGCCCTTCTGTTGGATCCAACTGCCATGAGGTTGGATAGTAGATGGGGTCAT
ACCATACTGCTCTG 
  
MT 
GACCATAGTTCTCTGCTATATTTATATGTTGAGTCAAGAAGCCACTATTACCTTCTGATTTCT
GTCTATCCCTAAGGAGATACTTATTTGGAATAGTTAAATCTCTGTAAACGTCTCCTCTCTCG
ATTTGGCCCTTCTGTTGGATCCAACTGCCATGAGGTTGGATAGTAGATGGGGTCATACCAT
ACTGCTCTG 
  
WT Forward (with 20bp random sequence tag – green) 
GGAGATACTTATTTGGAATAGTTAAATAAC 
  
MT Forward 
TCGGACCCCCTTGTCTATCCGGAGATACTTATTTGGAATAGTTAAATCTC 
  
Common Reverse 
CTACTATCCAACCTCATGGCAG 
 
 
Primers for RT qPCR amplification was tested using tumour DNA to select the best 
primers prior to ordering the Taqman probes, and to confirm the presence of the 
mutation in the tumours (patients). Primers used in bold font. 
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Table 2.17 Primers for amplification of mutation and wild type 
 
2.10.2.1 Optimisation of primers  
The primers were used for RT qPCR amplification of DNA extracted from the tumours 
to identify the optimum primer sequence pair. The ability to amplify the correct 
sequence flanking/capturing the gene was assessed using a SYBR green assay to 
quantify the relative expression of the target gene comparing it to the endogenous 
control GAPDH. Three sets of primers were tested for each mutation. The RT qPCR 
products were run on an electrophoresis gel to visualise the amplified band confirming 
the right size band. 
 
To confirm the probe’s ability to detect the mutation sequence, DNA extracted from the 
tumour was amplified and digital PCR was used to quantify the mutation and wild type 
sequence.  For the GENE X insertional frame-shift mutation, the PCR amplification 
product was sequenced confirming the primers amplified the intended region, as the 
assay had been developed manually. During the optimisation the DNA was tested 
under two different conditions with non-denatured DNA and following denaturing of 
DNA (95°C for 60 seconds), in order to see if denatured DNA would increase detection 
rate. 
2.10.3 Digital PCR 
Droplet digital PCR is a powerful tool to get quantitative measurement using Taqman 
primers and probes or similar hydrolysis/dual-labeled/FRET (fluorescence resonance 
energy transfer) probes. It gives absolute quantification of target DNA in the sample, 
unlike RT qPCR, which gives a relative quantification. PCR is performed within each 
TARGET FORWARD PRIMER TARGET REVERSE PRIMER
PIK3CA1_1F GCTCAAAGCAATTTCTACA PIK3CA1_1R ACCTGTGACTCCATAGAA
PIK3CA1_2F ACAGCTCAAAGCAATTTC PIK3CA1_2R ACCTGTGACTCCATAGAA
PIK3CA1_3F GCTCAAAGCAATTTCTACA PIK3CA1_3R CTGAGATCAGCCAAATTC
PIK3CA2_1F TAGCCTTAGATAAAACTGAG PIK3CA2_1R CCTGCTGAGAGTTATTAAC
PIK3CA2_2F CTAGCCTTAGATAAAACTGAG PIK3CA2_2R GCATGCTGTTTAATTGTG
PIK3CA2_3F TAGCCTTAGATAAAACTGAG PIK3CA2_3R TGAGCTTTCATTTTCTCAG
SETD_1F CAGACTGTTGGTTTGAATC SETD_1R CAGAGTGATGGTGTAGTAC
SETD_2F GACTGTTGGTTTGAATCC SETD_2R CAGAGTGATGGTGTAGTA
SETD_3F ATCCCAAACACTATAATTCTG SETD_3R GAGTGATGGTGTAGTACA
GENE X1_1F TGTTGAGTCAAGAAGCCACT GENE X1_1R AGCAGTATGGTATGACCCCA
GENE X1_2F ACAGGTAAGAGAGTGGTGGT GENE X1_2R CGAGAGAGGAGACGTTTACAG
GENE X1_3F AGTGGTGGTTTGACAACATCT GENE X1_3R CAGAAGGGCCAAATCGAGAG
GENE X2_1F ATGGCAGCATATGACTTA GENE X2_1R GAGACGGAAGACTGTTAA
GENE X2_2F GCAGCATATGACTTAAAGG GENE X2_2R GAGACGGAAGACTGTTAA
GENE X2_3F GCAGCATATGACTTAAAGG GENE X2_3R GCCAATGACTCAGAAGATA
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individual droplet, if the droplet contains the target sequence a fluorescent reporter dye 
will give off a fluorescent signal. If the target sequence is not present no PCR will take 
place and no fluorescent signal will be emitted. By scoring each droplet for fluorescent 
signal digital PCR obtains absolute quantification with high level of precision and single 
molecule sensitivity. The samples are amplified to endpoint in a conventional thermal 
cycler, if the droplets contain the targeted sequence they are read as positive while the 
droplets without the target sequence are read as negative. The assay can be 
multiplexed so that the target template probe is labeled with FAM and the wild-type 
template is labeled with VIC resulting in different colour fluorescent for the readout. The 
fraction of positive droplets determines the concentration of target template in the 
sample. The readout of the endpoint assay in the work in this thesis was done using 
BioRad QX200 droplet reader, digital technology automated system, where each 
droplet is individually passed through a two-colour fluorescent detector for the readout, 
determining which droplet contain the target template and which ones do not. The data 
using this method is recorded via QuantaSoft software, which allows the data to be 
visualised and analysed for quantification.  
 
 
Figure 2.4 Digital PCR  
The sample is prepared as a PCR assay and partitioned into droplets containing one nucleic 
acid containing the target template, the wild-type or no template sequence. Each droplet with an 
amplified sequence exhibits fluorescent, which is read for each droplet by two different channels 
2.10.4 Mutation detection in ctDNA 
Circulating tumour DNA was extracted from plasma and mutations were quantified by 
droplet digital PCR (dPCR) using Bio-Rad’s QX200 Droplet Digital PCR system. 
 
Count  PCR amplification Partitioning 
Sample + 
Assay 
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Figure 2.5 Illustration of Droplet digital PCR  
Adapted from BioRad information guide for dPCR 
2.10.4.1 Droplet generation 
Before droplet generation, dPCR reaction was prepared in a similar manner as real-
time PCR reactions using TaqMan hydrolysis probes labelled with FAM and HEX (or 
VIC) reporter fluorophores, or an intercalating dye such as EvaGreen. All reagents for 
the dPCR were from Bio-Rad and included dPCR supermix for probes and QX200 
dPCR EvaGreen supermix and oil to partition DNA. Samples were placed into the 
QX200 droplet generator, using specially developed reagents and microfluidics to 
partition each sample into 20,000 nanoliter-sizes droplets.  
 
 
 
Figure 2.6 Droplet generation  
Droplet generation produced 
uniform droplets, enabling precise target 
quantification 
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Adapted from BioRad manuel:  
http://www.bio-rad.com/webroot/web/pdf/lsr/literature/Bulletin_6407.pdf 
2.10.4.2 PCR amplification 
Droplets were transferred to a 96 well plate for PCR in a thermal cycler, as previously 
described. 
2.10.4.3 Droplet reading 
Following PCR amplification of the nucleic acid target in the droplets, the plate 
containing the droplets was placed in the QX200 droplet reader, which analyses each 
droplet individually using a two-colour detection system (set to FAM and HEX).  
 
 
  
The partitioning of the sample, allows one to estimate the number of target (mutant) 
molecules by assuming that the molecule population follows the Poisson distribution. 
The Poisson distribution takes into account the fraction of positive droplets to 
determine the concentration of target template in the sample. In conventional real time 
Droplets are being spaced out individually 
for fluorescence reading by the droplet 
reader. 
Positive droplets, which contains 
at least one copy of the target DNA 
molecule exhibit  increased fluorescence  
compared to negative droplets.  
Fluorescence readings are measured 
for each droplet in two channels.  
Adapted from BioRad’s protocol.  
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quantitative PCR the number of PCR amplification cycles is proportional to the starting 
copy number. Digital PCR is not dependent on the number of amplification cycles to 
determine the initial sample amount, eliminating the reliance on uncertain exponential 
data to quantify target nucleic acids providing an absolute quantification. 
2.10.4.4 dPCR analysis 
Droplet Digital PCR data can be viewed in d 2-D plot, data from a duplex experiment in 
which two targets are PCR amplified such as a wild type (WT) and a mutant (MT). 
Channel 1 fluorescence (FAM) is plotted against channel 2 fluorescence (HEX) for 
each droplet, example below: 
 
Example of 2-D plot of droplet fluorescence: Colour coding as our results, droplet 
clusters: blue was mutant sequence (FAM) detected, green was WT (HEX) sequence 
and orange droplets are double-positive droplets, containing both a WT and a MT 
(FAM and HEX) (not necessarily 1:1). Grey was DNA not containing the amplified 
sequences or empty droplets. 
 
QuantaSoftTM software measures the number of positive and negative droplets for each 
fluorophores in each sample. The software then fits the fraction of positive droplets into 
a Poisson algorithm to determine the starting concentration of the target DNA molecule 
in units of copies/µL input. 
 
In a typical digital PCR experiment, the sample is randomly distributed into discrete 
partitions such that some contain no nucleic acid template and others contain one or 
more template copies. The partitions are PCR amplified to end point and then read 
using a droplet reader to determine the fraction of positive partitions, from which the 
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concentration is estimated by modelling as a Poisson distribution. The positive and 
negative droplets are used to calculate the concentration of the target and reference 
DNA sequences.  
 
Estimating target concentration by dPCR, as dPCR is an end-point measurement that 
enables one to quantify nucleic acids without the use of standard curves and 
independent of reaction efficiency. The ability to distinguish between the positive and 
the negative droplet clusters means an ability to achieve an absolute quantification 
without the need for endogenous controls http://www.bio-
rad.com/webroot/web/pdf/lsr/literature/Bulletin_6407.pdf  
 
A control for the PCR reaction was included using an endogenous gene (RNase P 
gene)(labelled: RPP30 in our experiments) recommended by Life technologies for 
human TaqMan copy number reference assays. This functioned as a control for the 
DNA and PCR run, and not as an endogenous control (TaqMan Copy number 
reference Assay, Life technologies cat. # 4403328). 
2.10.4.5 Optimisation of DNA 
To optimise amplification of the tumour DNA various steps were tested as advised by 
BioRad protocol. 
a. Restriction digest was performed as previously described. Following confirmation 
the restrictions enzymes did not digest within the target sequence. This was tested 
as DNA extracted from FFPE can contain physical cross-links due to fixing with 
formalin, obstructing the partitioning and amplification of DNA. Restriction digestion 
can improve assay performance by improving template accessibility. 
b. Dilution of the tumour DNA (1:10) was tested as PCR inhibitors can remain after 
the DNA extraction and dilution can sometimes overcome the inhibition. 
c. Heat denaturation was done to separate the DNA strands to test if this would 
increase the detection of our target gene (DNA was heated to 92°C for 30 
seconds). 
d. PCR optimisation using thermal gradient to establish the optimal annealing 
temperature was tested.  
2.10.4.6 EvaGreen assay  
EvaGreen dsDNA binding dye enables double-stranded DNA detection with the 
convenience of only needing one primer to amplify and detect products. The idea being 
that the fluorescence amplitude of each droplet with EvaGreen varies with amplicon 
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length. Longer amplicons bind more EvaGreen dye molecules and are therefore 
brighter enabling quantification. This was the approach taken for the GENE X 1 
mutation. 
2.10.4.7 Statistical analysis of dPCR output 
DNA molecules and PCR reagents are partitioned into droplets. Some droplets contain 
one or more copies of the target DNA molecule, and some do not contain any copies of 
the target. Droplets are subjected to PCR amplification and the targeted PCR product, 
with an associated fluorescence signal, is generated in droplets that initially contained 
the target DNA. The concentration of the target in the original sample is determined 
from the fraction of droplets that have a fluorescence signal.  In dPCR, target 
molecules are distributed randomly into droplets. This assumption is at the heart of all 
digital PCR approaches. Random partitioning means a given target molecule is equally 
likely to end up in any of the 20,000 droplets. Random partitioning also means target 
molecules move independently of each other and do not interact with each other. 
 
The droplet generator partitions samples into approximately 20,000 droplets of identical 
volume (about 1nL). Some droplets are lost in transfer steps and others are eliminated 
by the stringent metrics applied by QuantaSoft software as the droplets pass through 
the droplet reader resulting ultimately in data from 12,000–16,000 droplets being used 
in subsequent concentration calculations. Reading only a subset of the total droplets 
has no impact on the concentration measurement, because the concentration is 
calculated based on the fraction of droplets carrying the wild type (WT). Below is an 
example of outcome of droplet dPCR in two modes of analysis. 
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Controls used: (negative) 
No template control (NTC) 
Pooled plasma 
Human genomic DNA (Bioline, Cat.# BIO-35025) 
2.10.4.8 Example of set up for experiment 
 
Date
Samples Sample ID
Human genomic DNA H
(1) 3814 Chordoma sample with PIK3CA c.1633G>A mutation C1
(2) 7187 Chordoma sample with PIK3CA c.3129G>T mutation C2
(4) 7168 Chordoma sample with c.6756delC mutation C3
PPC3_1 DNA extracted from pooled plasma with spike (Rosenfeld) 17/07/14 P1
PPC3_2 DNA extracted from pooled plasma (Rosenfeld) 17/07/14 P2
NTC NTC
PCR reaction mix setup (no-template room)
Final
Volume DNA template (µL) 2
Remaining volume (µL) 18
Total volume (µL) 20
Prepare ddPCR reaction mixes (without template):
Thaw all components to room temperature.
Vortexing and briefly centrifuge supermix to avoid concentration gradient.
Test of chordoma assays on tumour tissue
18/07/2014
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All chordoma assays 5
[Original] [Final] Unit
1 rxn + 
excess 
(µL)
Total 
rxns (µL)
2 1 x 15 75
10 0.9 µM 2.7 13.5
Reverse primer 10 0.9 µM 2.7 13.5
Mutant probe 10 0.25 µM 0.75 3.75
Wild-type probe 10 0.25 µM 0.75 3.75
- - - 5.1 25.5
Total (µL) 27 135
IDH1-R132C 6
[Original] [Final] Unit
1 rxn + 
excess 
(µL)
Total 
rxns (µL)
2 1 x 15 90
10 0.9 µM 2.7 16.2
Reverse primer 10 0.9 µM 2.7 16.2
Mutant probe 10 0.25 µM 0.75 4.5
Wild-type probe 10 0.25 µM 0.75 4.5
- - - 5.1 30.6
Total (µL) 27 162
RPP30 6
[Original] [Final] Unit
1 rxn + 
excess 
(µL)
Total 
rxns (µL)
2 1 x 15 90
20x oligo mix 20 1 x 1.5 9
- - - 10.5 63
Total (µL) 27 162
XENT 5
[Original] [Final] Unit
1 rxn + 
excess 
(µL)
Total 
rxns (µL)
2 1 x 15 75
20x oligo mix 20 1 x 1.5 7.5
- - - 10.5 52.5
Total (µL) 27 135
Aliquot 25.2 µL reaction mix into each well/tube of strip.
Supermix for probes
Water
Reagent
Supermix for probes
Water
Reagent
Water
Reagent
Supermix for probes
Forward primer
Forward primer
Water
Reagent
Supermix for probes
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RPP30: RNase P TaqMan control (control for PCR) (RPP gene) 
XENT: frog spike for quantification of DNA extraction efficiency. 
NTC: No template control 
 
 
 
Experimental plan for setting up dPCR testing primers and Taqman probes on tumour 
DNA (example representing all similar experiment): 
Sample addition
Limitations
Restriction digestion required for human gDNA concentrations above: 3.3 ng/µL
Reaction concentration must be below: 5000 copies/µL
And contain more than: 10 copies/reaction
Estimated number of positive droplets
Sample 
(ng/µL)
Reaction 
(ng/µL)
Reaction 
(copies/µ
L)
Copies/ 
reaction CPD
Est. +ve 
droplets*
20 2 6.06E+02 1.21E+04 0.606 45%
Diluting control DNA
Template: Human genomic DNA (Bioline; Cat# BIO-35025; Lot# HG-314103)
Diluent: Nuclease-free water (Ambion; Cat# AM9937, Lot# 1402201, 18/06/14)
[Stock] [Final]
Vol DNA 
(µL)
Vol 
diluent 
(µL)
Total vol 
(µL)
Req'd vol 
(µL)
200 20 5 45.0 50.0 25.2
Add 2.8 µL template into each well/tube of strip.
Setting up ddPCR
Follow instructions for:
QX200 Droplet Generator Oil for Probes: Cat# 1863030; BioRad
PX1 PCR Plate Sealer Thermal cycler:
QX200 Droplet Reader and QuantaSoft Software
Total
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Temperature gradient to establish the best temperature for optimization of primers, 
Experiment layout (example representing all similar experiments): 
 
 
 
2.10.5 Ion torrent 
Tumour DNA was used for detecting the PIK3CA p.E545K mutation, and the PIK3CA 
p.M1043I mutation from two chordoma patients. Ion Torrent is a method of DNA 
sequencing, based on the detection of hydrogen ions that are release during the 
polymerisation of DNA when a template DNA strand in a microwell is flooded with a 
single species of deoxyribonucleotide triphosphate (dNTP). If the introduced dNTP is 
complementary to the leading template nucleotide, it is incorporated into the growing 
96#well'plate'setup
1 2 3 4 5 6 7 8 9 10 11 12 KEY'(templates): KEY'(assays):
A H C2 P1 P2 H /Human/genomic/DNA /PIK3CA1_3
B H NTC P1 NTC C1 /Chordoma/PIK3CA1 /PIK3CA2_2
C C1 H P2 H C2 /Chordoma/PIK3CA2 /SETD_1
D C1 H P2 P1 C3 /Chordoma/SETD /RPP30
E NTC C3 NTC P1 P1 /PPC3_1 /XENT
F H C3 H P2 P2 /PPC3_2 /IDH1HR132C
G H NTC P1 P2 NTC /NTC
H C2 H P1 NTC
a Add 2.8 µL/of/template/to/each/well/tube.
b Transfer/reactions/to/the/droplet/generator/cartridge,/and/then/transfer/droplets/to/96Hwell/plate/according/to/the/above/layout.
Cycling/conditions
1
40
94
60
98
Infinite4
1
30/sec
1/min
10/min
Hold/(optional)
Cycling/step
Enzyme/activation
Denaturation
Annealing/extension
Enzyme/deactivation
Temp/(°C)
95
#/Cycles
1
Time
10/min
96#well'plate'setup
1 2 3 4 5 6 7 8 9 10 11 12 KEY'(templates): KEY'(assays):
A C1 C2 NTC 65.0 H 1Human1genomic1DNA 1PIK3CA1_3
B C1 C2 NTC 64.5 C1 1Chordoma1PIK3CA1 1PIK3CA2_2
C C1 C2 NTC 63.3 C1d 1C1,1digested1HindIII 1SETD2_11(wildLtype1only)
D C1d C2d NTC 61.4 C2 1Chordoma1PIK3CA21&1SETD2 1SETD2_11(mutant1only)
E C1d C2d NTC C2 C2 H NTC C2 C2 H NTC 59.0 C2d 1C2,1digested1HindIII
F C1 C2 NTC 57.0 NTC 1NucleaseLfree1water
G C1 C2 NTC 55.7
H C1 C2 NTC 55.0
a Add 2.8 µL1of1template1to1each1well/tube.
b Transfer1reactions1to1the1droplet1generator1cartridge,1and1then1transfer1droplets1to196Lwell1plate1according1to1the1above1layout.
Cycling1conditions
Hold1(optional)
Cycling1step
Enzyme1activation
Denaturation
Annealing/extension
Enzyme1deactivation
1
40
94
grad
98
Infinite4
1
301sec
11min
101min
Temp1(°C)
95
#1Cycles
1
Temp1(°C)
Time
101min
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complementary strand. The hydrogen release triggers an ion sensor indicating that a 
reaction has occurred.  
 
Selected regions from a multi-gene panel (Life Technologies Colon & Lung Panel V2) 
was amplified using a highly multiplex Polymerase Chain Reaction approach. These 
were labeled using DNA barcodes unique to each specimen and then collectively 
sequenced on a Life Technologies PGM instrument using Ion PGMTM Sequencing 200 
Kit v2 chemistry and a 318v2 chip. Data was analysed using Torrent suite v4.0.2 and 
VariantCaller v4.0 (r76860). An in-house developed script was then used to group 
Variant Caller output into the reported categories and construct variant descriptors 
according to Human Genome Variation Society recommended nomenclature 
(http://www.hgvs.org/) and COSMIC reference number. 
2.11 AKR1B10 ELISA assay 
2.11.1 Samples 
Samples included: standard provided with the ELISA kit, patient plasma generated as 
described in the section for ctDNA, however for this experiment plasma was used 
without further processing. MUG Chor cell line lysate (positive control) was generated 
from 1x107 MUG Chor cells. A cell pellet was washed with PBS and stored at -80°C 
over-night. The cells were freeze-thawed twice and then centrifuged at 4°C for 5 
minutes at 5000g. The supernatant was removed and used immediately or stored in 
aliquots at -80°C for later use. 
2.11.2 Materials 
Reagents Quantity 
Assay plate (12x8 coated microwells) 1 (96 wells) 
Standard (Freeze dried) 2 
Biotin-antibody (100x concentrate) 1 x 120µL 
HRP-avidin (100x concentrate) 1 x 120µL 
Biotin-antibody Diluent 1 x 15mL 
HRP-avidin Diluent 1 x 15mL 
Sample diluent 1 x 50mL 
Wash buffer (25x concentrate) 1 x 20mL 
TMB Substrate 1 x 10mL 
Stop solution 1 x 10mL 
Adhesive strip (for 96 wells) 4 
 
• Microplate reader for measuring absorbance at 450nm 
• Incubator at 37°C 
• Squirt bottle or automated microplate washer 
Targeted therapy for chordoma 
148 
• Absorbent paper for blotting the microtitre plate 
• Distilled water 
2.11.2.1 Preparation of standard  
The standard (purified recombinant AKR1B10 protein) vial was centrifuged at 5000g for 
30 seconds it was then reconstituted with 1.0mL of Sample Diluent producing a stock 
solution of 40ng/mL. 250µL of Sample Diluent was pipetted into each tube (S0-S6). 
The stock solution was used to produce a 2-fold dilution series (below). Each tube was 
mixed thoroughly before the next transfer. The undiluted Standard served as the high 
standard (40ng/mL). Sample Diluent served as the zero standard (0ng/mL).  
 
2.11.3 ELISA  
Human Aldo-keto reductase family 1 member B10 (AKR1B10) ELISA kit was 
purchased from CUSABIO® China, catalog number CSB-EL001540HU for the 
quantitative determination of human aldo-keto reductase family 1 member B10 
(AKR1B10) concentrations in serum, plasma, tissue homogenates. The assay employs 
the quantitative sandwich enzyme immunoassay technique. Antibody specific for 
AKR1B10 was pre-coated onto a micro-plate. Standards and samples were pipetted 
into the wells and the immobilised antibody binds any AKR1B10 present. After 
removing any unbound substances, a biotin-conjugated antibody specific for AKR1B10 
was added to the wells. After washing, avidin conjugated Horseradish Peroxidase 
(HRP) was added to the wells. Following a wash to remove any unbound avidin-
enzyme reagent, a substrate solution was added to the wells and colour developed in 
proportion to the amount of AKR1B10 bound in the initial step. The colour development 
is stopped and the intensity of the colour is measured.  The assay was performed 
according to the manufacture’s instruction. The detection range was 0.625ng/mL - 
40ng/mL.  
 
Protocol 
All reagents and samples were brought to room temperature before use. The samples 
were centrifuged after thawing before being used for the assay.  
1. The number of wells to be used was determined and remaining wells were 
stored in the pouch (ziplocked), and stored at 4°C.  
2. 100µL of standard or sample was added per well, covered with the adhesive 
strip provided, and incubated for 2 hours at 37°C.  
3. After 2 hours the liquid of each well was removed (not washed).  
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4. 100µL of Biotin-antibody (1x) was added to each well, covered with a new 
adhesive strip, and incubated for 1 hour at 37°C.  
5. Each well was aspirated and washed. This was repeated two times for a total of 
three washes. Washes was done by filling each well with Wash Buffer (200µL) 
using a squirt bottle or a multi-channel pipette, and left to stand for 2 minutes, 
complete removal of liquid at each step was essential for good performance. 
After the last wash, any remaining wash Buffer was removed by aspiration or 
decanting. The plate was then inverted and blotted against clean paper towels.  
6. 100µL of HRP-avidin (1x) was added to each well, covered with a new adhesive 
strip, and incubated for 1 hour at 37°C.  
7. The aspiration/wash process was repeated five times as in step 5.  
8. 90µL of TMB Substrate was added to each well and incubated for 15-30 
minutes at 37°C.  Protected from light.  
9. 50µL of Stop Solution was added to each well, gently tapping the plate to 
ensure thorough mixing.  
10. The optical density of each well was determined within 5 minutes, using a 
micro-plate reader set to 450nm. Wavelength correction was set to 540nm to 
subtract readings at 540nm from the readings at 450nm. This subtraction 
corrects for optical imperfections in the plate.  
11. Data was analysed using PRISM 6, GraphPad Software Inc. software. 
2.11.4 Statistical analysis 
The statistical analysis of data in the thesis was performed using GraphPad Prism 6 
Software Inc. Where data was available for further analysis it was analysed using the 
Student’s T-test (unpaired). The Student’s T-test assumes unproven normal 
distribution. Significance was interpreted as p < 0.05. Quantification of gene expression 
was done by the comparative threshold cycle (Ct) method with the calculation of 2-
[delta][delta]Ct.  
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3 GENE THERAPY USING AN ADENO-ASSOCIATED VIRAL 
VECTOR FOR DELIVERY OF RNAI TARGETING BRACHYURY 
IN CHORDOMA 
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3.1 Introduction 
Despite advances in our understanding of the processes involved in the development 
and progression of cancer, treatment options for many patients are limited and 
prognoses still remain poor. The current treatment strategies for chordoma have been 
reviewed previously. The lack of treatment options for unresectable, and in particular 
recurrent disease, highlights the need for alternative approaches for treatment of this 
rare tumour.  
 
Cancer is an acquired genetic disorder, with increasing evidence that there are 
extensive genetic variations not only between different cancers but also within each 
tumour(593). Gene and cell therapy promises the potential to deliver bespoke and 
effective treatment to the genetic structure of each tumour(248). Gene therapy consists 
of three basic steps: (1) construction of a gene-carrying vector, (2) transferring genes 
into cancer cells (3) expressing gene product to kill cancer cells.  
3.1.1 Brachyury implication in the pathogenesis of chordoma: 
Evidence, reviewed previously, suggests brachyury is involved in the pathogenesis of 
chordoma. In support of this is the fact that brachyury is highly expressed in the vast 
majority of chordomas(13,31,46). Germline tandem duplication of brachyury has been 
documented in familial cases, and brachyury gene amplification has been identified in 
a proportion of sporadic chordoma(36,87,89). 97% of patients with chordoma harbour 
at least one allele of the common non-synomous SNP (rs2305089) in the brachyury 
gene(87,90). In addition RNAi silencing of brachyury in chordoma cell lines induces 
growth arrest and apoptosis(89,91). 
3.1.2 Gene therapy targeting Brachyury 
Brachyury is important for gastrulation and mesodermal formation and is a major driver 
of EMT leading to tumour progression. It is expressed in several tumour types but not 
in normal adult tissue, with the exception of the testes. Expression in epithelial cancers 
has been associated with drug resistance and poor prognosis. The pathogenesis of 
resistance to therapy in chordoma is not understood, and may be similar to that 
associated with the gene expression involved in EMT. The wider implications of the 
involvement of brachyury in cancer, supports the rationale for development of therapies 
targeting this transcription factor.  
 
Transcription factors are traditionally considered non-targetable for classical small 
molecules and therapeutic antibodies, due to their intracellular localisation and limited 
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surface protein expression. Recent evidence from preliminary data and early phase 
clinical trials targeting transcription factors such as myc, SALL4 and TP53 have shown 
promising results using RNAi or small molecules targeting the interaction between the 
transcription factor and the effector gene(269,330,686,687).  
3.1.3 Viral vector for gene therapy in chordoma 
The experience preceding the work presented here includes silencing of brachyury in 
two different chordoma cell lines(89,91) using lentiviral constructs, confirming the 
potential for using RNAi targeting brachyury. These lentiviral constructs were not 
considered suitable for in vivo experiments, and were not of the standard currently 
used in human trials(683). This study describes the use of an AAV vector for delivery of 
the specific shRNA, which demonstrated high efficiency in silencing of brachyury in 
vitro, to establish therapeutic effect of the application in vivo. An AAV vector was 
chosen for this project for the delivery of RNAi due to the favourable biology with lack 
of pathogenicity, low host immune response, and long-term gene expression(251). Its 
safety profile has been proven in clinical trails(231).  
 
AAV serotype 5 was chosen for transduction of the chordoma cell line U-CH1, based 
on its ability to transduce primary cell lines efficiently in vitro(476). In addition AAV5 
uses sialic acid for cell surface binding(491) with PDGFR identified as a co-receptor for 
transduction in vitro and in vivo(490). PDGFR is expressed by the majority of 
chordomas(165) and AAV5 was therefore considered a suitable serotype to test as a 
vector for transducing chordoma cells.  
3.1.4 RNA interference  
The possibility of artificially interfering with endogenous gene expression through the 
RNAi pathway has emerged as one of the most exciting areas for the development of 
disease-modifying treatments in several therapeutic areas including cancer(429,688). 
RNAi has previously been reviewed. 
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3.2 Aim 
Can AAV vectors be engineered to deliver RNAi targeting brachyury and will brachyury 
silencing in vivo result in growth arrest and/or tumour regression?  
 
3.3 Objectives 
• To establish that the U-CH1 chordoma cell line is permissive to AAV5. 
• To generate a vector for delivery of shRNA targeting brachyury, and to test 
efficacy and specificity in vitro.  
• To assess response to recombinant AAV5 viral vector targeting brachyury in a 
chordoma xenograft model. 
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3.4 Results 
3.4.1 The U-CH1 chordoma cell line is permissive to AAV5  
3.4.1.1 Transduction and transgene expression 
The cell line was transduced with the AAV5 vector containing the shRNA from the 
vector pGIPZ_V2LHS_153725, targeting brachyury. The efficiency of this shRNA in a 
lentiviral vector has previously been described(89,91).  Successful transduction was 
assessed by transgene expression of GFP, using phase contrast fluorescence 
microscopy and fluorescence activated cell sorting (FACS) (Figure 3.1 & 3.2). 
 
 
 
Figure 3.1 GFP expression in U-CH1 cells following transduction with AAV5  
Phase contrast white light and fluorescent light microscopy of U-CH1 cells transduced with 
scAAV5_CMV_shRNA_GFP. The same cells are seen under different light sources. 
 
 
 
 
 
Figure 3.2 GFP expression by flow cytometry in AAV transduced U-CH1 cells  
GFP expression assessed by FACS, 5 days following transduction of the U-CH1 cell line, using 
AAV5 viral vector. Cells were transduced with an MOI of 1x105. (A) un-transduced U-CH1 cells 
used as negative control, gate set at 2%. (B) U-CH1 cells transduced by 
AAV5_CMV_shRNA_GFP showed 92% GFP expression. (C) U-CH1 cells transduced by 
AAV5_CMV_GFP showed 99.9% transduction.   
 
 
A U_CH1 cell un-transduced B U_CH1 cell transduced 
AAV5_CMV_shRNA_GFP 
C U_CH1 cell transduced 
AAV5_CMV_GFP 
 A 
ÁÀÃ ÂĀÄ 
GFP 92% GFP 99% 
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Continuous monitoring using the Incucyte image analyser was utilised to monitor GFP 
expression as well as assessment of morphologic changes and cell proliferation. GFP 
expression was observed from 24-48 hours following transduction with the AAV5 
vector. As the vector did not contain an antibiotic expression cassette no antibiotic 
selection could be undertaken. FACS sorting for GFP positive cells was attempted but 
was poorly tolerated by the cell line. Silencing of brachyury was expected to lead to 
growth arrest of the chordoma cell line, however the cells continued to proliferate and 
relative gene-expression assessed by RT qPCR confirmed comparable gene 
expression between the silencing and the non-silencing construct (Figure 3.3). 
 
 
Figure 3.3 U-CH1 cell line transduced with AAV5_CMV_shRNA_GFP 
Brachyury expression quantified by RT qPCR in the U-CH1 cell line generated. Expression of 
brachyury compared cells transduced with a non-silencing construct. Brachyury expression was 
corrected to the endogenous PGK expression as a reference gene. The experiment has been 
repeated n=3 and performed in triplicate. Error bars represent standard deviation. The 
comparative threshold cycle (Ct) method with the calculation of 2-[delta][delta]Ct was used to 
assess the relative level of expression of brachyury. 
 
Neither the cell morphology nor proliferation of the cells was altered by the transduction 
with the gene-silencing construct. The transduced U-CH1 cells were maintained in 
culture and monitored in the incucyte. Unexpectedly the transduced cells maintained 
intense level of GFP expression despite continued proliferating (Figure 3.4).  
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Figure 3.4 GFP expression maintained following transduction in U-CH1 
AAV5 transduced U-CH1 cell line demonstrating clonal proliferation and continued GFP 
expression. Images from the incucyte with fluorescent and phase contrast microscopy. (A) 
demonstrating confluency following cell passaging 4 weeks after transduction of U-CH1 cell line 
with AAV_shRNA_GFP vector, phase contrast image. (B & C) demonstrating persistent GFP 
expression at 4 weeks post transduction ((C phase + fluorescent contrast)((D) fluorescent only). 
(D) Confluency 4 days after passaging. The boxed area in (D) is super-imposed in (E & F) 
demonstrating increased number of GFP expressing cells (the same field as image (B)) (E) 
fluorescent + phase contrast image. (F) Fluorescent microscopy. (G-J) demonstrating the 
proliferation of cells, left to right: day 1, 3, 7 & day 17 are from the same window/field. 
Experiment repeated twice.  
 
Using flow cytometric analysis, 36% of the chordoma cells were found to have 
continued GFP expression five months post-transduction (Figure 3.5).  
 
 
Figure 3.5 GFP expression in U-CH1 cells 5 months after transduction 
The cells were maintained in the incucyte for 5 months and passaged when confluent. GFP 
expression was measured by FACS, Un-transduced U-CH1 cell used for setting the gate. GFP 
expression after 5 months was 36.6% Initial transduction efficiency/GFP expression using the 
AAV5_shRNA-GFP vector (MOI 105) showed 60-92% GFP expression 72 hours post 
transduction without Puromycin selection (data not shown).  
A 
F E D 
C B  
J G I H 
U-CH1 control (UT) U-CH1 transduced (AAV_shRNA_GFP) (A)   U-CH1 control (UT) (B)   U-CH1 transduced (AAV5_shRNA_GFP) 
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3.4.2 AAV5 with new shRNA expression cassette silences brachyury  
As a consequence of the lack of gene silencing, a different approach was pursued for 
the design of the knockdown construct. 
 
The pLKO.1 vector, which had been used for silencing of brachyury in the JHC7 
chordoma cell line causing cell senescence(91) had several advantages, over the 
GIPZ vector as a donor for the shRNA targeting brachyury. Whilst identical targeting 
sequences were available, the expression cassette within the pLKO.1 vector was 
smaller. In addition the expression cassette within the pLKO.1 vector contains a U6 
promoter driving expression of the shRNA and a PGK promoter for expression of 
Puromycin, adding the option of antibiotic selection for transduced cells.  
 
 
Figure 3.6 Expression cassettes for different shRNA constructs 
(A) Expression cassette in the AAV vector containing a CMV promoter and GFP flanking the 
shRNA (extracted/cloned from the GIPZ vector). (B) Expression cassette in the GIPZ vector 
(total 3000bp) with the shRNA downstream from Puromycin (3’UTR). (C) Expression cassette in 
the pLKO.1 vector. The entire expression cassette is under 1800bp and could therefore be 
accommodated within the scAAV vector. 
 
The design of the pLKO.1 vector allowed cloning of the whole expression cassette into 
the AAV vector. The use of the polymerase III (pol III) U6 promoter has been described 
and validated in vitro(343,689,690), and in vivo for expression in mice(691,692). 
3.4.2.1 Transfection of the U-CH1 cell line  
The U-CH1 cell line is known to be difficult to transfect, illustrated by the lack of 
publication on transfection of chordoma cell lines. Attempts were made to optimise the 
transfection using various transfection reagents. Results were unsatisfactory, achieving 
transfection efficiencies of less than 20% (data not shown). Following the initial 
experiments, though not in a timely manner, transfection of the U-CH1 cell line using X-
tremeGENE HP DNA transfection reagent was established with transfection 
efficiencies up to 50% (Figure 3.14). The production of AAV is labour intensive, and 
therefore attempts were made to identify a brachyury expressing cell line, to test the 
CMV$ GFP$
CMV$ GFP$ IRES$ PURO$
U6$ PURO$PGK$
A.#
B.#
C.# shRNA$
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efficiency of gene silencing of the different cloning constructs, by transfection, to avoid 
generating virus for each individual construct required for transduction of the chordoma 
cell line. 
3.4.2.2 Alternative brachyury expressing cell line 
Brachyury expression has been described in the colon cancer cell line SW480(97), and 
used for knockdown experiments(96,104), however differential expression at different 
cell confluency has been reported which could make interpretation of reduced 
expression, due to gene silencing, difficult. The expression of brachyury was found to 
be very low in the SW480 cell line compared to expression in the U-CH1 cell line.  No 
difference in expression was detected between 50% and 80% cell confluency (Figure 
3.7). Due to low, and on-going concern of variable expression, the SW480 cell line was 
not used as a model for quantifying gene silencing efficiency. 
 
 
Figure 3.7 Brachyury expression in colon cancer cell line SW480 
Relative expression of brachyury by RT qPCR in the SW480 colon cancer cell line, compared to 
expression in U-CH1 chordoma cell line (baseline), brachyury expression was corrected to the 
PGK expression as a reference gene. The comparative threshold cycle (Ct) method with the 
calculation of 2-[delta][delta]Ct was used to assess the relative level of expression of brachyury. 
Experiments run in triplicate, n=1. 
 
For the purpose of testing the different cloning constructs, a HEK 293T cell line was 
generated which stably expresses brachyury. Brachyury expression was confirmed in 
the 293T_brachyury cell line by RT qPCR (Figure 3.8).  This cell line was used to 
select the most efficient shRNA from a gene family set of 4 different shRNA sequences 
targeting brachyury. The HEK 293T cell line is generically resistant to Neomycin, as 
this was part of the expression cassette, together with the SV40 Large T-antigen added 
when initially developing the HEK 293T cell line(663). Neomycin and Puromycin 
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represented the only antibiotic selection marker available in the pLKO.1 vector leaving 
no possibility for selection in the 293T_brachyury cell line, which had been generated 
with a Puromycin selection cassette. 
3.4.2.3 Brachyury can be silenced in the 293T_brachyury cell line. 
To establish the ability to silence brachyury in the 293T_brachyury cell line, with 
brachyury expression driven by a viral promoter, the generated cell line was 
transfected using the lentiviral vector GIPZ_V2LHS_153725 targeting brachyury. This 
vector has previously been shown to silence brachyury in the U-CH1 cell line, with 
more than 90% reduction in expression(89). Transfection resulted in more than 70% 
reduction in gene expression 24 hours post-transfection (Figure 3.8).  
 
 
Figure 3.8 Brachyury expression in 293T brachyury expressing cells line 
(A) Brachyury expression was quantified by RT qPCR in the 293T_brachyury cell line generated 
by lentiviral transduction to stably express brachyury. Expression in 293T_brachyury cells was 
compared to in the U-CH1 cell line and a non-transduced HEK 293T cells. (B) Silencing of 
brachyury in the 293T_brachyury cell line transfected using the lentiviral construct 
GIPZ_V2LHS_153725, targeting brachyury. Brachyury expression was corrected to 
endogenous PGK expression as a reference gene, un-transfected 293T_brachyury cells were 
used as control. The experiment was run in triplicate repeated twice. 
3.4.2.4 Variation of efficacy between shRNA clones targeting brachyury 
The pLKO.1_TRCN000005484 expression cassette was selected as the most efficient 
brachyury silencing construct to be cloned into the AAV construct (Figure 3.9). This 
shRNA had an identical targeting sequence to the shRNA from the 
GIPZ_V2LHS_153725 and this construct could therefore be used for comparison of 
efficiency of gene silencing.  The shRNA target sequence was complimentary to the 
junction between the 3’ end of exon 4 and the 5’ end of exon 5 (Figure 3.10). 
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Figure 3.9 Efficiency in gene silencing by different clones of pLKO.1_shRNA  
Results of RT qPCR for brachyury knockdown in the generated 293_brachyury cell line. Four 
different pLKO.1_shRNAs (pLKO.1_TRCN000005481-TRCN000005484)(5481-5484) targeting 
brachyury were tested by transfection. Brachyury expression was corrected to the endogenous 
PGK expression as a reference gene. GIPZ_V2LHS_153725 (GIPZ) used as positive control. 
Relative expression was assessed comparing expression after transfection with a non-silencing 
construct (NS). The figure represents results from three different experiments, each performed 
in triplicate. Error bars represent standard deviation. Significant difference in expression 
following knockdown with vector 5484 (and GIPZ) compared to non-silencing. Non-paired t-test. 
 
 
 
 
 
 
Figure 3.10 Brachyury gene mapping the target region for the shRNA constructs  
The brachyury gene (transcript 1) depicted with its 9 exons (boxes) and the lines represents 
introns. The shRNA targeted region overlaps between exon 4 and exon 5. The GIPZ and the 
pLKO.1 construct have identical targeting sequence set within different scaffolds (flanking 
regions) and expressed off different promoters. Adapted from ENSEMBL genome browser.  
 
3.4.2.5 Brachyury expression significantly reduced by pLKO.1 vector  
In preparation for cloning the RNAi expression cassette into the AAV plasmid, 
efficiency of the pLKO.1_TRCN000005484 for silencing brachyury in the chordoma cell 
line U-CH1 was tested. The GIPZ_V2LHS_153725 construct was used as a positive 
control of gene silencing (Figure 3.11). 
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Figure 3.11 Silencing of brachyury in U-CH1 cell line (lentiviral transduction)  
Relative expression by RT qPCR for brachyury knockdown in the U-CH1 cell line, knockdown 
was performed using pLKO.1_TRCN00008484 (pLKO.1_5484) and GIPZ_V2LHS153725 
(GIPZ) (positive control) and a pLKO.1_non-silencing shRNA (NS)(negative control). Brachyury 
expression was corrected to the endogenous PGK expression as a reference gene and 
normalised to the non-silencing (NS) vector (2-ΔΔCT). The figure on the right represents results 
from 3 different experiments, each performed in triplicate. Error bars represent standard 
deviation. Non-paired t-test. 
 
3.4.2.6 Brachyury silencing leads to morphologic changes in the U-CH1 cells  
Knockdown of brachyury is known to alter the classic phenotype of chordoma cells 
including the physaliferous features and lead to stellate-appearing cells with spindling, 
flattening and extensive branching, as well as a significant decrease in average cell 
diameter size and near complete loss of cytoplasmic vacuoles(89,91,119). These 
morphological changes of the U-CH1 cell line were reproduced following transduction 
with the GIPZ_V2LHS153725 construct. The morphological changes in the U-CH1 
cells transduced with the pLKO.1_TRCN00005484 were much more pronounced by 
comparison and were followed by cell death within 10 days of transduction (Figure 
3.12). No morphologic changes were observed using a pLKO.1_non-silencing 
construct, used as a control for toxicity. 
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Figure 3.12 Morphological changes of U-CH1 cells after silencing of brachyury 
U-CH1 cell line transduced with lentiviral vector and selected with Puromycin. Images acquired 
8 days after transduction. Phase contrast photomicrographs of (A) U-CH1 cell line transduced 
with the pLKO.1_TCRN00005484 (B) U-CH1 cell line transduced with the pLKO.1 non-silencing 
(C) Phase contrast photomicrograph of U-CH1 cell transduced with the GIPZ_ V2LHS153725. 
(D) Fluorescent light photomicrograph demonstrating U-CH1 cell line expressing GFP 
transduced with GIPZ_ V2LHS_53725 (100% GFP expression), this image is a replicate of C. 
The pLKO.1 vector does not have a GFP expression cassette.  
 
 
FACS analysis of the U-CH1 cells transduced with GIPZ_V2LHS153725 confirmed 
100% GFP expression following selection with Puromycin of transduced cells (Figure 
3.13). 
 
Figure 3.13 Transduction and Puromycin selection efficiency by GFP expression 
Flow cytometry was used to assess the GFP expression in U-CH1 cell line, transduced with the 
GIPZ_V2LHS153725 construct (B), for assessing efficiency of transduction and subsequent 
Puromycin selection, validating the effect of gene silencing avoiding bias from un-transduced 
cells. Un-transduced U-CH1 cells used as control (A), gate set at <2%. 100% GFP positive cells 
correlated with 80% gene silencing shown in figure 3.11. 
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3.4.2.7 AAV vector with expression cassette for shRNA TCRN00005484  
The construct pAAV_U6_shRNA(5484)_Puromycin also referred to as pAVV_5484 and 
the control pAAV_U6_shRNA(Non-silencing)_Puromycin, referred to as pAAV_NS 
were tested by transfection of the U-CH1 cell line. Transfection protocols were 
optimised for the U-CH1 cell line as previously discussed.  
3.4.2.7.1 Transfection of U-CH1 cells 
Transfection efficiencies of up to 50% were achieved in the U-CH1 cell line as 
assessed by GFP expression (Figure 3.14). 
 
 
Figure 3.14 Transfection efficiency of AAV into U-CH1 cells 
FACS results measuring GFP expression after transfection of the U-CH1 cell line using X-
tremeGENE HP®. Un-transfected cells (Left).  U-CH1 cells transfected with pAAV_CMV_GFP 
showing 50% of cells are transfected with GFP expressing plasmid (Right). Transfection with a 
larger plasmid (lentivirus) resulted in 20% transfection (data not shown).  
 
 
 
  
U-CH1 un-transfected cells U-CH1 transfected cell / GPF 49.9% 
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The newly generated AAV constructs were transfected into U-CH1 cell line and 
efficiency of gene silencing assessed by relative gene expression. Brachyury 
expression was reduced by more than 90% following transfection and Puromycin 
selection (Figure 3.15). 
 
Figure 3.15 Silencing of brachyury in U-CH1 cells following transfection 
The efficiency of the new pAAV_5484 knockdown construct compared to the non-silencing (NS) 
control was validated by transfection of the U-CH1 cell line. The pLKO.1_5484 lentiviral 
knockdown construct was used as a control for gene silencing. Puromycin selection was 
commenced 72 hours after transfection, overcoming the difference in transfection efficiency due 
to discrepancy of plasmid size. Brachyury expression was assessed by RT qPCR, brachyury 
expression was corrected to the endogenous PGK expression as a reference gene. Both 
knockdown constructs showed more than 90% silencing of brachyury compared to expression 
in cells transduced with the non-silencing construct. The comparative threshold cycle (Ct) 
method with the calculation of 2-[delta][delta]Ct was used to assess the relative level of 
expression of brachyury. 
 
With confirmation that shRNA targeting brachyury was functional in the AAV vector the 
production of AAV5 was initiated.  
3.4.2.8 AAV5 delivered shRNA silence brachyury in U-CH1 
U-CH1 cells were transduced with AAV5 containing the expression cassette from the 
pLKO.1 vector for knockdown of brachyury. Three different conditions were tested to 
help understand toxicity and cell death. One condition was designed to assess the 
transduction efficiency and gene silencing without Puromycin selection, one to assess 
expression after Puromycin selection and one with the cells maintained in culture 7 
days without Puromycin selection, due to concern that gene expression might be lost 
with cell division, and therefore render the cells sensitive to Puromycin. Gene silencing 
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was comparable between the conditions with reduction in expression between 70-80% 
(Figure 3.16).  
 
 
Figure 3.16 Brachyury expression in U-CH1 cells following AAV5 transduction 
Results form RT qPCR (in triplicate) assessing relative brachyury expression compared to 
endogenous control (PGK). The knockdown was determined comparing to a non-silencing 
vector under the same conditions. (1) AAV_5484 & (2) AAV_non-silencing (NS) transduced 
cells were harvested for mRNA extraction at 72 hours post transduction. (3) AAV_5484 & (4) 
AAV_NS. Exposed to Puromycin selection 72 hours post transduction for 96 hours. (5) 
AAV_5484 & (6) AAV_NS (72+96h) where no Puromycin selection was undertaken, RNA was 
extracted day 7 (time scale as transduced cells under Puromycin selection. (7) UT=non-
transduced U-CH1 cells. MOI 105.  Experiment run in duplicate, n=1. The comparative threshold 
cycle (Ct) method with the calculation of 2-[delta][delta]Ct was used to assess the relative level 
of expression of brachyury. 
 
Silencing of Brachyury was reflected in the cell confluency assessed by phase contrast 
microscopy of the cells (Figure 3.17). 
 
Figure 3.17 Confluency of U-CH1 cells after AAV5 delivered brachyury silencing 
Phase contrast microscopy, U-CH1 cells 7 days following transduction with AAV5 knockdown 
construct and non-silencing vector. (A) U-CH1 cells transduced with non-silencing viral vector. 
(B) U-CH1 cells transduced with knockdown construct after 96 hours of Puromycin selection. 
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Morphological changes were observed in the U-CH1 cells transduced with the AAV5 
knockdown construct. These changes were similar to those observed after transfection 
with the AAV plasmid containing the knockdown expression cassette, as well as in the 
knockdown experiment using the pLKO.1 lentiviral vector (Figure 3.12).  The 
morphological changes were irreversible leading to cell death (Figure 3.18). 
 
 
Figure 3.18 Morphologic changes in U-CH1 cells transduced with AAV vector  
AAV vector transduction; phase contrast microscopy of U-CH1 cell line demonstrating 
morphologic changes typically seen following transduction (and transfection) using the shRNA 
(TRCN000005484) targeting brachyury. The cells become flattened, with changes to the 
cytoskeleton resulting in stellate appearance, and loss of the characteristic physaliferous 
features. The changes were irreversible and the cells died about day 10 post-transduction. (B) 
Technical replicate of the image highlighted in image (A). (C) U-CH1 cells transduced with non-
silencing construct. 
 
3.4.3 Toxicity of shRNA reproducible across various control cell lines 
The observed morphological changes observed after AAV5 transduction with the 
brachyury silencing construct, was not replicated in the cells transduced with the non-
silencing construct. Before proceeding with the viral vector, targeting brachyury in the 
xenograft, the construct was tested in a range of cell lines not known to express 
brachyury to assess toxicity (Table 3.1). Having established comparable efficiency of 
gene silencing between the AAV and lentiviral vectors, the lentiviral vector 
A B 
C 
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pLKO.1_TRCN00005484 was used for toxicity testing. Phase contrast images were 
taken for assessment of morphologic changes. 
 
Table 3.1 Cell lines for toxicity screening  
U-CH1 used as a control Chordoma  
U251 Glioblastoma 
U87 Glioblastoma 
A172 Glioblastoma 
MDA MB 231 Breast cancer (metastatic adenocarcinoma) 
MCF7 Breast cancer (metastatic adenocarcinoma) 
HUH7 Hepato-carcinoma  
HEK 293T Human embryonic kidney 
 
The morphological changes with flattening of the cells and stellate changes to the 
cytoskeleton as well as the general toxicity of the pLKO.1 TRCN000005484 observed 
in the U-CH1 cell lines was reproduced to various degrees in all the cell lines 
transduced with this lentiviral vector targeting brachyury (Figure 3.19 & 3.20). The 
changes were irreversible and the majority of cells died around day 7 post-
transduction. 
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Figure 3.19 Morphology changes in U87, HUH7 and U251 cell lines  
Phase contrast microscopy: Row 1: U87, row 2: HUH7, row 3: U251 cell line. A & B cell line transduced with brachyury silencing construct pLKO.1 
TRCN000005484 vector, B is representing the area boxed in A demonstrating morphologic changes. C & D cell lines transduced with control vector (non-
silencing) demonstrating morphologic changes. D represents boxed area in C.
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Figure 3.20 Morphology A172, MCF7 and MDA MB 231 cell lines  
Phase contrast microscopy: row 1: A172, row 2: MCF7, row 3: MDA MB 231 cell line. A & B cell lines transduced with brachyury silencing construct pLKO.1 
TRCN00005484 vector, B is representing the boxed in area in A demonstrating morphologic changes. C & D cell lines transduced with control vector (non-
silencing). D represents boxed area in C. 
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The HEK 293T cell line did not tolerate transduction with the TRCN000005484 
construct and the cells died during Puromycin selection. The non-silencing construct 
was tolerated without any obvious toxicity.  
 
Due to the toxicity of the shRNA TRCN000005484 targeting brachyury across all cell 
lines, each cell line was tested for brachyury expression and potential off-targets for the 
shRNA sequence was revisited. Only the U-CH1 cell line was found to express 
brachyury. 
3.4.4 Sequence homology supports potential off-target effect 
The sequence for pLKO.1 TRCN000005484 identical to the sequence for GIPZ 
V2LHS_153725 was entered into NCBI BLAST (Basic local alignment search tool) for 
review of potential off-targets sequences. The sequence was aligned against the 
human genome plus transcript database (Table 3.2). This had previously been done 
but the potential off-targets were considered minimal, as this hairpin in the GIPZ 
construct had previously been used without any documented toxicity in both Hela and 
HEK 293T cell lines (Thesis by Asem Shalaby supervised by Professor A. Flanagan).  
 
Table 3.2 Potential off-targets for shRNA pLKO.1 TRCN000005484 
NCBI BLAST sequence: 
CGAGGAGATCACAGCTCTTAA GENE 
Query 
cover E-Value 
Brachyury T 100% 0.006 
Teneurin transmembrane protein 3 TENM3 76% 5.7 
TTC28 antisense RNA1 (non-coding) TTC28-AS1 71% 22 
Dystonin DST 71% 22 
Zinc finger protein 829  ZNF829 66% 88 
Homo sapiens chromosome 11 ORF 35  C11orf35 66% 88 
Integral membrane protein 2C ITM2C 66% 88 
BLAST search as of April 2014. Query cover indicates the percentage of the query sequence 
covered by alignment to the database sequence. Brachyury has the lowest (best) E-value of 
0.006 indicating a true alignment i.e. qualification of true alignments when coverage crosses 
intron/exon boundaries (ref. blast.ncbi.nlm.nih.gov). TENM3 has an E-value of 5.7 whilst the 
other genes have much higher values indication less likely alignment. 
 
3.4.5 Brachyury-targeting shRNA demonstrates off-target silencing of TENM3 
The sequence for the shRNA targeting brachyury aligned against the TENM3 cDNA 
sequence with 16 of 21 nucleotides targeting within exon 5 of the TENM3 genome. 
Expression of TENM3 was assessed to validate this potential off-target effect as an 
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explanation for the toxicity observed, not only in the chordoma cell lines but also in the 
additional cell lines, none of which expressed brachyury (data not shown). The 
efficiency of gene silencing of TENM3 following transduction using the vector targeting 
brachyury was also reviewed demonstrating knockdown and thereby a potential causal 
effect of the toxicity observed (Figure 3.21). 
 
 
 
Figure 3.21 TENM3 expression and off-target gene silencing in multiple cell lines 
(A) Results of RT qPCR of relative expression of TENM3 in U-CH1, U87, U251, A172, HUH7, 
MCF7, MDA_MB 231 and HEK 293T cell lines; A172 cell line had the highest level of TENM3 
expression. TENM3 expression of the other cell lines has been shown relative to the expression 
in the A172 cell line. (B) Relative TENM3 expression following transduction with the pLKO.1 
TCRN000005484 (KD) vector compared to expression following transduction with the non-
silencing construct (NS). Not all cell lines were included in the assessment of off-target effect. 
Expression of TENM3 was relative to endogenous GAPDH expression, each cell line compared 
to itself, no comparison of gene silencing was done between different cell lines. 
 
3.4.6 Selection of alternative shRNA for silencing of brachyury. 
The gene-silencing construct pLKO.1_TCRN00005484 was discarded due to toxicity 
demonstrated in all cell lines tested. Previous data on efficiency of gene silencing of 
brachyury using different clones were reviewed to identify a different but equally 
efficient knockdown construct. All shRNA sequences were reviewed for possible off-
target effects by alignment of the sequence against the human genome using NCBI 
BLAST. Brachyury clones TRCN000005480-5483 were tested (Table 3.3). The 
potential interaction of genes affected was also reviewed in STRING protein network 
database (data not shown).  
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Table 3.3 Off-targets aligning with brachyury targeting shRNA sequence  
TRCN clone Gene Gene Sequence 
alignment 
TRCN000005480 Brachyury T 100% 
Presenilin 1 PSEN1 76% 
Nuclear receptor co-activator 5 NCOA5 71% 
Family with sequence similarity 21 
member A 
FAM21A 66% 
Family with sequence similarity 21 
member B 
FAM21B 66% 
Family with sequence similarity 21 
member C 
FAM21C 66% 
CUB domain containing protein 2 CDCP2 66% 
CUB and sushi multiple domains 1 CSMD1 66% 
TRCN000005481 Brachyury T 100% 
Norrie disease (pseudoglioma) NDP 66% 
Transmembrane protein 106C TMEM106C 66% 
Zink finger matrin type 1 ZMAT 61% 
TRCN000005482 Brachyury T 100% 
GABA B protein receptor GABRB 66% 
Zinc finger CCCH-type, antiviral 1-like ZC3HAV1L 66% 
Sprouty hologo 3 (Drosophila) SPRY3 66% 
TRCN000005483 Brachyury T 100% 
Methyltransferase like 25 METTL25 80% 
ATPase Na+/K+ transporting, alpha 1 
polypeptide 
ATP1A1 66% 
Cramped-like (Drosophila) CRAMP1L 61% 
Guanylate cyclase alpha 3 GUCY1A3 61% 
Inositos 1.4.5-triphosphate receptor, 
type 1 
ITPR1 61% 
Vitamin D receptor VDR 61% 
The TRCN clones as identifier for the different hairpins targeting brachyury. The target genes 
identified, according to NCBI BLAST alignment of the sequence against the Human genome. 
The column to the left shows the % of the maximum sequential alignment such as 16 
nucleotides out of total of 21 nucleotides (76%). TRCN000005481 was found to have the most 
favourable off-target profile.  
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3.4.7 The TRCN000005481 vector demonstrates no off-target toxicity  
Based on the results from previous gene silencing and the alignment for off-target 
effect, experiments proceeded with the pLKO.1_TRCN00005481 vector for silencing of 
brachyury in the U-CH1 chordoma cell line.  
3.4.7.1 No morphological changes observed in control cell lines 
 
 
Figure 3.22 Control cell lines transduced with pLKO.1 TRCN00005481 vector 
Phase contrast microscopy; the cell lines transduced with the pLKO.1_5481 (KD) vector 
targeting brachyury (right), for assessment of toxicity associated with potential off-target effect. 
Morphology compared to cell transduced with the non-silencing construct (left). MCF7, HEK 
293T and HUH7 showed no morphological difference between the KD and the NS construct 
(images not included). 
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3.4.7.2 Proliferation not affected by new brachyury targeting shRNA 
In addition to review of morphology, a WST-1 assay was used for further assessment 
of toxicity to determine whether proliferation was affected in cells transduced with the 
pLKO.1_TRCN00005481 construct. The pLKO.1_TCRN00005484 was used as a 
positive control in addition to the non-silencing vector. The proliferation assay showed 
no increase in cell death after transduction using the pLKO.1_ TRCN00005481 vector 
in contrast to the effect observed using the pLKO.1_ TRCN00005484 vector. 
 
Figure 3.23 Cell viability following transduction with brachyury targeting shRNA 
WST-1 assay used for assessment of proliferation. The different cell lines were transduced with 
the 3 different lentiviral constructs pLKO.1_5481, pLKO.1_5484 and pLKO.1_NS for 
assessment of toxicity of the selected hairpin (5481) replacing the hairpin (5484) following 
evidence of off-target effect. 3 plates were seeded for end-point assays for 3 different time 
points (24 hours, 48 hours and 72 hours) the assay was read at time 30 minutes only on day 1 
(24 hours) to have a starting point for the readout. The end-point readout was then done at 4 
hours for time point. Each condition was seeded in triplicates.  
 
3.4.8 pLKO.1_TRCN00005481 silence brachyury in U-CH1 
Following confirmation of the tolerability of the new construct suggesting no toxic off-
target effect, significant gene silencing of brachyury in the U-CH1 chordoma cell line 
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was confirmed (Figure 3.24) and the vector was tested in two additional chordoma cell 
lines: U-CH2 and MUG Chor. 
 
Figure 3.24 Brachyury knockdown with pLKO.1 TRCN000005481  
Result of RT qPCR for brachyury knockdown in U-CH1 cell line using Lentiviral pLKO.1 
TRCN00005481 and a non-silencing (NS) construct as control in U-CH1 cell line. Puromycin 
selection was done. Brachyury expression corrected to the endogenous PGK expression as a 
reference gene and normalised to the non-silencing vector, expression was reduced by 85%. 
The figure represents results from three different experiments, each performed in triplicate. 
Error bar represent standard deviation. No error bar for NS as set at 1 for comparison of 
expression.  
 
The expression of brachyury was compared across 3 chordoma cell lines by RT qPCR 
for gene expression and by western blot for protein expression.  
 
Figure 3.25 Brachyury expression in U-CH1, U-CH2 and MUG Chor cell lines 
RT qPCR gene expression quantified from mRNA (A) and Western blot (WB) quantifying protein 
(B) comparing brachyury expression across 3 different chordoma cell lines. U-CH1 cell line is 
the first and most well established cell line and has been set as the reference for comparing 
relative expression in the two additional chordoma cell lines, brachyury expression quantified in 
relation to endogenous PGK and GAPDH expression (different experiments done for 
comparison). The experiment was done n=3 in with each experiment run in triplicate. Error bars 
indicate standard deviation. Beta-actin was used as endogenous control for the WB. 
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Gene silencing of brachyury was achieved in all 3 chordoma cell lines (Figure 3.26). It 
has previously been reported that the U-CH2 cell line has lower brachyury expression 
than the U-CH1 cell line(197), which was reproduced on the data presented here 
(Figure 3.24). However as demonstrated below brachyury expression declined in the 
U-CH2 cell line with increasing passages in culture (Figure 3.27), which became 
evident with the lack reproducibility of gene silencing. Cell line authentication with DNA 
profiling by short tandem repeats (STR) of various passages of U-CH2 excluded cross 
contamination and confirmed authenticity of the cell line (data not shown). 
 
 
Figure 3.26 Brachyury silencing in three chordoma cell lines 
RT qPCR results for relative brachyury expression in U-CH1, U-CH2 and MUG Chor cell lines 
following transduction with pLKO.1_5481 lentiviral vector targeting brachyury. Puromycin 
selection was performed. Brachyury expression was corrected to endogenous PGK expression, 
as reference gene, and normalised to the pLKO.1_non-silencing construct. The two graphs 
demonstrate two different experiments done 5 months apart. (A) U-CH2 cell passage 22, (B) U-
CH2 cell passage 38. Brachyury expression in U-CH2 appeared not be silenced on the repeat 
experiment. The lack of knockdown was due to loss of brachyury expression in cell culture over 
time. U-CH1 and MUG Chor cell lines demonstrated consistent knockdown. 
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Figure 3.27 Brachyury expression in U-CH2 is lost in cell culture 
Brachyury expression quantified by RT qPCR, brachyury expression corrected to both 
endogenous PGK and GAPDH in two separate experiments, each experiment was run in 
triplicate. Brachyury expression was normalised to U-CH1 as a standard for brachyury 
expression as the cycle threshold (ct) remained stable for U-CH1 in culture. U-CH1 and MUG 
Chor cell lines maintained brachyury expression (consistent ct) (data not shown). 
 
 
The U-CH2 cell line was not included in further gene silencing experiment. Previous 
work within our lab found that gene silencing of brachyury in the U-CH2 cell line did not 
influence proliferation (PhD thesis by Dr Nischalan Pillay under Professor A. 
Flanagan’s supervision), which correlated with observations after knockdown was 
achieved (data not shown).  
 
Brachyury expression was quantified by Western blot following transduction with AAV 
and Lentiviral vector carrying the shRNA TRCN000005481 expression cassette for 
assessment of gene silencing at protein level (Figure 3.28). 
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Figure 3.28 Brachyury protein expression following gene silencing  
Brachyury protein expression in U-CH1 and MUG Chor cell lines transduced with viral vector 
targeting brachyury. Top image represents the Western blot images, and the image below 
represents densitometric measurement of relative brachyury expression corrected for beta-actin 
as a loading control. Expression in un-transduced (UT) cells shown for comparison. The cell 
lines were transduced with a Lentiviral vector (LV) or an AAV vector, both carrying the shRNA 
TRCN000005481 (5481) targeting brachyury. Puromycin selection was undertaken. Brachyury 
expression also assessed at RNA level by RT qPCR for the same experiment (Figure 3.29). 
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Figure 3.29 Brachyury gene silencing in U-CH1 and MUG (mRNA) 
The above data is from a duplicate experiment run at the same time as the experiment for 
quantification of protein by WB (Figure 3.29) Brachyury expression was quantified by RT qPCR, 
brachyury expression was corrected to PGK, and each experiment was run in triplicate. 
Brachyury expression was normalised to cells transduced with non-silencing construct. Due to 
lack of availability of AAV vector, only the data for lentiviral vector was available. 
 
3.4.8.1 Silencing of brachyury alters morphology in U-CH1 and MUG cell lines  
Following gene silencing of brachyury in U-CH1 and MUG Chor cell lines, the cells 
demonstrated morphologic changes described in U-CH1 and JHC7 chordoma cell 
lines(89,91). 
 
Figure 3.30 Morphologic changes in U-CH1 following silencing of brachyury 
Phase contrast microscopy image of U-CH1 cells transduced with pLKO.1_5481 targeting 
brachyury. MOI 10. Puromycin selection commenced 72 hours after transduction, and was 
maintained for 96 hours or longer. The left and centre image demonstrate morphologic changes 
following knockdown of brachyury. The cells are flattened, with loss of the characteristic 
physalipherous features, and exhibit a more differentiated phenotype with stellate-appearing, or 
long slim cells.  
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Figure 3.31 Morphologic changes in MUG Chor following silencing of brachyury 
Phase contrast microscopy, image of MUG Chor cells transduced with pLKO.1_5481 targeting 
brachyury. Puromycin selection performed. The MUG chor cell line has a different growth 
pattern in cell culture than U-CH1, the cells grow closely together and are more uniform in their 
appearance, some cells have maintained the characteristic physaliferous features(91,231,661). 
The cell lines here are representative of the cells used in our lab, they are of high passage 
(p80+). Authenticity was confirmed by STR testing, younger passages had much prolonged 
doubling time. (A): represent un-transduced MUG Chor cells, the highlighted area has been 
magnified in (B). (C): represent MUG Chor cells transduced with pLKO.1_5481 with highlighted 
area magnified in (D). The cells changed morphology following transduction, the cells flattened, 
lost their structure and changed growth pattern, most cells died following brachyury knockdown.  
 
 
Having established that the TRCN000005481 demonstrated no toxicity in non-
brachyury expressing cell lines and shown that silencing of brachyury in two different 
chordoma cell lines leads to growth arrest and cell death, large scale production of 
AAV5 viral vector for delivery of this brachyury targeting shRNA was undertaken. 
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3.4.9 Xenograft for testing AAV5 gene therapy  
As described in Chapter 5, a xenograft model was developed using the U-CH1 cell line 
modified to stably express luciferase. Following engraftment the tumours demonstrated 
typical chordoma morphology and immunohistochemistry.  Tumours developed in 5 out 
of 6 mice over 9 weeks following subcutaneous injection.  In three mice the tumour 
demonstrated accelerated growth and reached sufficient size for injection of viral 
vector. Two mice received the knockdown construct. One mouse was injected with an 
AAV5 viral vector containing a GFP expression cassette (Kindly supplied by Doyoung 
Lee in Professor Amit Nathwani’s lab, UCL). The AAV5 vector production with the non-
silencing construct did not generate sufficient titre for in vivo use. The tumour, in the 
two mice not initially included in the study, continued to grow and both were used as 
negative controls with injection of Phosphate Buffered Saline (PBS) day 14.  
 
Table 3.4 Table of Treatment given to xenografts 
Mouse Identifier Viral vector received  
Mouse 1 AAV5 KD construct 
Mouse 2 AAV5 GFP 
Mouse 3 No tumour developed 
Mouse 4 PBS 
Mouse 5 PBS 
Mouse 6 AAV5 KD construct 
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3.4.9.1 Reduced tumour growth following AAV5 brachyury targeting treatment 
The two mice receiving the AAV5_brachyury silencing vector showed reduced tumour 
growth compared to those treated with either AAV5_GFP or PBS injection (Figure 
3.32).  
 
Figure 3.32 Tumour volume following intra-tumoural injection of AAV5 vector 
Tumour volume depicted as percentage change (top), or total change (bottom) of volume from 
start of treatment. Mouse 1 & 6 received AAV5_shRNA targeting brachyury, mouse 2 received 
AAV5_GFP vector, and mouse 4 & 5 received PBS (injected week 3). Numbers on X-axis 
represents the weeks with week 1 being the time of intra-tumoral injection. The experiment was 
terminated week 4. 
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3.4.9.2 Expression of luciferase reduced with AAV5 brachyury targeting vector 
Luciferase expression was measured in photons. Both mice treated with the 
knockdown construct showed reduction of luciferase expression. Mouse 6 (KD) 
demonstrated a marked reduction (day 7) but then a subsequent increase of 
expression. Expression remained stable in the mouse injected with AAV5 GFP as well 
as the two mice injected with PBS.  
 
 
Figure 3.33 Luciferase expression following intra-tumoural injection of AAV5 vector 
Average radiance of luciferase was measured in photons as photons/second/cm2/steradian 
(p/s/cm2/sr). Radiance of luciferase was measured at different time points. The bars are 
grouped for each mouse (labelled according to treatment), each time point (1-4) indicates 
weeks of treatment with week 1 being the time point of AAV intra-tumour injection. Week 1 is 
the time-point for AAV injection of the 3 mice receiving knockdown (KD) or GFP vector (control). 
Note data from “mouse 2 GFP” week 2 is missing due to failed injection of D-luciferin. Mouse 4 
& 5 were injected with PBS week 3 as their tumours were too small for injection week 1 & 2, 
mouse 4 had the luciferase expression assessed week 2 and subsequent weeks, expression for 
mouse 5 was only measured week 3 & 4.  
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Figure 3.34 Live images of luciferase expression in xenograft tumours over time  
Images were generated using Living Image Software 3.2 (IVIS Imaging Systems). The images 
were acquired over 21 days with the 1st image generated prior to AAV intra-tumoral injection.  
The subsequent images were acquired weekly up till week 4. The images show luciferase 
expression following injection of D-luciferin substrate by intra-peritoneal injection. The images 
were analysed as a group enabling comparison of photon expression. The labelling Region of 
interest (ROI): ROI 1-3 was used for measurement of average radiance of luciferase by photons 
(p/s/cm2/sr), ROI 1: mouse 1, ROI 2: mouse 2, ROI 3: mouse 6. Mouse 4 & 5 image below. 
The crude data can be found in the appendix.  
 
 
 
Figure 3.35 Live images of luciferase expression in xenograft tumours (controls) 
Details as above (Figure 39), mice used for control (mouse 4 (ROI 1) & 5 (ROI 2)) on the left 
mouse 4 week 2, centre image and image in the right represents mouse 4 & 5 week 3 (time of 
PBS injection) and week 4. The analysis was grouped with the treatment group enabling 
comparison of photon expression at different time points. 
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The mice treated with AAV5 brachyury-silencing construct showed stable or reduced 
growth and reduced luciferase expression. Mouse 2 (GFP) showed increased tumour 
size but stable luciferase expression. Mouse 4 & 5 treated with PBS had increased 
tumour size, the luciferase expression was stable but the data set for the luciferase 
expression in those two mice was incomplete. 
 
3.4.9.3 AAV5 vector was widely distributed throughout the mouse  
To demonstrate the presence of AAV5 vector in xenografts injected with silencing 
vector detection of viral genome was assessed by qPCR (Figure 3.36). Vector bio-
distribution showed that viral DNA from the AAV5 brachyury targeting vector was 
detectable in all tissue samples obtained from the necropsied animal. The liver had 
retained the highest copy number correlating with known serotype tropism for 
AAV5(693).  
 
 
Figure 3.36 Vector genome in xenograft tumour and mouse organs   
The level of vector genomes present in the tumours (T) in mouse number: 1, 2, 4 & 6 and in 
biopsies from different organs harvested from mouse 1 was determined by qPCR. Primers 
detecting the U6 promoter region of the expression cassette, only present in the knockdown 
vector was used. The qPCR was normalised to mouse genomic GAPDH. T2 and T4 served as 
negative control. 
 
3.4.9.4 Xenograft retains chordoma histology and brachyury expression 
The tumours generated in the xenograft, resembled the histology of chordoma (Figure 
3.37). No changes in morphology or immunoreactivity were observed between the 
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tumours treated with different vectors. All tumours retained immunoreactivity for 
brachyury. None of the tumour samples demonstrated necrosis.  Immunoreactivity for 
Ki67 showed scattered Ki67 positive cells with low proliferation rate in all samples (data 
not shown).  
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Figure 3.37 Morphology of chordoma xenograft and human chordoma sample 
Xenograft (1-5) (1) Low power magnification x4, Haematoxylin and eosin stain (H&E) 
demonstrating ‘classic’ lobulated appearance; (2) Higher power magnification, x10, morphology 
in concordance with a ‘classic’ chordoma showing a myxoid matrix and embedded cords and 
tumor cells with eosinophilic cytoplasm as well as vacuolated tumor cells, known as 
physaliphorous cells. Central area is showing accumulation of lymphocytes. (3) Higher power 
magnification of lymphocytes from image 2; (4) higher power magnification, x20, xenograft 
displaying morphology with typical chordoma physaliphorous cells embedded in abundant 
eosinophilic extracellular matrix; (5) xenograft stained for brachyury, brachyury is expressed in 
the nucleus however in the xenograft there is a cross-reaction with the mouse antibody causing 
staining of the membrane. Human chordoma (6 & 7) (6) H&E stain showing classical 
appearance at high magnification (x10) and (7) brachyury stain demonstration nuclear reactivity. 
IHC was kindly done by the members of the histopathology lab at the Royal National 
Orthopaedic Hospital, under supervision of Professor A. Flanagan. 
 
 
 
Lymphocyte infiltration was identified by microscopy in every tumour sample and did 
not correlate with the treatment, though less infiltration was observed in the two 
xenografts treated with PBS. The subtype of the lymphocytes was not determined as 
they did not demonstrate immunoreactivity to human antibodies for CD20 or CD79a (T-
cell marker), or CD3 (B-cell marker).  
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3.5 Discussion 
In the work presented here I have shown that the U-CH1 cell line is permissive to 
infection with AAV5. It was also observed that the U-CH1 cell line maintained GFP 
expression through cell proliferation, possibly by clonal proliferation due to AAV 
chromosomal integration or episomal replication, though the latter is unlikely due to 
lack of replicative genes within the recombinant vector(466,467). Integration of rAAV 
has been reported to occur in less than 1% of transduction events(535), however a 
preponderance for integration in this slow growing cell line (doubling time 1 week)(134) 
cannot be excluded. 
 
In this study two separate examples demonstrated the difficulties of predicting the 
efficacy and specificity of the gene silencing construct, when shRNA from within one 
vector is transferred to another vector. The initial construct transferring the shRNA from 
the GIPZ_V2LHS vector, attempting to recapitulate the gene silencing described by 
Presneau et al.(89), demonstrated no evidence of brachyury silencing in the AAV 
vector. The detection of GFP expression suggests that this is not due to loss of viral 
vector but more likely due to insufficient shRNA expression.  When cloning the 
constructs, transferring the hairpin from the GIPZ_V2LHS vector into the AAV vector, 
two constructs were generated, one with the miR30 sequence and one without. Both 
approaches have been validated in the literature(397,689,693). By including the miR30 
flanking sequence, which has been reported to trigger the RNAi processing 
pathway(364), and maintaining the scaffolding for the shRNA(397), the processing of 
the hairpin was assumed to remain the same, retaining the specificity for the targeting 
sequence. Shifting the target sequence by just one or two bases has however been 
reported to change the silencing efficiency(405). It was not possible to establish if lack 
of expression or lack of specificity explains the lack of silencing of brachyury. It also 
cannot be excluded that the lack of gene silencing was due to compensatory brachyury 
gene expression from non-transduced cells, as the construct did not contain an 
antibiotic expression cassette for selection of the transduced cells. This however 
seems less likely as the initial transduction efficiency with AAV was excellent as 
evident by GFP expression.  
 
The subsequent AAV delivery system was generated using the shRNA from the 
pLKO.1 system, a system used for silencing brachyury in the JHC7 cell line(91). The 
shRNA sequence was identical to the hairpin used by Presneau et al.(89). Using this 
construct both within the lentiviral and the AAV vector, knockdown of brachyury was 
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observed to cause severe irreversible morphologic changes and cell death in the U-
CH1 cell line. The U6 promoter expressing the shRNA is more efficient than the 
previously tested CMV promoter(694) which would be expected to lead to more 
efficient knockdown. The increased toxicity was considered to be due to a higher level 
of expression of the hairpin, though the gene-silencing of brachyury was no more 
efficient compared to published data(89,91). The toxicity was unlikely to be caused by 
the viruses or the expression cassette, excluding the targeting sequence, as the 
morphologic changes were not observed using the non-silencing shRNA vector 
functioning as control for the expression cassette, the endogenous RNAi processing 
pathway and the virus. The dramatic effect on cell survival was reproduced in 7 non-
brachyury expressing cell lines suggesting toxicity was due to sequence specific, off-
target effects. 
 
When the potential targets and off-targets of the hairpin were re-assessed, the 
sequence was found to be specific for brachyury targeting 100% (21/21 nucleotides). 
An additional mRNA was targeted with 76% (16/21) sequence alignment within the 
gene TENM3. The rules for achieving shRNA specificity are not fully defined, and off-
target effect remains a concern(393). Some reports suggest that a single nucleotide 
mismatch in the middle of an shRNA can abolish its activity(695,696). In contrast, 
others have reported that shRNA can silence non-target genes containing as few as 
14–15 consecutive complementary nucleotides(697) or less(405,698). The off-target 
effects have been described to be more prominent when there is a match between the 
seed region of shRNA (positions 2–7) and sequences aligning to the 3′UTR of the 
gene(374). The brachyury targeting shRNA (pLKO.1TCRN00005484) targets TENM3 
from the nucleotide in position 4 but does not target within the 3’UTR. The 
recommendation for shRNA design is to allow for at least 2 nucleotide mismatches 
between shRNA and closely related non-target genes(407). Numerous factors 
influencing activity have been identified, including; the loop sequence, thermodynamic 
properties of the hairpin, and the surrounding sequences(398). This may explain why 
no toxicity was reported using the identical shRNA targeting sequence in the 
GIPZ_V2LHS vector. It has been recognised that varying levels of off-target silencing 
can occur with different silencing platforms because the concentration of shRNA 
vary(359). Dosing is a function of the copy number and how efficiently the hairpin is 
expressed and processed(699). Assessment to quantify the cellular copy number of 
shRNA expressed following transduction was attempted but failed for TRCN00005484 
shRNA. Expression level of the shRNA TRCN00005481 did not seem to correlate with 
gene silencing (data not included). Notably, AAV infect cells at multiple copies per cell, 
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which can be problematic with shRNA as dosing may be amplified. Higher expression 
is not always beneficial(359). In this study the toxicity was observed across all vectors 
including AAV and lentiviral vector as well as with naked plasmids. Supporting that 
toxicity was most likely due to a combination of higher expression of the shRNA 
achieved using the U6 promoter and/or the off-target alignment with TENM3.  
 
TENM3 belongs to the teneurin family of proteins that are highly conserved among 
species with significant homology between the four different family members(700). 
Teneurins are a type II transmembrane protein with a large extracellular domain 
containing an epidermal growth factor-like repeat domain, which was initially described 
in the Drosophilia as ODZ(701). TENM3 is expressed in the notochord in zebra fish 
and mice(702). The gene was not found to be highly expressed in chordoma(33) and 
expression in the U-CH1 cell line was found to be very low in the work presented here.  
Interestingly TENM3 was observed to be differentially expressed when brachyury was 
silenced in the U-CH1 cell line using a different GIPZ vector (GIPZ_V2LHS_153729) 
targeting within the 3’UTR of brachyury. This hairpin sequence did not align with 
TENM3 suggesting the regulation of brachyury and TENM3 may be linked(127). 
Teneurin function involves maintenance of basal membrane integrity and mediation of 
haemophilic intercellular adhesions(703,704). A recent study of teneurin signalling in 
neuromuscular synapse in Drosophila showed that alterations in teneurin expression 
affected microtubule organisation and severely disrupted the cytoskeleton(705). These 
functions support the consistent morphologic changes seen in the different cell lines 
exposed to the off-target effect following transduction with the shRNA_5484 construct 
reducing the TENM3 expression due to its off target effect. 
 
A different shRNA was subsequently used where the sequence had limited off-target 
effects as determined by BLAST alignment with the human genome and which showed 
no toxicity or reduction in proliferation of non-chordoma cell lines. The lentiviral vector 
(pLKO.1 TRCN000005481) as well as the AAV5 vector generated with the expression 
cassette induced significant gene silencing of brachyury in the U-CH1 and MUG Chor 
chordoma cell lines, inducing changes in morphology, growth arrest and cell death.  
 
A xenograft model was used to determine if our AAV vector targeting brachyury has 
therapeutic potential in vivo. Two mice were treated with the recombinant viral vector 
and in these mice the growth of the tumour stablised or reduced in size with diminished 
luciferase expression. Following intratumoural injection the AAV vector was detectable 
not only within the tumours but in all organs tested, indicating “off-target” tissue effects. 
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This is not likely to be of therapeutic concern as brachyury is not expressed in normal 
tissue, other than in testis. However, lack of tissue specificity may lead to insufficient 
dosing of target tissues(706). During post mortem evaluation brachyury 
immunoreactivity was retained in all tumour samples regardless of therapy received. In 
the two mice that received the brachyury-targeting vector it remains to be established if 
the lack of gene silencing was due to loss of the vector during cell division or the 
outgrowth of non-transduced cells. At the end of four weeks the average viral copy 
number per cell suggested that the ratio of tumour cell transduction was one to one. A 
marker was however not included in the construct to visualise distribution of the vector 
within the chordoma xenograft tumour specimen(707). It has not been established what 
level of shRNA expression is needed to maintain brachyury gene silencing.  As 
chordomas have slow growth kinetics the tumour cells were expected to experience 
lengthy RNAi effects with knockdown of brachyury leading to cell senescence or cell 
death. It is conceivable that the transduced tumour cells found a way to escape the 
gene silencing, a phenomenon accepted by scientists working with RNAi but rarely 
reported. In a study by Gu et al.(708) lentiviral delivered shRNA silencing was found 
only to be durable for 2-3 weeks after which time an increase in expression was 
observed. The transduced cells initially demonstrated evidence of apoptosis and cell 
senescence in vitro and inhibition of tumour growth in vivo(709), however the effect 
was not maintained. Lentiviral-mediated silencing is thought to be permanent as the 
vector integrates into the host cell genome(664). Integration of the vector was 
confirmed by demonstrating persistent GFP expression. This demonstrated that the 
plasmid was still able to express the transgene and that overgrowth of non-transduced 
cells did not account for the loss of gene silencing. Others have reported similar 
difficulties with lack of durable RNAi in cancer cell lines(710-712). Escape from a single 
shRNA silencing complex has also been demonstrated in HIV-1 with the virus 
regaining the ability to multiply(713). The viral escape was circumvented by adding 
multiple shRNAs to the vector, targeting different sites within the 
genome(397,713,714). The use of bi-functional shRNA has also been used in pre-
clinical studies in cancer cell lines, showing enhanced potency and durability of gene 
silencing(715,716). Having used a non-integrating viral vector for the study reported 
here there is less certainty regarding the possible causes for the lack of gene silencing. 
The possibility that cells have escaped gene silencing in this study is supported by the 
observation of reduction or stabilisation of tumour growth and reduction in luciferase 
expression early after transduction. 
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Loss of transgene expression might also explain the lack of a prolonged effect on 
tumour growth. Viral vectors and RNAi transgenes have been found to have immune 
stimulation potential(308,391,402). Though murine studies have not been helpful in 
predicting immune response to viral vectors(436,717), neutralising antibodies against 
the transgene are well documented in murine studies(235,435,718). The immune 
responses against vectors and transgene products can lead to silencing or loss of 
expression with only transient expression of the therapeutic genes(402,404,436). In the 
study presented here lymphocyte infiltration was identified by microscopy in every 
tumour sample and did not correlate with the treatment. The subtype of the 
lymphocytes was not determined, however the athymic Balb/c nude mouse is grossly 
deficient in peripheral T cells(719) and the lymphocyte population is mostly composed 
of B-lymphocytes(719-721), suggesting that B cells would most likely be present. 
Parameters for assessing immune stimulation, by detection of neutralising antibodies 
to the transgene or viral vector were not undertaken in this study and it was therefore 
not possible to assess the role this mechanism might play in the time dependent 
tumour effect.  
 
While the small scale of this experiment presented lacks statistical power, there 
remains an indication that brachyury silencing can reduce tumour growth. These 
preliminary results warrant further investigation as a novel anti-tumour approach for 
chordoma. Indeed, the three established chordoma cell lines used in this work were all 
found to be permissive to AAV5, indicating its ability to target chordoma in a clinical 
setting. The potential ability to escape RNAi will need to be addressed through 
optimisation of the construct to express multiple shRNA targeting sequences. An 
additional solution might be to optimize the vector to include an immune modulator 
such as interferon, IL-2, GM-CSF or a suicide gene to the construct. This will stimulate 
a targeted inflammatory response to transduced cells, guiding the immune system to 
eradicate the tumour. It may also prove beneficial to combine gene therapy targeting 
brachyury with cytotoxic- or targeted therapies as silencing of brachyury may render 
the tumour cells sensitive to other therapies. This approach is currently being tested in 
a phase II trial using the brachyury vaccine in combination with radiotherapy 
(NCT02383498)(298).  
 
Gene therapy for chordoma as defined by this experiment may not offer a definitive 
cure but delay of recurrence, offering relief and reduced morbidity for patients.  A 
challenge facing clinical development is defining a meaningful end-point, in particular 
where the patient population is small, the natural history of the disease progression is 
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slow and biomarkers to monitor therapeutic efficacy have not yet been identified or 
validated. Treatment options are likely to be multi-faceted and require novel drug 
therapies and novel biomarkers such as ctDNA. This will be adressed in subsequent 
chapters.  
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4 HIGH-THROUGHPUT DRUG SCREEN  
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4.1 Background 
The lack of effective treatment for chordoma has previously been discussed. Standard 
treatment includes surgery followed by proton beam radiotherapy. Chordoma has 
proven to be largely resistant to conventional ionising radiation and 
chemotherapy(56,722,723).  
 
In the past decade advances have been made in the treatment of many cancers. The 
recognition that somatic genetic alterations in tumours correlate with clinical response 
to specific tyrosine kinase inhibitors (TKI) and that molecular profiling can identify 
‘driver’ mutations allowing for genotype-directed therapy rather than empiric therapy 
has lead the concept of personalised medicine(162,579,724-728). One of the most 
successful examples of cancer-targeted therapy is inhibition of EGFR mutations which 
occurs in up to 30% of patients with NSCLC(729). The majority of patients with 
activating EGFR mutations have demonstrated good response to therapy with EGFR 
inhibitors(730). However, the vast majority of patients who initially responded to 
therapy developed resistance within 1-2 years(729,731,732). Mechanisms of acquired 
resistance include emergence of secondary mutations and altered gene expression 
within the targeted or alternative pathways(729,733,734). Many of the mechanisms of 
resistance are still unknown(729,735,736).  
 
With the exception of brachyury amplification in a proportion of chordomas, no unifying 
recurrent genetic alteration has been identified and, in particular, no targetable 
mutation(125,128,129,135). Analysis of tyrosine kinases in chordoma has detected 
activated PDGFR, EGFR and TGFα(164). Studies of the downstream pathways have 
described activation of the PI3K/AKT and RAS/MAPK pathways(40,164), but no 
mutation or amplification has been identified within these gene pathways(40,130,180). 
 
In view of the unmet need for effective treatment for chordoma and the lack of 
targetable genetic alterations, a high-throughput compound screen was undertaken. 
Performing a phenotypic screen has the potential to identify drug-sensitivity patterns, to 
help understand some of the mechanisms of this disease and potentially provide a 
strategy to identify biomarkers to guide the early-phase clinical trials of novel 
compounds.  
4.2 High-throughput drug screening in chordoma (Declaration) 
This project was undertaken in collaboration with Cancer Research Technologies UK 
(CRT) who gave technical assistance and advice on the project and provided a 
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screening report forming the basis for this chapter. CRT is in part funded by Cancer 
Research UK and has vast experience with high-throughput drug screening. The 
compound screening was done jointly with Michelle Barnard (CRT) and members of 
Professor A. Flanagan’s lab: Lucia Cottone PhD, Susanne Scheipl (MD), and I. 
Susanne Scheipl screened the GSK PKIS1 library manually before the collaboration 
with CRT was established. CRT analysed the data, and compounds were selected for 
inclusion into the subsequent screening. The compound screen involved collaboration 
with GlaxoSmithKline (GSK) (GlaxoSmithKline, NC, USA) who supplied two different 
compound libraries containing small kinase inhibitors at various stages of their 
compound development(737). GSK remained involved throughout the project giving 
advice, and received the data following completion of the screening process. In 
addition to the GSK compounds, CRT made a set of 160 kinase inhibitors available, 
which were included in the screen; these compounds were from Calbiochem (Merck 
KGaA, Darmstadt, Germany). The majority of these compounds are currently being 
tested in early phase clinical trials. In addition, a selection of cytotoxic anti-cancer 
drugs were included, as a few small studies have suggested a synergistic effect of 
cytotoxic drugs and kinase inhibitors(88,200-202) (Table 1.1). Two epigenetic libraries 
(SCG) were also included in the screen - this was part of Lucia Cottone’s project. The 
data features in the figures for the analysis and are included in the numbers, but will 
not be commented upon. 
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4.3 Aim 
The aim was to identity compounds with therapeutic effect in chordoma. Identifying 
therapeutic targets relevant for chordoma, by performing a phenotypic high throughput 
compound screen in three chordoma cell lines, might help understand the mechanisms 
of this disease. Target identification will guide patient selection and identify compounds 
for clinical trials in the development of treatment for chordoma. For this purpose a 
phenotypic high-throughput screen was undertaken, testing approximately 1200 
compounds, to identify small molecules which elicit a kill or arrest effect in three 
chordoma cell lines.  
4.4 Objectives 
1. To optimise cell lines to confirm authenticity by genetic fingerprinting using 
short tandem repeats (STR). 
2. To study the effect on cell proliferation in a single point screen (1µM) in three 
well established chordoma cell lines (U-CH1, U-CH2, MUG Chor).  
3. To confirm the hits from the single point screen in a dose-response format (IC50)  
4. To identify selective hits by including a counter screen using a control cell line 
(human dermal fibroblasts). 
5. To validate the mechanism of cell death by assessment of induction of 
apoptosis. 
6. To select the lead compounds and benchmark them against approved drugs 
targeting the same targets.    
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4.5 Results 
4.5.1 Chordoma cell lines  
Specific information on the origin of the cell lines used for this study can be found in 
Materials and Methods. 
4.5.1.1 Authentication of chordoma cell lines  
STR analysis examining 17 highly polymorphic genetic markers generated a DNA 
profile uniquely identifying the cell lines. The markers were aligned against the data 
held at the American Type Culture Collection (ATCC), which confirmed authenticity of 
the chordoma cell lines used for the compound screen.  
 
 
Figure 4.1 STR analysis of 3 chordoma cell lines 
U-CH1 passage18 (top), U-CH2 passage 26 (middle), MUG Chor-1 passage 93 (bottom). STR 
data represent allele size. The query cell line is highlighted in green, below are the cell lines to 
which the chordoma cell lines align in order of best match.  
 
Targeted therapy for chordoma 
206 
4.5.1.2 Cell lines tested negative for mycoplasma 
The cell lines used for the drug screen were tested for mycoplasma by culturing on 
broth and agar(738). All the cell lines tested negative for mycoplasma (data not 
shown).   
4.5.1.3 The cell lines harbour no common cancer gene mutations  
To support interpretation of the data from the compound screen the three chordoma 
cell lines were checked for mutations in common cancer-signalling pathways 
(hotspots). These included: EGFR, KRAS, NRAS BRAF, PIK3CA, AKT1, TP53, PTEN, 
MAP2K1, ALK, CTNNB1, MET (HGFR), FGFR1/2/3/4, NOTCH1, JAK2, KIT and 
PDGFR. No mutations were identified. 
4.5.2 Results of single point screening 
4.5.2.1 High-throughput screen set up and quality control 
The initial step of the high-throughput screen included optimisation. Cell density 
experiments were undertaken to establish the number of cells that were to be seeded 
on day 1 so as to reach 90% confluency on day 5. The optimal time point for assay 
readout was determined as 5 days from seeding, and following 4 days of compound 
treatment. This was established during the initial compound runs by evaluation of 
morphology and cell death (data not shown). The timing for the colorimetric assay 
read-out was determined based on the stability of the WST-1 assay, identifying the 
time point before reaching saturation of the assay The Staurosporine (SSP) 
concentration was chosen on the basis of achieving 100% cell death (positive control) 
on day 5, and the DMSO concentration which exerted no effect (negative control) was 
determined by undertaking a dilution experiments. Antibiotics were tested for 
interference with the data (no interference was noted). Results of the optimisation are 
outlined in Table 4.1 below. 
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Table 4.1 Outcome of optimisation  
Assay parameter MUG Chor U-CH2 U-CH1 
Endpoint read time 2 hours 3 hours 3 hours 
Cell density 5000 cells/well 2500 cells//well 5000 cells/well 
SSP blank 
concentration 
30µM 30µM 30µM 
DMSO (%) 0.25 0.25 0.25 
+/- Pen/Strep +Pen/Strep +Pen/Strep +Pen/Strep 
 
 
Table 4.2 Overview of compound libraries  
Compound library 
 
Number of compounds 
 
GSK PKIS2 522 
GSK PKIS1 364 
SGC 20 
Epigenetic  43 
Calbiochem 160 
Anti-cancer 43 
Total number of compounds 1152 
 
4.5.2.2 Good reproducibility of high-throughput screen data 
The single point screen was conducted at a single concentration of 1µM for each 
compound. Good reproducibility of data was observed in all cell lines across three 
independent experiments (Figure 4.2). 
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Figure 4.2 Distribution of percentage inhibition for each independent experiment  
The raw data for each independent experiment was converted to percentage inhibition relative 
to the negative controls (cells + 0.25% DMSO) and positive controls (cells + 30µM 
Staurosporine) on each plate. The data from each experiment (n=3) were overlaid to assess 
variance within the data. Different colours identify individual experiments. Distribution of 
percentage inhibition vs. well reference for each experiment. Data representative of 
Calbiochem, Epigenetics, SGC, and GSK PKIS2 libraries. GSK PKIS1 was screened separately 
and was not included, but demonstrated equally good reproducibility between separate 
experiments (data not shown). 
 
U-CH1 
U-CH2 
MUG Chor 
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4.5.3 Hit selection  
Due to the variability of activity between cell lines and/or only moderate percentage 
inhibition of proliferation, compounds causing a decrease in viability of more than 2x 
standard deviations (SD) (CI 95%) or, for some libraries, 1.5x SD compared to the 
controls were regarded as hits.  
 
 
Figure 4.3 Depiction of 3x, 2x and 1.5x standard deviation for hit selection 
SD of the data was used to determine mean percentage inhibition, and 1.5, 2 and 3 fold SD 
thresholds were calculated for each cell line. The difference in the number of hit selection 
between 1,5x, 2x and 3x SD is demonstrated. The red line is the SD above the threshold, the 
black line is the mean percentage inhibition, and the blue line is the SD below the threshold. 
The different coloured dots represent libraries with each dot representing a different compound. 
Green: Calbiochem, Blue: anti-cancer library. Orange: GSK PKIS2. Yellow & red: epigenetic 
libraries. These data are for the MUG Chor cell line. The data for U-CH2 and U-CH1 are similar 
(not shown). By lowering the SD it is possible to increase the yield and thereby ensuring 
inclusion of potential effective compounds.  
 
 
1.5x SD Threshold 2x#SD#Threshold#
3x SD Threshold 
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Figure 4.4 Compound hits according to 3x, 2x and 1.5x standard deviations 
Illustration of data in figure 3 demonstrating the number of hits according to different standard 
deviations of percentage inhibition in the three cell lines. Data ranges for each library vary with 
high SD for some libraries (Anti-cancer, SGC, Epigenetic) leading to biased thresholds. This 
resulted in few or no hits from the GSK PIKS2 library. The mean SD for the GSK PKIS2 (GSK 
552) library was re-calculated separately selecting hits according to 1.5x SD based on data for 
this library only and not across all libraries, in the interest of including potentially effective drugs. 
The purple line indicates mean percentage inhibition.  
 
 
The 2x SD above the threshold identified compounds which gave >46% inhibition in 
MUG Chor, >50% inhibition in U-CH1 and >53% inhibition in U-CH2. This yielded a 
total of 113 hits above the relative percentage inhibition thresholds across all cell lines. 
A 2x SD below the threshold was used for each cell line thereby identifying 23 potential 
activators of cell growth/interferers (< -20% inhibition in MUG Chor/U-CH2 and < -29% 
in U-CH1).  
 
The re-calculated thresholds using 1.5x SD based on mean percentage inhibition for 
each of the cell lines for the GSK PKIS2 library identified an additional 34 inhibitory hits 
above the relative thresholds (>33% inhibition in MUG Chor, >35% inhibition in U-CH1, 
and >41% inhibition in U-CH2). 20 potential activators of cell growth/interferers were 
identified below the relative thresholds (< -15% inhibition in MUG Chor, < -24% 
inhibition in U-CH1 and < -1% inhibition in U-CH2) inclusive of all cell lines. A total of 
147 compounds above the defined thresholds and 43 potential activators/interferers 
below the thresholds (Calbiochem, GSK PKIS2, and Anti-Cancer Libraries) were 
identified for further profiling.  
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The GSK PKIS1 library, which had been screened manually was analysed by CRT for 
compound commonality vs. selectivity. 37 additional compounds were identified as 
inhibitory hits: 15 common hits (either between two or all three cell lines) and 13 
selective hits for the MUG Chor, 8 selective hits for U-CH2 and 1 selective hit for U-
CH1. These hits were included in the IC50 profiling (Figure 4.6 & Table 4.3). 
 
The global hit rate was 16% for inhibitory hits (184/1153) and 3.7% for potential 
interferers/activators of cell growth (43/1153). Hits were either common or selective for 
chordoma cell lines. Identified compounds were profiled in a 10-point IC50 format in the 
three chordoma cell lines and a control cell line, Normal Adult Human Dermal 
Fibroblasts (NAHDF). 
 
 
Figure 4.5 Distribution of hits from single point screen for all libraries  
Hit distribution across libraries of interest according to cell lines (common or selective) with a 
total of 159 hits from all libraries, 68 hits were common to two or more cell lines, 27 hits were 
specific to U-CH2, 26 hits were specific to U-CH1, 28 hits specific to MUG Chor. The data for 
the epigenetic screen were not included in this figure, accounting for the discrepancy in the total 
number of hits. 
4.5.3.1 Summary of single point screen for GSK PKIS1 library 
The GSK PKIS1 library was analysed in more detail as the compound’s target class 
has previously been published(739), whereas the compound targets for the GSK 
PKIS2 were revealed following the IC50 profiling.  
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Figure 4.6 Compound targets with hits shared across cell lines  
Graphical representation of target class from GSK PKIS1 by a Venn diagram showed overlap of 
target class common to two or all three cell lines.  
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 Table 4.3 Selective hits for individual chordoma cell lines GSK PKIS1 library  
 
  
CRT ID GSK Cpd ID MUG Mean SP % Inhibition Pathway
CRT0363776 GW683768X 46 CDK
CRT0363482 GW583373A 39 ErbB71/ErbB2
CRT0363293 SB7725317 45 GSK73
CRT0363705 SB76752597M 52 GSK73
CRT0363496 GSK2220400A 52 IGF71R
CRT0363724 GSK1173862A 54 IGF71R
CRT0363757 GSK2213727A 38 IGF71R
CRT0363761 GSK2110236A 63 IGF71R
CRT0363762 GSK2163632A 51 IGF71R
CRT0363271 SB7737198 36 MSK71
CRT0363573 GW440139A 37 RET
CRT0363377 GW410563A 35 VEGFR
CRT0363378 GW612286X 37 VEGFR
M
U
G
 C
ho
r!!
CRT ID GSK Cpd ID UCH2 Mean SP % Inhibition Pathway
CRT0363419 GSK614526A 35 AKT
CRT0363273 SB2750140 40 MSK21
CRT0103145 SB22200252R 33 p386kinase
CRT0363345 GSK317314A 57 polo2like6kinase61
CRT0363347 GSK326090A 38 polo2like6kinase616
CRT0363348 GSK571989A 72 polo2like6kinase616
CRT0363350 GSK978744A 50 polo2like6kinase616
CRT0363390 GSK269962B 34 Rho2Kinase
U
C
H
2!
!
CRT ID GSK Cpd ID UCH1 Mean SP % Inhibition Pathway
CRT0363358 GW461104A 29 ErbB41/ErbB2U
C
H
1 
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4.5.3.2 Summary of single point screen of anti-cancer library 
To identify compounds already in clinical use, that could potentially be tested in 
combination with targeted therapy. To achieve this compounds from the anti-cancer 
library were selected based on the literature review of drugs tested in preclinical and 
clinical settings. Compounds reported to have demonstrated efficacy and 
chemotherapeutics currently used as standard of care in treatment for sarcoma were 
included. The compounds had various different mechanisms of action (Figure 4.7). For 
a full list of compounds included please see appendix.  
 
Figure 4.7 Mechanism of action (targets) of compounds, Anti-cancer library  
 
 
Compounds from the Anti-cancer library were selected for the IC50 profiling according 
to the percentage inhibition determined by the single point screening. Compounds 
identified as hits are listed below in Table 4.4. Multiple compounds demonstrated an 
overlap whilst some showed selectivity between cell lines as demonstrated in the Venn 
diagram below (Figure 4.8). No compound showed selectivity for the MUG Chor cell 
line. 
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Table 4.4 Anti-cancer library compounds for IC50 screening 
 
Compound hit selection threshold: MUG Chor: 46% mean inhibition, U-CH1: 50% mean 
inhibition and for U-CH2: 53% mean inhibition was used as selection criteria for compounds to 
be included in the IC50 profiling. 
 
 
 
 
Figure 4.8 Venn diagram of anti-cancer compounds selectivity/commonality 
Overview of mechanism of action or targets of compounds selected from the single point 
screen. 
  
ID/Compound name Target class U-CH2 Mean % inhibition
U-CH1 Mean % 
inhibition
MUG Chor 
Mean % 
inhibition
Deforolimus (Ridaforolimus) mTOR 53.1
Everolimus mTOR 55.63
PHA-793887 CDK 55.23
ABT-869 (Linifanib) CSF-1R 57.15
Decitabine DNA Methyltransferase 58.4
Lapatinib EGFR 64.1
Ellence Toposiomerase 65.17 45.3
GDC-0559 (Vismodegib) Hedgehog 67.3 46.93
OSI-930 c-Kit 84.5 67.37
BEZ235 (Dactolisib) ATM/ATR 61.37 77.6
Adriamycin (Doxorubicin) DNA Synthesis 67.23 93.56
Flavopiridol CDK 71.67 75.7
GSK1059615 mTOR/PI3K 52.8 48.35
Docetaxel Microtubule associated 48.7 63.8 58.7
AP24534 (Ponatinib) Bcr-Abl 58.83 82.67 55.8
AZD2281 (Olaparib) PARP 71.47 76.27 80.2
AZD8055 mTOR 59.13 76.33 82.45
Bortezomib Proetasome inhibitor 97.5 96.23 49.5
SB939 (Pracinostat) HDAC 85.57 64.37 80.25
GDC-0941 PI3K 55.8 64 59.3
Carboplatin DNA Synthesis 100 100 87.15
17-DMAG (Alvespimycin) HSP90 74.67 86.4 63
Belinostat DHAC 83.43 80.35
mTOR
CDKPI3K
DNA/RNA.Synthesis
HSP
Autophagy
Bcr@Abl
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mTOR
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Miccrotubule.Assoiated
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c@Kit
HDAC
ATM/ATR
mTOR/PI3K
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4.5.4 IC50 profiling for confirmation of compound hits  
Confirmation of hits was assessed by comparing the data from the single point screen 
with equivalent doses tested in the IC50 profiling to assess reproducibility of the data. 
Confirmation rates were satisfactory.  
4.5.4.1 Hit confirmation rate for GSK PKIS1 library 
Hit confirmation rate for GSK PKIS1 library was conducted separately, as the single 
point data from this screen was in a different format. The hit confirmation rate for MUG 
Chor was 72%, U-CH1 was 89% and U-CH2 was 81% (Figure 4.9). 
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Figure 4.9 Confirmation of hits from single point screen GSK PKIS1 library 
Illustration of confirmed hits in each cell line: right upper quadrant. Mean percentage inhibition 
for compounds at 1.1µM in 10-point IC50 assay vs. mean percentage inhibition for compounds 
at 1µM from the single point screen.  
 
 
 
U-CH1 
MUG Chor 
U-CH2 
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4.5.4.2 Hit confirmation for Calbiochem, GSK PKIS2 and anti-cancer libraries 
The global hit confirmation rate (independent of the GSK PKIS1 library) for MUG Chor 
was 81%, U-CH1 72% and U-CH2 79%. There were no potential activators/interferers 
identified (i.e. no dose response curves inverted below -20% inhibition).  
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Figure 4.10 Confirmation of hits from the single point across 3 libraries 
Hits identified in the single point screen were confirmed as hits in the IC50 profiling: right upper 
quadrant. A different colour represents each library. For each cell line the percentage inhibition 
at 1.1 to 0.740µM in the 10-point IC50 assay vs. percentage inhibition at 1µM in the single point 
screen.   
U-CH1 
U-CH2 
Mug Chor 
Targeted therapy for chordoma 
220 
4.5.4.3 Selectivity of compounds  
The data from the IC50 screen generated dose response curves, which demonstrated 
the differential phenotypic effect allowing for comparison of effect between cell lines, as 
demonstrated in Figures 4.12 & 4.13 below (dose response curves for all compounds 
can be found in the appendix). 
 
In order to identify compounds of target families potentially relevant to the disease, hits 
were triaged according to compounds eliciting selective cell death (toxicity) in 
chordoma cell lines compared to the ‘normal’ adult human dermal fibroblasts (NAHDF) 
control cell line. This was achieved by assessing the differential phenotypic effect.  
 
 
Figure 4.11 Profiling by IC50  
IC50 profiling enabled us to validate a dose response curve for the compounds, identifying active 
and inactive compounds as depicted on the left. By using a counter screen it was possible to 
define if the compound had no effect in the ‘normal’ cell line (fibroblasts) or that there was a 
differential dose-response between the ‘normal’ and the chordoma cell lines as depicted on the 
right. 
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Figure 4.12 Differential phenotypic effects observed in different cell lines 
Depiction of dose-response curve demonstrating the different phenotypic effect, observed in 
different cell lines, following compound treatment with an ErbB1/ErbB2 inhibitor. A differential 
phenotypic effect was observed between U-CH1 and NAHDF cell lines, a moderate effect was 
noted in the MUG Chor cell line (plateau around 35% Inhibition), and no effect in the U-CH2 cell 
line. 
 
 
Figure 4.13 Differential phenotypic effect with ErbB1/ErbB2 targeting compound 
Depiction of overlay of dose response curves from (U-CH1, MUG Chor and NAHDF), 
demonstrating the differential phenotypic effect. The graph is suggestive of a cytostatic effect in 
the U-CH1 cell line in doses > 1µM with maximum percentage inhibition reaching 60%. 
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4.5.5 EC50 
In order to compare efficacy of a compound that demonstrated heterogeneous effect 
between cell lines, EC50 values were used as a measure of potency on molecular 
targets. Values were determined from graphical plots of percentage inhibition vs. log 
[µM]. IC50 and EC50 are both used as a measure of potency, however, when using IC50, 
a classic sigmoidal graphical profile would be expected to span between 0 to 100% 
inhibition. Therefore, if reporting IC50, this is only informative if data includes the 
maximum percentage inhibition when efficacy varies across cell lines. EC50 is defined 
as the effective concentration, which elicits a half-maximal response (e.g. half way 
between the baseline and maximum response).   
 
To identify compounds that exerted differential effects in the three chordoma cell lines 
compared to the NAHDF cell line, the potency (pEC50 defined as the negative logarithm 
of EC50) was calculated and plotted for each compound in each cell line (Figure 4.14 
for all libraries screened at CRT, and figure 4.15 for GSK PKIS1 library). The mean 
pEC50 of each compound in chordoma cell lines vs. the NAHDF cell line was correlated 
using a threshold of <5µM for each chordoma cell line and >10µM for the NAHDF cell 
line. Off-target cytotoxicity was identified when there was no differential phenotypic 
effect between the chordoma cell lines and NAHDF. 
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Figure 4.14 Selectivity of compounds  all libraries excluding GSK PKIS1 
Selectivity versus off-target cytotoxicity. U-CH1 cell line mean pEC50 vs. mean NAHDF pEC50 in 
147 selected active and 43 potentially interfering or pathway activating compounds. 13 
compounds for U-CH1, 11 compounds for MUG Chor and 8 compounds for U-CH2 of interest. 
Left upper quadrant: compounds of interest; right upper quadrant compounds with similar 
differential phenotypic effect in chordoma and control cell line, some included (circled) due to 
high percentage inhibition. Left and right lower quadrant: doses above set dose range for 
chordoma cell line. pEC50 was defined as the negative logarithm of the EC50. The pEC50 scale 
equals: 6 = 1µM, 9 = 1nM. 
U-CH1 
MUG Chor 
U-CH2 
Targeted therapy for chordoma 
224 
 
Figure 4.15 Selectivity of compounds GSK PKIS1 library 
For each chordoma cell line mean pEC50 vs. mean NAHDF pEC50 for the 37 selected active 
compounds from the GSK PKIS1 library. 10 compounds for U-CH1 and 7 compounds for MUG 
Chor were of interest. There was a lack of selective cytotoxicity for U-CH2 cells. 3 compounds 
identified as selective for U-CH2 have a ‘liability’, as they are potentially biphasic in the control 
cell line. Left upper quadrant: compounds of interest; right upper quadrant compounds with 
similar differential phenotypic effect (in chordoma and NAHDF cell line); left and right lower 
quadrant: doses above set dose range for chordoma cell line.  
U-CH1 
MUG Chor 
U-CH2 
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4.5.6 Summary of compounds of interest across all libraries 
4.5.6.1 EGFR inhibitors selective for chordoma 
Differential phenotypic effect analysis yielded 28 of 184 compounds displaying 
chordoma selective cell death on 3 chordoma cell lines. The measure of the differential 
phenotypic effect was referred to as selectivity, i.e. the fold difference between NAHDF 
mean EC50 and the chordoma cell line mean EC50. Higher selectivity accounts for an 
increased differential effect. Compounds showed either a common differential 
phenotypic effect (selectivity for more than one chordoma cell line, though sometimes 
to varying degrees), or a specific differential phenotypic effect for one cell line. 
Selectivity values varied between compounds/cell lines therefore no triaging was 
conducted at this point. 
 
GSK released the target classes for the hits from the PKIS2 library. 14 compounds 
from this library had demonstrated differential phenotypic effect of which 10 
compounds (71%) were EGFR/ErbB family inhibitors. Five of these only targeted the 
EGFR/ErbB family, whilst three were classified as dual inhibitors as they also targeted 
BRAF and two targeted ErbB, BRAF and Src. In addition, one activin receptor-like 
kinase 5 (ALK5) inhibitor and two multi-kinase inhibitors co-targeting rho-associated, 
coiled-coil-containing protein kinase 1 (ROCK1), protein kinases A (PKA) and B (AKT), 
p70S6 kinase, Aurora A kinase and BRAF, were identified. For one compound the 
target(s) were unknown. CRT0423639:01 in the GSK PKIS2 library was revealed to be 
Erlotinib, a FDA-approved EGFR inhibitor. The targets from the additional libraries 
included 12 EGFR/ErbB family inhibitors, one phosphatidylinositol-3-kinase (PI3K) 
inhibitor and one VEGFR/FGFR inhibitor (CRT0363377:02), which was a commercial 
VEGFR2 inhibitor, Pazopanib HCl.  
 
The differential phenotypic screen had identified 27 compounds with identified targets 
of which 22 (81%) targeted the EGFR/ErbB family receptors.  
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Figure 4.16 Compound selectivity: GSK PIKS1 and PIKS2 libraries 
Data compiled from the two GSK libraries showed a trend for selectivity for targeting the EGFR 
pathway. U-CH1 showed a differential phenotypic effect as indicated by ‘fold selectivity’ for 
more compounds compared to the other chordoma cell lines, although with a low percentage 
inhibition.  
 
The U-CH1 cell line was found to be sensitive to a larger number of EGFR/Erb 
inhibitors, although with low percentage inhibition, while moderate sensitivity to this 
compound class was observed in the MUG Chor cell line. The MUG Chor cell line had 
a liability in maximum response e.g. had <1µM potency but a maximum response 
(inhibition) less than 100% (50-75%). U-CH2 cells were sensitive to the ALK5 inhibitor, 
multi-kinase inhibitors and EGFR/Erb family dual inhibitors, which also targeted BRAF. 
  
VE
GF
R,
'F
GF
R'
Targeted therapy for chordoma   
 227 
Table 4.5 Compounds with a differential phenotypic effect  
 
Compound ID 
GSK 
ID/Compound 
Name
Library Pathway UCH1 UCH2 MUG.Chor Effect 
CRT0047607:05 AG1478 Calbiochem EGFR 
Biphasic  
(Potency not 
Quantified) 
Arrest (~40%) 
between 
0.122-30uM 
Kill UCH1, Moderate 
Arrest MUG.Chor 
CRT0103071:02 Compound 56 Calbiochem EGFR 153 Kill UCH1
CRT0103079:02 EGFR/ErbB2/ErbB4 Inhibitor Calbiochem 
EGFR/ErbB-
2/ErbB-4 8
Arrest (~30%) 
between 1.1-
30uM
Kill UCH1, Moderate 
Arrest MUG.Chor 
CRT0103123:02 PD 174780 Calbiochem EGFR 176
Arrest (~35%) 
between 
0.366-30uM
Kill UCH1, Moderate 
Arrest MUG.Chor 
CRT0103124:02 PD 174265 Calbiochem EGFR  73
Arrest (~30%) 
between 3.3-
30uM
 Kill in UCH1, 
Moderate Arrest 
MUG.Chor 
CRT0159097:02 GDC-0941 Anticancer Class 1A PI3K Inhibitor 4 Kill in UCH2 
CRT0363358:02 GW461104A PKIS1 ErbB-1/ErbB2 9 10 Kill UCH1 & MUG.Chor 
CRT0363377:02 GW410563A PKIS1 VEGFR2, FGFR 6
Arrest (~40%) 
between 3.3-
30uM
Kill in UCH1, 
Moderate Arrest 
MUG.Chor 
CRT0363431:01 GW282449A PKIS1 EGFR/ErbB2 35 8 Kill UCH1, Arrest MUG.Chor 
CRT0363431:02 GW282449A PKIS1 EGFR/ErbB2 30 4 Kill UCH1, Arrest MUG.Chor 
CRT0363479:02 GW576609A PKIS1 ErbB-1/ErbB2 2
Arrest (~30%) 
between 1.1-
10uM 
Potential Kill in 
UCH1, Moderate 
Arrest MUG.Chor
CRT0363482:02 GW583373A PKIS1 ErbB-1/ErbB2 9
Arrest (~30%) 
between 1.1-
30uM
Kill in UCH1, 
Moderate Arrest 
MUG.Chor
CRT0363484:02 GW616030X PKIS1 ErbB-1/ErbB2 36
Arrest (~35%) 
between 1.1-
30uM
Kill in UCH1, 
Moderate Arrest 
MUG.Chor
CRT0363568:02 GW680191X PKIS1 EGFR/ErbB2 4 2 79
Kill UCH2, Arrest 
MUG.Chor, Potential 
Kill in UCH1 
CRT0423387:01 GI230329A PKIS2 EGFR 39
Arrest (~30%) 
between 
0.082-20uM 
Kill UCH1, Moderate 
Arrest MUG.Chor
CRT0423403:01 GSK1307810A PKIS2
ROCK1, AKT, 
PKA, 
P70S6K, 
Aurora A
21
Arrest (~35%) 
between 2.2-
20uM 
Kill UCH2, Moderate 
Arrest MUG.Chor
CRT0423493:01 GSK1660437A PKIS2 BRAF, SRC, LCK, LYN 4 Kill UCH2 
CRT0423504:01 GSK198271A PKIS2 ErbB family, BRAF 4 3 6
Kill UCH1, Moderate 
Kill Effect in UCH2 & 
MUG.Chor
CRT0423580:01 GSK299495A PKIS2 Src, ErbB family, BRAF 13 8 5
Kill UCH1, Moderate 
Kill Effect in UCH2 & 
MUG.Chor
CRT0423587:01 GSK326180A PKIS2 ErbB family, BRAF 19 25
Kill UCH1, Moderate 
Kill Effect in 
MUG.Chor
CRT0423593:01 GSK357952A PKIS2 Src, ErbB family, BRAF 10 10
Moderate Kill Effect 
in UCH2 & UCH1 
CRT0423594:01 GSK361061A PKIS2 BRAF, ErbB4 12 4
Moderate Kill Effect 
in UCH1 & 
MUG.Chor
CRT0423639:01 GW459135A Erlotinib (PKIS2) EGFR 46 6 102
Kill UCH1, Moderate 
Kill MUG.Chor & 
UCH2 
CRT0423669:01 GW569716A PKIS2 ErbB2/EGFR 13 Moderate Kill MUG.Chor
CRT0423674:01 GW582764A PKIS2 ErbB2/EGFR 10 Moderate Kill UCH1 
CRT0423676:01 GW583340C PKIS2 ErbB2/ EGFR 14
Arrest (~35%) 
between  
0.740-20uM
Kill UCH1, Moderate 
Arrest MUG.Chor
CRT0423770:01 GW876731X PKIS2
ALK5 series 
(TGF beta 
receptor)
19
Arrest (~35%) 
between  
0.246-20uM
Kill UCH2, Moderate 
Arrest MUG.Chor
CRT0423890:01 SKF-97184 PKIS2 Unknown 6 Moderate Kill MUG.Chor
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28 compounds elicited a differential phenotypic effect. Threshold of <5uM in chordoma cell line, 
>10uM in NAHDF cell line applied in conjunction with visual inspection of graphical curve 
overlays. 
4.5.7 Selectivity of anti-cancer library 
From the CRT Anti-cancer Library, 43 compounds were screened in the single-point 
profiling, which identified 23 compounds based on 2x SD hit selection threshold from 
each cell line. These compounds were profiled in a 10-point IC50 format for hit 
confirmation. Only one of the compounds for the anti-cancer library showed differential 
phenotypic effect between NAHDF and U-CH2, this was a PI3K kinase inhibitor: GDC-
0941 (Figure 4.17).  
 
 
Figure 4.17 GDC-0941 compound with a differential phenotypic effect in U-CH2 
From the anti-cancer library, only one compound showed differential phenotypic effect. The 
compound targets the PI3K kinase pathway. 
 
There were several classes of inhibitors with different potency rankings in each 
chordoma cell line, with no, limited or similar differential phenotypic effect in normal 
dermal fibroblast cells, which may still play a role in the treatment of chordoma. 
Bortezomib, a proteasome inhibitor was the most potent compound in all three 
chordoma cell lines (10-20nM), but was also equipotent in normal dermal fibroblasts 
(Figure 4.18). Several clinically approved drugs tested in this screen were observed to 
be efficacious in the chordoma cell lines, all of which showed toxicity in ‘normal’ cells 
(Table 4.6).  
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CRT0159097 02 4.38 92.09 1.89 91.58 2.90 65.39 1.21 88.16
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Figure 4.18 Phenotypic effect of Bortezomib 
Bortezomib, a proteasome inhibitor, was found to be highly potent in all cell lines. Maximum 
percentage inhibition was 100% at doses ranging from 10-20nM. 
 
 
Additional standard of care drugs, not initially included in the screening, were added 
based on the identified targets of interest. These drugs included: Foretinib 
(MET/VEGFR2), Erlotinib (EGFR), Gefitinib (EGFR), Tivozanib (VEGFR), Cediranib 
(VEGFR), and Regorafenib (VEGFR) kinase inhibitors, which were included in the 
follow-on screen. Imatinib (Bcl-Abl, PDGFR, c-Kit) was also included as patients have 
been treated with this drug and it is considered potentially effective in chordoma 
treatment. No effect was observed in any of the chordoma cell lines following treatment 
with Imatinib (Table 4.6). 
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CRT0276355 01 0.01 100.13 0.01 100.53 0.02 100.59 0.01 98.15
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 Table 4.6 Potency of compounds determined by IC50 profiling of anti cancer library  
 
Compound concentration and percentage inhibition for each compound in each cell line. The most intense red colour indicates the lowest effective compound 
concentration, whereas the lightest blue colour indicated the highest percentage inhibition. (Geomean: Geometric mean: average ratios of change)
Compound(ID Batch(Ref.
Supplier(ID/Compound(
Name
NAHDF(Geomean(
[uM]
NAHDF(Mean(Max(%(
Inhibition
UCH1(Geomean(
[uM]
UCH1(Mean(Max(%(
Inhibition
MUG.Chor1(
Geomean([uM]
MUG.Chor1(Mean(
Max(%(Inhibition
UCH2(Geomean([uM]
UCH2(Mean(Max(%(
Inhibition
CRT0276355 01 Bortezomib 0.01 100.00 0.01 100.53 0.02 99.74 0.01 98.15
CRT0276378 01 Docetaxel=(Taxotere) 0.01 74.69 0.03 48.06 0.06 30.55 0.02 43.73
CRT0276190 01 17@DMAG 0.08 100.87 0.15 97.88 0.14 101.72 0.17 98.88
CRT0276344 01 AZD8055 0.37 82.32 0.21 77.77 0.88 53.74 0.32 70.13
CRT0276385 01 Erlotinib=Hydrochloride 29.72 39.90 0.26 80.38 30.00 31.79 6.52 47.75
CRT0276390 01 Flavopiridol(Alvocidib) 0.78 71.12 0.37 65.29 0.45 48.43 0.19 71.78
CRT0159098 02 BEZ235(NVP@BEZ235) 0.80 91.98 0.89 79.65 2.37 43.03 1.38 73.43
CRT0276427 01 SB939 1.16 100.23 0.90 100.64 1.85 98.55 2.09 65.14
CRT0276325 01 Adriamycin 0.20 78.59 1.37 70.91 0.89 46.44 0.30 59.32
CRT0276395 01 GDC@0449(Vismodegib) 0.67 90.23 2.37 46.32 2.31 50.96 1.67 85.62
CRT0159097 02 GDC@0941 3.99 84.76 2.68 92.95 3.57 70.81 3.63 79.05
CRT0276404 01 Lapatinib=Ditosylate 5.94 100.53 3.35 96.92 8.40 89.26 20.67 69.74
CRT0276347 01 Belinostat(PXD101) 1.73 99.43 3.78 97.06 1.64 91.21 11.15 73.53
CRT0276444 01 XL880(GSK1363089) 3.05 97.00 3.80 104.22 1.53 100.71 2.77 83.27
CRT0276331 01 AP24534 0.60 101.33 4.20 103.02 3.98 105.48 1.40 97.79
CRT0276398 01 GSK1059615 1.13 97.46 4.51 85.88 5.51 68.58 1.57 93.95
CRT0162212 02 Carboplatin 30.00 3.88 5.16 26.72 30.00 19.08 30.00 19.90
CRT0276422 01 PHA@793887 0.31 90.66 8.17 63.91 20.57 61.91 0.90 71.52
CRT0276452 01 Ellence 1.82 99.52 10.89 89.66 7.14 93.98 3.02 93.52
CRT0276337 01 AV@951(Tivozanib) 30.00 28.66 11.21 81.15 7.13 41.85 14.21 80.53
CRT0276346 01
BAY=73@
4506(Regorafenib)
15.41 42.08 28.13 48.60 17.98 79.17 15.01 45.90
CRT0276194 01 ABT@869(Linifanib) 19.02 45.25 30.00 16.57 13.78 39.05 30.00 20.10
CRT0162533 02 Cisplatin=(In=Water) 6.72 86.50 30.00 5.00 30.00 30.50 30.00 8.50
CRT0276341 01 AZD2281(Olaparib) 10.01 49.49 30.00 32.47 17.00 39.65 30.00 22.02
CRT0276362 01 Cediranib(AZD2171) 2.65 35.94 30.00 42.51 30.00 13.58 15.34 44.88
CRT0276374 01 Decitabine 2.44 48.69 30.00 20.17 30.00 @0.20 30.00 23.90
CRT0276375 01 Deforolimus(MK@8669) 0.01 45.00 30.00 31.97 30.00 3.20 0.03 49.14
CRT0276400 01 Imatinib=Mesylate 30.00 @5.44 30.00 32.07 30.00 12.61 30.00 39.11
CRT0276415 01 OSI@930 29.93 44.35 30.00 0.03 30.00 4.01 18.06 60.00
CRT0276417 01 Pazopanib=Hydrochloride 7.23 42.04 30.00 32.37 30.00 13.02 30.00 38.74
CRT0276387 01 Everolimus(RAD001) 100.00 99.15 100.00 57.80 18.22 60.29 100.00 68.52
Compound(ID Batch(Ref.
Supplier(ID/Compound(
Name
NAHDF(Geom (
[uM]
NAHDF(MeanMax(%(
Inhibition
UCH1(Geom (
[uM]
UCH1(Mean(Max(%(
Inhibiti n
MUG.Chor1(
Geomean([uM]
MUG.Chor1(Mean(
Max(%(Inhibition
UCH2(Geomean([uM]
UCH2(Mean(Max(%(
Inhibition
CRT0276355 01 Bortezomib 0.01 100.00 0.01 100.53 0.02 99.74 0.01 98.15
CRT0276378 01 Docetaxel=(Taxotere) 0.01 74.69 0.03 48.06 0.06 30.55 0.02 43.73
CRT0276 90 0 17@DMAG 0.08 100.87 0.15 97.88 0.14 101.72 0.17 98.88
CRT0276344 01 AZD8055 0.37 82.32 0.21 77.77 0.88 53.74 0.32 70.13
CRT0276385 01 Erl tinib=Hydrochloride 29.72 39.90 0.26 80.38 30.00 31.79 6.52 47.75
CRT0276390 01 Flavopiridol(Alvocidib) 0.78 71.12 0.37 65.29 0.45 48.43 0.19 71.78
CRT0159098 02 BEZ235(NVP@BEZ235) 0.80 91.98 0.89 79.65 2.37 43.03 1.38 73.43
CRT0276427 01 SB939 1.16 100.23 0.90 100.64 1.85 98.55 2.09 65.14
CRT0276325 01 Adriamycin 0.20 78.59 1.37 70.91 0.89 46.44 0.30 59.32
CRT0276395 01 GDC@0449(Vismodegib) 0.67 90.23 2.37 46.32 2.31 50.96 1.67 85.62
CRT0159097 02 GDC@0941 3.99 84.76 2.68 92.95 3.57 70.81 3.63 79.05
CRT0276404 01 L patinib=Ditosylate 5.94 100.53 3.35 96.92 8.40 89.26 20.67 69.74
CRT0276347 01 Belinostat(PXD 01) 1.73 99.43 3.78 97.06 1.64 91.21 11.15 73.53
CRT0276444 01 XL880(GSK1363089) 3.05 97.00 3.80 104.22 1.53 100.71 2.77 83.27
CRT0276331 01 AP24534 0.60 101.33 4.20 103.02 3.98 105.48 1.40 97.79
CRT0276398 01 GSK1059615 1.13 97.46 4.51 85.88 5.51 68.58 1.57 93.95
CRT0162 12 02 Carboplatin 30.00 3.88 5.16 26.72 30.00 19.08 30.00 19.90
CRT0276422 01 PHA@793887 0.31 90.66 8.17 63.91 20.57 61.91 0.90 71.52
CRT0276452 01 Ellence 1.82 99.52 10.89 89.66 7.14 93.98 3.02 93.52
CRT0276337 01 AV@951(Tivozanib) 30.00 28.66 11.21 81.15 7.13 41.85 14.21 80.53
CRT0276346 01
BAY=73@
4506(Regorafenib)
15.41 42.08 28.13 48.60 17.98 79.17 15.01 45.90
CRT0276 94 01 ABT@869(Linifanib) 19.02 45.25 30.00 16.57 13.78 39.05 30.00 20.10
CRT0162533 02 Cisplatin=(In=Water) 6.72 86.50 30.00 5.00 30.00 30.50 30.00 8.50
CRT0276341 01 AZD2281(Olaparib) 10.01 49.49 30.00 32.47 17.00 39.65 30.00 22.02
CRT0276362 01 Cediranib(AZD2171) 2.65 35.94 30.00 42.51 30.00 13.58 15.34 44.88
CRT0276374 01 Decitabine 2.44 48.69 30.00 20.17 30.00 @0.20 30.00 23.90
CRT0276375 01 Deforolimus(MK@8669) 0.01 45.00 30.00 31.97 30.00 3.20 0.03 49.14
CRT0276400 01 Imatinib=Mesylate 30.00 @5.44 30.00 32.07 30.00 12.61 30.00 39.11
CRT0276415 01 OSI@930 29.93 44.35 30.00 0.03 30.00 4.01 18.06 60.00
CRT0276417 01 Pazopanib=Hydrochloride 7.23 42.04 30.00 32.37 30.00 13.02 30.00 38.74
CRT0276387 01 Everolimus(RAD 1) 100.00 99.15 100.00 57.80 18.22 60.29 100.00 68.52
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4.6 Mechanism of cell death 
The mechanism of cell death was assessed for all 27 hits confirmed from the IC50 
profiling, as well as the additional compounds listed above. Chemotherapy kills 
cells primarily by inducing apoptosis(740). On target effect was assessed by 
mechanism of cell death by confirmation of apoptosis as the identified by 
induction of caspase 3/7. The assay was combined with assessment of cell 
viability of compound treated cells compared to controls, reported as percentage 
inhibition.  An example of the read out for this assay has been demonstrated in 
chordoma cells treated with Bortezomib (Figure 4.19-4.21).  
 
 
 
Figure 4.19 Mechanism of cell death MUG Chor 
Mechanism of cell death by induction of apoptosis related to percentage inhibition. MUG 
Chor cell line treated with Bortezomib (CRT0276355). The caspase Glo (CG) 3/7 assay 
was used for detection of induction of apoptosis and Cell Titre Glow (CTG) assay, a cell 
viability assay, was used to determine the number of viable cells. The percentage 
induction of caspase (green) and percentage inhibition of compound treated cells 
compared to controls (black) is shown at 0 hour (top left), 24 hours (top right), 48 hours 
(bottom left) & 72 hours (bottom right). Each assay was performed on separate plates (for 
each time point). 
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Figure 4.20 Mechanism of cell death U-CH1 
Mechanism of cell death by induction of apoptosis related to percentage inhibition. U-CH1 
cell line was treated with Bortezomib (CRT0276355) and assessed both for percentage 
inhibition (black), and percentage induction of caspase (green) at 0 (top left), 24 hours 
(top right), 48 hours (bottom left) & 72 hours (bottom right). 
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Figure 4.21 Mechanism of cell death U-CH2 
Mechanism of cell death by induction of apoptosis related to percentage inhibition U-CH2 
cell line was treated with Bortezomib (CRT0276355) and assessed for both percentage 
inhibition (black), and percentage induction of caspase (green) at 0 (top left), 24 hours 
(top right), 48 hours (bottom left) & 72 hours (bottom right).  
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4.6.1 Validation of compounds of interest 
In view of the high number of EGFR/ErbB inhibitors selected during the screening 
process of U-CH1 and MUG Chor cell lines, this was the primary target identified 
to validate. Five commercially available EGFR/ErbB family inhibitors, either FDA-
approved or in clinical trials were purchased (referred to as the targeted therapy 
or TT set). Afatinib and Canertinib had an irreversible mode of action (MOA). The 
other three EGFR inhibitors Erlotinib, Gefitinib and Sapitinib were reversible.   
 
Hits identified in the IC50 profiling (Table 4.5) were re-tested using a second batch 
of compounds and profiled alongside the additional 5 EGFR inhibitors in a 10-
point IC50 format in the WST-1 assay for NAHDF, U-CH1, U-CH2 and MUG Chor 
cell lines. This was done to ensure that each compound was tested at least twice.  
Irreversible compounds in the targeted therapy set appeared potentially biphasic 
in some cell lines, assessed by differential phenotypic effect, and therefore fold 
selectivity and potency were not calculated (Table 4.7). EGFR inhibitors showed 
variability of effect between different compounds. U-CH1 proved most sensitive 
to EGFR inhibitors at low doses and with high maximum percentage inhibition. 
MUG Chor confirmed response but with liability in maximum percentage inhibition 
whilst U-CH2 demonstrated little or no effect. The fold selectivity indicating 
differential phenotypic effect between the individual chordoma cell lines and 
NAHDF demonstrated good selectivity between U-CH1 and MUG Chor 
compared to NAHDF, whilst U-CH2 confirmed selectivity with an EGFR inhibitor 
also targeting BRAF and ALK5 (TGF-β receptor) (Table 4.7). The differential 
phenotypic effect observed between supposedly identical targets raised the 
potential to identify specific chemotypes within the compound group of EGFR 
inhibitors.  
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 Table 4.7 Confirmation of selected hits and target therapy compounds 
 
Repeat screen of selected hits and TT compounds. Geomean EC50, maximum percentage inhibition and differential phenotypic effect selectivity data of 28 
compounds from libraries tested (hits) and 5 commercial compounds  (TT) for NAHDF, U-CH1, U-CH2 and MUG Chor cell lines (Geomean: Geometric mean: 
average ratios of change). Fold selectivity used to determine the differential phenotypic effect between NADPH and chordoma cell lines. Darkest red: lowest 
concentration, darkest green: highest percentage inhibition, darkest blue; highest fold selectivity. 
Compound ID GSK ID/ Commercial name Library Pathway 
NAHDF EC50 
Geomean [uM]
NAHDF Mean 
M%I
UCH1 EC50 
Geomean [uM]
UCH1 Mean 
M%I
UCH2 EC50 
Geomean 
[uM]
UCH2 Mean 
M%I
MUG.Chor1 EC50 
Geomean [uM]
MUG.Chor1 
Mean M%I
UCH1 Fold 
Selectivity 
UCH2 Fold 
Selectivity 
MUG.Chor1 Fold 
Selectivity 
CRT0047607 AG 1478 Calbiochem EGFR 20.74 10
Small 
Span.Potency not 
Quantified
76 18.82 52 0.08 64 Selectivity not Calculated 1 248
CRT0103071 Compound 56 Calbiochem EGFR 22.79 77 0.57 86 20.00 27 0.01 62 40 1 2349
CRT0103079 EGFR/ERBB2/ERBB4 Inhibitor Calbiochem EGFR/ERBB2/ERBB4 12.91 96 0.18 79 16.69 38 0.02 64 72 1 548
CRT0103123 PD174780 Calbiochem EGFR 30.00 29 0.21 80 19.66 35 0.10 55 143 2 296
CRT0103124 PD174265 Calbiochem EGFR 30.00 11 0.38 75 13.25 43 0.15 70 78 2 201
CRT0159097 GDC-0941 Anticancer Class 1A PI3K Inhibitor 3.99 85 2.68 93 3.63 79 3.57 71 1 1 1
CRT0276366 Canertinib Targeted Therapy EGFR/ErbB2  5.19 100 0.13 81 9.30 60 Potentially Biphasic. Potency not Quantified 95 41 1
Selectivity not 
Calculated
CRT0276385 Erlotiniib Targeted Therapy EGFR 14.57 48 0.35 86 15.50 40 0.22 74 42 1 66
CRT0276396 Gefitinib Targeted Therapy EGFR 11.18 87 0.22 76 9.84 79 0.36 68 50 1 31
CRT0363358 GW461104A GSK PKIS1 ErbB-1/ErbB2 17.08 85 2.02 80 30.00 32 2.06 58 8 1 8
CRT0363377 GW410563A GSK PKIS1 VEGFR 22.03 68 1.91 80 19.39 67 4.41 47 12 1 5
CRT0363431 GW282449A GSK PKIS1 EGFR/ErbB2 29.30 55 0.80 65 20.88 34 1.80 45 37 1 16
CRT0363431 GW282449A GSK PKIS1 EGFR/ErbB2 28.12 70 0.93 66 30.00 33 6.54 49 30 1 4
CRT0363479 GW576609A GSK PKIS1 ErbB-1/ErbB2 12.10 85 4.06 77 23.04 38 100.00 49 3 1 0
CRT0363482 GW583373A GSK PKIS1 ErbB-1/ErbB2 10.96 62 1.39 71 17.93 44 30.00 32 8 1 0
CRT0363484 GW616030X GSK PKIS1 ErbB-1/ErbB2 19.40 53 0.54 69 30.00 27 1.62 39 36 1 12
CRT0363568 GW680191X GSK PKIS1 EGFR/ErbB2 30.00 41 1.26 86 17.83 61 0.37 45 24 2 81
CRT0423387 GI230329A GSK PKIS2 EGFR 16.87 96
Potentially 
Biphasic. Potency 
not Quantified
94 20.00 40 0.19 41 Selectivity not Calculated 1 90
CRT0423403 GSK1307810A GSK PKIS2 ROCK1, AKT, PKA, P70S6K, Aurora A 13.65 100 16.44 61 1.85 64 5.68 30 1 7 2
CRT0423493 GSK1660437A GSK PKIS2 BRAF, SRC, LCK, LYN 3.02 78 15.41 45 1.00 58 18.44 56 0 3 0
CRT0423504 GSK198271A GSK PKIS2 ErbB family, BRAF 3.70 48 0.34 78 3.09 43 0.22 50 11 1 17
CRT0423580 GSK299495A GSK PKIS2 Src, ErbB family, BRAF 20.00 38 1.49 79 3.90 49 6.54 38 13 5 3
CRT0423587 GSK326180A GSK PKIS2 ErbB family, BRAF 20.00 35 0.89 74 0.43 44 2.96 48 22 46 7
CRT0423593 GSK357952A GSK PKIS2 Src, ErbB family, BRAF 20.00 17 1.99 61 6.19 40 20.00 31 10 3 1
CRT0423594 GSK361061A GSK PKIS2 BRAF, ErbB4 22.13 17 1.51 56 22.89 28 11.26 33 15 1 2
CRT0423639 GW459135A GSK PKIS2 EGFR 19.34 60 0.42 69 3.33 46 0.19 58 46 6 101
CRT0423669 GW569716A GSK PKIS2 ErbB2/EGFR 8.77 99 4.74 81 13.48 71 0.59 46 2 1 15
CRT0423674 GW582764A GSK PKIS2 ErbB2/EGFR 21.10 78 1.72 54 22.89 20 22.13 25 12 1 1
CRT0423676 GW583340C GSK PKIS2 ErbB2/ EGFR 15.13 55 1.06 66 13.08 40 20.00 34 14 1 1
CRT0423770 GW876731X GSK PKIS2 ALK5 series (TGF beta receptor) 8.88 83 10.92 94 0.58 74 12.76 39 1 15 1
CRT0423890 SKF-97184 GSK PKIS2 Unknown 20.00 9 19.17 55 20.00 24 6.37 42 1 1 3
CRT0509501 Afatinib Targeted Therapy EGFR/ErbB2 5.88 100
Potentially 
Biphasic. Potency 
not quantified
89 5.14 100 Potentially Biphasic. Potency not quantified 100
Selectivity not 
Calculated 1
Selectivity not 
Calculated
CRT0509503 Sapitinib (AZD 8931) Targeted Therapy EGFR/ErbB2  20.00 39 0.05 82 8.98 47 0.24 68 417 2 83
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4.7 Chemotype and Substituent Trend Analysis (GSK) 
GSK carried out a chemotype analysis of the 22 EGFR/ErbB hits from the 
differential phenotypic effect triaging and the 5 EGFR/ErbB commercial 
compounds in the targeted therapy library. Two chemotypes were identified: 
Quinazoline and Pyrimidine(741). Further analysis by substituent trend (R groups 
around the core) showed two subtypes of Quinazoline compounds those with 
large substituents on position 4 and those with small substituents at position 4. 
 
The potency observed in the different chordoma cell lines treated with various 
EGFR inhibitors were correlated with the chemotypes. This produced a shortlist 
of compounds to undergo further screening. This list included 22 compounds 
consisting of 2 Pyrimidines, 7 Quinazoline ‘large R group’ compounds and 13 
Quinazoline ‘small R group’ compounds including known EGFR inhibitors: 
Erlotinib, Gefitinib, Sapitinib, and Afatinib. Lapatinib was added to the shortlist 
based on its Quinazoline ‘large R groups’ as a comparison to hits of the same 
chemotype. Lapatinib was also of interest as it had been used in a clinical trial 
where it demonstrated minimal activity(179) (Table 4.8).  
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Table 4.8 EGFR inhibitor according to chemotypes 
 
Analysis of potency according to chemotype. Geomean EC50 and mean maximum percentage inhibition of shortlist of 22 compounds from table 4.7 based on 
chemotype and potency in sensitive chordoma cell lines. Orange to Red = nM to µM for potency. Light blue to Dark blue = High to low maximum percentage 
inhibition.
Compound ID GSK ID /Commercial Name Library Pathway Chemotype
NAHDF EC50 
Geomean [uM]
NAHDF Mean 
M%I
UCH1 EC50 
Geomean [uM]
UCH1 Mean 
M%I
UCH2 EC50 
Geomean [uM]
UCH2 Mean 
M%I
MUG.Chor1 EC50 
Geomean [uM]
MUG.Chor1 
Mean M%I
UCH7 EC50 
Geomean [uM]
UCH7 Mean 
M%I
CRT0423504 GSK198271A GSK PKIS2 ErbB family, BRAF Pyramidine 3.70 48 0.34 78 3.09 43 0.22 50 0.33 58
CRT0423587 GSK326180A GSK PKIS2 ErbB family, BRAF Pyramidine 20.00 35 0.89 74 0.43 44 2.96 48 1.20 69
CRT0276404 Lapatinib Ditosylate Anticancer EGFR Quinazoline large 5.94 101 3.35 97 11.13 90 8.40 89 2.30 76
CRT0363431 GW282449A GSK PKIS1 EGFR/ErbB2 Quinazoline large 29.30 55 0.80 65 20.88 34 1.80 45 1.36 58
CRT0363482 GW583373A GSK PKIS1 ErbB-1/ErbB2 Quinazoline large 10.96 62 1.39 71 17.93 44 30.00 32 0.48 44
CRT0363484 GW616030X GSK PKIS1 ErbB-1/ErbB2 Quinazoline large 19.40 53 0.54 69 30.00 27 1.62 39 0.45 55
CRT0423669 GW569716A GSK PKIS2 ErbB2/EGFR Quinazoline large 8.77 99 4.74 81 13.48 71 0.59 46 2.20 47
CRT0423674 GW582764A GSK PKIS2 ErbB2/EGFR Quinazoline large 21.10 78 1.72 54 22.89 20 22.13 25 NT NT
CRT0423676 GW583340C GSK PKIS2 ErbB2/ EGFR Quinazoline large 15.13 55 1.06 66 13.08 40 20.00 34 7.09 39
CRT0103071 Compound 56 Calbiochem EGFR Quinazoline small 22.79 77 0.57 86 20.00 27 0.01 62 0.22 50
CRT0103079 EGFR/ERBB2/ERBB4 Inhibitor Calbiochem EGFR/ERBB2/ERBB4 Quinazoline small 12.91 96 0.18 79 16.69 38 0.02 64 0.78 61
CRT0103123 PD174780 Calbiochem EGFR Quinazoline small 30.00 29 0.21 80 19.66 35 0.10 55 0.27 49
CRT0103124 PD174265 Calbiochem EGFR Quinazoline small 30.00 11 0.38 75 13.25 43 0.15 70 0.33 71
CRT0276366 Canertinib Targeted Therapy EGFR/ErbB2  Quinazoline small 5.19 100 0.13 81 9.30 60
Potentially Biphasic. 
Potency not 
Quantified
95 0.25 41
CRT0276385 Erlotiniib Targeted Therapy EGFR Quinazoline small 14.57 48 0.35 86 15.50 40 0.22 74 0.70 56
CRT0276396 Gefitinib Targeted Therapy EGFR Quinazoline small 11.18 87 0.22 76 9.84 79 0.36 68 0.24 66
CRT0363358 GW461104A GSK PKIS1 ErbB-1/ErbB2 Quinazoline small 17.08 85 2.02 80 30.00 32 2.06 58 1.91 51
CRT0363568 GW680191X GSK PKIS1 EGFR/ErbB2 Quinazoline small 30.00 41 1.26 86 17.83 61 0.37 45 3.15 61
CRT0423387 GI230329A GSK PKIS2 EGFR Quinazoline small 16.87 96
Potentially 
Biphasic. 
Potency not 
Quantified
94 20.00 40 0.19 41 0.37 71
CRT0423639 GW459135A (Erlotinib) GSK PKIS2 EGFR Quinazoline small 19.34 60 0.42 69 3.33 46 0.19 58 NT NT
CRT0509503 Sapitinib (AZD 8931) Targeted Therapy EGFR/ErbB2  Quinazoline small 20.00 39 0.05 82 8.98 47 0.24 68 1.01 46
CRT0509501 Afatinib Targeted Therapy EGFR/ErbB2 Quinazoline small 5.88 100
Potentially 
Biphasic. 
Potency not 
Quantified
89 5.14 101
Potentially Biphasic. 
Potency not 
Quantified
101 12.36 107
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The trend in terms of cell line sensitivity (potency), ranked: U-CH1 > MUG Chor > 
U-CH2 with a maximum response liability in MUG Chor with compounds 
demonstrating 50-75% inhibition. In terms of trend with regard to 
chemotype/substituent trend, it appeared, albeit with a small number of 
compounds, that Quinazoline ‘large’ compounds exerted activity in U-CH1 but 
were less potent in the MUG Chor cell line. Quinazoline ‘small’ compounds 
exerted activity in the U-CH1 and MUG Chor cell lines but neither subset was 
routinely active in the U-CH2 cell line. The two Pyrimidine compounds 
(GSK198271A and GSK326180A) were generally pan-inhibitors across three 
chordoma cell lines with a potency range of 217nM to 3uM.  
 
At this stage of the screening cascade several EGFR/ErbB inhibitors were 
identified from independent pharmacologically active libraries. These hits were 
used to benchmark commercially available compounds to help understand the 
chemistry. The favourable chemotype, determined from chemotype/substituent 
analysis by GSK, was the Quinazoline with small R groups at position 4. Sapitinib 
(AZD 8931) was identified as the ‘lead’ candidate for further screening, based on 
its compound profile. Sapitinib, a dual EGFR/HER2 inhibitor(742), demonstrated 
phenotypic potencies of 50nM, 242nM and 9µM in U-CH1, MUG Chor and U-
CH2 respectively, with reversible mode of action, and differential phenotypic 
effect fold selectivity of 417 in the most sensitive cell line (U-CH1) (Table 4.7 & 
Figure 4.22).  
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Figure 4.22 Differential phenotypic effect with Sapitinib (AZD 8931) 
Graphical plot demonstrating percentage inhibition in a 10-point dosing (IC50), using the 
WST-1 assay in NAHDF, MUG Chor, U-CH1 and U-CH2 cell lines. Data representative of 
at least n=2. Phenotypic Geomean EC50: NAHDF >20µM, MUG Chor 0.24µM, U-CH1 
0.05µM, U-CH2 6.88µM (Table 4.7). 
 
4.7.1 EGFR inhibitors in chordoma 
A general trend was observed with EGFR/ErbB inhibitors inducing caspase-3/7 
activity between 6 to 24 hours post compound treatment, followed by a decrease 
in cell viability from 24 hours in the U-CH1 cell line. Minimal induction of caspase-
3/7 activity (<30% induction) was observed in U-CH2 and MUG Chor cells. This 
observation was reflected in the phenotypic assay with U-CH1 being the most 
sensitive cell line (Appendix). 
 
Sapitinib displayed high induction of caspase-3/7 activity in the U-CH1 cell line 
between 6 and 48 hours followed by decrease in cell viability observed from 24 
hours onwards. MUG Chor showed high induction of caspase-3/7 activity and 
>40% growth inhibition at 72 hours. The U-CH2 cell line showed ~50% induction 
of caspase-3/7 activity between 24 and 72 hours at the three top concentrations 
of the dose-response (20µM, 6.6µM and 2.2µM) but <40% growth inhibition was 
observed (Figure 4.23).  
 
Erlotinib was used as a bench mark compound for comparison to Sapitinib as 
Erlotinib has previously been used in the treatment of patients with chordoma. 
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Erlotinib induced caspase-3/7 activity in the U-CH1 cells between 24 to 72 hours 
and a decrease in cell viability from 48 hours. Minimal caspase-3/7 induction was 
observed in U-CH2 and MUG Chor cell lines at all time points (Figure 4.24).  
 
 
 
Figure 4.23 Caspase-Glo 3/7 and CellTitre-Glo assay for Sapitinib treated cells 
Graphical plots of Sapitinib in the Caspase-Glo 3/7 (left) and CellTiter-Glo (right) assay. 
Data are representative for each cell line at 6, 24, 48 and 72 hours. Increase in 
percentage caspase induction correlates with increase in percentage inhibition (n=3). 
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Figure 4.24 Caspase-Glo 3/7 and CellTitre-Glo assay for Erlotinib treated cells 
Graphical plots of Erlotinib in the Caspase-Glo 3/7 (left) and CellTiter-Glo (right) assay. 
Data are representative for each cell line at 6, 24, 48 and 72 hours. Increase in 
percentage caspase induction correlates with increase in percentage inhibition. 
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4.8 Discussion 
In this study we used three fully characterised chordoma cell lines authenticated 
with STR DNA profiling. The objective of this project was to identify compounds 
that elicit a kill or growth arrest on chordoma cell lines.  Nearly 1200 compounds 
were screened by single point screening, and compounds that elicited kill or 
growth arrest were taken forward for IC50 screening. The single point screen is a 
fairly crude screening process and compounds of interest may have been 
missed. An alternative approach would have been to perform an IC50 screen of all 
the compounds but reducing it from a 10-point screen to a 4- or 6-point screen. 
To avoid potential exclusion of effective compounds the selection criteria was 
based on 2x SD rather than 1.5x SD to increase the number of compounds 
entered into the IC50 screen. 
 
Of the 1153 compounds screened, 1046 were small molecule kinase inhibitors. 
27 compounds of interest were identified of which 22 (81%) targeted the 
EGFR/ErbB family. Five commercially available EGFR inhibitors were used to 
benchmark our results and help understand the chemistry.  
 
EGFR was the first growth factor to be linked with tumorigenesis(743-745). 
Amplification and mutations were first identified and associated with the altered 
expression of EGFR in brain tumours(746,747), but have subsequently been 
identified in other cancers(729,735,736). Response to EGFR inhibitors has been 
shown to be associated with specific mutations(730,734). EGFR is expressed by 
the majority of chordomas(166,186) yet no EGFR mutation or mutations within 
the signalling pathway have been identified to account for the increased 
activation. A proportion of chordomas exhibit polysomy 7 which can explain the 
overexpression of EGFR in those tumours(735). 70-80% of cells used in this 
study, from all three chordoma cell lines, have been observed to have polysomy 
7 by FISH analysis. No EGFR amplification was detected (personal 
correspondence by Professor A. Flanagan, data provided by Hongtao Ye, Royal 
National Orthopaedic Hospital). In addition no EGFR mutation was identified in 
the cell lines. The absence of EGFR mutations in chordoma is shared with other 
cancers which despite this are known to respond to anti-EGFR therapy to a 
varying degree(748). These include pancreatic cancer(749), colorectal 
cancer(750) and head and neck squamous cell carcinoma(751,752). As with 
these tumours, the majority of chordomas express the activated form of 
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EGFR(164,165,180). The chordoma cell lines used in this study all express the 
activated form of the receptor (Appendix).  
 
Variation of efficacy was demonstrated between different EGFR inhibitors. 
Chemotype analysis identified the favourable chemotype to be Quinazoline 
derivatives with a small substituent group in the 4th position of the quinazoline 
ring. The compounds in this group included Erlotinib, Gefitinib and Sapitinib, as 
well as two irreversible compounds: Afatinib and Canertinib. Sapitinib, a dual 
EGFR/HER2 inhibitor(742), was identified as the ‘lead’ compound based on its 
profile. It is currently in clinical trials for breast cancer and NSCLC(753,754) but 
has never been studied in chordoma. Erlotinib and Gefitinib have previously been 
found to inhibit chordoma proliferation of U-CH1 in vitro and in vivo in a 
PDX(178,185). There are also reports of beneficial activity of Erlotinib in patients 
with chordoma: one patient achieved stabilisation of disease following single drug 
therapy(206), as did three patients treated with Erlotinib and Bevacizumab(176). 
Lapatinib, a Quinazoline large chemotype, was recently used in a phase II trial in 
patients with advanced chordoma where it showed minimal activity(179). 
Lapatinib has also been tested in PDX models where it demonstrated incomplete 
and heterogeneous switching off of EGFR and its signalling(177). No clinical 
studies in chordoma patients have included post-treatment biopsies to assess the 
tumour response and potential resistance mechanism.  Lapatinib in the study 
reported here demonstrated high mean percentage inhibition in all cell lines but 
at relative high dose concentrations (3-11µM) and showed no differential 
phenotypic effect between the chordoma cell lines and the normal fibroblasts. 
The irreversible EGFR inhibitors demonstrated a biphasic response suggesting 
non-specific cytotoxicity(755). 
 
Variation in the sensitivity to EGFR inhibitors was demonstrated between the 
three cell lines, with U-CH1 and MUG Chor being the most sensitive cell lines, 
with little response in the U-CH2 cell line. This suggests an inherent resistance to 
EGFR inhibition in the U-CH2 cell line. There is support for resistance from other 
sources. Various mechanisms of resistance to EGFR inhibitors have been 
described(729). In NSCLC the emergence of a specific mutation conferring 
resistance to Gefitinib is well recognised(734). Other mechanisms of resistance 
to EGFR inhibitors include KRAS, BRAF and PI3K mutations(756,757) which in 
their absence, does not account for the variation in response to EGFR inhibitors 
in the chordoma cell lines. PTEN has been found to be a modulator of drug 
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sensitivity with loss of PTEN expression leading to resistance to EGFR 
inhibitors(735,750). PTEN loss in chordoma has been reported in 25-80% of 
chordomas, as a consequence of chromosomal abnormality(128,129,197,661). 
Sensitivity to EGFR inhibitors in the cell lines did not correlate with PTEN 
expression(134,197,661) (WB data in appendix). Loss of PTEN expression in 
chordoma and other cancers has been associated with increased levels of mTOR 
expression, increased invasiveness and a decrease in EFS(129,735,758,759). 
 
Rapamycin, an mTOR inhibitor, has been reported to reduce tumour growth in 
one patient with chordoma. This tumour had a KRAS mutation(193), a mutation 
which has not been reported in other studies in chordoma(130,180). Four mTOR 
inhibitors were included in the study reported here. None of these compounds 
showed differential phenotypic effect, yet some of the compounds have been 
approved for cancer therapy, having demonstrated an accepted toxicity 
prolife(760-763). Deforolimus which targets the FKBP12-rapamycin binding 
domain(764) demonstrated 50% maximum inhibition at low doses (nM) in the U-
CH2 cell line. Though similar effect was noted in the NAHDF cell line, it is 
potentially interesting as two phase I mTOR inhibitors with dual inhibition of PI3K 
(AZD8055 and GSK1059615) both demonstrated high percentage inhibition at 
low doses (nM) in all cell lines. In addition the only compound from the anti-
cancer library with differential phenotypic effect between the NAHDF and the U-
CH2 cell lines was a PI3K inhibitor. This compound has been reported in multiple 
pre-clinical settings(765) and has recently been tested in a phase I clinical 
trial(766). Few compounds demonstrated an effect on the U-CH2 cell line. 
 
In this compound screen several clinically approved drugs demonstrated activity 
in chordoma cell lines, but also exerted toxicity in ‘normal’ cells. As these drugs 
are already approved for clinical use, with a known toxicity profile, further testing 
to assess response in PDX models, potentially in combination with targeted 
therapy, could identify treatment options for chordoma. From this study 
compounds to highlight as potentially interesting include HDAC inhibitors and 
compounds targeting HSP90. In concordance with the results from Xia et al(185) 
no effect was observed in any of the chordoma cell lines following treatment with 
Imatinib. 
 
Bortezomib a proteasome inhibitor demonstrated potency in all three chordoma 
cell lines at <20nM doses. This correlates with the findings of a recent high-
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throughput screen in U-CH1 and U-CH2(185). Bortezomib has been used in a 
chordoma PDX. Treatment resulted in significantly reduced tumour growth and 
has the potential to be an important component in chordoma drug therapy(767). 
 
Bortezomib has FDA approval for treatment of multiple myeloma(768) and is 
being tested in multiple early phase trials for solid tumours(769-773). It is a 
selective inhibitor of the ubiquitin-proteasome pathway, which is essential for the 
degradation of most regulatory intracellular proteins(774). Preclinical studies 
have shown that treatment with proteasome inhibitors results in decreased 
proliferation, induction of apoptosis, and sensitisation of tumour cells to 
conventional chemotherapeutic agents and irradiation. The effects were 
conferred to stabilisation of p21, p27, Bax, TP53 and inhibition of nuclear factor-
κB (NF-κB) activation(775). Gene expression in the chordoma PDX tumours 
treated with Bortezomib showed down regulation of NF-κB target genes Bcl-2, IL-
6, IL-8 and CD44 compared with untreated mice. Interestingly two other target 
genes, Bcl-x and AKT, were upregulated in the drug-treated chordoma xenograft 
tumours compared with controls(767). Activation of AKT leads to phosphorylation 
of PI3K with subsequent inactivation of TSC1/TSC2 complex and 
phosphorylation of mTOR(40). Expression of AKT in chordoma has been found 
to be inversely correlated to outcome(166,758). These associations demonstrate 
a potential mechanism for the beneficial effects of bortezomib in chordoma as 
well as highlights possible mechanisms for the tumour to circumvent the effect of 
treatment. 
 
In hepatocellular carcinoma and in head and neck squamous cellular carcinoma 
preclinical studies with Bortezomib found that induced up-regulation of 
phosphorylated AKT (pAKT) protected cells from Bortezomib induced 
apoptosis(776-778). Subsequent preclinical studies have combined Bortezomib 
with a PI3K pathway inhibitor for synergistic effect, and have found enhanced 
Bortezomib induced apoptosis(779-781). It would be of interest to investigate this 
combination in the chordoma PDX and in early clinical trials. 
 
The complete selectivity profile of compounds is rarely known, making it difficult 
to be confident that a cellular effect is due to inhibition of a single kinase. The 
more compounds that share a common target and demonstrate similar 
phenotypic effect, the more likely it is that the effect of the compound is due to 
target specificity(682).  More than 1000 TKIs were included in the screen 
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reported here. EGFR inhibitors represented 81% of the compounds identified as 
hits. Additional EGFR inhibitors were included and experiments were repeated 
with different batches of reagents confirming the target effect.  Subsequent 
experiments have been undertaken by S. Scheipl and M. Barnard. This further 
work has confirmed dose response and ‘on-target’ effect, including effect on the 
downstream signalling pathways following treatment with EGFR inhibitors. 
Additional cell lines have become available for a focussed screen of EGFR 
inhibitors, which may improve the understanding of the heterogeneous response 
between cell lines and possible mechanisms of resistance.  
 
A comprehensive study including well-characterised patient samples is required 
to address issues of resistance. Specifically a clinical trial examining patient 
samples before and after EGFR inhibitor treatment is likely to be informative. 
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5  XENOGRAFT MODEL FOR ONCOLOGY DRUG 
DEVELOPMENT 
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5.1 Background 
Over the past 10 years molecular targets have been identified in chordoma with the 
potential for therapeutic drug development(40,163,164,180,210). However, the 
decision on when targeted treatment is to be given and how a compound is selected is 
often flawed. For instance, therapeutic agents are often selected for treatment of 
recurrent disease on the basis that the primary lesion harbours the targetable molecule 
without confirmation that the target is present in the recurrent disease(177,616).  
Another example includes the use of targeted therapies being used in the absence of 
an evidence basis(171,179). 
 
Progress in oncological drug development has been difficult due to a lack of preclinical 
models able to reliably predict clinical activity(589). Immortalised human cancer cell 
lines are valuable for understanding the pathophysiology of disease and can be 
successfully used to predict the clinical effect of cancer therapies(782-785). Chordoma 
cell lines have proven difficult to establish and until very recently there was no cell line 
generated from a clival chordoma. Currently seven characterised chordoma cell lines 
are available through the Chordoma foundation (www.chordoma.org). The availability 
of multiple cell lines provides a better representation of the inter-tumour 
heterogeneity(786). 
 
Recently a zebrafish model of chordoma was discovered following stable expression of 
HRASV12 in notochord cells during development. Extensive intra-notochordal tumour 
development was found with 100% penetrance ultimately leading to larval death. The 
HRASV12-expressing zebrafish tumours had histological, immunohistochemical and 
structural features similar to human chordoma. Mutations of RAS family members are 
not common in patients with chordoma(787). Activation of HRAS can mimic an 
increase in downstream signaling pathways driven by cell surface receptors, such as 
EGFR which has been implicated in the pathogenesis of chordoma(181,182,184,206). 
Zebrafish lend themselves to high throughput drug screening(788,789), however the 
chordoma zebrafish model has some limitations due to an inability to test upstream 
inhibitors of HRAS such as EGFR.  Rapamycin was tested in this chordoma zebrafish 
model demonstrating a delay in onset of tumour phenotype and longer survival(787).  
 
A recent study using integrated functional genomics identified several target genes of 
brachyury(127), suggesting that the mechanism of chordoma formation involves 
multiple signaling pathways directly or indirectly controlled by the transcription factor. 
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Limited in vitro models and a lack of in vivo models has hindered the translation of 
these observations into novel therapies(767). 
 
There has been a rapidly growing interest in the establishment of patient-derived 
mouse xenografts (PDX). PDX models have been found to closely recapitulate primary 
tumour biology and clinical outcome(590,592,602,767). Numerous studies have 
demonstrated that PDX models sustain genotypical and phenotypical features over 
subsequent generations(589,790,791). They may serve as important models to 
investigate mechanisms of resistance to targeted therapies and for preclinical testing of 
novel treatment strategies(589,592,792). The PDX model has been described as the 
Avatar model, which has been used for guiding personalised therapy(592,793). Hidalgo 
et al. generated PDX models for 14 patients with refractory solid or early-stage, poor 
prognosis tumours of different types and treated them with 63 drugs in order to guide 
the choice of chemotherapy(592). Eleven patients were treated with 17 treatment 
regimens based on their corresponding PDX tumours and 15 of these regimens 
resulted in durable partial remission. PDX models have been found to retain all primary 
tumour mutations and display mutation enrichment patterns resembling the 
metastases. The identification of emerging mutations in the PDX models improves the 
understanding of tumour progression and treatment resistance(794). The ability of 
tumours to engraft has been found to be a poor prognostic marker(794-796), but may 
represent a useful tool for identifying treatment options for the patients.  
 
Only recently has the development of mouse models for chordoma been undertaken as 
a means to advance understanding of chordoma biology(89,91,609,767). The different 
chordoma models have been reviewed previously. 
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5.2 Aim 
To establish two novel chordoma mouse models. The first PDX chordoma model to 
establish the method, monitor engraftment and review the phenotypic and genotypic 
features in comparison to the parent tumour. This model has been shared with Gary 
Gallia in Harvard for in vivo drug screen and frozen tumour sections were sent via the 
Chordoma Foundation to the START lab (South Texas Accelerated Research 
Therapeutics) to start a PDX-model from frozen tissue from the xenograft. The second 
model, a cell line xenograft (CLX), was generated for in vivo imaging of the tumour for 
the purpose of testing the viral vector delivering RNAi as described in chapter 3.  
5.3 Objective 
1. To establish a chordoma PDX model and assess molecular and phenotypic 
features and determine genetic stability. 
2. To generated at CLX with tumours expressing luciferase and assess 
molecular and phenotypic features in the CLX tumour. 
3. To generate CLX models for gene therapy study. 
  
I performed the experiments involving the patient-derived xenograft with support from 
Dr M. Eskandapour PhD, Dr N. Presneau PhD, and Dr S. Scheipl MD. 
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5.4 Results 
5.4.1 Establishment of a primary chordoma xenograft  
 
 
Figure 5.1 Overview of procedure for establishing PDX 
Adapted from Tentler et al. (589).  
 
The patient from whom the xenograft was generated presented at the age of 47 with a 
primary coccygeal conventional chordoma with poorly differentiated areas. Initial 
treatment consisted of surgical resection and Proton beam radiation therapy. The 
tumour recurred locally five years after initial presentation and re-excision was 
attempted. INI1 expression was maintained. Fluorescence in situ hybridisation (FISH) 
revealed that brachyury was disomic. EGFR showed a low level of polysomy (Figure 
5.2).  
 
Consented patient 
With cancer 
Surgically removed 
Tumour (P0) 
Expansion 
Phase P2-P6 
Treatment phase PX-PY) Engraftment  
Phase P1 
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Figure 5.2 FISH analysis of brachyury and EGFR in chordoma used for PDX 
Brachyury (A&B) and EGFR (C&D) red signal probe. Green signals represent chromosome 
enumeration probe (CEP) to correct for chromosomal region. Disomy of brachyury with 2 
signals for brachyury and 2 signals for CEP6. EGFR demonstrating low level of polysomy 
compared to CEP7 (> 2 copies/cell in ≤ 40% of cells). Images kindly provided by Roberto 
Tirabosco, Pathologist Royal National Orthopaedic Hospital. 
 
 
The tumour was implanted into two BalbC/nude mice. The first PDX tumours grew from 
about 8 weeks and were serially transplanted over the course of 14 months. The 
xenograft lineage was passaged 5 times. On each occasion the tumour was passaged 
into new mice and tumour was snap frozen for histology and DNA extraction. A small 
piece was put into formalin for immunohistochemistry and when available tumour was 
frozen in re-engraftment medium. Tissue from the primary tumour and the xenograft 
passage 1, 4 and 6 confirmed concordance of histology (Figure 5.3) and brachyury 
expression was maintained in the xenograft (Figure 5.4).  
 
 
B 
D C 
A 
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Figure 5.3 Morphology primary tumour and patient derived xenograft 
Photo-microscopy H&E-stained tumour which was used to generate a PDX-derived xenograft 
(A) and xenograft (B) P1, (C) P4, (D) P6.  
 
 
 
 
Figure 5.4 Xenograft tumour from PDX 
PDX P6. Photo-microscopy H&E-stained tumour (A) 10x and (B) 40x (C) brachyury 
immunoreactivity. 
 
 
5.4.2 Genomic analysis of resected tumour and PDX tumour 
5.4.2.1 TP53 and PI3K mutation in the patient tumour 
The recurrent tumour used for the PDX underwent whole genome sequencing at the 
Wellcome Trust Sanger Institute Hinxton, Cambridge and was found to have a TP53 
and a PI3K mutation (Table 5.1). 
A"
C" D"
B"
A C B 
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Table 5.1 Sequencing data from patient tumour used for PDX 
Whole genome sequencing data from tumour compared with constitutional DNA. The TP53 mutation is listed in the COSMIC database. This tumour also had 
a PIK3 mutation but not at a common site (COSMIC). Information within the table: The frequency or percentage of cells identified with the mutation , the effect 
of the mutation (missense) and when visualised and compared to constitutional DNA identified if the mutation was determined as a somatic mutation. CDS: 
Coding DNA sequence with identified location of mutation within exons coding for protein. 
 
 
Gene Freq gene
Paired 
or 
unpaired
Assay CDS Protein Effect Cosmic Visual
TP53 17 paired Genome c.814G>A p.V272M missense 32 somatic
TP53 17 paired Genome c.814G>A p.V272M missense 32 somatic
HLA-C 66 paired Genome c.419C>A p.S140Y missense 0 .
ROS1 20 paired Genome c.3530C>T p.T1177M missense 1 .
BRAF 17 paired Genome c.31G>T p.G11C missense 0 .
NCOR1 14 paired Genome c.1375T>G p.F459V missense 0 .
PDE4DIP 3 paired Genome c.180G>A p.W60* nonsense 0 .
PIK3R1 3 paired Genome c.812_816delTGCTT p.M271fs*9 frameshift 0 somatic
DNAJC10 1 paired Genome c.820C>T p.Q274* nonsense 0 .
C5orf39 1 paired Genome c.308C>A p.P103H missense 0 .
ENSG00000205857 1 paired Genome c.55G>A p.A19T missense 0 .
FBLN2 1 paired Genome c.872C>T p.A291V missense 0 .
INTS1 1 paired Genome c.5317G>T p.D1773Y missense 0 .
MYT1 1 paired Genome c.938T>A p.F313Y missense 0 .
PHRF1 1 paired Genome c.3084C>A p.S1028R missense 0 .
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5.4.3 TP53 mutation in the PDX 
The PDX tumour DNA from P6 was screened using a large panel for common cancer 
mutations identified in the COSMIC (Catalogue Of Somatic Mutations In Cancer 
http://cancer.sanger.ac.uk/) database, performed by the UCL Advanced Diagnostic 
laboratory. The identical TP53 mutation: p.Val272Met, c.814G>A COSM10891 was 
detected at 100% variant frequency i.e. 100% of the cells carried the mutation. In the 
original tumour the TP53 mutation was identified in 17% of the cells, suggesting that a 
clonal expansion of the cells containing the TP53 mutation occurred in the xenograft. 
No other mutations were detected in the xenograft tumour DNA using the panel for 
common cancer mutations. 
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5.4.4 Xenograft for in vivo imaging 
5.4.4.1 Luciferase expressing U-CH1 cell line  
The U-CH1 cell line was engineered to stably express the firefly luciferase gene to 
enable in vivo imaging of cell line engraftment in BalbC/nude mice. This was done for 
the purpose of assessing the response to viral vector delivered gene therapy using an 
AAV vector carrying RNAi targeting brachyury.  
 
 
 
Figure 5.5 Luciferase expression in U-CH1 
Luminescence was measured using a luminometer. Relative light intensity was compared 
between the engineered U-CH1_luciferase cell line and the un-transduced U-CH1 cell line as 
well as PBS. 4 different passages of U-CH1_luciferase cells were measured. Each sample was 
measured in triplicate. The results are expressed as the mean+/- SD. 
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5.4.4.2 Engraftment of CLX 
The generated cell line was injected into the flank of BalbC/nude mice.  Successful 
engraftment of the U-CH1 cell line has been achieved previously and confirmed in this 
study(89). CLX engrafted over 8-10 weeks. Luminescence and tumour growth was 
assessed at regular intervals (Figure 5.6). 
 
 
 
Figure 5.6 Image of xenograft with luciferase-expressing tumour 
Image of two BalbC/nude mice both injected with U-CH1_luciferase expressing cells, only one 
mouse developed a tumour as identified by the arrow (C). (A) and (B) images of the mice at 
different time-points indication tumour growth and increase in luciferase expression (images 
acquired 3 weeks apart). Image (C) is a white light photographic image used for overlaying the 
bioluminescence signal as demonstrated in (D) taken 4 weeks after (A). D-luciferin was injected 
into both mice at all time-points. 
  
A B 
  
D C 
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5.4.4.3 CLX morphology and histology resembles chordoma 
 
Figure 5.7 Chordoma CLX  
BalbC/nude mouse xenograft generated from the U-CH1_luciferase cell line  (left). Image on the 
left is the subcut exophytic nodule (generated from 1x107 cells). The middle image shows a 
well-circumscribed nodule surrounded by a thin fibrous membrane loosely attached to the sub-
dermal layer. In 10 xenografts a single feeder arterial/venous blood supply was observed. 
Tumour from an animal injected grossly resembled chordoma with grey-white complexion and 
lobulated appearance (image on right). 
 
 
Figure 5.8 Morphology and immunoreactivity CLX and human chordoma 
(A) CLX U-CH1_luciferase tumour, haematoxylin and eosin stain (H&E) demonstrating ‘classic’ 
lobulated appearance; with a myxoid matrix, embedded cords and tumour cells with eosinophilic 
cytoplasm as well as vacuolated tumour cells, known as physalipherous cells (x10). (B) CLX 
immunoreactive for brachyury. (C) Human chordoma specimen typical chordoma 
physalipherous cells embedded in abundant eosinophilic extracellular matrix; (D) Human 
chordoma; brachyury antibody highlights the nucleus. IHC was kindly done by the members of 
the histopathology lab at the Royal National Orthopaedic Hospital, under supervision of 
Professor A. Flanagan. 
!
A B 
C D 
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5.5 Discussion 
The aim of this study was achieved. Two different preclinical xenograft models were 
constructed to allow for future investigation of tumourigenesis and development and 
evaluation of therapeutics.  
 
The luciferase-expressing CLX model offers an opportunity for in vivo functional 
(metabolic) imaging. This provides an advantage over using RECIST criteria for 
assessing tumour response. The lessons from chordoma patients treated with Imatinib 
showed that the RECIST criteria for assessing tumour response were inadequate(722). 
In this patient group a limited alteration in tumour size was identified following 
treatment, however there was a change in tumour density and vascularity identified by 
positron emission tomography (PET) imaging, using fluorine-18-fluorodeoxyglucose 
(18F-FDG). PET was found to be highly sensitive for detecting early response to 
treatment with Imatinib in chordoma patients(722). The uptake of 18F-FDG by tissue is 
a marker for the tissue uptake of glucose, which correlates with tissue 
metabolism(797). The use of luciferase in our xenograft model offers a similar 
correlation with cell viability. The photon flux that is measured as bioluminescence is 
proportional to live cells expressing luciferase and can therefore be used for monitoring 
tumour growth and cell death. Luciferase expression was more sensitive than caliper 
measurement of the tumour size and therefore gave a better assessment of cell 
number/cell death, in concordance with reported data(798,799). The model described 
here was used for evaluation of the therapeutic effect of gene therapy using an AAV 
vector for delivery of RNAi described in Chapter 3 and can be used for screening of 
drug efficacy. 
  
The PDX model was developed as part of an international collaboration to establish 
new models for drug screening. It is increasingly clear that models representing cancer 
heterogeneity are required for pre-clinical drug development, as well as the 
development of biomarkers for assessment of response to therapy. These models offer 
the opportunity to support this research. Genetic, phenotypic and tumour 
microenvironment heterogeneity is likely to have implications for the ability to 
recapitulate accurate cancer biology in cell line-, CLX and PDX models. Using cell lines 
to generate tumour models has its limitations. The cells can undergo clonal selection in 
vitro leading to high homogeneity of established cell lines. This results in tumours that 
do not always exhibit the histological characteristics observed in the clinical 
specimens(568,592,786). The cell line used for the CXL described here was 
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characterised by STR to confirm authenticity against the initial U-CH1 cell line (as 
discussed in Chapter 3). In addition immunoreactivity and histology were retained in 
the CXL, resembling the features of chordoma.  Yet, it is accepted that cell lines 
derived and cultured from a single biopsy may not represent the overall phenotype of 
the original tumour(591,786). This was demonstrated by Barranco et al. who generated 
4 melanoma cell lines from a single melanoma nodule and observed differential effect 
to therapy between the different cell lines(800). Others have demonstrated differential 
morphology, growth rate, tumourigenicity and therapeutic sensitivity between clones 
generated from the same tumour(801,802). In circumstances where tumour features 
are not preserved it is difficult to interpret outcomes to therapeutic intervention. 
 
PDX models have been shown to have stable gene expression and similar 
histopathology to the tumour of origin(609,790,791). As PDX models are generated 
from small human tumour fragments obtained from surgically resected tumours or 
metastatic biopsy specimens, they potentially have similar limitation in their 
representation of the original tumour(593,614,786). This was reported in colorectal 
cancer where multiple samples from the same tumour were engrafted in PDX models 
which demonstrated differential response to therapy(795).   However multiple studies 
have reported the utility of PDX models to predict treatment 
response(589,592,793,803) supporting their use for evaluating treatment response in 
preclinical studies. 
 
A particular advantage of the PDX model is the ability to combine sequencing data with 
biological data to help understand the significance of the mutations identified and their 
relevance as a target for therapies(793). For example, in the chordoma used for the 
PDX model reported here, a PI3K mutation was detected. It would be possible to 
confirm the presence of the mutation, and if detected, use the PDX model to assess 
response to treatment with a PI3K inhibitor(766,804). In a recent systematic review and 
meta-analysis of activation of the PI3K/AKT/mTOR pathway in solid tumours and the 
impact on patient survival, activation of the pathway was confirmed to be associated 
with a significantly worse outcome(805). Garralda et al.(793) described a PDX model 
where the sequencing data from the primary tumour had identified a PI3K mutation, 
however the PDX model did not respond to treatment with a PI3K inhibitor. The PDX 
model enabled a more complete analysis demonstrating that the PI3K pathway was not 
activated despite the presence of the mutation(793). 
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Creating PDX models for individual tumours has been found to provide prognostic 
information. Tumours which are able to engraft, often are the more aggressive and 
have greater metastatic potential(590,796). It has been reported that the signature of 
the PDX tumours is often genetically closer to the metastatic lesions than the primary 
tumour, suggesting that selection occurs within the initial passaging of the 
xenografts(590,794-796). The transformation into a more aggressive tumour was 
described in a chordoma PDX where a tumour characterised as a classical chordoma 
was used for engraftment, but transformed into a dedifferentiated chordoma in the PDX 
model. The transformed characterisation was in concordance with the recurrent tumour 
observed on relapse in the patient(767). This has the potential to provide useful 
information for appropriate therapeutic intervention in the clinical setting. The PDX 
model presented here transformed after implantation. The tumour demonstrated clonal 
selection of TP53 mutated cells. Sequencing of the PDX tumour identified the TP53 
mutation with 100% penetrance. The sequencing data from the primary tumour was not 
available for TP53 mutation review, but in the recurrent tumour the allele frequency 
was 17%. This finding emphasises the importance of this mutation for tumour 
development, and represents a potential target for therapy(253,806-809). This effect 
has been observed in other tumours with respect to TP53 mutations. In 
medulloblastoma it was identified that MYC gene amplification and TP53 mutations 
commonly emerges at relapse suggesting a clonal expansion and a aggressive 
tumour(602). TP53 expression has been reported to be associated with aggressive 
growth and significantly shorter recurrence-free survival in skull base chordomas, 
though this has been reported only in one study where the detection was based on an 
immunohistochemistry assay(810). TP53 copy number loss has also been reported in 
chordoma identified CGH (microarray-based comparative genomic hybridization) (125). 
In a recent study using targeted sequencing of 9 chordoma a TP53 mutation was 
identified in 8 (89%) of the tumours. The specific mutation is a known germline 
mutation thought to be benign(811). 
 
The xenograft models presented here have identified some of the inherent challenges 
associated with these techniques. They include immense resources in expense and 
time, compounded by the fact that primary chordomas are very slow to establish and 
as seen with similar models, a proportion of tumours do not engraft(177,589,609). 
Other limitations of the mouse model include the need for using immunocompromised 
mice for tumour engraftment and propagation and therefore have limited use for 
screening of immune-mediating compounds, such as vaccines and immune-
modulators. Another critical aspect is the substitution of human stromal cell 
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compartment with murine stromal cells. Multiple studies have demonstrated that after 
3-5 passages, when the model is ready for drug testing, the stromal cells are of murine 
origin(589,592). These changes may impact on cancer biology, altering paracrine 
regulation and physical properties. This is an important consideration when using 
therapeutics targeting the microenvironment(587,812).  
 
It is becoming increasingly clear that novel preclinical models that closely recapitulate 
the heterogeneity of human tumours are needed for biological studies. For many 
cancers it is becoming increasingly common practice to analyse a set of 50 to 100 
relevant cancer genes for hundreds of mutations. From this approach, numerous 
potential targets have emerged for individual patients that may potentially be linked to 
clinical response. In addition to bioinformatics and in silico prediction data from cancer 
cell line data, personalised PDX models may be useful in this setting, as they facilitate 
testing of candidate regimens in the patient’s own tumour(582,592,813). 
 
With the addition of our PDX to the wider chordoma research community there is an 
opportunity for validation of drugs that enter clinical trials for chordoma patients and 
provide a model for investigating chordoma cell biology.  Interestingly the PDX model 
reported here, provided information regarding the possible driver mutation (TP53) for 
this particular tumour. This may be of therapeutic significance further supporting the 
role of PDX models in guiding individualised therapy.  
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6 BIOMARKERS IN CHORDOMA 
  
Targeted therapy for chordoma 
268 
 
  
Targeted therapy for chordoma   
 269 
6.1 Tumour Biomarkers 
6.1.1 Circulating tumour DNA 
The ever-increasing availability of sequencing data allows identification of tumour-
specific genetic alterations in individual patients. These alterations include point 
mutations, amplifications and rearrangements. Recent technical advances have 
allowed these alterations to be detected in plasma(617,618,644). This can now be 
exploited in clinical practice for risk stratification, monitoring of disease and guiding 
therapy(618,634,639,652,814-816). 
6.1.2 Burden of disease and minimal residual disease 
The concept of monitoring for minimal residual disease by detection of persistent or 
recurrent mutations in childhood leukaemia and its utility to risk stratify, prognosticate, 
and guide treatment decisions is well established(817,818), as is monitoring for the 
BCR-ABL1 fusion gene in specific forms of leukaemia. Digital PCR leukaemia(819-821) 
was first described by Sykes et al. in 1992(822) as a method for quantifying the total 
number of DNA target molecules initially present in a sample, rather than PCR 
amplified products. This was done in an attempt to track and measure the absolute 
lowest number of leukaemic cells with the aim of monitoring residual disease, allowing 
patients with detectable recurrent disease to be treated at the earliest opportunity(823).  
 
Many somatic cancer genes have been identified in solid tumours. Since the launch of 
the Catalogue Of Somatic Mutations In Cancer (COSMIC) in 2004, 136 cancer genes 
and more than 12000 cancer genomes have been fully curated. Currently 572 genetic 
mutations have been causally implicated in cancer and are listed on the Cancer 
Genome Consensus website (cancer.sanger.ac.uk)(824,825). Inter-tumour 
heterogeneity and lack of recurrent mutations have delayed the opportunity to apply 
the concept of monitoring for minimal residual disease in patients with solid tumours. 
The availability of sequencing data from individual tumours combined with technical 
advances has improved detection of ctDNA in plasma. This has led to the concept of 
‘liquid biopsy’ with ctDNA providing the same genetic information as a tissue 
biopsy(623). There are clear advantages to monitoring ctDNA as a marker of tumour 
dynamics over conventional protein biomarkers and imaging studies; the short half-life 
of ctDNA allows for evaluation of treatment response and recurrence which are more 
sensitive than protein markers(637) and early detection of tumour specific mutation 
after surgery can detect recurrence predating  imaging studies(618,634,636,815).  
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Several studies have shown that ctDNA can be a surrogate for tumour burden in 
patients with advanced disease. Rapid increase in ctDNA levels indicates disease 
progression and decline in levels correspond with response to 
treatment(618,634,637,826-828). Levels of ctDNA may predict treatment response 
early during the course of therapy, which may allow for real-time modification of the 
treatment regimen, avoiding prolonged exposure to toxic treatment with little or no 
effect(623).  
 
In tumours where no single recurrent mutation has been identified, as in chordoma, 
whole tumour genome or exome sequencing is required to identify specific mutations. 
To date the majority of evidence of ctDNA monitoring in solid tumours is from patients 
with advanced disease or high-grade tumours rather than low grade or slow growing 
tumours(634-636). 
6.1.3 Protein serum markers 
Efforts have been made to discover novel cancer biomarkers but few have made it into 
clinical practice(829,830). Serum-based protein markers are currently used for 
detection and monitoring for a few specific cancers(831-833).  
6.1.3.1 Aldo-keto reductase 1B10 (AKR1B10) as a serum marker 
AKR1B10 is a human member of the aldo–keto reductase (AKR) superfamily, a group 
of proteins implicated in intracellular detoxification. AKR1B10 was originally identified 
as an aldose reductase like protein mainly expressed in the human colon, the large 
and small intestines, the adrenal glands and at low levels in the liver. It catalyses the 
NAD(P)H-dependent oxidoreduction of various carbonyl compounds(834,835). More 
recently AKR1B10 has been implicated in tumorigenesis and identified as a potential 
biomarker(836). 
 
AKR1B10 reduces retinal to retinol, thus limiting retinoic acid formation, an important 
signalling molecule directing cell differentiation, thereby controlling the retinoid 
signalling pathway stimulating carcinogenesis(837). Under physiological conditions, 
highly reactive aldehyde and ketone groups lead to cell death by carbonyl-induced 
apoptosis. AKR1B10 plays a role in the detoxification of cytotoxic carbonyl compounds 
and promotes cell survival by controlling carbonyl metabolism(838). Furthermore, 
AKR1B10 can reduce the carbonyl groups and participate in the metabolism of some 
anticancer drugs, thereby decreasing effectiveness and has been linked with drug 
resistance in cancer derived cell lines(836,839-841). 
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6.1.3.2 AKR1B10 and tumorigenic formation 
AKR1B10 in cancer was initially described in hepatocellular carcinoma (HCC)(842) and 
found to be a prognostic biomarker. High levels of expression indicate less aggressive 
tumour behaviour(843) and low levels correlate with advanced disease(844). More 
recently AKR1B10 was found to be up-regulated in pre-neoplastic conditions such as 
chronic hepatitis and cirrhosis(845,846) suggesting a role in the pathogenesis of HCC. 
AKR1B10 has also been found to be implicated in tumour carcinogenesis in breast 
cancer(847), bladder cancer(848), smoking induced lung cancer(849,850), endometrial 
cancer(851) and pancreatic cancer(852).  
 
AKR1B10 has been described as a potential protein biomarker in patients with breast 
cancer. Overexpression was found to be associated with increased tumour size, lymph 
node metastasis and inversely with patient survival. Expression in the primary tumour 
correlated with metastatic deposits in lymph nodes and protein levels were found to be 
significantly elevated in serum from patients with breast cancer supporting its use as a 
potential serum marker(853). 
6.1.3.3 AKR1B10 and it role in chordoma 
The AKR1B10 gene locus (7q33) has been identified as a putative chordoma 
susceptibility region by genome-wide linkage studies in familial chordoma(19). No 
mutations or loss of heterozygosity have been identified for the gene, but chromosomal 
gain of the region has been described(125,135). AKR1B10 is differentially expressed in 
chordoma compared to other bone and soft tissue tumours(33). It has been found to be 
expressed in all benign and malignant notochordal tumours but not in embryonic 
notochord or notochordal rests(197,854). AKR1B10 has also been linked with 
brachyury. Brachyury was found to indirectly regulate AKR1B10 expression in the U-
CH1 chordoma cell line(127). Despite this potential association no previous work has 
investigated AKR1B10 as a biomarker in chordoma. AKR1B10 expression levels may 
be prognostic if correlated with clinical outcome, and could potentially be a plasma 
marker for monitoring disease.  
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6.2 Aim 
The aim of this work was to establish proof of concept for detecting ctDNA in plasma 
from chordoma patients, and to establish if AKR1B10 could be detected and used as a 
protein serum biomarker for disease monitoring.  
6.3 Objectives 
1. To select mutations, identified by Sanger Sequencing, in a group of chordoma 
patients for which TaqMan assays could be developed and to establish proof of 
concept for mutation detection in ctDNA from chordoma patients. 
2. To compare dPCR to Ion Torrent sequencing for detection and quantification of 
mutations in chordoma. 
3. To establish if AKR1B10 protein represents a potential tumour marker in 
patients with chordoma.  
 
The work in this chapter on circulating DNA was done with support from Tim 
Forshew PhD and Alice Gutteridge from Tim Forshew’s lab at UCL, London. 
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6.4 Results 
6.4.1 Mutations detected in chordoma 
Whole genome (n=9) and exome (n=23) sequencing of chordoma from 32 chordoma 
patients was performed at the Wellcome Trust Sanger Institute. Only 12 of these 
tumours had mutations detected in known cancer genes; CDKN2A (n=6), PTEN (n=1), 
PIK3CA (n=2), SOX5/6 (n=3), TP53 (n=1), PTPRD (n=1), ARID1A (n=1), MIFT (n=1), 
SMAD4 (n=1), PBRM1 (n=1), SETD2 (n=1). Some tumours had 2 mutations (n=4) 
whilst 2 tumours had a total of 3 mutations in known cancer genes. Of these 12 
tumours 4 were identified for this project, each with one or two mutations of interest.  
 
Mutations were selected based on the ability to design a TaqMan probe by which they 
could be detected and for whom plasma samples were available. For 2 of 4 patients 
pre-op plasma samples were available, one patient had surgery 8 years earlier but had 
recurrent progressive disease at the time of plasma sampling and was included as a 
pre-op sample in view of progressive and measurable disease. No sequential samples 
were available for this patient. For one mutation, which was selected for the study, it 
was subsequently discovered that only a post-op plasma sample was available. The 
patient sample was included in the analysis.  
 
Patient demographics were collected (Table 6.1). The follow-up time was between 3-12 
years (mean 6 years). Three patients are alive and in clinical remission, one patient 
(patient 4) had died of metastatic disease. This patient was known to have recurrent 
disease with small volume metastases at the time of the tumour biopsy, and collection 
of plasma. 
 
Table 6.1 Patient demographic, treatment and mutations detected in tumour 
Patient 
ID 
Sex Age Tumour Histology Disease 
status 
Treatment Mutation 
1  
(3814) 
F 74 Sacral Conventional Stable 
 
Surgery & 
Radiotherapy 
PIK3CA 
2  
(7187) 
F 65 Sacral Conventional Stable 
 
Surgery & 
Radiotherapy 
PIK3CA 
SETD2 
3 
(4927) 
M 56 Sacral Conventional Stable 
 
Surgery GENE X  
4 
(7186) 
M 67 Metastatic 
lesions 
(multiple) 
small volume 
Conventional Progressive 
 
Surgery & 
proton beam 
therapy + 
TKI 
GENE X 
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Mutation sequences are listed in Table 6.2. Please note the name of one mutation has 
been changed to GENE X as publication for this data is pending. The primer 
sequences are listed in Material and Methods Chapter 2. Selection and optimisation of 
the primers included target amplification visualised by electrophoresis and target 
sequencing confirming specificity of primers (data not shown). The assay probes were 
tested using tumour DNA from formalin-fixed paraffin-embedded (FFPE) samples. 
Optimisation of assays included testing primers across a temperature gradient, dilution 
of DNA samples in order to dilute potential inhibitors remaining in the sample after DNA 
extraction, and performing restriction digest to overcome cross-linking caused by 
formalin from FFPE samples. Data for this can be found in the appendix. Only the 
temperature optimisation of primers was relevant for evaluating ctDNA in the plasma 
samples.  
 
Table 6.2 Mutations (annotated sequences) 
PIK3CA (1) 
Wild-type (WT) 
 
 
CCDS43171.1 / r.1790g>a / c.1633G>A / p.E545K / missense 
chr3:178935992-178936191 5'pad=100 3'pad=100  
 
TTACAGAGTAACAGACTAGCTAGAGACAATGAATTAAGGGAAAATG
ACAAAGAACAGCTCAAAGCAATTTCTACACGAGATCCTCTCTCTGA
AATCACTGAGCAGGAGAAAGATTTTCTATGGAGTCACAGGTAAGT
GCTAAAATGGAGATTCTCTGTTTCTTTTTCTTTATTACAGAAAAAAT
AACTGAATTTGGCTGA 
PIK3CA (1) 
Mutant (MT) 
 
ID: 3814 
TTACAGAGTAACAGACTAGCTAGAGACAATGAATTAAGGGAAAATG
ACAAAGAACAGCTCAAAGCAATTTCTACACGAGATCCTCTCTCTGA
AATCACTAAGCAGGAGAAAGATTTTCTATGGAGTCACAGGTAAGT
GCTAAAATGGAGATTCTCTGTTTCTTTTTCTTTATTACAGAAAAAAT
AACTGAATTTGGCTGA 
PIK3CA (2) 
WT 
 
 
CCDS43171.1 / r.3286g>u / c.3129G>T / p.M1043I Sub
 missense 
chr3:178951975-178952174  
 
GCCAGAACTACAATCTTTTGATGACATTGCATACATTCGAAAGACC
CTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATGA
AACAAATGAATGATGCACATCATGGTGGCTGGACAACAAAAATGG
ATTGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGA
TAACTGAGAAAATGAAA 
PIK3CA (2) 
MT 
 
ID: 7187 
GCCAGAACTACAATCTTTTGATGACATTGCATACATTCGAAAGACC
CTAGCCTTAGATAAAACTGAGCAAGAGGCTTTGGAGTATTTCATGA
AACAAATTAATGATGCACATCATGGTGGCTGGACAACAAAAATGGA
TTGGATCTTCCACACAATTAAACAGCATGCATTGAACTGAAAAGAT
AACTGAGAAAATGAAA 
SETD 
WT 
CCDS2749.2  /  r.6799delC / c.6756delC    p.S2253fs*56 Del 
frameshift 
chr3:47098418-47098617  
 
ACTGCTGCTGTACACTGACAGACTGTTGGTTTGAATCCCAAACACT
ATAATTCTGTCCCTGAACTGGGCCGGGGGCCGGCACTGGCAAGA
CAGCAACGCTGGAGTCTTGGTGTACTACACCATCACTCTGGGCCA
CATACTGGGAACTGGAAACTTCCACAGGAGCTGCCACATGTGGCA
CCACTGGTACTGGTGGAGGG 
SETD ACTGCTGCTGTACACTGACAGACTGTTGGTTTGAATCCCAAACACT
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MT 
 
ID: 7187 
ATAATTCTGTCCCTGAACTGGGCCGGGGGCCGGCACTGGCAAGA
CAGCAACG_TGGAGTCTTGGTGTACTACACCATCACTCTGGGCCA
CATACTGGGAACTGGAAACTTCCACAGGAGCTGCCACATGTGGCA
CCACTGGTACTGGTGGAGGG 
GENE X (1) 
WT 
  
CCDS31062.1  r.9069_9073delGUUAU c.8894_8898delGTTAT  
p.C2965fs*6 Del frameshift 
chr1:235894281-235894480  
 
GACCATAGTTCTCTGCTATATTTATATGTTGAGTCAAGAAGCCACT
ATTACCTTCTGATTTCTGTCTATCCCTAAGGAGATACTTATTTGGAA
TAGTTAAATAACATCTCTGTAAACGTCTCCTCTCTCGATTTGGCCC
TTCTGTTGGATCCAACTGCCATGAGGTTGGATAGTAGATGGGGTC
ATACCATACTGCTCTG 
GENE X (1) 
MT 
 
ID 4927 
GACCATAGTTCTCTGCTATATTTATATGTTGAGTCAAGAAGCCACT
ATTACCTTCTGATTTCTGTCTATCCCTAAGGAGATACTTATTTGGAA
TAGTTAAATCTCTGTAAACGTCTCCTCTCTCGATTTGGCCCTTCTG
TTGGATCCAACTGCCATGAGGTTGGATAGTAGATGGGGTCATACC
ATACTGCTCTG 
GENE X (2) 
WT 
CCDS31062.1 / r.2960_2961insggcu /  c.2785_2786insGGCT  
p.Y929fs*3 Ins frameshift 
chr1:235969551-235969750  
 
TCTGCTGCTTGGTGCATATGTTCAGGAGAAGGCAAGACAAGGCTC
TCGAGAGATATACATGGCAGCATATGACTTAAAGGCTCGCTGGCT
GTGCTGTCATAGCCAGAAGTATCTTCTGAGTCATTGGCCGACTCC
CTGTCAGACTCTGCTTCTTTACTTACGCATAAAAAAGCCACACAGA
GGAATAGGTTTATTGTGTT 
GENE X (2) 
MT 
 
ID: 7186 
TCTGCTGCTTGGTGCATATGTTCAGGAGAAGGCAAGACAAGGCTC
TCGAGAGATATACATGGCAGCATATGACTTAAAGGCTCGCTGGCT
GTGCTGTCATAGCCAGCCAGAAGTATCTTCTGAGTCATTGGCCGA
CTCCCTGTCAGACTCTGCTTCTTTACTTACGCATAAAAAAGCCACA
CAGAGGAATAGGTTTATTGTGTT 
 
Mutations (MT): (blue)/ Wild-type (WT) black, specific mutation highlighted (red/black) 
identifying the change. CCDS-number is the identifier in the NCBI Consensus Coding Sequence 
Database.  
 
Two patients had known hotspot mutations in the PIK3CA gene. Alterations was found 
in GENE X in two chordomas, which has not been linked with any other cancer, but 
was confirmed to be somatic through evaluation of germline DNA from the same 
patients. CtDNA was assessed by droplet digital Polymerase Chain Reaction (dPCR), 
described in Materials and Methods.  
6.4.2 Capture of mutation by digital PCR is as sensitive as Ion torrent 
Each assay was individually designed to enable patient-specific mutation detection. 
The advantage of using dPCR includes a quick turn around time as each assay can 
run with a few samples at no extra cost. Two of the mutations identified were within the 
PIK3CA gene. This gene is known to have well characterised cancer hotspot 
mutations, identifiable using a cancer-gene panel. To evaluate the methodology it was 
of interest to establish if the sensitivity of dPCR was comparable to Ion Torrent 
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sequencing, which is currently the gold standard for detection and quantification of 
mutations, using specific cancer-gene panels for known cancer gene mutations. The 
Ion Torrent is a more expensive technique, and there is a delay in data output, as the 
assay requires a higher number of samples per run to be cost efficient.  
  
The allele frequency was tested using tumour DNA from the two patients with PIK3CA 
mutations. The sensitivity correlated well between dPCR and the Ion Torrent (the Ion 
Torrent analysis was run by Carlos De Andrea, PhD Scientist in UCL Advanced 
Diagnostic). 
 
Table 6.3 Sensitivity of detection rate with Digital PCR and Ion Torrent 
Patient ID Detection by ddPCR Detection by Ion Torrent 
1 (3814) 22.7% 25.07% 
2 (7187) 19.4% 21.34% 
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Figure 6.1 Ion Torrent detection of PIK3CA mutation 
Screen shot showing the PIK3CA mutation: p.Glu545Lys (c.1633G>A, allele frequency: 25.07%). A: green, G: brown; mutation. PIK3CA p.E545K hotspot 
mutation has been reported nearly 2000 times in COSMIC database. 
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Figure 6.2 Ion Torrent detection of PIK3CA mutation 
Screen shot showing the PIK3CA mutation: p.Met1043Ile (c.3129G>T, allele frequency: 21.34%). G: brown, T: red; mutation. PIK3CA p.M1043I hotspot 
mutation has been reported about 60 times in COSMIC database.
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6.4.3 Detection of tumour-specific ctDNA in plasma 
Detection of tumour-specific mutations in plasma was done by dPCR.  Low levels of copy 
numbers were detected for three of four patients. The development of the probe for one of 
the GENE X mutations failed, as no differentiation was possible between the mutation and 
the wild-type sequence in the tumour sample. The plasma sample was therefore not 
analysed.  
 
Below is the dPCR data from the multiplexed experiments viewed in a 2-D plot. The 
detection of mutation (channel 2 / y-axis) is plotted against the wild-type sequence (channel 
1 / x-axis). The data represents detection of the mutation/wild-type in the tumour 
demonstrating the presence of the targets and the ability of the assay to detect the target 
sequences. Notably the frequency of mutation detection in the plasma is much lower than in 
the tumour DNA (Table 6.4).  
 
 
Figure 6.3 Result of dPCR for PIK3CA(1) mutation in tumour and plasma  
Data from a duplex experiment in which two targets are PCR amplified and viewed in a 2-D plot: 
channel 1 fluorescence (FAM/mutant)(y-axis) is plotted against channel 2 fluorescence (VIC/wild-
type)(x-axis) for each droplet. Analysis by QX200 droplet reader; the blue dots indicates droplets with 
the amplified mutant sequence, the green dots represents droplets containing the wild-type sequence, 
the orange droplets contains both wild-type and mutant molecules, and the grey dots are droplets that 
did not contain the amplified target sequence. (A) Assay for the FFPE tumour sample. (B) Plasma: 
one mutant molecule was detected; this was noted in 2 of 4 runs. The blue and green droplet 
identification is manual. Non-template control (NTC)(i.e. water) was negative.  
 
 
 
A 
B 
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Figure 6.4 Result of dPCR for PIK3CA(2) mutation in tumour and plasma 
Analysis by QX200 droplet reader; the blue dots indicates droplets with the amplified mutant 
sequence, the green dots represents droplets containing the wild-type sequence, the orange droplets 
contains both wild-type and mutant molecules, and the grey dots are droplets that did not contain the 
amplified target sequence. (A) FFPE tumour sample, (B) plasma: 1 mutant molecule was detected. 
 
 
Figure 6.5 Result of dPCR for SETD2 mutation in tumour sample 
Analysis by QX200 droplet reader; SETD2 insertion mutation run at 60°C; the assay did not work as 
the SETD2-probe was non-specific for mutant/wild-type tested in FFPE tumour sample. The orange 
droplets contain both the wild-type and mutant DNA indicating the probes inability to discriminate 
between the two sequences.  Grey droplets are either empty or does not contain the amplified target 
sequence. 
 
 
 
 B 
A 
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Figure 6.6 Results of dPCR for GENE X(2) mutation in tumour and plasma 
Droplet Digital PCR data from a duplex experiment in which two targets are PCR amplified viewed in a 
2-D plot in which channel 1 fluorescence (FAM/mutant) is plotted against channel 2 fluorescence 
(VIC/wild-type) for each droplet. Analysis by QX200 droplet reader; GENE X(2) insertion frame-shift 
mutation. (A) Tumour sample assay, (B) plasma: two mutant molecules were detected in plasma 
(demonstrated within the red circle), in total 4 molecules were detected in approximately 1,8mL of 
plasma (2 molecules/run). 
 
B 
A 
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Table 6.4 Results of ctDNA in plasma from 3 chordoma patients  
Patient ID Surgery status Mutation 
# FAM-
positive 
droplets 
Mutant 
copies/mL 
plasma 
Total 
copies/mL 
plasma 
% Mutant 
Equivalent 
plasma 
volume 
(µL) 
Mean 
mutant 
copies/mL 
plasma 
1 (3814) POST PIK3CA 
0 0.0 1243 0.0% 1122 
0.6 
1 1.3 1172 0.1% 1046 
0 0.0 925 0.0% 1072 
1 1.2 1200 0.1% 1086 
2 (7187) PRE 1 PIK3CA  
0 0.0 1004 0.0% 835 
0.3 
1 1.5 857 0.2% 949 
0 0.0 1141 0.0% 786 
0 0.0 747 0.0% 850 
0 0.0 624 0.0% 740 
0 0.0 489 0.0% 962 
4 (7186) Recurrent GENE X 
2 4.5 1220 0.4% 794 4.1 
2 3.7 1143 0.3% 703 
Summary table of the results, patient ID, timing of samples taken in relation to surgery (pre-/post op, or at recurrence), mutation identified by exome 
sequencing, positive droplets (total/run), mutant copies/mL and total copies of droplets (wlld-type and mutant), percentage of mutant copies compared to wild-
type, plasma volume tested, and mutant copy number/mL of plasma total from all runs.! 
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For patient 1 (ID 3814) the plasma sample used was taken 5 years after surgical 
resection and radiotherapy. The sample tested positive at low levels for tumour-specific 
mutant PIK3CA. The patient has no clinical evidence of recurrent disease 3 years after 
the sample was taken. No pre-op or additional samples were available for this patient.  
 
For patient 2 (ID 7187) a pre-op sample was tested, this patient had both a PIK3CA 
and a SETD2 mutation. This patient had low levels of mutant DNA detected using the 
PIK3CA probe. The Taqman probe for the SETD2 mutation did not work, as the 
SETD2 probe was non-specific for mutant/wild-type. The patient had been treated with 
surgery and radiotherapy. A recent MRI reported stable disease, serial post-op 
samples were not tested for the mutation, as levels were low prior to surgery and the 
patient continue to be in clinical remission.  
 
For patient 3 (ID 4927), no results are available, as various attempts to generate a 
probe for the GENE X deletion failed.  
 
Patient 4 (ID 7168) had recurrent metastatic disease at the time the sample was taken. 
The tumour harboured a GENE X mutation. The initial surgical resection for the 
patient’s primary disease had been done 8 years earlier. Since then the patient has 
suffered multiple recurrences, undergone further surgery, and received proton beam 
therapy. Various targeted therapies including: Sirolimus, Imatinib, and Dasatinib had 
been trialled. This patient had the highest level of mutant copies detected compared to 
the other patient samples tested, though still accounting for a low level of mutant 
copies.  
6.4.3.1 Sensitivity and specificity 
Pooled plasma controls (blood collected from 12 healthy controls, from whom the 
plasma was mixed to generate identical aliquots) and high quality genomic DNA 
(Bioline) was tested to assess for false positive droplets. No false positive (mutant 
droplets) were observed in the pooled plasma or the genomic DNA. The false positive 
rate for the PIK3CA(1) assay was determined to be lower than 1 in 18945 wild-type 
copies of DNA equivalent to < 0.005% combining all runs with this assay. The false 
positive rate for the PIK3CA(2) assay was less than 0.003% and the false positive rate 
for the GENE X assay was determined to be lower than 1 in 12,536 wild-type copies of 
good-quality human genomic DNA (equivalent to 0.008%), and lower than 1 in 29,930 
for heat-denatured DNA (equivalent to 0.003%). Combining the runs for the GENE X 
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assay the false positive rate was determined to be less than 1 in 42,466 wild-type 
copies equivalent to less than 0.002%. None of the non-template controls (NTC) run 
with each assay had positive droplets ensuring no cross contamination across wells.  
 
Table 6.5 Control for false positive droplets 
  
This table shows that no ‘mutant only’ (blue) droplets were detected in our controls (false 
positive). Pooled plasma was tested from healthy controls as well as purchased genomic DNA 
(gDNA) both were tested as denatured DNA, and non-denatured DNA. The wild-type detection 
rate in green column (WT) and the sum of total copies include all droplets (orange column). 
False positive rate was calculates as <1 per total number of droplets for each individual run of 
gDNA and pooled plasma DNA. The total false positive detection rate was calculated as <1 per 
total number of droplet for each assay. The difference here is between positive droplets 
(coloured columns) and copies screened (‘sum of total copies’). The Poisson distribution is 
applied to the droplet counts to get the copies screened, in order to account for multiple copies 
of DNA co-occurring in a single droplet – the orange droplets have at least 1 mutant and 1 wild-
type sequence. The more concentrated the sample, the more likely that a mutant/wild-type 
droplet also has more than one copy inside it. The false positive detection rate for the 
PIK3CA(1) assay was <0.005%, for the PIK3CA(2) the false detection rate was < 0.03% and for 
the GENE X assay was determined to be lower than 0.002%.  
  
Assay Sum of mutant
Sum of wild-
type 
Sum of WT 
and MT
Sum of Total 
copies
Equivalent 
mutant % 
PIK3CA_1 (total) 0 16850 5 18945 0.005%
Denatured DNA 0 3683 1 3971 0.025%
Pooled plasma control 0 257 1 265
BioLine gDNA 0 3426 0 3706
non-denatured DNA (total) 0 13167 4 14974 0.007%
Pooled plasma control 0 168 0 172
BioLine gDNA 0 12999 4 14802
PIK3CA_2 (total) 0 32514 5 39323 0.003%
Denatured DNA 0 19741 4 28644 0.003%
BioLine gDNA 0 19741 4 28644
non-denatured DNA 0 12773 1 10679 0.009%
BioLine gDNA 0 12773 1 10679
LYST_2 (total) 0 32611 0 42466 0.002%
Denatured DNA 0 23076 0 29930 0.003%
Pooled plasma control 0 56 0 57
BioLine gDNA 0 23020 0 29873
non-denatured DNA 0 9535 0 12536 0.008%
Pooled plasma control 0 55 0 56
BioLine gDNA 0 9480 0 3056
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6.4.3.2 Extraction efficiency of DNA from plasma 
The extraction efficiency of DNA from plasma was assessed by adding an exogenous 
(frog/XenT) DNA spike into the plasma sample prior to DNA extraction in order to 
establish the efficiency and to rule out that the low mutation detection rate was not due 
to poor DNA extraction(685). The extraction efficiency of DNA was consistent with a 
mean of 75% of DNA recovered from the samples. 
 
Table 6.6 Extraction efficiency for each assay 
Mutation Patient ID
# FAM-
positive 
droplets*
Mutant 
copies/mL 
plasma
Total 
copies/mL 
plasma
XenT 
efficiency
PIK3CA(1) 3814 0 0 1243 79%
3814 1 1 1172 85%
3814 0 0 925 71%
3814 1 1 1200 81%
GENE X(2) 7186 2 5 1220 72%
7186 2 4 1143 73%
PIK3CA(2) 7187 0 0 1004 79%
7187 1 2 857 81%
7187 0 0 1141 85%
7187 0 0 747 67%
7187 0 0 624 70%
7187 0 0 489 59%
Mean: 0.7515107
SD: 8%  
Percentage of XenT recovered. Relative detection of the XenT was compared to a endogenous 
control RPP30. 
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6.5 AKR1B10 in chordoma  
AKR1B10 protein has been reported to be measurable at low levels in plasma from 
healthy controls(853). To establish if AKR1B10 was detectable at elevated levels in 
plasma from patient with chordoma, plasma samples taken prior to surgery were used. 
Four patients with large sacrococcygeal chordomas for whom plasma samples were 
available had been identified for the study. None of the patients had metastatic 
disease. Enzyme-linked immunosorbent assay (ELISA) was used for detection of 
AKR1B10 in plasma samples as described in Materials and Methods. 
  
Table 6.7 Demographic of Patients in study for AKR1B10 detection in plasma 
 
 
 
Figure 6.7 AKR1B10 protein expression in chordoma 
Light photomicrograph of a representative case of a chordoma showing immunoreactivity for 
AKR1B10 (images provided by Professor A. Flanagan).  
 
 
Three chordoma cell lines were tested for AKR1B10 gene expression by RT qPCR.  
Variation in expression levels was observed between cell lines. The expression levels 
of AKR1B10 correlate with the relative gene expression level of brachyury. 
 
Sample ID Sex Age at diagnosis
Tumour 
location
Tumour size 
(mm)
Histology 
type Outcome 
Metastatic 
disease Y/N
31403 M 67 Sacrum 155 x 70 x 130 Conventional Deceased N
20603 F 67 Sacrum 170 x 110 x 140 Conventional Recurrence N
29192 M 60 Sacrum 280 x 150 Conventional Stable N
6583 M 63 Sacrum 210 x 110 x 30 Conventional Recurrence N
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Figure 6.8 AKR1B10 gene expression (mRNA) in chordoma cell lines  
RT qPCR data for relative expression levels of AKR1B10 and brachyury across three chordoma 
cell lines: U-CH1, U-CH2 and MUG Chor (*UCH2 AKR1B10 expression 0.0003). Expression of 
AKR1B10 and brachyury was corrected to the endogenous PGK expression as a reference 
gene, and normalised to U-CH1 expression levels. Error bars demonstrate SD. 
 
 
                   
Figure 6.9 AKR1B10 expression (protein) in chordoma cell lines  
Western blot demonstrating brachyury and AKR1B10 expression with Beta-actin used as a 
loading control. 
 
 
6.5.1 AKR1B10 not detectable in plasma from chordoma patients 
AKR1B10 protein was not detected in plasma from the chordoma patients despite all of 
their tumours demonstrating immunoreactivity for this protein (data not shown), and 
having large tumours in situ at the time of the sampling. The levels detected were 
below the detection level for the negative control. Lysate from the MUG Chor cell line 
used as a positive control, had levels above 1.25ng/mL.  
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Figure 6.10 AKR1B10 protein not detectable in plasma from chordoma patients 
ELISA assay of AKR1B10 level in patients samples (31403, 20603, 29192, 6583) were at the 
level of the negative control. Photometric readout was done measuring absorbance at 450nm 
with the correction wavelength set at 540nm, using a 96-well plate reader Anthos 2001 
spectrophotometer. The samples and the positive control were plotted with the un-diluted 
sample (the stock solution of 40ng/mL). Data represent 2 separate experiments run with 
duplicate samples. The standard: serial dilution of recombinant AKR1B10 (0-40ng/mL). 
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6.6 Discussion 
Genomic analysis had identified tumour specific mutations in chordoma. The work 
presented here establish proof of concept that tumour-specific ctDNA is detectable in 
plasma from chordoma patients, though at very low levels. The assays worked well for 
the tumour DNA samples, providing confidence in the generated probes and their 
ability to detect the mutations. The amplitude for the PIK3CA(1) mutation detected in 
patient 1 was low suggesting a need for caution regarding calling this a true mutant 
droplet. A low amplitude or fluorescence could be a technical issue or might indicate 
damaged DNA or late amplification due to inhibitors, neither of which is commonly 
seen in plasma(685). The clinical scenario suggest that this result may represent a 
false positive as this patient had surgery 5 years prior to the sample collection, which 
was done 3 years ago. In this time frame the patient has remained in clinical remission. 
For the other mutations detected (PIK3CA and GENE X) the amplitude was 
satisfactory, and those samples were collected whilst the patients had measurable 
disease. With very low copy numbers it can be assumed that this value directly 
correlates to the number of mutant molecules, and the reason for low detection may 
reflect low mutant allele frequency(855,856). Experiences so far suggest that false 
positive are unlikely as benign lesions and non-neoplastic conditions do not give rise to 
ctDNA mutations(617,857,858).  
6.6.1 Sensitivity and specificity of ctDNA 
Digital PCR has been shown to be highly sensitive and specific(641), Milbury et al. 
(859) detected 1 mutant molecule in 180.000 wild-type molecules and one mutant 
molecule in over four million WT molecules when screening 70 million copies of DNA, 
with the limit of detection (LoD) being restricted by the amount of amplifiable DNA 
analysed. Mutation detection assays using dPCR can have false-positive molecules 
detected which might arise from the fluorescence detection (“system”) noise, and 
molecular biology (“assay”) noise(859). It is known that PCR polymerase error can 
occur at approximately 1x10-5 with a propensity to base substitute A-T to G-C(860). The 
false positive detection rate in the same study by Milbury et al. (859) was 1 in 14 
million. Other studies have reported detection of mutant molecules at levels down to 1-
2 molecules/mL accepting these as positive samples as their negative control assays 
did not show any mutant molecules(635,651). In a study of 52 breast cancer patients 
the sensitivity of dPCR assay allowed for the detection of a mutant allele fraction of 
0.1% or more(634) which is similar to the detection in the 3 of 4 chordomas. 
Importantly no false positives were detected in the controls used for the study reported 
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here. The mutant template was not detected in all samples (false negative), this can be 
explained by low copy number due to the low turnover of cells characterising a slow 
growing tumour such as chordoma. This may also explain why the levels of wild-type 
molecules generated from plasma from patients with chordoma were not elevated as 
often observed in cancer patients, particularly in advanced disease. Diehl at al. 
describe levels in healthy controls ranging from 1150-8280 DNA fragments/mL whilst 
for patients with colorectal cancer the levels ranged from 1350-230,000 DNA 
fragments/mL(617,635,861). In the samples used there the highest levels of wild-type 
DNA was about 1200 copies (fragments)/mL.  
 
The ability to isolate ctDNA is dependent on adherence to stringent standards of 
procedures for sample collection and storage as well as the methodology for extraction 
of DNA from plasma. This has in particular been demonstrated in the use of cfDNA in 
prenatal diagnostics(862-865). It is well described that the level of cfDNA increases 
with time following the venepuncture as lysis of white cell leads to release of genomic 
DNA. This may result in decreased sensitivity of detection of ctDNA(864,866). For the 
study presented here peripheral blood was collected into EDTA collecting tubes and 
was stored on ice until it was subjected to centrifugation for separation of plasma, 
within one hour. Isolation of plasma was done in accordance with published 
protocols(618). It has been reported that the absolute quantity of fetal DNA remained 
stable for up to 24 hours when the sample was left unprocessed at room 
temperature(865,867). And a different study did not detect differences in quantities of 
cfDNA after samples had been thawed and refrozen(868).  The low level of detection of 
ctDNA reported here is therefore not likely to be due to potential divergence from the 
standard of procedure. Extraction of DNA from plasma is critical in ensuring clinical 
sensitivity for measuring small quantities of ctDNA(685). The kit used for this study has 
been reported to have the highest extraction efficiency when compared with other 
similar kits(685). The efficiency for all the assays were analysed demonstrating a 70-
85% recovery. One aspect however, which may have compromised the detection of 
ctDNA in this study, is the dPCR analysis on the 200QX BioRad analyser. After 
completion of the analysis reported here, and following servicing of the machine it was 
discovered that there had been an issue with dead-space. Analysis had therefore been 
performed on approximately 10000 droplets rather then the expected 20,000 
droplets/sample, potentially underestimating the level of ctDNA.  
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Bettegowda et al.(635) found the concentration of ctDNA in plasma correlated with the 
stage of disease. Yet, they were able to detect the presence of ctDNA in 50% of 
patients across 14 tumour types with early stage (localised) disease. Most chordomas 
are localised and recur locally(56). The patient with evidence of systemic disease with 
widespread metastases included in the study presented here had the highest level of 
ctDNA. Interestingly in the study by Bettegowda et al. they found that mucinous 
histology was associated with low detection of ctDNA. Chordomas are mucinous 
tumours, and the fact that they are slow growing with limited necrosis formation 
account for factors recognised to influence the level of ctDNA(623), and further explain 
the low levels detected in plasma from the patients with chordoma presented here.  
 
To increase the specificity for tumours with low levels of ctDNA to ensure confidence in 
the detection of tumour recurrence without imaging studies to support this. Screening 
for more than one tumour-specific mutation or for tumour-specific rearrangements 
could be considered. Most solid tumours have up to a dozen rearrangements or 
translocations, with the majority being passengers rather than driver mutations(869). In 
chordoma numerical and structural rearrangement have been described(125,134,135), 
and rearrangements due to chromothripsis have been reported to be observed more 
frequently in chordoma than many other cancers(131), emphasising using this method 
for detection of ctDNA. One of the tumours used for the study reported here had two 
mutations identified. Unfortunately due to technical difficulties it was not possible to 
detect the 2nd mutation. In order to increase the sensitivity of detection of ctDNA in 
chordoma, an increase in sample size may be required. This, strategy, is currently 
being evaluated. 
  
In cancer patients the proportion of ctDNA has been demonstrated to relate to burden 
of disease. Regular sampling can demonstrate the dynamic of the 
disease(634,653,815). For our patients only a single time-point was assessed, in order 
to establish proof of concept of detection of ctDNA in a slow growing tumour. 
Preferably the utility of the test would be to identify mutations or rearrangement in the 
primary chordoma and to monitor for these gene alterations following surgery, with 
serial sampling to monitor for disease recurrence. It has been suggested that a tumour 
containing approximately 50 million malignant cells is sufficient for the detection of 
ctDNA, however a tumour of that size will not be definable by imaging(126,636,855). 
 
Targeted therapy for chordoma 
294 
For chordoma patients, and indeed other bone tumours where surgical resection is the 
main therapy, excision may be technically easier and potentially associated with less 
morbidity if recurrence is detected early.  It is perceivable that ctDNA can be used to 
guide timing of imaging and surgical resection.  
 
For cancer with mutations that represents druggable targets, and mutations leading to 
treatment resistance, ctDNA has true clinical application. This has been shown for 
colorectal cancer(870,871) and NSCLC(638,872), where patients treated with EGFR 
inhibitors demonstrated initial clinical response, but subsequently developed resistance 
by the emergence of specific EGFR mutations. Circulation tumour DNA offers and 
excellent opportunity to monitor for the emergence of resistant clones to guide 
therapy(637,657,873). Though EGFR has not been found to be mutated in chordoma 
as previously discussed, the work presented in this thesis demonstrated evidence of 
EGFR’s involvement in chordoma. Future trials may identify genomic alterations, which 
can be used as a biomarker, to help guide therapy in chordoma.  
6.6.2 AKR1B10 
The work in this chapter has shown that AKR1B10 protein was not detectable in 
plasma samples from chordoma patients. Though only a few samples were included, 
they came from patients with large tumours, immunoreactive for AKR1B10, suggesting 
that AKR1B10 may not have a utility as a serum protein biomarker in patients with 
chordoma. This data is in contrast to the published data for patients with breast cancer. 
In the study by Ma et al.(853) breast cancer patients had AKR1B10 levels of 15.18 +/- 
9.08ng/mL with the highest level measuring 58.4ng/mL. The levels correlated to 
outcome. The controls had levels of 3.34 +/- 2.27ng/mL, in the serum measured by 
ELISA. The standard containing recombinant AKR1B10 used in the experiments 
reported here worked well, and the level for the MUG Chor lysate was detectable 
though at low levels. It is possible that the processing or storage of the plasma 
samples rendered the sample suboptimal. However, these were biobanked according 
to standard operating procedures and were all stored within 4 hours of being taken 
from patients. The samples included were collected at different time points so even if a 
delay had occurred in processing one of the samples, for none of the samples to work 
suggests that the levels in chordoma patients are too low to measure. The role of 
AKR1B10 in chordoma patients is still to be determined. 
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7 CONCLUSIONS AND FUTURE WORK 
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Treatment options are currently limited for patients with chordoma and in particular for 
patients with recurrent disease. The work presented here provides insight into different 
modalities of treatment for chordoma. 
 
In the absence of recurrent targetable genetic alterations in chordoma a phenotypic 
screening approach was undertaken to identify the mechanism/s by which this disease 
is driven, and targets which could potentially be translated into clinic practice. Targeted 
therapy for chordoma has to date been chosen based on immunoreactivity and 
activated molecular pathways in chordoma. Only one large in vitro compound screen 
has previously been reported in chordoma cell lines. In the work presented here from 
the high-throughput compound screen which included 1152 compounds, 28 
compounds were identified to have a selective cell kill effect on the chordoma cell lines. 
81% of these compounds were found to be EGFR/ErbB family inhibitors. Analysis of 
substituent patterns suggested that EGFR-inhibitors with small aniline substituents in 
the 4th position of the quinazoline ring were more effective than inhibitors with large 
substituents in that position. Chemotype analysis thereby identified the compounds 
Sapitinib and Erlotinib as the EGFR inhibitors most likely to succeed in a clinical trial for 
chordoma. Not all of the cell lines demonstrated equal sensitivity to EGFR inhibitors 
and further work is required to uncover the different mechanisms for treatment 
resistance. Next generation sequencing failed to detect mutations covering the 
hotspots in 22 tumour-related genes which included EGFR, ERBB2 and ERBB4 and 
their downstream effectors (KRAS, BRAF, PIK3CA, AKT1, PTEN, NRAS, MAPK). 
Thus, no obvious genetic explanations for sensitivity and/or resistance in the cell line 
screened.  Work is currently being completed screening an additional four cell lines 
with the identified compounds. In addition experiments have been undertaken to 
establish the on-target effect of the compounds by Western Blot and ELISA analysis. 
Future work is to include testing the most efficacious compounds in the CLX and PDX 
models to test if the compounds reduce tumour growth in vivo. Sapitinib has recently 
showed promising result significantly reducing tumour growth in 2 xenograft models (U-
CH1 xenograft and a patient-derived xenograft SF8894(874)) tested at South Texas 
Accelerated Research Therapeutics (START) (Personal communication Professor 
Flanagan). The xenograft models may help understand the pathways involved in 
tumour growth and treatment response. Ultimately, whether some patients with 
chordoma benefit from the TKIs identified is likely only to be resolved in a clinical trial. 
Any such study should involve in depth biological studies of the tumour samples pre- 
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and post-treatment, with the aim of explaining the mechanism by which some 
chordomas are primarily resistant or develop secondary resistance to EGFR inhibitors. 
 
It is unlikely that a single treatment compound will cure chordoma. Screening of 
combination of compounds is being planned to identify compounds with synergistic 
effect aiming to optimise treatment.  
 
As an alternative approach to treatment, representing untested teritory, I developed an 
AAV vector for silencing brachyury in a xenograft model. In vitro work demonstrated 
that knockdown of brachyury in chordoma cell lines induced growth arrest and 
apoptosis. The work presented here demonstrated chordoma cell lines to be 
permissive to AAV5 and the in vitro work demonstrated growth arrest in the U-CH1 and 
MUG Chor cell lines following transduction with the generated AAV vector. This work 
also highlighted the difficulties involved in using RNAi technology. The in vivo work 
demonstrated a beneficial effect on the tumour causing growh arrest or reduction in 
size. Luciferase expression was reduced in the tumour suggesting loss of viable cells. 
Though the sample size is too small to assess the statistical significance of this 
particular vector model the study shows a signal of anti-tumour effect and therefore the 
potential supporting further developmen as a bigger study would be needed to 
establish efficacy. Whilst undertaking the work for this study RNAi techonology has 
made great advances with the introduction of gene editing using CRISPR/Cas9 for 
targeted genome editing. This technology is promising and may have the potential to 
target brachyury leading to sustained silencing in chordoma. Multiple options for vector 
optimisations are available and include considerations such as a different choice of 
vector for delivery and options for engineering the vector to elicit an immune-
stimulatory response. The use of nano-technology enables repeat dosing in contrast to 
the viral vector which is a one-off therapeutic option, and nano-technology should 
therefore be considered as a model for delivery. Multiple improvements to the 
experiments should be done, including optimisation of the xenograft model.  
 
1. The viral vector delivering the gene-silencing construct could be engineered to 
express a different bioluminescent or immunofluorescent marker to identify the 
transduced cells. This would offer an opportunity to assess if persistent 
brachyury expression was due to failure of transduction, or failure of the vector 
(cells overcoming the gene silencing).  
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2. The U-CH1 cells could also be engineered to stably express brachyury from a 
viral vector (cDNA) upstream from a flourescent or luminescent marker which 
would not be expressed if the brachyury gene upstream was silenced.  
3. An alternative to this would be to engineer the U-CH1 cell to stably express 
GFP or a different colour luciferase and then engineer the vector to deliver a 
GFP or luciferase silencing shRNA as well as the brachyury silencing 
expression cassette to confirm the presence and efficacy of the viral vector in 
the situation where brachyury silencing was not maintained.  
 
The lack of brachyury silencing, observed four weeks after the vector injection, may 
reflect the chordoma cells ability to overcome the silencing as discussed in chapter 3. 
To establish this the xenograft experiment could include sacrificing some of the mice at 
earlier timepoints to assess the immunoreactivity of brachyury (kinetic study). 
 
An alternative to sacrificing the xenograft or modifying the tumour cells (the U-CH1 cell 
line) would be to monitor response to therapy by quantifying ctDNA in the plasma from 
the xenograft(875,876), this would enable serial monitoring and reduce the number of 
mice needed for the experiments. As the DNA from the tumour is human origin it would 
not rely on tumour specific mutations. The method could be applied both to the gene 
therapy experiments and drug screening in the xenograft model. 
 
Targeting brachyury holds promise for potentially overcoming treatment resistance to 
other therapeutics. The transformation of epithelial cancers by the process of EMT has 
demonstrated increase resistance to therapy. Brachyury has been implicated in EMT 
and reversal of the process has been observed after silencing of brachyury(106). 
Though EMT is not fully understood it raised the possibility that targeting brachyury in 
chordoma may render the tumours sensitive to chemotherapy.  This will need to be 
assessed in future studies, preliminary data could be obtained using a xenograft 
model. A current vaccine study targeting brachyury is combining the vaccine with 
radiotherapy, it will be interesting if this approach demonstrates better local 
control(298).  
 
This work has also reported on the experience of the development of two xenograft 
models. The PDX model identified TP53 mutation as a driver of tumourigenicity 
demonstrated by the clonal expansion of TP53 mutated cells in the xenograft. This 
finding, together with similar reports of PDX models being representative of tumour 
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progression, supports the use of these models for drug screening and biological 
studies to understand the significance of identified mutations. The Avatar model may 
help assess the patient’s risk of recurrence and identify drivers as well as potential 
actionable targets to guide compounds treatment in the PDX providing the biological 
rationale for targeting certain mutations(793). The concept of the Avatar model has the 
potential to revolutionise drug development and optimise personalised medicine. The 
model presented here has been shared with collaborators for further development. To 
set up a lab generating Avatar models a significant commitment on time and funding is 
required, however due to the slow growth of many chordomas the personal model may 
truly benefit the patient as there is time to establish the model, screen for mutations 
and treat the mice in real time. Compounds can be selected based on preclinical 
studies or according to individual targetable mutations. 
 
Assays developed for detection of ctDNA in chordoma was also established. Detection 
of ctDNA in low-grade tumours has been reported to be less successful and 
optimisation will be required for this method to be a useful and consistent tool for 
detection of recurrence and evaluation of response to treatment. Further evaluation is 
currently being undertaken to determine if a larger sample size will increase the level of 
detection. Another method for optimising specificity in cancers with low levels of ctDNA 
would be to identify more than one mutation for each tumour, including gene 
rearrangements or amplified genes, this would add confidence and validity when levels 
are low. With the increased availability of sequencing data for the majority of tumours, 
ctDNA is likely to become as important in solid tumours as it currently is in leukaemia 
for disease stratification and detection of minimal residual disease. Mutation panels are 
under development for various cancer groups to be used for detection of tumour 
specific mutations by sequencing. Sequencing of additional chordoma samples may 
identify mutations, which frequently occur in chordoma enabling a panel to be 
developed. With further technological advances detection threshold for ctDNA is likely 
to further improve and become an integrated part of standard of care for many cancers. 
 
  
Targeted therapy for chordoma   
 301 
8 REFERENCES 
  
Targeted therapy for chordoma 
302 
 
  
Targeted therapy for chordoma   
 303 
1. Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, et al. 
Incidence and survival of malignant bone sarcomas in England 1979-2007. 
Int J Cancer. 2012 Aug 15;131(4):E508–17.  
2. Mindell ER. Chordoma. J Bone Joint Surg Am. 1981 Mar;63(3):501–5.  
3. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. 
Chordoma: the nonsarcoma primary bone tumor. Oncologist. 2007 
Nov;12(11):1344–50.  
4. Ishida T, Dorfman HD. Chondroid chordoma versus low-grade 
chondrosarcoma of the base of the skull: can immunohistochemistry 
resolve the controversy? J Neurooncol. 1994;18(3):199–206.  
5. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC. Lumbosacral 
chordoma. Prognostic factors and treatment. Spine. 1999 Aug 
15;24(16):1639–45.  
6. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. 
Chordoma: incidence and survival patterns in the United States, 1973-
1995. Cancer Causes Control. 2001 Jan;12(1):1–11.  
7. Smoll NR, Gautschi OP, Radovanovic I, Schaller K, Weber DC. Incidence 
and relative survival of chordomas: the standardized mortality ratio and the 
impact of chordomas on a population. Cancer. 2013 Jun 1;119(11):2029–
37.  
8. Chambers KJ, Lin DT, Meier J, Remenschneider A, Herr M, Gray ST. 
Incidence and survival patterns of cranial chordoma in the United States. 
Laryngoscope. 2013 Oct 1.  
9. Jones PS, Aghi MK, Muzikansky A, Shih HA, Barker FG, Curry WT. 
Outcomes and patterns of care in adult skull base chordomas from the 
Surveillance, Epidemiology, and End Results (SEER) database. J Clin 
Neurosci. 2014 Sep;21(9):1490–6.  
10. Lauer SR, Edgar MA, Gardner JM, Sebastian A, Weiss SW. Soft tissue 
chordomas: a clinicopathologic analysis of 11 cases. Am J Surg Pathol. 
2013 May;37(5):719–26.  
11. Kikuchi Y, Yamaguchi T, Kishi H, Azuhata K, Kimizuka G, Hiroshima K, et 
al. Pulmonary tumor with notochordal differentiation: report of 2 cases 
suggestive of benign notochordal cell tumor of extraosseous origin. Am J 
Surg Pathol. 2011 Aug;35(8):1158–64.  
12. Park SY, Kim SR, Choe YH, Lee KY, Park SJ, Lee HB, et al. Extra-Axial 
Chordoma Presenting as a Lung Mass. Respiration. 2009;77(2):219–23.  
13. Tirabosco R, Mangham DC, Rosenberg AE, Vujovic S, Bousdras K, 
Pizzolitto S, et al. Brachyury expression in extra-axial skeletal and soft 
tissue chordomas: a marker that distinguishes chordoma from mixed 
tumor/myoepithelioma/parachordoma in soft tissue. Am J Surg Pathol. 
2008 Apr;32(4):572–80.  
Targeted therapy for chordoma 
304 
14. O’donnell P, Tirabosco R, Vujovic S, Bartlett W, Briggs TWR, Henderson 
S, et al. Diagnosing an extra-axial chordoma of the proximal tibia with the 
help of brachyury, a molecule required for notochordal differentiation. 
Skeletal Radiol. 2007 Jan;36(1):59–65.  
15. Lantos JE, Agaram NP, Healey JH, Hwang S. Recurrent skeletal extra-
axial chordoma confirmed with brachyury: Imaging features and review of 
the literature. Skeletal Radiol. 2013 Oct;42(10):1451–9.  
16. Difrancesco LM, Castillo CAD, Temple WJ. Extra-axial chordoma. Arch 
Pathol Lab Med. 2006 Dec;130(12):1871–4.  
17. Heffelfinger MJ, Dahlin DC, MacCarty CS, Beabout JW. Chordomas and 
cartilaginous tumors at the skull base. Cancer. 1973 Aug;32(2):410–20.  
18. Lee J, Bhatia NN, Hoang BH, Ziogas A, Zell JA. Analysis of Prognostic 
Factors for Patients with Chordoma with Use of the California Cancer 
Registry. J Bone Joint Surg Am. The Journal of Bone and Joint Surgery; 
2012 Feb 15;94(4):356–63.  
19. Kelley MJ, Korczak JF, Sheridan E, Yang X, Goldstein AM, Parry DM. 
Familial chordoma, a tumor of notochordal remnants, is linked to 
chromosome 7q33. Am J Hum Genet. 2001 Aug;69(2):454–60.  
20. Hoch BL, Nielsen GP, Liebsch NJ, Rosenberg AE. Base of skull 
chordomas in children and adolescents: a clinicopathologic study of 73 
cases. Am J Surg Pathol. 2006 Jul;30(7):811–8.  
21. Virchow R. Untersuchungen über die Entwickelung des Schädelgrundes 
im gesunden und krankhaften zustand: und über den einfluss derselben 
auf Schädelform, …. 1857.  
22. Owen CI, Hershey LN, Gurdjian ES. Chordoma Dorsalis of the Cervical 
Spine. The American Journal of Cancer. 1932 Jul 1;16(4):830–40.  
23. Ribbert H. Ecchordosis physaliphora sphenooccipitalis. Zbl alg Path path 
Anat. 1894.  
24. Salisbury JR. The pathology of the human notochord. J Pathol. 1993 
Dec;171(4):253–5.  
25. Salisbury JR, Deverell MH, Cookson MJ, Whimster WF. Three-
dimensional reconstruction of human embryonic notochords: clue to the 
pathogenesis of chordoma. J Pathol. 1993 Sep;171(1):59–62.  
26. Choi K-S, Cohn MJ, Harfe BD. Identification of nucleus pulposus precursor 
cells and notochordal remnants in the mouse: Implications for disk 
degeneration and chordoma formation. Dev Dyn. 2008 Dec;237(12):3953–
8.  
27. Yamaguchi T, Yamato M, Saotome K. First histologically confirmed case of 
a classic chordoma arising in a precursor benign notochordal lesion: 
differential diagnosis of benign and malignant notochordal lesions. Skeletal 
Radiol. 2002 Jul;31(7):413–8.  
Targeted therapy for chordoma   
 305 
28. Yamaguchi T, Suzuki S, Ishiiwa H, Ueda Y. Intraosseous benign 
notochordal cell tumours: overlooked precursors of classic chordomas? 
Histopathology. 2004 Jun;44(6):597–602.  
29. Deshpande V, Nielsen GP, Rosenthal DI, Rosenberg AE. Intraosseous 
benign notochord cell tumors (BNCT): further evidence supporting a 
relationship to chordoma. Am J Surg Pathol. 2007 Oct;31(10):1573–7.  
30. Kyriakos M, Totty WG, Lenke LG. Giant vertebral notochordal rest: a 
lesion distinct from chordoma: discussion of an evolving concept. Am J 
Surg Pathol. 2003 Mar;27(3):396–406.  
31. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, Tirabosco R, 
et al. Brachyury, a crucial regulator of notochordal development, is a novel 
biomarker for chordomas. J Pathol. 2006;209(2):157–65.  
32. Shen J, Shi Q, Lu J, Wang D-L, Zou T-M, Yang H-L, et al. Histological 
study of chordoma origin from fetal notochordal cell rests. Spine. 2013 Dec 
1;38(25):2165–70.  
33. Henderson SR, Guiliano D, Presneau N, McLean S, Frow R, Vujovic S, et 
al. A molecular map of mesenchymal tumors. Genome Biol. 
2005;6(9):R76.  
34. Stepanek J, Cataldo SA, Ebersold MJ, Lindor NM, Jenkins RB, Unni K, et 
al. Familial chordoma with probable autosomal dominant inheritance. Am J 
Med Genet. 1998 Jan 23;75(3):335–6.  
35. Dalprà L, Malgara R, Miozzo M, Riva P, Volonte M, Larizza L, et al. First 
cytogenetic study of a recurrent familial chordoma of the clivus. Int J 
Cancer. 1999 Mar 31;81(1):24–30.  
36. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, et al. T 
(brachyury) gene duplication confers major susceptibility to familial 
chordoma. Nat Genet. 2009 Oct 4;41(11):1176–8.  
37. Dutton RV, Singleton EB. Tuberous sclerosis: a case report with aortic 
aneurysm and unusual rib changes. Pediatr Radiol. 1975 Jun 13;3(3):184–
6.  
38. Schroeder BA, Wells RG, Starshak RJ, Sty JR. Clivus chordoma in a child 
with tuberous sclerosis: CT and MR demonstration. J Comput Assist 
Tomogr. 1987 Jan;11(1):195–6.  
39. McMaster ML, Goldstein AM, Parry DM. Clinical features distinguish 
childhood chordoma associated with tuberous sclerosis complex (TSC) 
from chordoma in the general paediatric population. J Med Genet. 2011 
Jul;48(7):444–9.  
40. Presneau N, Shalaby A, Idowu B, Gikas P, Cannon SR, Gout I, et al. 
Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR 
pathway. Br J Cancer. Nature Publishing Group; 2009 May 5;100(9):1406–
14.  
Targeted therapy for chordoma 
306 
41. Fletcher CDM. WHO Classification of Tumours of Soft Tissue and Bone. 
World Health Organization; 2013. 1 p.  
42. Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M. Chordoma 
and chondrosarcoma: similar, but quite different, skull base tumors. 
Cancer. 2007 Dec 1;110(11):2457–67.  
43. Saito A, Hasegawa T, Shimoda T, Toda G, Hirohashi S, Tajima G, et al. 
Dedifferentiated chordoma: a case report. Jpn J Clin Oncol. 1998 
Dec;28(12):766–71.  
44. Hanna SA, Tirabosco R, Amin A, Pollock RC, Skinner JA, Cannon SR, et 
al. Dedifferentiated chordoma: a report of four cases arising 'de novo'. J 
Bone Joint Surg Br. 2008 May;90(5):652–6.  
45. Meis JM, Raymond AK, Evans HL, Charles RE, Giraldo AA. 
“Dedifferentiated” chordoma. A clinicopathologic and immunohistochemical 
study of three cases. Am J Surg Pathol. 1987 Jul;11(7):516–25.  
46. Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M, Puri A. Revisiting 
chordoma with brachyury, a “new age” marker: analysis of a validation 
study on 51 cases. Arch Pathol Lab Med. 2010 Aug;134(8):1181–7.  
47. Walcott BP, Nahed BV, Mohyeldin A, Coumans J-V, Kahle KT, Ferreira 
MJ. Chordoma: current concepts, management, and future directions. 
Lancet Oncol. 2012 Feb;13(2):e69–76.  
48. Disler DG, Miklic D. Imaging findings in tumors of the sacrum. AJR Am J 
Roentgenol. 1999 Dec;173(6):1699–706.  
49. Chambers PW, Schwinn CP. Chordoma. A clinicopathologic study of 
metastasis. Am J Clin Pathol. 1979 Nov;72(5):765–76.  
50. Fagundes MA, Hug EB, Liebsch NJ, Daly W, Efird J, Munzenrider JE. 
Radiation therapy for chordomas of the base of skull and cervical spine: 
patterns of failure and outcome after relapse. Int J Radiat Oncol Biol Phys. 
1995 Oct 15;33(3):579–84.  
51. Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile 
spine. A clinicopathologic analysis of 40 patients. Cancer. 1993 Feb 
1;71(3):735–40.  
52. Kishimoto R, Omatsu T, Hasegawa A, Imai R, Kandatsu S, Kamada T. 
Imaging characteristics of metastatic chordoma. Jpn J Radiol. 2012 
Jul;30(6):509–16.  
53. Sopta J, Tulic G, Mijucic V, Mamontov P, Mandic N. Solitary lymph node 
metastasis without local recurrence of primary chordoma. Eur Spine J. 
2009 Jul;18 Suppl 2:191–5.  
54. Ruiz HA, Goldberg LH, Humphreys TR, Blacklock JB. Cutaneous 
metastasis of chordoma. Dermatol Surg. 2000 Mar;26(3):259–62.  
55. Boriani S, Chevalley F, Weinstein JN, Biagini R, Campanacci L, De Iure F, 
Targeted therapy for chordoma   
 307 
et al. Chordoma of the spine above the sacrum. Treatment and outcome in 
21 cases. Spine. 1996 Jul 1;21(13):1569–77.  
56. Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a 
global consensus approach to chordoma: a position paper from the 
medical and patient community. Lancet Oncol. 2015 Feb;16(2):e71–83.  
57. York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, et al. 
Sacral chordoma: 40-year experience at a major cancer center. 
Neurosurgery. 1999 Jan;44(1):74–9–discussion79–80.  
58. Azzarelli A, Quagliuolo V, Cerasoli S, Zucali R, Bignami P, Mazzaferro V, 
et al. Chordoma: natural history and treatment results in 33 cases. J Surg 
Oncol. 1988 Mar;37(3):185–91.  
59. Boriani S, Bandiera S, Biagini R, Bacchini P, Boriani L, Cappuccio M, et al. 
Chordoma of the mobile spine: fifty years of experience. Spine. 2006 Feb 
15;31(4):493–503.  
60. Bergh P. Prognostic Factors in Chordoma of the Sacrum and Mobile 
Spine. Cancer. 2000 May 1;88(9):2122–34.  
61. Sundaresan N, Huvos AG, Krol G, Lane JM, Brennan M. Surgical 
treatment of spinal chordomas. Arch Surg. 1987 Dec;122(12):1479–82.  
62. Wold LEL, Laws ERE. Cranial chordomas in children and young adults. 
Journal of Neurosurgery. 1983 Dec 1;59(6):1043–7.  
63. Borba LA, Al-Mefty O, Mrak RE, Suen J. Cranial chordomas in children 
and adolescents. Journal of Neurosurgery. 1996 Apr;84(4):584–91.  
64. Coffin CM, Swanson PE, Wick MR, Dehner LP. Chordoma in childhood 
and adolescence. A clinicopathologic analysis of 12 cases. Arch Pathol 
Lab Med. 1993 Sep;117(9):927–33.  
65. Kaneko Y, Sato Y, Iwaki T, Shin RW, Tateishi J, Fukui M. Chordoma in 
early childhood: a clinicopathological study. Neurosurgery. 1991 
Sep;29(3):442–6.  
66. Matsumoto J, Towbin RB, Ball WS. Cranial chordomas in infancy and 
childhood. A report of two cases and review of the literature. Pediatr 
Radiol. 1989;20(1-2):28–32.  
67. Sibley RK, Day DL, Dehner LP, Trueworthy RC. Metastasizing chordoma 
in early childhood: a pathological and immunohistochemical study with 
review of the literature. Pediatr Pathol. 1987;7(3):287–301.  
68. Mobley BC, McKenney JK, Bangs CD, Callahan K, Yeom KW, 
Schneppenheim R, et al. Loss of SMARCB1/INI1 expression in poorly 
differentiated chordomas. Acta Neuropathol. 2010 Dec;120(6):745–53.  
69. Yin H, Dorris KMO, Wagner LM, Collins MH, Towbin A, Nagarajan R. INI1 
and mib-1 expression in childhood chordomas. ASCO Meeting Abstracts. 
2011 May 20;29(15_suppl):9556.  
Targeted therapy for chordoma 
308 
70. Yadav R, Sharma MC, Malgulwar PB, Pathak P, Sigamani E, Suri V, et al. 
Prognostic value of MIB-1, p53, epidermal growth factor receptor, and INI1 
in childhood chordomas. Neuro-oncology. 2013 Dec 17.  
71. Tirabosco R, Jacques T, Berisha F, Flanagan AM. Assessment of 
integrase interactor 1 (INI-1) expression in primary tumours of bone. 
Histopathology. 2012 Jun 17;:–.  
72. Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Parsa AT. A 
comprehensive analysis of intracranial chordoma and survival: a 
systematic review. Br J Neurosurg. 2011 Aug;25(4):446–53.  
73. Uhl M, Mattke M, Welzel T, Roeder F, Oelmann J, Habl G, et al. Highly 
effective treatment of skull base chordoma with carbon ion irradiation using 
a raster scan technique in 155 patients: First long-term results. Cancer. 
2014 Nov 1;120(21):3410–7.  
74. Holliday EB, Frank SJ. Proton radiation therapy for head and neck cancer: 
a review of the clinical experience to date. Int J Radiat Oncol Biol Phys. 
2014 Jun 1;89(2):292–302.  
75. Edwards YH, Putt W, Lekoape KM, Stott D, Fox M, Hopkinson DA, et al. 
The human homolog T of the mouse T(Brachyury) gene; gene structure, 
cDNA sequence, and assignment to chromosome 6q27. Genome 
Research. 1996 Mar;6(3):226–33.  
76. Mariman E, Edwards YH. Genetic mapping of the human homologue (T) of 
mouse T (Brachyury) and. Human Molecular Genetics. 1996.  
77. Stemple DL. Structure and function of the notochord: an essential organ 
for chordate development. Development. 2005 Jun;132(11):2503–12.  
78. Stemple DL. The notochord. Curr Biol. 2004 Oct 26;14(20):R873–4.  
79. Herrmann BG, Labeit S, Poustka A, King TR, Lehrach H. Cloning of the T 
gene required in mesoderm formation in the mouse. Nature. 1990 Feb 
15;343(6259):617–22.  
80. Wilkinson DG, Bhatt S, Herrmann BG. Expression pattern of the mouse T 
gene and its role in mesoderm formation. Nature. 1990 Feb 
15;343(6259):657–9.  
81. Chesley P. Development of the short-tailed mutant in the house mouse. J 
Exp Zool. 1935 May;70(3):429–59.  
82. Postma AV, Alders M, Sylva M, Bilardo CM, Pajkrt E, van Rijn RR, et al. 
Mutations in the T (brachyury) gene cause a novel syndrome consisting of 
sacral agenesis, abnormal ossification of the vertebral bodies and a 
persistent notochordal canal. J Med Genet. 2013 Nov 19.  
83. Ghebranious N, Blank RD, Raggio CL, Staubli J, McPherson E, Ivacic L, et 
al. A missense T (Brachyury) mutation contributes to vertebral 
malformations. J Bone Miner Res. 2008 Oct;23(10):1576–83.  
Targeted therapy for chordoma   
 309 
84. Jensen LE, Barbaux S, Hoess K, Fraterman S, Whitehead AS, Mitchell LE. 
The human T locus and spina bifida risk. Hum Genet. 2004 
Nov;115(6):475–82.  
85. Zhang L, Guo S, Schwab JH, Nielsen GP, Choy E, Ye S, et al. Tissue 
microarray immunohistochemical detection of brachyury is not a prognostic 
indicator in chordoma. PLoS ONE. 2013;8(9):e75851.  
86. Nibu Y, José-Edwards DS, Di Gregorio A. From notochord formation to 
hereditary chordoma: the many roles of Brachyury. BioMed Research 
International. 2013;2013:826435.  
87. Kelley MJ, Shi J, Ballew B, Hyland PL, Li W-Q, Rotunno M, et al. 
Characterization of T gene sequence variants and germline duplications in 
familial and sporadic chordoma. Hum Genet. 2014 Oct;133(10):1289–97.  
88. Yang C, Schwab JH, Schoenfeld AJ, Hornicek FJ, Wood KB, Nielsen GP, 
et al. A novel target for treatment of chordoma: signal transducers and 
activators of transcription 3. Molecular Cancer Therapeutics. 2009 
Sep;8(9):2597–605.  
89. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, et al. Role of the 
transcription factor T (brachyury) in the pathogenesis of sporadic 
chordoma: a genetic and functional-based study. J Pathol. 2010 Nov 
24;223(3):327–35.  
90. Pillay N, Plagnol V, Tarpey PS, Lobo SB, Presneau N, Szuhai K, et al. A 
common single-nucleotide variant in T is strongly associated with 
chordoma. Nat Genet. 2012 Nov;44(11):1185–7.  
91. Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman 
NI, et al. Generation of chordoma cell line JHC7 and the identification of 
Brachyury as a novel molecular target. Journal of Neurosurgery. 2011 
Oct;115(4):760–9.  
92. Thiery JP. [Epithelial-mesenchymal transitions in cancer onset and 
progression]. Bull Acad Natl Med. 2009 Dec 1;193(9):1969–9.  
93. Fernando RI, Litzinger M, Trono P, Hamilton DH, Schlom J, Palena C. The 
T-box transcription factor Brachyury promotes epithelial-mesenchymal 
transition in human tumor cells. J Clin Invest [Internet]. 2010 Feb 
1;120(2):533–44. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2810072 
94. Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal 
transitions in development and disease. Cell. 2009 Nov 25;139(5):871–90.  
95. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, Palmirotta 
R, et al. Brachyury, a driver of the epithelial-mesenchymal transition, is 
overexpressed in human lung tumors: an opportunity for novel 
interventions against lung cancer. Clin Cancer Res. 2012 Jul 
15;18(14):3868–79.  
96. Larocca C, Cohen JR, Fernando RI, Huang B, Hamilton DH, Palena C. An 
Targeted therapy for chordoma 
310 
autocrine loop between TGF-β1 and the transcription factor brachyury 
controls the transition of human carcinoma cells into a mesenchymal 
phenotype. Molecular Cancer Therapeutics. 2013 Sep;12(9):1805–15.  
97. Sarkar D, Shields B, Davies ML, Müller J, Wakeman JA. BRACHYURY 
confers cancer stem cell characteristics on colorectal cancer cells. Int J 
Cancer. 2011 May 28;130(2):328–37.  
98. Shimoda M, Sugiura T, Imajyo I, Ishii K, Chigita S, Seki K, et al. The T-box 
transcription factor Brachyury regulates epithelial-mesenchymal transition 
in association with cancer stem-like cells in adenoid cystic carcinoma cells. 
BMC Cancer. 2012;12(1):377.  
99. Imajyo I, Sugiura T, Kobayashi Y, Shimoda M, Ishii K, Akimoto N, et al. T-
box transcription factor Brachyury expression is correlated with epithelial-
mesenchymal transition and lymph node metastasis in oral squamous cell 
carcinoma. Int J Oncol. 2012 Dec;41(6):1985–95.  
100. Haro A, Yano T, Kohno M, Yoshida T, Koga T, Okamoto T, et al. 
Expression of Brachyury Gene Is a Significant Prognostic Factor for 
Primary Lung Carcinoma. Ann Surg Oncol. 2013 Mar 1.  
101. Du R, Wu S, Lv X, Fang H, Wu S, Kang J. Overexpression of brachyury 
contributes to tumor metastasis by inducing epithelial-mesenchymal 
transition in hepatocellular carcinoma. J Exp Clin Cancer Res. 2014 Dec 
14;33(1):105.  
102. Xu K, Liu B, Liu Y. Impact of Brachyury on epithelial-mesenchymal 
transitions and chemosensitivity in non-small cell lung cancer. Mol Med 
Rep. 2015 Feb 13.  
103. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, Krukovskaya 
LL, et al. The Human T-Box Mesodermal Transcription Factor Brachyury Is 
a Candidate Target for T-Cell-Mediated Cancer Immunotherapy. Clinical 
Cancer Research. 2007 Apr 15;13(8):2471–8.  
104. Palena C, Roselli M, Litzinger MT, Ferroni P, Costarelli L, Spila A, et al. 
Overexpression of the EMT driver brachyury in breast carcinomas: 
association with poor prognosis. J Natl Cancer Inst. 2014 May;106(5).  
105. Pinto F, Pértega-Gomes N, Pereira MS, Vizcaíno JR, Monteiro P, 
Henrique RM, et al. T-box Transcription Factor Brachyury Is Associated 
with Prostate Cancer Progression and Aggressiveness. Clin Cancer Res. 
2014 Jul 9.  
106. Palena C, Fernando RI, Litzinger MT, Hamilton DH, Huang B, Schlom J. 
Strategies to target molecules that control the acquisition of a 
mesenchymal-like phenotype by carcinoma cells. Experimental Biology 
and Medicine. 2011 May 6;236(5):537–45.  
107. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C. Cancer 
vaccines targeting the epithelial-mesenchymal transition: tissue distribution 
of brachyury and other drivers of the mesenchymal-like phenotype of 
carcinomas. Semin Oncol. 2012 Jun;39(3):358–66.  
Targeted therapy for chordoma   
 311 
108. Hamilton DH, Fernando RI, Schlom J, Palena C. Aberrant expression of 
the embryonic transcription factor brachyury in human tumors detected 
with a novel rabbit monoclonal antibody. Oncotarget. 2014 Dec 26.  
109. Kobayashi Y, Sugiura T, Imajyo I, Shimoda M, Ishii K, Akimoto N, et al. 
Knockdown of the T-box transcription factor Brachyury increases 
sensitivity of adenoid cystic carcinoma cells to chemotherapy and radiation 
in vitro: implications for a new therapeutic principle. Int J Oncol. 2014 
Apr;44(4):1107–17.  
110. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat 
Rev Cancer. 2002 Jun;2(6):442–54.  
111. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of 
E-cadherin promotes metastasis via multiple downstream transcriptional 
pathways. Cancer Research. 2008 May 15;68(10):3645–54.  
112. Guarino M. Epithelial-mesenchymal transition and tumour invasion. Int J 
Biochem Cell Biol. 2007;39(12):2153–60.  
113. Naka T, Kuester D, Boltze C, Scheil-Bertram S, Samii A, Herold C, et al. 
Expression of hepatocyte growth factor and c-MET in skull base 
chordoma. Cancer. 2008 Jan 1;112(1):104–10.  
114. Froehlich EV, Scheipl S, Lazáry A, Varga PP, Schmid C, Stammberger H, 
et al. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: 
a clinical and immunohistochemical analysis. Spine. 2012 Jun 
1;37(13):E757–67.  
115. Horiguchi H, Sano T, Qian ZR, Hirokawa M, Kagawa N, Yamaguchi T, et 
al. Expression of cell adhesion molecules in chordomas: an 
immunohistochemical study of 16 cases. Acta Neuropathol. 2004 
Feb;107(2):91–6.  
116. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in 
normal and neoplastic tissues and it value in diagnostic tumor pathology. 
Cancer. 1981 Apr 1;47(7):1786–95.  
117. Cho H-Y, Lee M, Takei H, Dancer J, Ro JY, Zhai QJ. 
Immunohistochemical comparison of chordoma with chondrosarcoma, 
myxopapillary ependymoma, and chordoid meningioma. Appl 
Immunohistochem Mol Morphol. 2009 Mar;17(2):131–8.  
118. Laskin WB, Miettinen M. Epithelial-type and neural-type cadherin 
expression in malignant noncarcinomatous neoplasms with epithelioid 
features that involve the soft tissues. Arch Pathol Lab Med. 2002 Mar 
31;126(4):425–31.  
119. Hu Y, Mintz A, Shah SR, Quiñones-Hinojosa A, Hsu W. The 
FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth 
and survival. Carcinogenesis. 2014 Jan 20.  
120. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour 
progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 
Targeted therapy for chordoma 
312 
2007 Jun;7(6):415–28.  
121. Wu S-Y, McClay DR. The Snail repressor is required for PMC ingression in 
the sea urchin embryo. Development. 2007 Mar;134(6):1061–70.  
122. Barrallo-Gimeno A, Nieto MA. The Snail genes as inducers of cell 
movement and survival: implications in development and cancer. 
Development. 2005.  
123. Ciruna B, Rossant J. FGF signaling regulates mesoderm cell fate 
specification and morphogenetic movement at the primitive streak. Dev 
Cell. 2001 Jul;1(1):37–49.  
124. Rinner B, Weinhaeusel A, Lohberger B, Froehlich EV, Pulverer W, Fischer 
C, et al. Chordoma characterization of significant changes of the DNA 
methylation pattern. PLoS ONE. 2013;8(3):e56609.  
125. Hallor KH, Staaf J, Jönsson G, Heidenblad M, Vult von Steyern F, Bauer 
HCF, et al. Frequent deletion of the CDKN2A locus in chordoma: analysis 
of chromosomal imbalances using array comparative genomic 
hybridisation. Br J Cancer. 2008 Jan 29;98(2):434–42.  
126. Diaz RJ, Guduk M, Romagnuolo R, Smith CA, Northcott P, Shih D, et al. 
High-resolution whole-genome analysis of skull base chordomas 
implicates FHIT loss in chordoma pathogenesis. Neoplasia. 2012 
Sep;14(9):788–98.  
127. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, Halai D, et 
al. An integrated functional genomics approach identifies the regulatory 
network directed by brachyury (T) in chordoma. J Pathol. 2012 
Nov;228(3):274–85.  
128. Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, Deshpande V, 
et al. Recurrent chromosomal copy number alterations in sporadic 
chordomas. PLoS ONE. 2011;6(5):e18846.  
129. Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, et al. 
Genotyping cancer-associated genes in chordoma identifies mutations in 
oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and 
SMARCB1. PLoS ONE. 2014;9(7):e101283.  
130. Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco 
R, et al. Analysis of the fibroblastic growth factor receptor-
RAS&sol;RAF&sol;MEK&sol;ERK-ETS2&sol;brachyury signalling pathway 
in chordomas. Nature Publishing Group; 2009 May 1;22(8):996–1005.  
131. Stephens PJ, Mcbride DJ, Lin M-L, Varela I, Pleasance ED, Simpson JT, 
et al. Complex landscapes of somatic rearrangement in human breast 
cancer genomes. Nature. 2009 Dec 24;462(7276):1005–10.  
132. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and 
consequences of chromosome shattering. Nat Rev Cancer. 2012 
Oct;12(10):663–70.  
Targeted therapy for chordoma   
 313 
133. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. 
Massive genomic rearrangement acquired in a single catastrophic event 
during cancer development. Cell. 2011 Jan 7;144(1):27–40.  
134. Scheil S, Brüderlein S, Liehr T, Starke H, Herms J, Schulte M, et al. 
Genome-wide analysis of sixteen chordomas by comparative genomic 
hybridization and cytogenetics of the first human chordoma cell line, U-
CH1. Genes Chromosom Cancer. 2001 Nov;32(3):203–11.  
135. Scheil-Bertram S, Kappler R, Baer von A, Hartwig E, Sarkar M, Serra M, et 
al. Molecular profiling of chordoma. Int J Oncol. 2014 Jan 21.  
136. Meng T, Yin H, Li B, Li Z, Xu W, Zhou W, et al. Clinical features and 
prognostic factors of patients with chordoma in the spine: a retrospective 
analysis of 153 patients in a single center. Neuro-oncology. 2014 Dec 
8;0(2014):3311–31.  
137. Sen C, Triana AI, Berglind N, Godbold J, Shrivastava RK. Clival 
chordomas: clinical management, results, and complications in 71 
patients. Journal of Neurosurgery. 2010 Nov;113(5):1059–71.  
138. Wu Z, Zhang J, Zhang L, Jia G, Tang J, Wang L, et al. Prognostic factors 
for long-term outcome of patients with surgical resection of skull base 
chordomas-106 cases review in one institution. Neurosurg Rev. 2010 
Oct;33(4):451–6.  
139. Di Maio S, Kong E, Yip S, Rostomily R. Converging paths to progress for 
skull base chordoma: Review of current therapy and future molecular 
targets. Surg Neurol Int. 2013;4:72.  
140. Ahmed R, Sheybani A, Menezes AH, Buatti JM, Hitchon PW. Disease 
outcomes for skull base and spinal chordomas: a single center experience. 
Clin Neurol Neurosurg. 2015 Mar;130:67–73.  
141. Moran D, Zadnik PL, Taylor T, Groves ML, Yurter A, Wolinsky J-P, et al. 
Maintenance of bowel, bladder, and motor functions after sacrectomy. 
Spine J. 2015 Feb 1;15(2):222–9.  
142. Dubory A, Missenard G, Lambert B, Court C. “En bloc” resection of sacral 
chordomas by combined anterior and posterior surgical approach: a 
monocentric retrospective review about 29 cases. Eur Spine J. 2014 
Sep;23(9):1940–8.  
143. Bugoci DM, Girvigian MR, Chen JCT, Miller MM, Rahimian J. Photon-
based fractionated stereotactic radiotherapy for postoperative treatment of 
skull base chordomas. Am J Clin Oncol. 2013 Aug;36(4):404–10.  
144. Amichetti M, Cianchetti M, Amelio D, Enrici RM, Minniti G. Proton therapy 
in chordoma of the base of the skull: a systematic review. Neurosurg Rev. 
2009 Oct;32(4):403–16.  
145. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. 
Phase II study of high-dose photon/proton radiotherapy in the 
management of spine sarcomas. Int J Radiat Oncol Biol Phys. 2009 Jul 
Targeted therapy for chordoma 
314 
1;74(3):732–9.  
146. Holliday EB, Mitra HS, Somerson JS, Rhines LD, Mahajan A, Brown PD, 
et al. Post-operative Proton Therapy for Chordomas and 
Chondrosarcomas of the Spine: Adjuvant vs. Salvage Radiation Therapy. 
Spine. 2015 Jan 23.  
147. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Weyman EA, Yeap BY, et 
al. Long-term results of Phase II study of high dose photon/proton 
radiotherapy in the management of spine chordomas, chondrosarcomas, 
and other sarcomas. J Surg Oncol. 2014 Aug;110(2):115–22.  
148. Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, et al. 
Proton radiation therapy for chordomas and chondrosarcomas of the skull 
base. Journal of Neurosurgery. 1999 Sep;91(3):432–9.  
149. Combs SE, Ellerbrock M, Haberer T, Habermehl D, Hoess A, Jäkel O, et 
al. Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the 
first 80 patients. Acta Oncol. 2010 Oct;49(7):1132–40.  
150. Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, et al. Effect 
of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and 
Phase II clinical trials. Int J Radiat Oncol Biol Phys. 2010 Aug 
1;77(5):1470–6.  
151. Nishida Y, Kamada T, Imai R, Tsukushi S, Yamada Y, Sugiura H, et al. 
Clinical outcome of sacral chordoma with carbon ion radiotherapy 
compared with surgery. Int J Radiat Oncol Biol Phys. 2011 Jan 
1;79(1):110–6.  
152. Dhall G, Traverso M, Finlay JL, Shane L, Gonzalez-Gomez I, Jubran R. 
The role of chemotherapy in pediatric clival chordomas. J Neurooncol. 
2011 Jul;103(3):657–62.  
153. Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of 
megavoltage radiation therapy. Int J Radiat Oncol Biol Phys. 1983 
May;9(5):633–42.  
154. Razis DV, Tsatsaronis A, Kyriazides I, Triantafyllou D. Chordoma of the 
cervical spine treated with vincristine sulfate. J Med. 1974;5(5):274–7.  
155. Sundaresan N, Galicich JH, Chu FC, Huvos AG. Spinal chordomas. 
Journal of Neurosurgery. 1979 Mar;50(3):312–9.  
156. Chugh R, Dunn R, Zalupski MM, Biermann JS, Sondak VK, Mace JR, et 
al. Phase II study of 9-nitro-camptothecin in patients with advanced 
chordoma or soft tissue sarcoma. J Clin Oncol. 2005 May 20;23(15):3597–
604.  
157. VR A. Camptothecins in Cancer Therapy. Adams VR, Burke TG, editors. 
Totowa, NJ: Humana Press; 2005.  
158. Scimeca PG, James-Herry AG, Black KS, Kahn E, Weinblatt ME. 
Chemotherapeutic treatment of malignant chordoma in children. J Pediatr 
Targeted therapy for chordoma   
 315 
Hematol Oncol. 1996 May;18(2):237–40.  
159. Ashwood N, Hoskin PJ, Saunders MI. Metastatic chordoma: pattern of 
spread and response to chemotherapy. Clin Oncol (R Coll Radiol). 
1994;6(5):341–2.  
160. Flemming G, Samuels BL. Dedifferentiated Chrodoma. 1993 Aug 1;:1–5.  
161. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. 
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast 
crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with 
the Philadelphia chromosome. N Engl J Med. 2001 Apr 5;344(14):1038–
42.  
162. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et 
al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal 
transduction mediated by c-kit and platelet-derived growth factor receptors. 
J Pharmacol Exp Ther. 2000 Oct;295(1):139–45.  
163. Tamborini E, Miselli F, Negri T, Lagonigro MS, Staurengo S, Dagrada GP, 
et al. Molecular and biochemical analyses of platelet-derived growth factor 
receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas. Clin 
Cancer Res. 2006 Dec 1;12(23):6920–8.  
164. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, et al. 
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in 
chordomas. Neuro-oncology. 2010 Aug;12(8):776–89.  
165. Fasig JH, Dupont WD, LaFleur BJ, Olson SJ, Cates JMM. 
Immunohistochemical analysis of receptor tyrosine kinase signal 
transduction activity in chordoma. Neuropathol Appl Neurobiol. 2008 
Feb;34(1):95–104.  
166. de Castro Msc CV, Guimaraes G, Aguiar S, Lopes A, Baiocchi G, da 
Cunha IW, et al. Tyrosine kinase receptor expression in chordomas: 
phosphorylated AKT correlates inversely with outcome. Hum Pathol. 2013 
Sep;44(9):1747–55.  
167. Casali PG, Stacchiotti S, Messina A, Tamborini E, Martini C, Ripamonti C, 
et al. Imatinib mesylate in 18 advanced chordoma patients. ASCO Meeting 
Abstracts. 2005 Jun 1;23(16_suppl):9012.  
168. Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr 
Opin Oncol. 2007 Jul;19(4):367–70.  
169. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, et 
al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. 
2009 Oct 27;20(11):1886–94.  
170. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, 
Rubinstein L, et al. New Guidelines to Evaluate the Response to 
Treatment in Solid Tumors. JNCI Journal of the National Cancer Institute. 
2000 Feb 2;92(3):205–16.  
Targeted therapy for chordoma 
316 
171. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, 
et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. 2012 
Mar 20;30(9):914–20.  
172. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, et al. 
Imatinib in advanced chordoma: A retrospective case series analysis. Eur 
J Cancer. 2015 Aug 14.  
173. Hof H, Welzel T, Debus J. Effectiveness of cetuximab/gefitinib in the 
therapy of a sacral chordoma. Onkologie. 2006 Dec;29(12):572–4.  
174. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, 
et al. Multicenter phase II trial of sunitinib in the treatment of 
nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 
1;27(19):3154–60.  
175. Lindén O, Stenberg L, Kjellén E. Regression of cervical spinal cord 
compression in a patient with chordoma following treatment with 
cetuximab and gefitinib. Acta Oncol. 2009;48(1):158–9.  
176. Asklund T, Sandström M, Shahidi S, Riklund K, Henriksson R. Durable 
stabilization of three chordoma cases by bevacizumab and erlotinib. Acta 
Oncol. 2014 Jan 23.  
177. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, et al. 
Development of transplantable human chordoma xenograft for preclinical 
assessment of novel therapeutic strategies. Neuro- …. 2014.  
178. Siu I-M, Ruzevick J, Zhao Q, Connis N, Jiao Y, Bettegowda C, et al. 
Erlotinib inhibits growth of a patient-derived chordoma xenograft. PLoS 
ONE. 2013;8(11):e78895.  
179. Stacchiotti S, Tamborini E, Vullo Lo S, Bozzi F, Messina A, Morosi C, et al. 
Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann 
Oncol. 2013 Apr 4.  
180. Shalaby A, Presneau N, Ye H, Halai D, Berisha F, Idowu B, et al. The role 
of epidermal growth factor receptor in chordoma pathogenesis: a potential 
therapeutic target. J Pathol. 2011 Feb;223(3):336–46.  
181. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, et al. 
Differential expression of epidermal growth factor receptor, c-Met, and 
HER2/neu in chordoma compared with 17 other malignancies. Arch 
Otolaryngol Head Neck Surg. 2005 Aug;131(8):707–11.  
182. Dewaele B, Maggiani F, Floris G, Ampe M, Vanspauwen V, Wozniak A, et 
al. Frequent activation of EGFR in advanced chordomas. Clin Sarcoma 
Res. BioMed Central Ltd; 2011 Jul 25;1(1):4.  
183. Walter BA, Begnami M, Valera VA, Santi M, Rushing EJ, Quezado M. 
Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in 
chordomas is correlated to c-MET expression. J Neurooncol. 2011 
Jan;101(2):199–206.  
Targeted therapy for chordoma   
 317 
184. Ptaszyński K, Szumera-Ciećkiewicz A, Owczarek J, Mrozkowiak A, Pekul 
M, Barańska J, et al. Epidermal growth factor receptor (EGFR) status in 
chordoma. Pol J Pathol. 2009;60(2):81–7.  
185. Xia M, Huang R, Sakamuru S, Alcorta D, Cho M-H, Lee D-H, et al. 
Identification of repurposed small molecule drugs for chordoma therapy. 
Cancer Biol Ther. 2013 Jul;14(7):638–47.  
186. Akhavan-Sigari R, Abili M, Gaab MR, Rohde V, Zafar N, Emami P, et al. 
Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-
Met, and EGFR in skull base chordoma. Neurosurg Rev. 2014 Oct 17.  
187. Akhavan-Sigari R, Gaab MR, Rohde V, Abili M, Ostertag H. Prognostic 
significance of immunohistochemical expression of VEGFR2 and iNOS in 
spinal chordoma. Eur Spine J. 2014 Nov;23(11):2416–22.  
188. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. 
Therapeutic Advances in Medical Oncology. 2011 Nov 1;3(1 Suppl):S7–
S19.  
189. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a 
theme. Oncogene. Nature Publishing Group; 2008 Sep 15;27(41):5497–
510.  
190. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N. The 
RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer 
pathogenesis and implications for therapeutic approaches. Expert Opin 
Ther Targets. 2012 Apr;16 Suppl 2:S17–27.  
191. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein 
kinase cascade to treat cancer. Nat Rev Cancer. Nature Publishing Group; 
2004 Dec;4(12):937–47.  
192. Schwab J, Antonescu C, Boland P, Healey J, Rosenberg A, Nielsen P, et 
al. Combination of PI3K/mTOR inhibition demonstrates efficacy in human 
chordoma. Anticancer Res. 2009 Jun;29(6):1867–71.  
193. Ricci-Vitiani L, Runci D, D'Alessandris QG, Cenci T, Martini M, Bianchi F, 
et al. Chemotherapy of skull base chordoma tailored on responsiveness of 
patient-derived tumor cells to rapamycin. Neoplasia. 2013 Jul;15(7):773–
82.  
194. Akhavan-Sigari R, Gaab MR, Rohde V, Brandis A, Tezval H, Abili M, et al. 
Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), 
inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base 
chordoma: a series of 145 tumors. Neurosurg Rev. 2013 Sep 3.  
195. Chen K-W, Yang H-L, Lu J, Wang G-L, Ji Y-M, Wu G-Z, et al. Expression 
of vascular endothelial growth factor and matrix metalloproteinase-9 in 
sacral chordoma. J Neurooncol. 2010 Jun 15;101(3):357–63.  
196. Asklund T, Danfors T, Henriksson R. PET response and tumor stabilization 
under erlotinib and bevacizumab treatment of an intracranial lesion non-
invasively diagnosed as likely chordoma. Clin Neuropathol. 2011 
Targeted therapy for chordoma 
318 
Sep;30(5):242–6.  
197. Brüderlein S, Sommer JB, Meltzer PS, Li S, Osada T, Ng D, et al. 
Molecular characterization of putative chordoma cell lines. Sarcoma. 
2010;2010:630129.  
198. Scheipl S, Lohberger B, Rinner B, Froehlich EV, Beham A, Quehenberger 
F, et al. Histone deacetylase inhibitors as potential therapeutic approaches 
for chordoma: An immunohistochemical and functional analysis. J Orthop 
Res. 2013 Jul 24.  
199. Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, et al. 
Establishment and characterization of a novel chordoma cell line: CH22. J 
Orthop Res. 2012 Apr 13;30(10):1666–73.  
200. Bayrak OF, Aydemir E, Gulluoglu S, Sahin F, Sevli S, Yalvac ME, et al. 
The effects of chemotherapeutic agents on differentiated chordoma cells. J 
Neurosurg Spine.  American Association of Neurological Surgeons; 2011 
Dec;15(6):620–4.  
201. Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Mankin H, et al. 
Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. 
Spine. 2010 Aug 15;35(18):1668–75.  
202. Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, Iafrate J, et al. 
Characterization and analysis of human chordoma cell lines. Spine. 2010 
Jun 1;35(13):1257–64.  
203. Han S, Polizzano C, Nielsen GP, Hornicek FJ, Rosenberg AE, Ramesh V. 
Aberrant hyperactivation of akt and Mammalian target of rapamycin 
complex 1 signaling in sporadic chordomas. Clin Cancer Res. 2009 Mar 
15;15(6):1940–6.  
204. Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay J-Y, et 
al. A dose-escalating phase I of imatinib mesylate with fixed dose of 
metronomic cyclophosphamide in targeted solid tumours. Br J Cancer. 
2013 Nov 12;109(10):2574–8.  
205. Al-Adra D, Bennett A, Gill R, Lees G. Pediatric metastatic sacrococcygeal 
chordoma treated with surgery. Eur J Pediatr Surg. 2011 May;21(3):196–8.  
206. Launay SG, Chetaille B, Medina F, Perrot D, Nazarian S, Guiramand J, et 
al. Efficacy of epidermal growth factor receptor targeting in advanced 
chordoma: case report and literature review. BMC Cancer. BioMed Central 
Ltd; 2011 Oct 4;11(1):423.  
207. Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, et al. 
Chordoma: clinical characteristics, management and prognosis of a case 
series of 25 patients. BMC Cancer. 2010;10:22.  
208. Geoerger B, Morland B, Ndiaye A, Doz F, Kalifa G, Geoffray A, et al. 
Target-driven exploratory study of imatinib mesylate in children with solid 
malignancies by the Innovative Therapies for Children with Cancer (ITCC) 
European Consortium. Eur J Cancer. 2009 Sep;45(13):2342–51.  
Targeted therapy for chordoma   
 319 
209. Singhal N, Kotasek D, Parnis FX. Response to erlotinib in a patient with 
treatment refractory chordoma. Anticancer Drugs. 2009 Nov;20(10):953–5.  
210. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et 
al. Imatinib mesylate in chordoma. Cancer. 2004 Oct 18;101(9):2086–97.  
211. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev 
Genet. Nature Publishing Group; 2011 Apr 6;12(5):316–28.  
212. Klug B, Celis P, Carr M, Reinhardt J. Regulatory structures for gene 
therapy medicinal products in the European Union. Meth Enzymol. 
2012;507:337–54.  
213. Sia RH, Dawson MH. In Vitro Transformation Of Pneumococcal Types : Ii. 
The Nature Of The Factor Responsible For The Transformation Of 
Pneumococcal Types. J Exp Med. 1931 Oct 31;54(5):701–10.  
214. Dawson MH, Sia RH. In Vitro Transformation Of Pneumococcal Types : I. 
A Technique For Inducing Transformation Of Pneumococcal Types In 
Vitro. J Exp Med. 1931 Oct 31;54(5):681–99.  
215. Lynch RG. Pneumococcal Transformation: Genes are Made of DNA. 
Journal of Experimental Medicine. 1944.  
216. Zinder ND, Lederberg J. GENETIC EXCHANGE IN SALMONELLA. J 
Bacteriol. 1952.  
217. Lederberg J. A view of genetics. Les Prix Nobel en. 1958.  
218. Rogers S, Pfuderer P. Use of viruses as carriers of added genetic 
information. Nature. 1968 Aug 17;219(5155):749–51.  
219. Rogers S, Lowenthal A, Terheggen HG, Columbo JP. Induction of 
arginase activity with the Shope papilloma virus in tissue culture cells from 
an argininemic patient. J Exp Med. 1973 Apr 1;137(4):1091–6.  
220. Terheggen HG, Lowenthal A, Lavinha F, Colombo JP, Rogers S. 
Unsuccessful trial of gene replacement in arginase deficiency. Z 
Kinderheilkd. 1975;119(1):1–3.  
221. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013 
Apr 23.  
222. Jackson DA, Symons RH, Berg P. Biochemical method for inserting new 
genetic information into DNA of Simian Virus 40: circular SV40 DNA 
molecules containing lambda phage genes and the galactose operon of 
Escherichia coli. Proc Natl Acad Sci USA. 1972 Oct;69(10):2904–9.  
223. Lobban PE, Kaiser AD. Enzymatic end-to-end joining of DNA molecules. J 
Mol Biol. 1973.  
224. Cohen SN, Chang AC, Boyer HW, Helling RB. Construction of biologically 
functional bacterial plasmids in vitro. Proc Natl Acad Sci USA. 1973 
Nov;70(11):3240–4.  
Targeted therapy for chordoma 
320 
225. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al. T 
lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 
years. Science. 1995 Oct 20;270(5235):475–80.  
226. Stolberg SG. The biotech death of Jesse Gelsinger. The New York times 
magazine. 1999 Nov 28;:136–140–149–150.  
227. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, 
Nusbaum P, et al. Gene therapy of human severe combined 
immunodeficiency (SCID)-X1 disease. Science. 2000 Apr 
28;288(5466):669–72.  
228. Hacein-Bey-Abina S, Kalle von C, Schmidt M, Le Deist F, Wulffraat N, 
McIntyre E, et al. A serious adverse event after successful gene therapy 
for X-linked severe combined immunodeficiency. N Engl J Med. 2003 Jan 
16;348(3):255–6.  
229. Kohn DB. Update on gene therapy for immunodeficiencies. Clin Immunol. 
2010 May;135(2):247–54.  
230. Hacein-Bey-Abina S, Pai S-Y, Gaspar HB, Armant M, Berry CC, Blanche 
S, et al. A modified γ-retrovirus vector for X-linked severe combined 
immunodeficiency. N Engl J Med. 2014 Oct 9;371(15):1407–17.  
231. High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia 
gene therapy. Haemophilia. 2014 May;20 Suppl 4:43–9.  
232. Sauer AV, Di Lorenzo B, Carriglio N, Aiuti A. Progress in gene therapy for 
primary immunodeficiencies using lentiviral vectors. Curr Opin Allergy Clin 
Immunol. 2014 Dec;14(6):527–34.  
233. Knight S, Zhang F, Mueller-Kuller U, Bokhoven M, Gupta A, Broughton T, 
et al. Safer, silencing-resistant lentiviral vectors: optimization of the 
ubiquitous chromatin-opening element through elimination of aberrant 
splicing. J Virol. 2012 Sep;86(17):9088–95.  
234. Schambach A, Zychlinski D, Ehrnstroem B, Baum C. Biosafety features of 
lentiviral vectors. Human Gene Therapy. 2013 Feb;24(2):132–42.  
235. Nathwani AC, Tuddenham EGD, Rangarajan S, Rosales C, McIntosh J, 
Linch DC, et al. Adenovirus-Associated Virus Vector–Mediated Gene 
Transfer in Hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357–65.  
236. Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, 
Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: 
immune challenges and strategies to circumvent them. Rev Med Virol. 
2013 Nov;23(6):399–413.  
237. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson 
P, et al. Long-term evaluation of a phase 1 study of AADC gene therapy 
for Parkinson's disease. Human Gene Therapy. 2012 Apr;23(4):377–81.  
238. Loring HS, Flotte TR. Current status of gene therapy for α-1 antitrypsin 
deficiency. Expert Opin Biol Ther. 2015 Mar;15(3):329–36.  
Targeted therapy for chordoma   
 321 
239. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, 
et al. Intramuscular administration of AAV1-lipoprotein lipase S447X 
lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler 
Thromb Vasc Biol. 2008 Dec;28(12):2303–4.  
240. Nierman MC, Rip J, Twisk J, Meulenberg JJM, Kastelein JJP, Stroes ESG, 
et al. Gene therapy for genetic lipoprotein lipase deficiency: from promise 
to practice. Neth J Med. 2005 Jan;63(1):14–9.  
241. Flemming A. Regulatory watch: Pioneering gene therapy on brink of 
approval. Nat Rev Drug Discov. Nature Publishing Group; 2012 Aug 
31;11(9):664–4.  
242. Gruber K. Europe gives gene therapy the green light. The Lancet. Elsevier; 
2012 Nov 17;380(9855):e10.  
243. Ylä-Herttuala S. Endgame: glybera finally recommended for approval as 
the first gene therapy drug in the European union. Molecular Therapy. 
2012 Oct;20(10):1831–2.  
244. Gancberg D, Kessler C, Hoeveler A, Draghia-Akli R. European Union 
Support of Gene Therapy Research: A Success Story. Molecular Therapy. 
Nature Publishing Group; 2012 Dec;20(12):2191–3.  
245. Zhu X, McTiernan CF, Rajagopalan N, Shah H, Fischer D, Toyoda Y, et al. 
Immunosuppression decreases inflammation and increases AAV6-
hSERCA2a-mediated SERCA2a expression. Human Gene Therapy. 2012 
Jul;23(7):722–32.  
246. Zouein FA, Booz GW. AAV-mediated gene therapy for heart failure: 
enhancing contractility and calcium handling. F1000Prime Rep. 2013;5:27.  
247. Giacca M, Zacchigna S. Virus-mediated gene delivery for human gene 
therapy. J Control Release. 2012 Jul 20;161(2):377–88.  
248. Brenner MK, Gottschalk S, Leen AM, Vera JF. Is cancer gene therapy an 
empty suit? Lancet Oncol. 2013 Oct;14(11):e447–56.  
249. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy 
clinical trials worldwide to 2012 - an update. J Gene Med. 2013 
Feb;15(2):65–77.  
250. Jazwa A, Florczyk U, Jozkowicz A, Dulak J. Gene therapy on demand: 
Site specific regulation of gene therapy. Gene. 2013 Apr 6.  
251. Luo J, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-
mediated cancer gene therapy: current status. Cancer Letters. 2015 Jan 
28;356(2 Pt B):347–56.  
252. Amer MH. Gene therapy for cancer: present status and future perspective. 
2014 Sep 10;2(1):1–19.  
253. Hong B, Pieter J van den Heuvel A, V Prabhu V, Zhang S, S El-Deiry W. 
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, 
Targeted therapy for chordoma 
322 
Challenges and Opportunities. Current drug …. Bentham Science 
Publishers; 2014.  
254. Roth JA, Swisher SG, Meyn RE. p53 tumor suppressor gene therapy for 
cancer. Oncology (Williston Park, NY). 1999 Oct;13(10 Suppl 5):148–54.  
255. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, 
Merritt JA, et al. Adenovirus-mediated p53 gene transfer in patients with 
advanced recurrent head and neck squamous cell carcinoma. J Clin 
Oncol. 1998 Jun;16(6):2221–32.  
256. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. 
Cell. Elsevier Inc; 2011 Mar 4;144(5):646–74.  
257. Muller PAJ, Vousden KH. Mutant p53 in cancer: new functions and 
therapeutic opportunities. Cancer Cell. 2014 Mar 17;25(3):304–17.  
258. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: 
database reassessment and prospects for the next decade. Hum Mutat. 
2014 Jun;35(6):672–88.  
259. Zhao H, Wang D-D, Xu Y-X, Zhu C-Q. [Localization and expression 
pattern of MDM2 in axon initial segments of neuron in rodent brain]. Sheng 
Li Xue Bao. 2014 Apr 25;66(2):107–17.  
260. Cheok CF, Verma CS, Baselga J, Lane DP. Translating p53 into the clinic. 
Nat Rev Clin Oncol. 2011 Jan;8(1):25–37.  
261. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nature 
Biotechnology. 2004 Jan;:3–4.  
262. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 
agent for treatment of cancers. Human Gene Therapy. 2005 
Sep;16(9):1016–27.  
263. Yang Z-X, Wang D, Wang G, Zhang Q-H, Liu J-M, Peng P, et al. Clinical 
study of recombinant adenovirus-p53 combined with fractionated 
stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin 
Oncol. 2010 Apr;136(4):625–30.  
264. Voon Y-L, Ahmad M, Wong P-F, Husaini R, Ng WT-W, Leong C-O, et al. 
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced 
cytotoxicity. Oncol Rep. 2015 Oct;34(4):1692–700.  
265. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? 
Lancet Oncology. 2003 Jul;4(7):415–22.  
266. Shi J, Zheng D. An update on gene therapy in China. Curr Opin Mol Ther. 
2009 Oct;11(5):547–53.  
267. Speetjens FM, Kuppen PJK, Welters MJP, Essahsah F, Voet van den 
Brink AMEG, Lantrua MGK, et al. Induction of p53-specific immunity by a 
p53 synthetic long peptide vaccine in patients treated for metastatic 
colorectal cancer. Clin Cancer Res. 2009 Feb 1;15(3):1086–95.  
Targeted therapy for chordoma   
 323 
268. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN-
225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung 
cancer: observed association between immune response and enhanced 
chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983–91.  
269. Zhao Y, Aguilar A, Bernard D, Wang S. Small-Molecule Inhibitors of the 
MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials 
for Cancer Treatment. J Med Chem. 2015 Feb 12;58(3):1038–52.  
270. Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotech. 2012 
Jul;30(7):658–70.  
271. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic 
engineering. Mol Ther. 2007 Apr;15(4):651–9.  
272. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes 
virus encoding GM-CSF for unresectable stage III or IV melanoma. Future 
Oncology.  Future Medicine Ltd London, UK; 2010 Jun;6(6):941–9.  
273. Meerani S, Yao Y. Oncolytic viruses in cancer therapy. Eur J Sci Res. 
2010.  
274. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer 
virotherapy. Cancer Gene Therapy. 2002 Dec;9(12):967–78.  
275. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double 
suicide gene therapy augments the antitumor activity of a replication-
competent lytic adenovirus through enhanced cytotoxicity and 
radiosensitization. Human Gene Therapy. 2000 Jan 1;11(1):67–76.  
276. Gabel M, Kim JH, Kolozsvary A, Khil M, FREYTAG S. Selective in vivo 
radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells 
transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat 
Oncol Biol Phys. 1998 Jul 1;41(4):883–7.  
277. Kim JH, Kolozsvary A, Rogulski K, Khil MS, Brown SL, Freytag SO. 
Selective radiosensitization of 9L glioma in the brain transduced with 
double suicide fusion gene. Cancer J Sci Am. 1998 Nov;4(6):364–9.  
278. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, et al. Phase 
I Trial of Replication-competent Adenovirus-mediated Suicide Gene 
Therapy Combined with IMRT for Prostate Cancer. Molecular Therapy. 
2007 Mar 20;15(5):1016–23.  
279. Moolten FL. Tumor chemosensitivity conferred by inserted herpes 
thymidine kinase genes: paradigm for a prospective cancer control 
strategy. Cancer Research. 1986 Oct;46(10):5276–81.  
280. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine 
kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990 
Feb 21;82(4):297–300.  
281. Nyati MK, Symon Z, Kievit E, Dornfeld KJ, Rynkiewicz SD, Ross BD, et al. 
The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug 
Targeted therapy for chordoma 
324 
gene therapy in an intrahepatic colon cancer model. Gene Ther. 2002 
Jul;9(13):844–9.  
282. Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, et al. 
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: 
relationship between viral replication, transgene expression, prodrug 
bioactivation. Cancer Gene Therapy. 2012 Mar;19(3):160–70.  
283. Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, et al. 
Prospective randomized phase 2 trial of intensity modulated radiation 
therapy with or without oncolytic adenovirus-mediated cytotoxic gene 
therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 
2014 Jun 1;89(2):268–76.  
284. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, 
et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating 
factor-encoding, second-generation oncolytic herpesvirus in patients with 
unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 
1;27(34):5763–71.  
285. Sheridan C. Amgen announces oncolytic virus shrinks tumors : Nature 
Biotechnology : Nature Publishing Group. Nat Biotech. 2013.  
286. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney 
J, et al. Talimogene Laherparepvec Improves Durable Response Rate in 
Patients With Advanced Melanoma. J Clin Oncol. 2015 May 26.  
287. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving 
beyond current vaccines. Nat Med. 2004 Sep;10(9):909–15.  
288. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat 
Rev Cancer. Nature Publishing Group; 2012 Mar 22;12(4):265–77.  
289. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat 
Biotech. 2009 Feb;27(2):129–39.  
290. Zhou P, Shaffer DR, Alvarez Arias DA, Nakazaki Y, Pos W, Torres AJ, et 
al. In vivo discovery of immunotherapy targets in the tumour 
microenvironment. Nature. 2014 Feb 6;506(7486):52–7.  
291. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. 
The prioritization of cancer antigens: a national cancer institute pilot project 
for the acceleration of translational research. Clin Cancer Res. 2009 Sep 
1;15(17):5323–37.  
292. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 
2003;21(6):873–86.  
293. Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, et 
al. The use of dendritic cells in cancer immunotherapy. Critical Reviews in 
Oncology/Hematology. 2008 Mar;65(3):191–9.  
294. Palena C, Fernando RI, Hamilton DH. An immunotherapeutic intervention 
against tumor progression: Targeting a driver of the epithelial-to-
Targeted therapy for chordoma   
 325 
mesenchymal transition. Oncoimmunology. 2014 Jan 1;3(1):e27220.  
295. Hamilton DH, Litzinger MT, Jales A, Huang B, Fernando RI, Hodge JW, et 
al. Immunological targeting of tumor cells undergoing an epithelial-
mesenchymal transition via a recombinant brachyury-yeast vaccine. 
Oncotarget. 2013 Oct;4(10):1777–90.  
296. Tucker JA, Jochems C, Boyerinas B, Fallon J, Greiner JW, Palena C, et al. 
Identification and characterization of a cytotoxic T-lymphocyte agonist 
epitope of brachyury, a transcription factor involved in epithelial to 
mesenchymal transition and metastasis. Cancer Immunol Immunother. 
2014 Dec;63(12):1307–17.  
297. Donahue RN, Grenga I, Lepone L, Gulley JL, Heery CR, Madan RA, et al. 
Identification of tumor associated immune responses against brachyury, a 
transcription factor and driver of EMT, in chordoma patients receiving a 
yeast-brachyury vaccine (gi-6301). J Immunother Cancer. BioMed Central; 
2014;2(Suppl 3):P148.  
298. Heery CR, Singh BH, Rauckhorst M, Marte JL, Donahue RN, Grenga I, et 
al. Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) 
targeting the transcription factor brachyury. Cancer Immunol Res. 2015 
Jun 30.  
299. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, 
Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy 
with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic 
hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089–
94.  
300. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et 
al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N 
Engl J Med. 2010 Jul 29;363(5):411–22.  
301. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, 
Kirkpatrick P, et al. Sipuleucel-T. Nature reviews Drug discovery. 2010 
Jul;:513–4.  
302. Sonpavde G, Di Lorenzo G, Higano CS, Kantoff PW, Madan R, Shore ND. 
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: 
a critical analysis of the literature. Eur Urol. 2012 Apr;61(4):639–47.  
303. Di Lorenzo G, Ferro M, Buonerba C. Sipuleucel-T (Provenge®) for 
castration-resistant prostate cancer. BJU Int. 2012 Jul;110(2 Pt 2):E99–
104.  
304. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, 
et al. Improved Survival with Ipilimumab in Patients with Metastatic 
Melanoma. N Engl J Med. 2010 Aug 19;363(8):711–23.  
305. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for 
cancer: harnessing the T cell response. Nat Rev Immunol. 2012 
Apr;12(4):269–81.  
Targeted therapy for chordoma 
326 
306. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: 
CARs take the front seat for hematologic malignancies. Blood. 2014 Apr 
24;123(17):2625–35.  
307. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to 
go? Cancer J. 2014 Mar;20(2):151–5.  
308. Sioud M. RNA interference: mechanisms, technical challenges, and 
therapeutic opportunities. Methods Mol Biol. 2015;1218:1–15.  
309. Alvarado V, Scholthof HB. Plant responses against invasive nucleic acids: 
RNA silencing and its suppression by plant viral pathogens. Semin Cell 
Dev Biol. 2009 Dec;20(9):1032–40.  
310. Jeang K-T. RNAi in the regulation of mammalian viral infections. BMC Biol. 
2012;10:58.  
311. Russo A, Potenza N. Antiviral effects of human microRNAs and 
conservation of their target sites. FEBS Lett. 2011 Aug 19;585(16):2551–5.  
312. Waterhouse PM, Wang MB, Lough T. Gene silencing as an adaptive 
defence against viruses. Nature. 2001 Jun 14;411(6839):834–42.  
313. Pasquinelli AE, Ruvkun G. Control of developmental timing by micrornas 
and their targets. Annu Rev Cell Dev Biol. 2002;18:495–513.  
314. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. 
Cell. 2004 Jan 23;116(2):281–97.  
315. Wienholds E, Plasterk R. MicroRNA function in animal development. FEBS 
Lett. 2005.  
316. Cheng Y, Zhang C. MicroRNA-21 in Cardiovascular Disease. J of 
Cardiovasc Trans Res. Springer US; 2010 May 1;3(3):251–5.  
317. Christensen M, Schratt GM. microRNA involvement in developmental and 
functional aspects of the nervous system and in neurological diseases. 
Neuroscience Letters. 2009 Dec;466(2):55–62.  
318. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA 
regulatory networks. Nat Cell Biol. Nature Publishing Group; 2013 Jun 
3;15(6):546–54.  
319. Fuchs U, Damm-Welk C, Borkhardt A. Silencing of disease-related genes 
by small interfering RNAs. Curr Mol Med. 2004 Aug;4(5):507–17.  
320. Jorgensen R. Altered gene expression in plants due to trans interactions 
between homologous genes. Trends Biotechnol. 1990 Dec;8(12):340–4.  
321. Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric Chalcone 
Synthase Gene into Petunia Results in Reversible Co-Suppression of 
Homologous Genes in trans. Plant Cell. 1990 Apr;2(4):279–89.  
322. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent 
Targeted therapy for chordoma   
 327 
and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. Nature. 1998 Feb 19;391(6669):806–11.  
323. Montgomery MK, Fire A. Double-stranded RNA as a mediator in 
sequence-specific genetic silencing and co-suppression. Trends Genet. 
1998 Jul;14(7):255–8.  
324. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA 
degradation by double-stranded RNA in vitro. Genes & Development. 1999 
Dec 15;13(24):3191–7.  
325. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. 
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured 
mammalian cells. Nature. 2001 May 24;411(6836):494–8.  
326. Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-
mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad 
Sci USA. 1998 Dec 22;95(26):15502–7.  
327. Hannon GJ. RNA interference. Nature. 2002 Jul 11;418(6894):244–51.  
328. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA 
directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide 
intervals. Cell. 2000 Mar 31;101(1):25–33.  
329. Wang Z, Rao DD, Senzer N, Nemunaitis J. RNA Interference and Cancer 
Therapy. Pharm Res. 2011 Oct 19;28(12):2983–95.  
330. Wu SY, Lopez-Berestein G, Calin GA, Sood AK. RNAi therapies: drugging 
the undruggable. Science Translational Medicine. 2014 Jun 
11;6(240):240ps7.  
331. Deng JH, Deng P, Lin S-L, Ying S-Y. Targeting bcr-abl Transcripts with 
siRNAs in an Imatinib-Resistant Chronic Myeloid Leukemia Patient: 
Challenges and Future Directions. Methods Mol Biol. 2015;1218:321–40.  
332. Hutvágner G, Zamore PD. A microRNA in a multiple-turnover RNAi 
enzyme complex. Science. 2002 Sep 20;297(5589):2056–60.  
333. Brummelkamp TR, Bernards R, Agami R. A system for stable expression 
of short interfering RNAs in mammalian cells. Science. 2002 Apr 
19;296(5567):550–3.  
334. Brummelkamp TR, Bernards R, Agami R. Stable suppression of 
tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2002 
Sep;2(3):243–7.  
335. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded 
RNA. Nature. 2004 Sep 16;431(7006):343–9.  
336. Zhang H, Kolb FA, Brondani V, Billy E, Filipowicz W. Human Dicer 
preferentially cleaves dsRNAs at their termini without a requirement for 
ATP. EMBO J. 2002 Nov 1;21(21):5875–85.  
Targeted therapy for chordoma 
328 
337. Park J-E, Heo I, Tian Y, Simanshu DK, Chang H, Jee D, et al. Dicer 
recognizes the 5′ end of RNA for efficient and accurate processing. Nature. 
Nature Publishing Group; 2011 Jul 13;475(7355):201–5.  
338. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD. Passenger-strand 
cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme 
complexes. Cell. 2005 Nov 18;123(4):607–20.  
339. Meister G, Landthaler M, Patkaniowska A, Dorsett Y. Human Argonaute2 
Mediates RNA Cleavage Targeted by miRNAs and siRNAs. Mol Cell. 
2004.  
340. Moore CB, Guthrie EH, Huang MT-H, Taxman DJ. Short hairpin RNA 
(shRNA): design, delivery, and assessment of gene knockdown. Methods 
Mol Biol. 2010;629:141–58.  
341. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: 
similarities and differences. Adv Drug Deliv Rev. 2009 Jul 25;61(9):746–
59.  
342. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-
based therapeutics : Abstract : Nature. Nature. 2009.  
343. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short 
hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian 
cells. Genes & Development. 2002 Apr 15;16(8):948–58.  
344. Lee Y, Jeon K, Lee J-T, Kim S, Kim VN. MicroRNA maturation: stepwise 
processing and subcellular localization. EMBO J. 2002 Sep 
2;21(17):4663–70.  
345. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III 
Drosha initiates microRNA processing. Nat Cell Biol. Nature Publishing 
Group; 2003 Sep 25;425(6956):415–9.  
346. Cullen BR. Transcription and processing of human microRNA precursors. 
Mol Cell. 2004 Dec 22;16(6):861–5.  
347. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export 
of pre-microRNAs and short hairpin RNAs. Genes & Development. 2003 
Dec 15;17(24):3011–6.  
348. Lee YS, Nakahara K, Pham JW, Kim K, He Z, Sontheimer EJ, et al. 
Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA 
silencing pathways. Cell. 2004 Apr 2;117(1):69–81.  
349. Rand TA, Petersen S, Du F, Wang X. Argonaute2 Cleaves the Anti-Guide 
Strand of siRNA during RISC Activation. Cell. 2005 Nov;123(4):621–9.  
350. Preall JB, Sontheimer EJ. RNAi: RISC gets loaded. Cell. 2005 Nov 
18;123(4):543–5.  
351. Perwitasari O, Bakre A, Tompkins SM, Tripp RA. siRNA Genome 
Screening Approaches to Therapeutic Drug Repositioning. 
Targeted therapy for chordoma   
 329 
Pharmaceuticals (Basel). 2013;6(2):124–60.  
352. Flowers GP, Timberlake AT, McLean KC, Monaghan JR, Crews CM. 
Highly efficient targeted mutagenesis in axolotl using Cas9 RNA-guided 
nuclease. Development. 2014 May;141(10):2165–71.  
353. Doudna JA, Charpentier E. The new frontier of genome engineering with 
CRISPR-Cas9. Science. 2014.  
354. Koo T, Lee J, Kim J-S. Measuring and Reducing Off-Target Activities of 
Programmable Nucleases Including CRISPR-Cas9. Mol Cells. 2015 Jun 
30;38(6):475–81.  
355. Hsu PD, Lander ES, Zhang F. Development and Applications of CRISPR-
Cas9 for Genome Engineering. Cell. 2014.  
356. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome 
engineering using the CRISPR-Cas9 system. Nature Protocols. Nature 
Publishing Group; 2013 Oct 24;8(11):2281–308.  
357. Whelan J. First clinical data on RNAi. Drug Discovery Today. 2005.  
358. Kaiser PK, Symons RCA, Shah SM, Quinlan EJ, Tabandeh H, Do DV, et 
al. RNAi-based treatment for neovascular age-related macular 
degeneration by Sirna-027. Am J Ophthalmol. 2010 Jul;150(1):33–39.e2.  
359. Davidson BL, McCray PB. Current prospects for RNA interference-based 
therapies. Nat Rev Genet. 2011 May;12(5):329–40.  
360. Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. 
Science. 2002 Jul 5;297(5578):63–4.  
361. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, 
Heimerikx M, et al. A large-scale RNAi screen in human cells identifies 
new components of the p53 pathway. Nature. 2004 Mar 
25;428(6981):431–7.  
362. Lord CJ, Martin SA, Ashworth A. RNA interference screening demystified. 
J Clin Pathol. 2009 Mar;62(3):195–200.  
363. Murugaesu N, Iravani M, van Weverwijk A, Ivetic A, Johnson DA, 
Antonopoulos A, et al. An In Vivo Functional Screen Identifies 
ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor. 
Cancer Discovery. 2014 Feb 11.  
364. Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ, et al. Second-
generation shRNA libraries covering the mouse and human genomes. Nat 
Genet. 2005 Nov;37(11):1281–8.  
365. Brummelkamp TR, Fabius AWM, Mullenders J, Madiredjo M, Velds A, 
Kerkhoven RM, et al. An shRNA barcode screen provides insight into 
cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol. 2006 
Apr;2(4):202–6.  
Targeted therapy for chordoma 
330 
366. Bernards R, Brummelkamp TR, Beijersbergen RL. shRNA libraries and 
their use in cancer genetics - Nature Methods. Nat Methods. 2006.  
367. Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, et al. 
Integrated functional, gene expression and genomic analysis for the 
identification of cancer targets. PLoS ONE. 2009;4(4):e5120.  
368. Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, et al. Whole 
genome in vivo RNAi screening identifies the leukemia inhibitory factor 
receptor as a novel breast tumor suppressor. Breast Cancer Res Treat. 
2012 Aug;135(1):79–91.  
369. Phalon C, Rao DD, Nemunaitis J. Potential use of RNA interference in 
cancer therapy. Expert Rev Mol Med. 2010;12:e26.  
370. Yang W-Q, Zhang Y. RNAi-mediated gene silencing in cancer therapy. 
Expert Opin Biol Ther. 2012 Nov;12(11):1495–504.  
371. Lam AQ, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre 
JV. Rapid and Efficient Differentiation of Human Pluripotent Stem Cells 
into Intermediate Mesoderm That Forms Tubules Expressing Kidney 
Proximal Tubular Markers. J Am Soc Nephrol. 2013 Dec 19.  
372. Li C, Feng Y, Coukos G, Zhang L. Therapeutic MicroRNA Strategies in 
Human Cancer. AAPS J. 2009 Oct 29;11(4):747–57.  
373. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA 
therapeutics in clinical trials. Biotechnol J. 2011 Sep;6(9):1130–46.  
374. Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of 
siRNA/miRNA in combination with chemotherapeutic agents for cancer 
therapy: Current progress and advances. J Control Release. 2014 Sep 
7;194C:238–56.  
375. Zhou Y, Zhang C, Liang W. Development of RNAi technology for targeted 
therapy - A track of siRNA based agents to RNAi therapeutics. J Control 
Release. 2014 May 6.  
376. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, et 
al. Evidence of RNAi in humans from systemically administered siRNA via 
targeted nanoparticles. Nature. 2010 Apr 15;464(7291):1067–70.  
377. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss 
GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting 
VEGF and KSP in cancer patients with liver involvement. Cancer 
Discovery. 2013 Apr;3(4):406–17.  
378. Ramanathan. Abstract LB-289: A phase I dose escalation study of TKM-
080301, a RNAi therapeutic directed against PLK1, in patients with 
advanced solid tumors. Cancer Research. 2013;73(8 Supplement):LB–
LB–289.  
379. Rolle K, Nowak S, Wyszko E, Nowak M, Zukiel R, Piestrzeniewicz R, et al. 
Promising human brain tumors therapy with interference RNA intervention 
Targeted therapy for chordoma   
 331 
(iRNAi). Cancer Biol Ther. 2010 Mar 1;9(5):396–406.  
380. Zukiel R, Nowak S, Wyszko E, Rolle K, Gawrońska I, Barciszewska MZ, et 
al. Suppression of human brain tumor with interference RNA specific for 
tenascin-C. Cancer Biol Ther. 2006 Aug;5(8):1002–7.  
381. Wyszko E, Rolle K, Nowak S, Zukiel R, Nowak M, Piestrzeniewicz R, et al. 
A multivariate analysis of patients with brain tumors treated with ATN-
RNA. Acta Pol Pharm. 2008 Nov;65(6):677–84.  
382. Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus 
KJ, et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 
gene in age-related macular degeneration patients. Eye (Lond). 2012 May 
25;26(8):1099–105.  
383. Khvalevsky EZ, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach 
A, et al. Mutant KRAS is a druggable target for pancreatic cancer. 
Proceedings of the …. 2013.  
384. Landen CN, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, 
Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using 
neutral liposomal small interfering RNA delivery. Cancer Research. 2005 
Aug 1;65(15):6910–8.  
385. Dannull J, Haley NR, Archer G, Nair S, Boczkowski D, Harper M, et al. 
Melanoma immunotherapy using mature DCs expressing the constitutive 
proteasome. J Clin Invest. 2013 Jul 1;123(7):3135–45.  
386. Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, et al. 
Phase I clinical development of Atu027, a siRNA formulation targeting 
PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 
2012 Jan;50(1):76–8.  
387. Hansen BJ, Westergaard M, Frieden M, Hansen HF, Kjaerulff LS, Thrue 
CA, et al. SPC2996--A Bcl-2 RNA antagonist being studied in chronic 
lymphocytic leukemia. ASCO Meeting Abstracts. 2006 Jun 
20;24(18_suppl):6610.  
388. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, et al. Phase I 
trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine 
(FANG) in advanced cancer. Molecular Therapy. 2012 Mar;20(3):679–86.  
389. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the 
clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008 
Jul;5(4):505–15.  
390. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA 
therapeutics. Nat Mater. 2013 Nov;12(11):967–77.  
391. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. 
Sequence-dependent stimulation of the mammalian innate immune 
response by synthetic siRNA. Nat Biotech. 2005 Apr;23(4):457–62.  
392. Sioud M, Furset G, Cekaite L. Suppression of immunostimulatory siRNA-
Targeted therapy for chordoma 
332 
driven innate immune activation by 2'-modified RNAs. Biochemical and 
Biophysical Research Communications. 2007 Sep 14;361(1):122–6.  
393. Sioud M. Overcoming the challenges of siRNA activation of innate 
immunity: design better therapeutic siRNAs. Methods Mol Biol. 
2015;1218:301–19.  
394. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, 
Uematsu S, et al. Sequence-specific potent induction of IFN-alpha by short 
interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med. 
2005 Mar;11(3):263–70.  
395. Cekaite L, Furset G, Hovig E, Sioud M. Gene expression analysis in blood 
cells in response to unmodified and 2'-modified siRNAs reveals TLR-
dependent and independent effects. J Mol Biol. 2007 Jan 5;365(1):90–108.  
396. Lambeth LS, Smith CA. Short Hairpin RNA-Mediated Gene Silencing - 
Springer. siRNA Design. 2013.  
397. Lambeth LS, Smith CA. Short hairpin RNA-mediated gene silencing. 
Methods Mol Biol. 2013;942:205–32.  
398. Guzman-Villanueva D, El-Sherbiny IM, Herrera-Ruiz D, Vlassov AV, 
Smyth HDC. Formulation approaches to short interfering RNA and 
MicroRNA: challenges and implications. J Pharm Sci. 2012 
Nov;101(11):4046–66.  
399. Rao MK, Wilkinson MF. Tissue-specific and cell type-specific RNA 
interference in vivo. Nature Protocols. 2006;1(3):1494–501.  
400. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tetracycline-controlled 
transcriptional regulation systems: advances and application in transgenic 
animal modeling. Semin Cell Dev Biol. 2002 Apr;13(2):121–8.  
401. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, et al. 
Inducible shRNA expression for application in a prostate cancer mouse 
model. Nucleic Acids Research. 2003 Nov 1;31(21):e127.  
402. Zhou H-S, Liu D-P, Liang C-C. Challenges and strategies: the immune 
responses in gene therapy. Med Res Rev. 2004 Nov;24(6):748–61.  
403. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, 
Sabatino DE, et al. Modulation of tolerance to the transgene product in a 
nonhuman primate model of AAV-mediated gene transfer to liver. Blood. 
2007 Oct 1;110(7):2334–41.  
404. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr 
Gene Ther. 2007 Oct;7(5):316–24.  
405. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et 
al. Expression profiling reveals off-target gene regulation by RNAi. Nat 
Biotech. 2003 Jun;21(6):635–7.  
406. Clark PR, Pober JS, Kluger MS. Knockdown of TNFR1 by the sense 
Targeted therapy for chordoma   
 333 
strand of an ICAM-1 siRNA: dissection of an off-target effect. Nucleic Acids 
Research. 2008 Mar;36(4):1081–97.  
407. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects 
for target identification and therapeutic application. Nat Rev Drug Discov. 
2010 Jan;9(1):57–67.  
408. Ui-Tei K, Naito Y, Takahashi F, Haraguchi T, Ohki-Hamazaki H, Juni A, et 
al. Guidelines for the selection of highly effective siRNA sequences for 
mammalian and chick RNA interference. Nucleic Acids Research. 2004. 
pp. 936–48.  
409. Taxman DJ, Livingstone LR, Zhang J, Conti BJ, Iocca HA, Williams KL, et 
al. Criteria for effective design, construction, and gene knockdown by 
shRNA vectors. BMC Biotechnology. 2006;6:7.  
410. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. 
Rational siRNA design for RNA interference. Nat Biotech. 2004 
Mar;22(3):326–30.  
411. Gu S, Jin L, Zhang Y, Huang Y, Zhang F, Valdmanis PN, et al. The loop 
position of shRNAs and pre-miRNAs is critical for the accuracy of dicer 
processing in vivo. Cell. 2012 Nov 9;151(4):900–11.  
412. Grimm D, Streetz KL, Jopling CL, Storm TA, Pandey K, Davis CR, et al. 
Fatality in mice due to oversaturation of cellular microRNA/short hairpin 
RNA pathways. Nature. Nature Publishing Group; 2006 May 
25;441(7092):537–41.  
413. Suhy DA, Kao S-C, Mao T, Whiteley L, Denise H, Souberbielle B, et al. 
Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman 
Primate Model. Molecular Therapy. 2012 Jun 26;20(9):1737–49.  
414. McBride JL, Boudreau RL, Harper SQ, Staber PD, Monteys AM, Martins I, 
et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: 
implications for the therapeutic development of RNAi. Proceedings of the 
National Academy of Sciences. 2008 Apr 15;105(15):5868–73.  
415. Ehlert EM, Eggers R, Niclou SP, Verhaagen J. Cellular toxicity following 
application of adeno-associated viral vector-mediated RNA interference in 
the nervous system. BMC Neurosci. 2010;11:20.  
416. Martin JN, Wolken N, Brown T, Dauer WT, Ehrlich ME, Gonzalez-Alegre 
P. Lethal toxicity caused by expression of shRNA in the mouse striatum: 
implications for therapeutic design. Gene Ther. 2011 Jul;18(7):666–73.  
417. Boudreau RL, Martins I, Davidson BL. Artificial MicroRNAs as siRNA 
Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo. 
Molecular Therapy. Nature Publishing Group; 2008 Nov 11;17(1):169–75.  
418. Giering JC, Grimm D, Storm TA, Kay MA. Expression of shRNA from a 
tissue-specific pol II promoter is an effective and safe RNAi therapeutic. 
Molecular Therapy. 2008 Sep;16(9):1630–6.  
Targeted therapy for chordoma 
334 
419. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by 
nanoparticles. Expert Opin Drug Deliv. 2011 Apr;8(4):521–36.  
420. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for 
drug delivery in cancer. Clin Cancer Res. 2008 Mar 1;14(5):1310–6.  
421. Lee J-M, Yoon T-J, Cho Y-S. Recent developments in nanoparticle-based 
siRNA delivery for cancer therapy. BioMed Research International. 
2013;2013:782041.  
422. Majidi S, Zeinali Sehrig F, Samiei M, Milani M, Abbasi E, Dadashzadeh K, 
et al. Magnetic nanoparticles: Applications in gene delivery and gene 
therapy. Artif Cells Nanomed Biotechnol. 2015 Mar 2;:1–8.  
423. Koenig O, Walker T, Perle N, Zech A, Neumann B, Schlensak C, et al. 
New aspects of gene-silencing for the treatment of cardiovascular 
diseases. Pharmaceuticals (Basel). 2013;6(7):881–914.  
424. Landesman-Milo D, Ramishetti S, Peer D. Nanomedicine as an emerging 
platform for metastatic lung cancer therapy. Cancer Metastasis Rev. 2015 
May 7.  
425. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: 
advances in siRNA delivery. Nat Rev Drug Discov. 2009 Feb;8(2):129–38.  
426. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming 
the RNAi-mediated mechanism of action of siRNA-based cancer 
therapeutics in mice. J Clin Invest. 2009 Mar;119(3):661–73.  
427. Li L, Wang R, Wilcox D, Zhao X, Song J, Lin X, et al. Tumor vasculature is 
a key determinant for the efficiency of nanoparticle-mediated siRNA 
delivery. Gene Ther. 2012 Jul;19(7):775–80.  
428. Ribas A, Kalinoski L, Heidel JD, Peterkin J, Seligson DB, Zuckerman JE, 
et al. Systemic delivery of siRNA via targeted nanoparticles in patients with 
cancer: Results from a first-in-class phase I clinical trial. ASCO Meeting 
Abstracts. 2010 May 20;28(15_suppl):3022.  
429. Guo W, Chen W, Yu W, Huang W, Deng W. Small interfering RNA-based 
molecular therapy of cancers. Chin J Cancer. 2013 Jan 18.  
430. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety 
and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 
2013 Aug 29;369(9):819–29.  
431. Bouard D, Alazard-Dany D, Cosset F-L. Viral vectors: from virology to 
transgene expression. Br J Pharmacol. 2009 May;157(2):153–65.  
432. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of 
viral vectors for gene therapy. Nat Rev Genet. 2003 May;4(5):346–58.  
433. Weber C, Neacsu I, Krautz B, Schlegel P, Sauer S, Raake P, et al. 
Therapeutic safety of high myocardial expression levels of the molecular 
inotrope S100A1 in a preclinical heart failure model. Gene Ther. 2014 
Targeted therapy for chordoma   
 335 
Feb;21(2):131–8.  
434. Gong Y, Mu D, Prabhakar S, Moser A, Musolino P, Ren J, et al. 
Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked 
Adrenoleukodystrophy. Molecular Therapy. 2015 Jan 16.  
435. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, 
et al. Long-term safety and efficacy following systemic administration of a 
self-complementary AAV vector encoding human FIX pseudotyped with 
serotype 5 and 8 capsid proteins. Molecular Therapy. 2011 
May;19(5):876–85.  
436. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming 
barriers to successful gene therapy. Blood. 2013 Apr 17.  
437. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease 
using AAV: progress and challenges. Nat Rev Genet. 2011 
May;12(5):341–55.  
438. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide 
epidemiology of neutralizing antibodies to adeno-associated viruses. J 
Infect Dis. 2009 Feb 1;199(3):381–90.  
439. Samulski RJ, Muzyczka N. AAV-Mediated Gene Therapy for Research 
and Therapeutic Purposes. Annual Review of Virology. 2014 Nov 
3;1(1):427–51.  
440. Stilwell JL, Samulski RJ. Adeno-associated virus vectors for therapeutic 
gene transfer. Biotech. 2003 Jan;34(1):148–50–152–154passim.  
441. Nathwani AC, Reiss UM, Tuddenham EGD, Rosales C, Chowdary P, 
McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy 
in hemophilia B. N Engl J Med. 2014 Nov 20;371(21):1994–2004.  
442. Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant 
adeno-associated virus vectors. Curr Gene Ther. 2013 Dec;13(6):434–52.  
443. Atchison Rw, Casto Bc, Hammon Wm. Adenovirus-Associated Defective 
Virus Particles. Science. 1965 Aug 13;149(3685):754–6.  
444. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol 
Immunol. 1996;218:1–23.  
445. Buller RM, Janik JE, Sebring ED, Rose JA. Herpes simplex virus types 1 
and 2 completely help adenovirus-associated virus replication. J Virol. 
1981 Oct;40(1):241–7.  
446. Carter BJ, Koczot FJ, Garrison J, Rose JA, Dolin R. Separate helper 
functions provided by adenovirus for adenovirus-associated virus 
multiplication. Nature New Biol. 1973 Jul 18;244(133):71–3.  
447. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging 
capacity of recombinant adeno-associated virus. Human Gene Therapy. 
1996 Nov 10;7(17):2101–12.  
Targeted therapy for chordoma 
336 
448. Hoggan MD, Thomas GF. Continuous carriage of adenovirus-associated 
virus genome in cell culture in the absence of helper adenovirus. In 
Proceedings of the Fourth Lepetit Colloquium. 1972.  
449. R M Kotin RMLKIB. Characterization of a preferred site on human 
chromosome 19q for integration of adeno-associated virus DNA by non-
homologous recombination. EMBO J. Nature Publishing Group; 1992 Dec 
1;11(13):5071.  
450. R J Samulski. Targeted integration of adeno-associated virus (AAV) into 
human chromosome 19. EMBO J. Nature Publishing Group; 1991 Dec 
1;10(12):3941.  
451. Duan D, Sharma P, Yang J, Yue Y, Dudus L, ZHANG Y, et al. Circular 
intermediates of recombinant adeno-associated virus have defined 
structural characteristics responsible for long-term episomal persistence in 
muscle tissue. J Virol. 1998 Nov;72(11):8568–77.  
452. Koczot FJ, Carter BJ, Garon CF, Rose JA. Self-complementarity of 
terminal sequences within plus or minus strands of adenovirus-associated 
virus DNA. Proc Natl Acad Sci USA. 1973 Jan;70(1):215–9.  
453. Ni TH, McDonald WF, Zolotukhin I, Melendy T, Waga S, Stillman B, et al. 
Cellular proteins required for adeno-associated virus DNA replication in the 
absence of adenovirus coinfection. J Virol. 1998 Apr;72(4):2777–87.  
454. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-
dependent site-specific endonuclease with DNA helicase activity. Cell. 
1990 May 4;61(3):447–57.  
455. Im DS, Muzyczka N. Partial purification of adeno-associated virus Rep78, 
Rep52, and Rep40 and their biochemical characterization. J Virol. 1992 
Feb;66(2):1119–28.  
456. King JA, Dubielzig R, Grimm D, Kleinschmidt JA. DNA helicase-mediated 
packaging of adeno-associated virus type 2 genomes into preformed 
capsids. EMBO J. 2001 Jun 15;20(12):3282–91.  
457. Weitzman MD, Linden RM. Adeno-associated virus biology. Methods Mol 
Biol. 2011;807:1–23.  
458. Grieger JC, Snowdy S, Samulski RJ. Separate basic region motifs within 
the adeno-associated virus capsid proteins are essential for infectivity and 
assembly. J Virol. 2006 Jun;80(11):5199–210.  
459. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector 
toolkit for human gene therapy. Mol Ther. 2006 Sep;14(3):316–27.  
460. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores 
at the fivefold symmetry axes of adeno-associated virus type 2 capsids 
reveals a dual role in genome packaging and activation of phospholipase 
A2 activity. J Virol. 2005 Feb;79(4):2528–40.  
461. Girod A, Wobus CE, Zádori Z, Ried M, Leike K, Tijssen P, et al. The VP1 
Targeted therapy for chordoma   
 337 
capsid protein of adeno-associated virus type 2 is carrying a 
phospholipase A2 domain required for virus infectivity. J Gen Virol. 2002 
May;83(Pt 5):973–8.  
462. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes 
AAV2 capsid formation in the nucleolus. 2010 Jun 1;107(22):10220–5.  
463. Sonntag F, Kother K, Schmidt K, Weghofer M, Raupp C, Nieto K, et al. 
The Assembly-Activating Protein Promotes Capsid Assembly of Different 
Adeno-Associated Virus Serotypes. J Virol. 2011 Nov 3;85(23):12686–97.  
464. Naumer M, Sonntag F, Schmidt K, Nieto K, Panke C, Davey NE, et al. 
Properties of the adeno-associated virus assembly-activating protein. J 
Virol. 2012 Dec;86(23):13038–48.  
465. Gonçalves MA. Adeno-associated virus: from defective virus to effective 
vector. Virol J. 2005;2(1):43.  
466. Lusby E, Bohenzky R, Berns KI. Inverted terminal repetition in adeno-
associated virus DNA: independence of the orientation at either end of the 
genome. J Virol. 1981 Mar;37(3):1083–6.  
467. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J 
Virol. 1998 Apr;72(4):3241–7.  
468. Muzyczka N. Use of adeno-associated virus as a general transduction 
vector for mammalian cells. Curr Top Microbiol Immunol. 1992;158:97–
129.  
469. Samulski RJ, Chang LS, Shenk T. A recombinant plasmid from which an 
infectious adeno-associated virus genome can be excised in vitro and its 
use to study viral replication. J Virol. 1987 Oct;61(10):3096–101.  
470. Berns KI, Adler S. Separation of two types of adeno-associated virus 
particles containing complementary polynucleotide chains. J Virol. 1972 
Feb;9(2):394–6.  
471. McCarty DM, Monahan PE, Samulski RJ. Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient 
transduction independently of DNA synthesis. Gene Ther. 2001 
Aug;8(16):1248–54.  
472. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant 
adeno-associated virus vector genomes and intermolecular recombination 
are responsible for stable transduction of liver in vivo. J Virol. 2000 
Oct;74(20):9451–63.  
473. McCarty DM. Self-complementary AAV vectors; advances and 
applications. Molecular Therapy. 2008 Oct;16(10):1648–56.  
474. Nathwani AC, Gray JT, Ng CYC, Zhou J, Spence Y, Waddington SN, et al. 
Self-complementary adeno-associated virus vectors containing a novel 
liver-specific human factor IX expression cassette enable highly efficient 
transduction of murine and nonhuman primate liver. Blood. 2006 Apr 
Targeted therapy for chordoma 
338 
1;107(7):2653–61.  
475. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. 
Adeno-associated virus terminal repeat (TR) mutant generates self-
complementary vectors to overcome the rate-limiting step to transduction 
in vivo. Gene Ther. 2003 Dec;10(26):2112–8.  
476. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, et al. Cross-
packaging of a single adeno-associated virus (AAV) type 2 vector genome 
into multiple AAV serotypes enables transduction with broad specificity. J 
Virol. 2002 Jan;76(2):791–801.  
477. Hoggan MD, Blacklow NR, Rowe WP. Studies of small DNA viruses found 
in various adenovirus preparations: physical, biological, and immunological 
characteristics. Proc Natl Acad Sci USA. 1966 Jun;55(6):1467–74.  
478. Hauck B, Xiao W. Characterization of tissue tropism determinants of 
adeno-associated virus type 1. J Virol. 2003 Feb;77(4):2768–74.  
479. Gurda BL, Dimattia MA, Miller EB, Bennett A, McKenna R, Weichert WS, 
et al. Capsid Antibodies to Different Adeno-Associated Virus Serotypes 
Bind Common Regions. J Virol. 2013 Jun 12.  
480. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF, 
et al. Prevalence of Serum IgG and Neutralizing Factors Against Adeno-
Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy 
Population: Implications for Gene Therapy Using AAV Vectors. Human 
Gene Therapy.  Mary Ann Liebert, Inc.  140 Huguenot Street, 3rd Floor 
New Rochelle, NY 10801 USA; 2010 Jun;21(6):704–12.  
481. Märsch S, Huber A, Hallek M, Büning H, Perabo L. A novel directed 
evolution method to enhance cell-type specificity of adeno-associated virus 
vectors. Comb Chem High Throughput Screen. 2010 Nov;13(9):807–12.  
482. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the 
clinical crossroads. Molecular Therapy. 2012 Apr;20(4):699–708.  
483. Weinberg MS, Nicolson S, Bhatt AP, McLendon M, Li C, Samulski RJ. 
Recombinant adeno-associated virus utilizes cell-specific infectious entry 
mechanisms. J Virol. 2014 Nov;88(21):12472–84.  
484. Hacker UT, Wingenfeld L, Kofler DM, Schuhmann NK, Lutz S, Herold T, et 
al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed 
gene transfer and improvement of transduction efficiency. J Gene Med. 
2005 Nov;7(11):1429–38.  
485. Asokan A, Schaffer DV, Samulski RJ. Molecular Therapy - The AAV 
Vector Toolkit: Poised at the Clinical Crossroads. Molecular Therapy. 
2012.  
486. Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, 
Samulski RJ. Single amino acid changes can influence titer, heparin 
binding, and tissue tropism in different adeno-associated virus serotypes. J 
Virol. 2006 Nov;80(22):11393–7.  
Targeted therapy for chordoma   
 339 
487. Summerford C, Samulski RJ. Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J 
Virol. 1998 Feb;72(2):1438–45.  
488. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. The 37/67-
kilodalton laminin receptor is a receptor for adeno-associated virus 
serotypes 8, 2, 3, and 9. J Virol. 2006 Oct;80(19):9831–6.  
489. Xie Q, Lerch TF, Meyer NL, Chapman MS. Structure-function analysis of 
receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology. 
2011 Nov 10;420(1):10–9.  
490. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, et 
al. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med. 
2003 Oct;9(10):1306–12.  
491. Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, et al. 
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is 
required for gene transfer. J Biol Chem. 2001 Jun 8;276(23):20610–6.  
492. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. Alpha2,3 and 
alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by 
adeno-associated virus types 1 and 6. J Virol. 2006 Sep;80(18):9093–103.  
493. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked 
galactose is the primary receptor for adeno-associated virus 9. J Biol 
Chem. 2011 Apr 15;286(15):13532–40.  
494. Bartlett JS, Wilcher R, Samulski RJ. Infectious entry pathway of adeno-
associated virus and adeno-associated virus vectors. J Virol. 2000 
Mar;74(6):2777–85.  
495. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. 
Extrachromosomal recombinant adeno-associated virus vector genomes 
are primarily responsible for stable liver transduction in vivo. J Virol. 2001 
Aug;75(15):6969–76.  
496. Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR. Gene transfer into 
the CNS using recombinant adeno-associated virus: analysis of vector 
DNA forms resulting in sustained expression. J Drug Target. 1999 
Dec;7(4):269–83.  
497. Schnepp BC, Jensen RL, Clark KR, Johnson PR. Infectious molecular 
clones of adeno-associated virus isolated directly from human tissues. J 
Virol. 2009 Feb;83(3):1456–64.  
498. Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein 
kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc 
Natl Acad Sci USA. 2001 Mar 27;98(7):4084–8.  
499. Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene 
expression occurs in nondividing cells in the absence of vector DNA 
integration. Am J Respir Cell Mol Biol. 1994 Nov;11(5):517–21.  
Targeted therapy for chordoma 
340 
500. Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Chérel Y, 
Chenuaud P, et al. Adeno-associated virus vector genomes persist as 
episomal chromatin in primate muscle. J Virol. 2008 Aug;82(16):7875–85.  
501. Vincent-Lacaze N, Snyder RO, Gluzman R, Bohl D, Lagarde C, Danos O. 
Structure of Adeno-Associated Virus Vector DNA following Transduction of 
the Skeletal Muscle. Journal of Virology1999.  
502. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, et al. 
Stable in vivo expression of the cystic fibrosis transmembrane 
conductance regulator with an adeno-associated virus vector. Proc Natl 
Acad Sci USA. 1993 Nov 15;90(22):10613–7.  
503. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, et al. 
Long-term gene expression and phenotypic correction using adeno-
associated virus vectors in the mammalian brain. Nat Genet. 1994 
Oct;8(2):148–54.  
504. Lalwani AK, Walsh BJ, Carvalho GJ, Muzyczka N, Mhatre AN. Expression 
of adeno-associated virus integrated transgene within the mammalian 
vestibular organs. Am J Otol. 1998 May;19(3):390–5.  
505. Hauswirth WW, Lewin AS, Zolotukhin S, Muzyczka N. Production and 
purification of recombinant adeno-associated virus. Meth Enzymol. 
2000;316:743–61.  
506. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, et al. 
Age-dependent effects of RPE65 gene therapy for Leber's congenital 
amaurosis: a phase 1 dose-escalation trial. Lancet. 2009 Nov 
7;374(9701):1597–605.  
507. Flotte TR. Adeno-associated virus-mediated gene transfer for lung 
diseases. Human Gene Therapy. 2005 Jun;16(6):643–8.  
508. McCarty DM, Young SM, Samulski RJ. Integration of adeno-associated 
virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 
2004;38:819–45.  
509. Gernoux G, Guilbaud M, Dubreil L, Larcher T, Babarit C, Ledevin M, et al. 
Early interaction of adeno-associated virus serotype 8 vector with the host 
immune system following intramuscular delivery results in weak but 
detectable lymphocyte and dendritic cell transduction. Human Gene 
Therapy. 2015 Jan;26(1):1–13.  
510. Geoffrey L Rogers ATMGVAGRJASRWH. Innate Immune Responses to 
AAV Vectors. Front Microbiol. Frontiers Media SA; 2011;2.  
511. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune 
responses to adenovirus and adeno-associated virus in humans. Gene 
Ther. 1999 Sep;6(9):1574–83.  
512. He Y, Weinberg MS, Hirsch M, Johnson MC, Tisch R, Samulski RJ, et al. 
Kinetics of Adeno-Associated Virus Serotype 2 (AAV2) and AAV8 Capsid 
Antigen Presentation In Vivo Are Identical. Human Gene Therapy. 2013 
Targeted therapy for chordoma   
 341 
May;24(5):545–53.  
513. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR. Latent 
adeno-associated virus infection elicits humoral but not cell-mediated 
immune responses in a nonhuman primate model. 1999.  
514. Li CC, He YY, Nicolson SS, Hirsch MM, Weinberg MSM, Zhang PP, et al. 
Adeno-associated virus capsid antigen presentation is dependent on 
endosomal escape. J Clin Invest. 2013 Mar 1;123(3):1390–401.  
515. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. 
Successful transduction of liver in hemophilia by AAV-Factor IX and 
limitations imposed by the host immune response. Nat Med. 2006 
Mar;12(3):342–7.  
516. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, et al. 
Stable gene transfer and expression of human blood coagulation factor IX 
after intramuscular injection of recombinant adeno-associated virus. Proc 
Natl Acad Sci USA. 1997 May 27;94(11):5804–9.  
517. High KA, Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, et al. 
Long-term correction of canine hemophilia B by gene transfer of blood 
coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 
Nature Publishing Group; 1999 Jan 1;5(1):56–63.  
518. Hagstrom JN, Couto LB, Scallan C, Burton M, McCleland ML, Fields PA, 
et al. Improved muscle-derived expression of human coagulation factor IX 
from a skeletal actin/CMV hybrid enhancer/promoter. Blood. American 
Society of Hematology; 2000 Apr 15;95(8):2536–42.  
519. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. 
Evidence for gene transfer and expression of factor IX in haemophilia B 
patients treated with an AAV vector. Nat Genet. 2000 Mar;24(3):257–61.  
520. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et 
al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with 
severe hemophilia B. Blood. 2003 Apr 15;101(8):2963–72.  
521. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr 
Gene Ther. 2011 Aug;11(4):321–30.  
522. Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer 
DV. Antibody neutralization poses a barrier to intravitreal adeno-
associated viral vector gene delivery to non-human primates. Gene Ther. 
2015 Feb;22(2):116–26.  
523. Scott LJ. Alipogene tiparvovec: a review of its use in adults with familial 
lipoprotein lipase deficiency. Drugs. 2015 Feb;75(2):175–82.  
524. Zaiss AK, Muruve DA. Immunity to adeno-associated virus vectors in 
animals and humans: a continued challenge. Gene Ther. 2008 
Jun;15(11):808–16.  
525. Gao G-P, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel 
Targeted therapy for chordoma 
342 
adeno-associated viruses from rhesus monkeys as vectors for human 
gene therapy. Proc Natl Acad Sci USA. 2002 Sep 3;99(18):11854–9.  
526. Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, et al. In Vitro 
and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding 
and Retargeting of Adeno-Associated Viruses. J Virol. 2008 May 
22;82(12):5887–911.  
527. Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, et al. 
Reengineering a receptor footprint of adeno-associated virus enables 
selective and systemic gene transfer to muscle. Nat Biotech. 2009 Dec 
27;28(1):79–82.  
528. Arruda VR, Xiao W. It's all about the clothing: capsid domination in the 
adeno-associated viral vector world - ARRUDA - 2006 - Journal of 
Thrombosis and Haemostasis - Wiley Online Library. Journal of 
Thrombosis and Haemostasis. 2007.  
529. Tseng Y-S, Gurda BL, Chipman P, McKenna R, Afione S, Chiorini JA, et 
al. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody 
complex structures reveal evolutionary commonalities in parvovirus 
antigenic reactivity. J Virol. 2015 Feb;89(3):1794–808.  
530. Gurda BL, Raupp C, Popa-Wagner R, Naumer M, Olson NH, Ng R, et al. 
Mapping a neutralizing epitope onto the capsid of adeno-associated virus 
serotype 8. J Virol. 2012 Aug;86(15):7739–51.  
531. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, et al. 
Neutralizing antibodies against adeno-associated virus examined 
prospectively in pediatric patients with hemophilia. Gene Ther. 2012 
Mar;19(3):288–94.  
532. Erles K, Sebökovà P, Schlehofer JR. Update on the prevalence of serum 
antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol. 
1999 Nov;59(3):406–11.  
533. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of 
adeno-associated virus type 5. J Virol. 1999 Feb;73(2):1309–19.  
534. Kotin RM, Menninger JC, Ward DC, Berns KI. Mapping and direct 
visualization of a region-specific viral DNA integration site on chromosome 
19q13-qter. Genomics. 1991.  
535. Nakai H, Montini E, Fuess S, Storm TA, Grompe M, Kay MA. AAV 
serotype 2 vectors preferentially integrate into active genes in mice. Nat 
Genet. 2003 Jul;34(3):297–302.  
536. Deyle DR, Russell DW. Adeno-associated virus vector integration. Curr 
Opin Mol Ther. 2009 Aug;11(4):442–7.  
537. Inagaki K, Piao C, Kotchey NM, Wu X, Nakai H. Frequency and spectrum 
of genomic integration of recombinant adeno-associated virus serotype 8 
vector in neonatal mouse liver. J Virol. 2008 Oct;82(19):9513–24.  
Targeted therapy for chordoma   
 343 
538. Miller DG, Wang P-R, Petek LM, Hirata RK, Sands MS, Russell DW. Gene 
targeting in vivo by adeno-associated virus vectors. Nat Biotech. 2006 
Aug;24(8):1022–6.  
539. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-
associated virus vector-cellular DNA junctions from mouse liver. J Virol. 
1999 Jul;73(7):5438–47.  
540. Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E, et al. Large-
scale molecular characterization of adeno-associated virus vector 
integration in mouse liver. J Virol. 2005 Mar;79(6):3606–14.  
541. Rosas LE, Grieves JL, Zaraspe K, La Perle KM, Fu H, McCarty DM. 
Patterns of scAAV vector insertion associated with oncogenic events in a 
mouse model for genotoxicity. Molecular Therapy. 2012 Nov;20(11):2098–
110.  
542. Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, 
Senac JS, et al. Vector design influences hepatic genotoxicity after adeno-
associated virus gene therapy. J Clin Invest. 2015 Feb;125(2):870–80.  
543. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, Flotte T, et al. 
Observed incidence of tumorigenesis in long-term rodent studies of rAAV 
vectors. Gene Ther. 2001 Sep;8(17):1343–6.  
544. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, et al. AAV 
vector integration sites in mouse hepatocellular carcinoma. Science. 2007 
Jul 27;317(5837):477.  
545. Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, Hoang A, et al. Analysis 
of tumors arising in male B6C3F1 mice with and without AAV vector 
delivery to liver. Mol Ther. 2006 Jul;14(1):34–44.  
546. Wu K, Li S, Bodhinathan K, Meyers C, Chen W, Campbell-Thompson M, 
et al. Enhanced expression of Pctk1, Tcf12 and Ccnd1 in hippocampus of 
rats: Impact on cognitive function, synaptic plasticity and pathology. 
Neurobiol Learn Mem. 2012 Jan;97(1):69–80.  
547. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D, et al. No 
evidence for tumorigenesis of AAV vectors in a large-scale study in mice. 
Mol Ther. 2005 Aug;12(2):299–306.  
548. Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, Edmonson 
SE, et al. Assessing the potential for AAV vector genotoxicity in a murine 
model. Blood. 2011 Mar 24;117(12):3311–9.  
549. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, 
et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature. Nature Publishing Group; 2012 Mar 
29;483(7391):603–7.  
550. Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, et al. Generation of 
robust cytotoxic T lymphocytes against prostate specific antigen by 
transduction of dendritic cells using protein and recombinant adeno-
Targeted therapy for chordoma 
344 
associated virus. Cancer Immunol Immunother. 2007 Oct;56(10):1615–24.  
551. Chiu T-L, Peng C-W, Wang M-J. Enhanced anti-glioblastoma activity of 
microglia by AAV2-mediated IL-12 through TRAIL and phagocytosis in 
vitro. Oncol Rep. 2011 May;25(5):1373–80.  
552. Yiang G-T, Harn H-J, Yu Y-L, Hu S-C, Hung Y-T, Hsieh C-J, et al. 
Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor 
growth in mice. J Biomed Sci. 2009;16:47.  
553. Yiang G-T, Chou P-L, Tsai H-F, Chen L-A, Chang W-J, Yu Y-L, et al. 
Immunotherapy for SV40 T/t antigen-induced breast cancer by 
recombinant adeno-associated virus serotype 2 carrying interleukin-15 in 
mice. Int J Mol Med. 2012 May;29(5):809–14.  
554. Han T, Abdel-Motal UM, Chang DK, Sui J, Muvaffak A. PLOS ONE: 
Human Anti-CCR4 Minibody Gene Transfer for the Treatment of 
Cutaneous T-Cell Lymphoma. PLoS ONE. 2012.  
555. Meijer DH, Maguire CA, LeRoy SG, Sena-Esteves M. Controlling brain 
tumor growth by intraventricular administration of an AAV vector encoding 
IFN-beta. Cancer Gene Therapy. 2009 Aug;16(8):664–71.  
556. Liu X, Lu J, He ML, Li Z, Zhang B, Zhou LH, et al. Antitumor Effects of 
Interferon-Alpha on Cell Growth and Metastasis in Human 
Nasopharyngeal Carcinoma. Current cancer drug …. Bentham Science 
Publishers; 2012.  
557. Nieto K, Kern A, Leuchs B, Gissmann L, Müller M, Kleinschmidt JA. 
Combined prophylactic and therapeutic intranasal vaccination against 
human papillomavirus type-16 using different adeno-associated virus 
serotype vectors. Antivir Ther (Lond). 2009;14(8):1125–37.  
558. Li R, Hu H, Ma H, Chen L, Zhou B, Liu Y, et al. The anti-tumor effect and 
increased tregs infiltration mediated by rAAV-SLC vector. Mol Biol Rep. 
2013 Oct;40(10):5615–23.  
559. Di L, Zhu Y, Jia J, Yu J, Song G, Zhang J, et al. Clinical safety of induced 
CTL infusion through recombinant adeno-associated virus-transfected 
dendritic cell vaccination in Chinese cancer patients - Springer. Clinical 
and …. 2012.  
560. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, et 
al. Safety and Survival With GVAX Pancreas Prime and Listeria 
Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for 
Metastatic Pancreatic Cancer. J Clin Oncol. 2015 Jan 12.  
561. De Remigis A, de Gruijl TD, Uram JN, Tzou S-C, Iwama S, Talor MV, et al. 
Development of thyroglobulin antibodies after GVAX immunotherapy is 
associated with prolonged survival. Int J Cancer. 2015 Jan 1;136(1):127–
37.  
562. Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 
blockade together with vaccine therapy facilitates effector T-cell infiltration 
Targeted therapy for chordoma   
 345 
into pancreatic tumors. J Immunother. 2015 Jan;38(1):1–11.  
563. Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for 
prostate cancer. Ann Oncol. 2014 Sep;25(9):1700–9.  
564. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway 
blockade augments with other modalities of immunotherapy T-cell function 
to prevent immune decline in ovarian cancer. Cancer Research. 2013 Dec 
1;73(23):6900–12.  
565. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert 
Rev Vaccines. 2005 Jun;4(3):259–74.  
566. Haycock JW. 3D cell culture: a review of current approaches and 
techniques. Methods Mol Biol. 2011;695:1–15.  
567. Dawson CW, Port RJ, Young LS. The role of the EBV-encoded latent 
membrane proteins LMP1 and LMP2 in the pathogenesis of 
nasopharyngeal carcinoma (NPC). Semin Cancer Biol. 2012 
Apr;22(2):144–53.  
568. Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from 
patient-derived xenografts for better in vitro modeling of human cancer. 
Adv Drug Deliv Rev. 2014 Dec 15;79-80:222–37.  
569. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? 
Nat Rev Drug Discov. 2004 Aug;3(8):711–5.  
570. Reichert JM, Wenger JB. Development trends for new cancer therapeutics 
and vaccines. Drug Discovery Today. 2008 Jan;13(1-2):30–7.  
571. Thakur Das M, Pryer NK, Singh M. Mouse tumour models to guide drug 
development and identify resistance mechanisms. J Pathol. 2013 Dec 
10;232(2):103–11.  
572. Masters JR. HeLa cells 50 years on: the good, the bad and the ugly. Nat 
Rev Cancer. 2002 Apr;2(4):315–9.  
573. Gey GO, Coffman WD. Gey: Tissue culture studies of the proliferative... - 
Google Scholar. Cancer. 1952.  
574. Weinstein JN. Drug discovery: Cell lines battle cancer. Nature. 2012 Mar 
29;483(7391):544–5.  
575. Masters JRW. Access : Human cancer cell lines: fact and fantasy : Nature 
Reviews Molecular Cell Biology. Nat Rev Mol Cell Biol. 2000 Dec 
1;1(3):233–6.  
576. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, 
et al. Systematic identification of genomic markers of drug sensitivity in 
cancer cells. Nature. 2012 Mar 29;483(7391):570–5.  
577. Drews J. Drug discovery: a historical perspective. Science. 2000 Mar 
17;287(5460):1960–4.  
Targeted therapy for chordoma 
346 
578. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. 
Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 
27;417(6892):949–54.  
579. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. 
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J 
Med. 2010 Aug 26;363(9):809–19.  
580. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical 
efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant 
melanoma. Nature. 2010 Sep 30;467(7315):596–9.  
581. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et 
al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E 
Mutation. N Engl J Med. 2011 Jun 30;364(26):2507–16.  
582. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, 
et al. The Cancer Cell Line Encyclopedia enables predictive modelling of 
anticancer drug sensitivity. Nature. 2012 Mar 29;483(7391):603–7.  
583. Jaeger S, Duran-Frigola M, Aloy P. Drug sensitivity in cancer cell lines is 
not tissue-specific. Mol Cancer. 2015 Dec;14(1):312.  
584. Ravi M, V P, Sr K, E A, Paul SFD. 3D Cell Culture Systems - Advantages 
and Applications. J Cell Physiol. 2014 Jun 9.  
585. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. 
Bioengineered 3D platform to explore cell-ECM interactions and drug 
resistance of epithelial ovarian cancer cells. Biomaterials. 2010 
Nov;31(32):8494–506.  
586. Richmond A, Su Y. Mouse xenograft models vs GEM models for human 
cancer therapeutics. Dis Model Mech. 2008 Sep;1(2-3):78–82.  
587. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J 
Pathol. 2003 Jul;200(4):429–47.  
588. Morton CL, Houghton PJ. Establishment of human tumor xenografts in 
immunodeficient mice. Nature Protocols. 2007 Feb;2(2):247–50.  
589. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. 
Patient-derived tumour xenografts as models for oncology drug 
development. Nat Rev Clin Oncol. 2012 Jun;9(6):338–50.  
590. Whittle JR, Lewis MT, Lindeman GJ, Visvader JE. Patient-derived 
xenograft models of breast cancer and their predictive power. Breast 
Cancer Res. 2015 Dec;17(1):523.  
591. Gillet J-P, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. 
Redefining the relevance of established cancer cell lines to the study of 
mechanisms of clinical anti-cancer drug resistance. Proceedings of the 
National Academy of Sciences. 2011 Nov 15;108(46):18708–13.  
592. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, et al. 
Targeted therapy for chordoma   
 347 
Patient-Derived Xenograft Models: An Emerging Platform for Translational 
Cancer Research. Cancer Discovery. 2014 Sep 1;4(9):998–1013.  
593. Burrell RA, Swanton C. The evolution of the unstable cancer genome. Curr 
Opin Genet Dev. 2014 Feb;24:61–7.  
594. Sipos F, Constantinovits M, Műzes G. Intratumoral functional 
heterogeneity and chemotherapy. World J Gastroenterol. 2014 Mar 
14;20(10):2429–32.  
595. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug 
resistance. Lancet Oncol. 2012 Apr;13(4):e178–85.  
596. Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, O'Laughlin M, 
et al. Functional heterogeneity of genetically defined subclones in acute 
myeloid leukemia. Cancer Cell. 2014 Mar 17;25(3):379–92.  
597. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, et 
al. Genome-wide cDNA Microarray Screening to Correlate Gene 
Expression Profiles with Sensitivity of 85 Human Cancer Xenografts to 
Anticancer Drugs. Cancer Research. 2002.  
598. Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, et al. 
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium 
pathway modulator, cyclosporin A, in preclinical models of colorectal 
cancer. Clin Cancer Res. 2013 Aug 1;19(15):4149–62.  
599. Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, et 
al. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell 
lines and patient-derived tumor explants. Molecular Cancer Therapeutics. 
2015 Feb;14(2):317–25.  
600. Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived 
xenograft mouse models. Nat Rev Cancer. 2015 Apr 24;15(5):311–6.  
601. Chesler L, Weiss WA. Genetically engineered murine models--contribution 
to our understanding of the genetics, molecular pathology and therapeutic 
targeting of neuroblastoma. Semin Cancer Biol. 2011 Oct;21(4):245–55.  
602. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. 
Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse 
and Define Rapidly Progressive, Therapeutically Targetable Disease. 
Cancer Cell. 2014 Dec 18.  
603. Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, 
et al. A bioengineered microenvironment to quantitatively measure the 
tumorigenic properties of cancer-associated fibroblasts in human prostate 
cancer. Biomaterials. 2013 Jul;34(20):4777–85.  
604. Stratton MR. Exploring the genomes of cancer cells: progress and 
promise. Science. 2011 Mar 25;331(6024):1553–8.  
605. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer. 2007 
Mar;7(3):213–21.  
Targeted therapy for chordoma 
348 
606. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as 
disorders of normal development. Curr Opin Pediatr. 2006 Dec;18(6):634–
8.  
607. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, et al. 
Epigenomic alterations define lethal CIMP-positive ependymomas of 
infancy. Nature. 2014 Feb 27;506(7489):445–50.  
608. Karikari IO, Gilchrist CL, Jing L, Alcorta DA, Chen J, Richardson WJ, et al. 
Molecular characterization of chordoma xenografts generated from a novel 
primary chordoma cell source and two chordoma cell lines. J Neurosurg 
Spine. 2014 Jun 6;:1–8.  
609. Siu I-M, Salmasi V, Orr BA, Zhao Q, Binder ZA, Tran C, et al. 
Establishment and characterization of a primary human chordoma 
xenograft model. Journal of Neurosurgery. 2012 Apr;116(4):801–9.  
610. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, et al. 
Development of transplantable human chordoma xenograft for preclinical 
assessment of novel therapeutic strategies. Neuro-oncology. 2013 Dec 16.  
611. Haagensen EJ, Thomas HD, Wilson I, Harnor SJ, Payne SL, Rennison T, 
et al. The enhanced in vivo activity of the combination of a MEK and a 
PI3K inhibitor correlates with [18F]-FLT PET in human colorectal cancer 
xenograft tumour-bearing mice. PLoS ONE. 2013;8(12):e81763.  
612. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJG, et al. 
Assessing the response to targeted therapies in renal cell carcinoma: 
technical insights and practical considerations. Eur Urol. 2014 
Apr;65(4):766–77.  
613. O'Connor J, Jackson A, Asselin MC, Buckley DL. Quantitative imaging 
biomarkers in the clinical development of targeted therapeutics: current 
and future perspectives. Lancet Oncol. 2008.  
614. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, 
et al. Intratumor heterogeneity and branched evolution revealed by 
multiregion sequencing. N Engl J Med. 2012 Mar 8;366(10):883–92.  
615. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, 
Stebbings LA, et al. The patterns and dynamics of genomic instability in 
metastatic pancreatic cancer. Nature. 2010 Oct 28;467(7319):1109–13.  
616. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the 
clinic. Nature. 2013 Sep 19;501(7467):355–64.  
617. Diehl F, Dressman D, Vogelstein B. Detection and quantification of 
mutations in the plasma of patients with colorectal tumors. PNAS. 2005 
Oct 31;102(45):163686–116373.  
618. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. 
Circulating mutant DNA to assess tumor dynamics. Nat Med. 2007 Jul 
31;14(9):985–90.  
Targeted therapy for chordoma   
 349 
619. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et 
al. Presence of fetal DNA in maternal plasma and serum. The Lancet. 
1997 Aug 16;350(9076):485–7.  
620. Lo YMD, Chiu RWK. Genomic analysis of fetal nucleic acids in maternal 
blood. Annu Rev Genomics Hum Genet. 2012;13:285–306.  
621. Lo KK, Boustred C, Chitty LS, Plagnol V. RAPIDR: an analysis package for 
non-invasive prenatal testing of aneuploidy. Bioinformatics. 2014 Oct 
15;30(20):2965–7.  
622. Beulen L, Grutters JPC, Faas BH, Feenstra I, van Vugt JMG, Bekker MN. 
The consequences of implementing non-invasive prenatal testing in Dutch 
national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol 
Reprod Biol. 2014 Nov;182:53–61.  
623. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J 
Clin Oncol. 2014 Feb 20;32(6):579–86.  
624. Choi J-J, Reich CF, Pisetsky DS. The role of macrophages in the in vitro 
generation of extracellular DNA from apoptotic and necrotic cells. 
Immunology. 2005 May;115(1):55–62.  
625. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer--
a survey. Biochim Biophys Acta. 2007 Jan;1775(1):181–232.  
626. Delgado PO, Alves BCA, Gehrke F de S, Kuniyoshi RK, Wroclavski ML, 
Del Giglio A, et al. Characterization of cell-free circulating DNA in plasma 
in patients with prostate cancer. Tumor Biol. 2013 Apr;34(2):983–6.  
627. Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a 
diagnostic marker for breast cancer. J Clin Lab Anal. 2012 Nov;26(6):467–
72.  
628. No JH, Kim K, Park KH, Kim Y-B. Cell-free DNA level as a prognostic 
biomarker for epithelial ovarian cancer. Anticancer Res. 2012 
Aug;32(8):3467–71.  
629. Park J-L, Kim HJ, Choi BY, Lee H-C, Jang H-R, Song KS, et al. 
Quantitative analysis of cell-free DNA in the plasma of gastric cancer 
patients. Oncol Lett. 2012 Apr 1;3(4):921–6.  
630. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell J-P, 
Rebillard X, et al. Cell-free tumor DNA in blood plasma as a marker for 
circulating tumor cells in prostate cancer. Clin Cancer Res. 2009 Feb 
1;15(3):1032–8.  
631. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as 
biomarkers in cancer patients. Nat Rev Cancer. 2011 Jun;11(6):426–37.  
632. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, et al. 
DNA fragments in the blood plasma of cancer patients: quantitations and 
evidence for their origin from apoptotic and necrotic cells. Cancer 
Research. 2001 Feb 15;61(4):1659–65.  
Targeted therapy for chordoma 
350 
633. Yoon K-A, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating 
plasma DNA levels between lung cancer patients and healthy controls. J 
Mol Diagn. 2009 May;11(3):182–5.  
634. Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. 
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N 
Engl J Med. 2013 Mar 28;368(13):1199–209.  
635. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. 
Detection of circulating tumor DNA in early- and late-stage human 
malignancies. Science Translational Medicine. 2014 Feb 
19;6(224):224ra24.  
636. Roschewski M, Dunleavy K, Pittaluga S, Moorhead M, Pepin F, Kong K, et 
al. Circulating tumour DNA and CT monitoring in patients with untreated 
diffuse large B-cell lymphoma: a correlative biomarker study. Lancet 
Oncol. 2015 Apr 1.  
637. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DWY, Kaper F, et al. 
Noninvasive identification and monitoring of cancer mutations by targeted 
deep sequencing of plasma DNA. Science Translational Medicine. 2012 
May 30;4(136):136ra68.  
638. Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. 
An ultrasensitive method for quantitating circulating tumor DNA with broad 
patient coverage. Nat Med. 2014 Apr 6.  
639. Murtaza M, Dawson S-J, Tsui DWY, Gale D, Forshew T, Piskorz AM, et al. 
Non-invasive analysis of acquired resistance to cancer therapy by 
sequencing of plasma DNA. Nature. 2013 Apr 7.  
640. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci USA. 1999 Aug 
3;96(16):9236–41.  
641. Bidard F-C, Weigelt B, Reis-Filho JS. Going with the flow: from circulating 
tumor cells to DNA. Science Translational Medicine. 2013 Oct 
16;5(207):207ps14.  
642. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, 
Makarewicz AJ, et al. High-throughput droplet digital PCR system for 
absolute quantitation of DNA copy number. Anal Chem. 2011 Nov 
15;83(22):8604–10.  
643. Bratman SV, Newman AM, Alizadeh AA, Diehn M. Potential clinical utility 
of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert 
Review of Molecular Diagnostics. 2015 Mar 16;:1–5.  
644. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. 
Detection of tumor PIK3CA status in metastatic breast cancer using 
peripheral blood. Clin Cancer Res. 2012 Jun 15;18(12):3462–9.  
645. Richardson AL, Iglehart JD. BEAMing up personalized medicine: mutation 
detection in blood. Clin Cancer Res. 2012 Jun 15;18(12):3209–11.  
Targeted therapy for chordoma   
 351 
646. Rosell R, Molina MA, Serrano MJ. EGFR mutations in circulating tumour 
DNA. Lancet Oncol. 2012 Oct;13(10):971–3.  
647. Schneck H, Blassl C, Meier-Stiegen F, Neves RP, Janni W, Fehm T, et al. 
Analysing the mutational status of PIK3CA in circulating tumor cells from 
metastatic breast cancer patients. Mol Oncol. 2013 Oct;7(5):976–86.  
648. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, 
et al. Detection of mutations in EGFR in circulating lung-cancer cells. N 
Engl J Med. 2008 Jul 24;359(4):366–77.  
649. Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. 
Detection and characterization of carcinoma cells in the blood. Proc Natl 
Acad Sci USA. 1998 Apr 14;95(8):4589–94.  
650. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating 
breast tumor cells exhibit dynamic changes in epithelial and mesenchymal 
composition. Science. 2013 Feb 1;339(6119):580–4.  
651. Bidard F-C, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, 
Servois V, et al. Detection rate and prognostic value of circulating tumor 
cells and circulating tumor DNA in metastatic uveal melanoma. Int J 
Cancer. 2014 Mar 1;134(5):1207–13.  
652. Olsson E, Winter C, George A, Chen Y, Howlin J, Tang M-HE, et al. Serial 
monitoring of circulating tumor DNA in patients with primary breast cancer 
for detection of occult metastatic disease. EMBO Mol Med. 2015 May 18.  
653. Madic J, Kiialainen A, Bidard F-C, Birzele F, Ramey G, Leroy Q, et al. 
Circulating tumor DNA and circulating tumor cells in metastatic triple 
negative breast cancer patients. Int J Cancer. 2015 May 1;136(9):2158–
65.  
654. Yoo C, Ryu M-H, Na YS, Ryoo B-Y, Park SR, Kang Y-K. Analysis of serum 
protein biomarkers, circulating tumor DNA, and dovitinib activity in patients 
with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. 
Ann Oncol. 2014 Nov;25(11):2272–7.  
655. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. 
Emergence of KRAS mutations and acquired resistance to anti-EGFR 
therapy in colorectal cancer. Nature. 2012 Jun 28;486(7404):532–6.  
656. Qiu M, Wang J, Xu Y, Ding X, Li M, Jiang F, et al. Circulating tumor DNA is 
effective for the detection of EGFR mutation in non-small cell lung cancer: 
a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):206–
12.  
657. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. 
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of 
Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer. 
Science Translational Medicine. 2014 Feb 19;6(224):224ra26.  
658. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The 
molecular evolution of acquired resistance to targeted EGFR blockade in 
Targeted therapy for chordoma 
352 
colorectal cancers. Nature. 2012 Jun 28;486(7404):537–40.  
659. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, 
Parton M, et al. Noninvasive Detection of HER2 Amplification with Plasma 
DNA Digital PCR. Clinical Cancer Research. 2013 Jun 13;19(12):3276–84.  
660. Bidard F-C, Pierga J-Y, Soria J-C, Thiery JP. Translating metastasis-
related biomarkers to the clinic--progress and pitfalls. Nat Rev Clin Oncol. 
2013 Mar;10(3):169–79.  
661. Rinner B, Froehlich EV, Buerger K, Knausz H, Lohberger B, Scheipl S, et 
al. Establishment and detailed functional and molecular genetic 
characterisation of a novel sacral chordoma cell line, MUG-Chor1. Int J 
Oncol. 2012 Feb;40(2):443–51.  
662. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci USA. 1977 Dec;74(12):5463–7.  
663. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human 
cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 
1977 Jul;36(1):59–74.  
664. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. 
A versatile viral system for expression and depletion of proteins in 
mammalian cells. PLoS ONE. 2009;4(8):e6529.  
665. Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, et al. MicroRNA-
1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. J 
Orthop Res. 2014 Aug;32(8):1075–82.  
666. Zhang Y, Schiff D, Park D, Abounader R. MicroRNA-608 and microRNA-
34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. 
PLoS ONE. 2014;9(3):e91546.  
667. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in 
the nude mouse. J Surg Oncol. 1986 Apr;31(4):229–34.  
668. Sato A, Klaunberg B, Tolwani R. In vivo bioluminescence imaging. Comp 
Med. 2004 Dec;54(6):631–4.  
669. Greer LF, Szalay AA. Imaging of light emission from the expression of 
luciferases in living cells and organisms: a review. Luminescence. 2002 
Jan;17(1):43–74.  
670. Inoue Y, Kiryu S, Watanabe M, Tojo A, Ohtomo K. Timing of imaging after 
d-luciferin injection affects the longitudinal assessment of tumor growth 
using in vivo bioluminescence imaging. Int J Biomed Imaging. 
2010;2010:471408.  
671. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, Antich PP, et al. 
Validating bioluminescence imaging as a high-throughput, quantitative 
modality for assessing tumor burden. Mol Imaging. 2004 Apr;3(2):117–24.  
672. Baba S, Cho SY, Ye Z, Cheng L, Engles JM, Wahl RL. How reproducible 
Targeted therapy for chordoma   
 353 
is bioluminescent imaging of tumor cell growth? Single time point versus 
the dynamic measurement approach. Mol Imaging. 2007 Sep;6(5):315–22.  
673. Inoue Y, Kiryu S, Izawa K, Watanabe M, Tojo A, Ohtomo K. Comparison of 
subcutaneous and intraperitoneal injection of D-luciferin for in vivo 
bioluminescence imaging. Eur J Nucl Med Mol Imaging. 2009 
May;36(5):771–9.  
674. Boden D, Pusch O, Silbermann R, Lee F, Tucker L, Ramratnam B. 
Enhanced gene silencing of HIV-1 specific siRNA using microRNA 
designed hairpins. Nucleic Acids Research. 2004;32(3):1154–8.  
675. Sambrook J, Russell DW. Molecular cloning. 2001.  
676. Landy A. Dynamic, structural, and regulatory aspects of lambda site-
specific recombination. Annu Rev Biochem. 1989;58:913–49.  
677. Hartley JL, Temple GF, Brasch MA. DNA cloning using in vitro site-specific 
recombination. Genome Research. 2000 Nov;10(11):1788–95.  
678. Liang X, Peng L, Baek C-H, Katzen F. Single step BP/LR combined 
Gateway reactions. Biotech. 2013 Nov;55(5):265–8.  
679. Chang K, Marran K, Valentine A, Hannon GJ. Creating an miR30-based 
shRNA vector. Cold Spring Harbor Protocols. 2013 Jul;2013(7):631–5.  
680. Vandenberghe LH, Xiao R, Lock M, Lin J, Korn M, Wilson JM. Efficient 
Serotype-Dependent Release of Functional Vector into the Culture 
Medium During Adeno-Associated Virus Manufacturing. Human Gene 
Therapy.  Mary Ann Liebert, Inc.  140 Huguenot Street, 3rd Floor New 
Rochelle, NY 10801 USA; 2010 Oct;21(10):1251–7.  
681. Zhang J, Chung T, Oldenburg K. A Simple Statistical Parameter for Use in 
Evaluation and Validation of High Throughput Screening Assays. J Biomol 
Screen. 1999;4(2):67–73.  
682. Bamborough P, Drewry D, Harper G, Smith GK, Schneider K. Assessment 
of chemical coverage of kinome space and its implications for kinase drug 
discovery. J Med Chem. 2008 Dec 25;51(24):7898–914.  
683. Houghton BC, Booth C, Thrasher AJ. Lentivirus technologies for 
modulation of the immune system. Curr Opin Pharmacol. 2015 Sep 
9;24:119–27.  
684. Messaoudi El S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: 
Preanalytical considerations. Clin Chim Acta. 2013 Sep 23;424:222–30.  
685. Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, et 
al. Towards standardisation of cell-free DNA measurement in plasma: 
controls for extraction efficiency, fragment size bias and quantification. 
Anal Bioanal Chem. 2014 May 24.  
686. Verdine GL, Walensky LD. The challenge of drugging undruggable targets 
in cancer: lessons learned from targeting BCL-2 family members. Clin 
Targeted therapy for chordoma 
354 
Cancer Res. 2007 Dec 15;13(24):7264–70.  
687. Zhang X, Yuan X, Zhu W, Qian H, Xu W. SALL4: an emerging cancer 
biomarker and target. Cancer Letters. 2015 Feb 1;357(1):55–62.  
688. Malhotra M, Toulouse A, Godinho BMDC, Mc Carthy DJ, Cryan JF, 
O'Driscoll CM. RNAi therapeutics for brain cancer: current advancements 
in RNAi delivery strategies. Mol Biosyst. 2015 Sep 15;11(10):2635–57.  
689. Paddison PJ, Hannon GJ. RNA interference: the new somatic cell 
genetics? Cancer Cell. 2002 Jul;2(1):17–23.  
690. Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-
Cardo C, et al. An epi-allelic series of p53 hypomorphs created by stable 
RNAi produces distinct tumor phenotypes in vivo. Nat Genet. 2003 
Mar;33(3):396–400.  
691. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, et al. 
Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotech. 
2003 Jun;21(6):639–44.  
692. Carmell MA, Zhang L, Conklin DS, Hannon GJ, Rosenquist TA. Germline 
transmission of RNAi in mice. Nat Struct Biol. 2003 Feb;10(2):91–2.  
693. Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 
1-9 mediated gene expression and tropism in mice after systemic injection. 
Molecular Therapy. 2008 Jun;16(6):1073–80.  
694. Lebbink RJ, Lowe M, Chan T, Khine H, Wang X, McManus MT. 
Polymerase II promoter strength determines efficacy of microRNA adapted 
shRNAs. PLoS ONE. 2011;6(10):e26213.  
695. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. 
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila 
melanogaster embryo lysate. EMBO J. 2001 Dec 3;20(23):6877–88.  
696. Miller VM, Xia H, Marrs GL, Gouvion CM, Lee G, Davidson BL, et al. 
Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci 
USA. 2003 Jun 10;100(12):7195–200.  
697. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. 
Specificity of short interfering RNA determined through gene expression 
signatures. Proc Natl Acad Sci USA. 2003 May 27;100(11):6347–52.  
698. Lin X, Ruan X, Anderson MG, McDowell JA, Kroeger PE, Fesik SW, et al. 
siRNA-mediated off-target gene silencing triggered by a 7 nt 
complementation. Nucleic Acids Research. 2005;33(14):4527–35.  
699. Boudreau RL, Monteys AM, Davidson BL. Minimizing variables among 
hairpin-based RNAi vectors reveals the potency of shRNAs. RNA. 2008 
Sep;14(9):1834–44.  
700. Oohashi T, Zhou XH, Feng K, Richter B, Mörgelin M, Perez MT, et al. 
Mouse ten-m/Odz is a new family of dimeric type II transmembrane 
Targeted therapy for chordoma   
 355 
proteins expressed in many tissues. J Cell Biol. 1999 May 3;145(3):563–
77.  
701. Levine A, Bashan-Ahrend A, Budai-Hadrian O, Gartenberg D, 
Menasherow S, Wides R. Odd Oz: a novel Drosophila pair rule gene. Cell. 
1994 May 20;77(4):587–98.  
702. Mieda M, Kikuchi Y, Hirate Y, Aoki M, Okamoto H. Compartmentalized 
expression of zebrafish ten-m3 and ten-m4, homologues of the Drosophila 
ten(m)/odd Oz gene, in the central nervous system. Mech Dev. 1999 
Sep;87(1-2):223–7.  
703. Rubin BP, Tucker RP, Brown-Luedi M, Martin D, Chiquet-Ehrismann R. 
Teneurin 2 is expressed by the neurons of the thalamofugal visual system 
in situ and promotes homophilic cell-cell adhesion in vitro. Development. 
2002 Oct;129(20):4697–705.  
704. Trzebiatowska A, Topf U, Sauder U, Drabikowski K, Chiquet-Ehrismann R. 
Caenorhabditis elegans teneurin, ten-1, is required for gonadal and 
pharyngeal basement membrane integrity and acts redundantly with 
integrin ina-1 and dystroglycan dgn-1. Mol Biol Cell. 2008 Sep;19(9):3898–
908.  
705. Mosca TJ, Hong W, Dani VS, Favaloro V, Luo L. Trans-synaptic Teneurin 
signalling in neuromuscular synapse organization and target choice. 
Nature. 2012 Apr 12;484(7393):237–41.  
706. Pan X, Yue Y, Zhang K, Hakim C, Kodippili K, McDonald T, et al. AAV-8 is 
more efficient than AAV-9 in transducing neonatal dog heart. Hum Gene 
Ther Methods. 2015 Mar 12.  
707. Hoffman RM. The multiple uses of fluorescent proteins to visualize cancer 
in vivo. Nat Rev Cancer. 2005 Oct;5(10):796–806.  
708. Gu W, Payne E, Sun S, Burgess M, McMillan NAJ. Inhibition of cervical 
cancer cell growth in vitro and in vivo with dual shRNAs. Cancer Gene 
Therapy. 2011 Mar;18(3):219–27.  
709. Gu W, Putral L, McMillan N. siRNA and shRNA as anticancer agents in a 
cervical cancer model. Methods Mol Biol. 2008;442:159–72.  
710. Fish RJ, Kruithof EKO. Short-term cytotoxic effects and long-term 
instability of RNAi delivered using lentiviral vectors. BMC Mol Biol. 2004 
Aug 3;5:9.  
711. Tang S, Tao M, McCoy JP, Zheng ZM. Short-term induction and long-term 
suppression of HPV16 oncogene silencing by RNA interference in cervical 
cancer cells. Oncogene. 2006 Mar 30;25(14):2094–104.  
712. Zheng Z-M, Tang S, Tao M. Development of resistance to RNAi in 
mammalian cells. Ann N Y Acad Sci. 2005 Nov;1058:105–18.  
713. Brake ter O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 
with RNA interference: a multiple shRNA approach. Mol Ther. 2006 
Targeted therapy for chordoma 
356 
Dec;14(6):883–92.  
714. Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for 
treatment of HIV-1 infection. Genome Med. 2015;7(1):50.  
715. Rao DD, Senzer N, Wang Z, Kumar P, Jay CM, Nemunaitis J. Bifunctional 
short hairpin RNA (bi-shRNA): design and pathway to clinical application. 
Methods Mol Biol. 2013;942:259–78.  
716. Rao DD, Maples PB, Senzer N, Kumar P, Wang Z, Pappen BO, et al. 
Enhanced target gene knockdown by a bifunctional shRNA: a novel 
approach of RNA interference. Cancer Gene Therapy. 2010 
Nov;17(11):780–91.  
717. Nathwani AC, Nienhuis AW, Davidoff AM. Our journey to successful gene 
therapy for hemophilia B. Human Gene Therapy. 2014 Nov;25(11):923–6.  
718. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, 
Hagstrom JN, et al. Role of vector in activation of T cell subsets in immune 
responses against the secreted transgene product factor IX. Mol Ther. 
2000 Mar;1(3):225–35.  
719. Roitt IM, Cooke A. Idiotypic interactions in autoimmunity: an editorial 
overview. J Autoimmun. 1988 Feb;1(1):3–6.  
720. Mond JJ, Scher I, Cossman J, Kessler S, Mongini PK, Hansen C, et al. 
Role of the thymus in directing the development of a subset of B 
lymphocytes. J Exp Med. 1982 Mar 1;155(3):924–36.  
721. Wortis HH, Burkly L, Hughes D, Roschelle S, Waneck G. Lack of mature B 
cells in nude mice with X-linked immune deficiency. J Exp Med. 1982 Mar 
1;155(3):903–13.  
722. Stacchiotti S, Casali PG. Systemic therapy options for unresectable and 
metastatic chordomas. Curr Oncol Rep. 2011 Aug;13(4):323–30.  
723. Muro K, Das S, Raizer JJ. Chordomas of the craniospinal axis: 
multimodality surgical, radiation and medical management strategies. 
Expert Rev Neurother. 2007 Oct;7(10):1295–312.  
724. Arteaga CL. Overview of epidermal growth factor receptor biology and its 
role as a therapeutic target in human neoplasia. Semin Oncol. 2002 
Oct;29(5 Suppl 14):3–9.  
725. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et 
al. Use of chemotherapy plus a monoclonal antibody against HER2 for 
metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 
Mar 15;344(11):783–92.  
726. Heinrich MC, Corless CL, Demetri GD, Blanke CD, Mehren von M, 
Joensuu H, et al. Kinase mutations and imatinib response in patients with 
metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 
1;21(23):4342–9.  
Targeted therapy for chordoma   
 357 
727. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. 
Erlotinib plus gemcitabine compared with gemcitabine alone in patients 
with advanced pancreatic cancer: a phase III trial of the National Cancer 
Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 
20;25(15):1960–6.  
728. Kobayashi M, Tojo A. The BRAF-V600E mutation in circulating cell-free 
DNA is a promising biomarker of high-risk adult Langerhans cell 
histiocytosis. Blood. 2014 Oct 16;124(16):2610–1.  
729. Stewart EL, Tan SZ, Liu G, Tsao M-S. Known and putative mechanisms of 
resistance to EGFR targeted therapies in NSCLC patients with EGFR 
mutations-a review. Transl Lung Cancer Res. 2015 Feb;4(1):67–81.  
730. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, 
Brannigan BW, et al. Activating mutations in the epidermal growth factor 
receptor underlying responsiveness of non-small-cell lung cancer to 
gefitinib. N Engl J Med. 2004 May 20;350(21):2129–39.  
731. Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P. Beyond 
EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main 
challenges still to be overcome. Cancer Treat Rev. 2014 Jul;40(6):723–9.  
732. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. 
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor 
genomic profiling. Journal of Clinical Oncology. 2011 Aug 1;29(22):3085–
96.  
733. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas 
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS 
upregulation. Nature. 2010 Dec 16;468(7326):973–7.  
734. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, 
et al. EGFR mutation and resistance of non-small-cell lung cancer to 
gefitinib. N Engl J Med. 2005 Feb 24;352(8):786–92.  
735. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets 
systems biology. Nat Rev Cancer. Nature Publishing Group; 2012 Jul 
12;12(8):553–63.  
736. Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: 
couples therapy. Nat Rev Cancer. Nature Publishing Group; 2013 Aug 
16;13(9):663–73.  
737. Drewry DH, Willson TM, Zuercher WJ. Seeding collaborations to advance 
kinase science with the GSK Published Kinase Inhibitor Set (PKIS). Curr 
Top Med Chem. 2014;14(3):340–2.  
738. Young L, Sung J, Stacey G, Masters JR. Detection of Mycoplasma in cell 
cultures. Nature Protocols. Nature Publishing Group; 2010 Apr 
22;5(5):929–34.  
739. Dranchak P, MacArthur R, Guha R, Zuercher WJ, Drewry DH, Auld DS, et 
al. Profile of the GSK published protein kinase inhibitor set across ATP-
Targeted therapy for chordoma 
358 
dependent and-independent luciferases: implications for reporter-gene 
assays. PLoS ONE. 2013;8(3):e57888.  
740. Igney FH, Krammer PH. Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer. 2002 Apr;2(4):277–88.  
741. Zhou W, Ercan D, Chen L, Yun C-H, Li D, Capelletti M, et al. Novel 
mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 
2009 Dec 24;462(7276):1070–4.  
742. Hickinson DM, Klinowska T, Speake G, Vincent J, Trigwell C, Anderton J, 
et al. AZD8931, an equipotent, reversible inhibitor of signaling by 
epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique 
agent for simultaneous ERBB receptor blockade in cancer. Clin Cancer 
Res. 2010 Feb 15;16(4):1159–69.  
743. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. 
Close similarity of epidermal growth factor receptor and v-erb-B oncogene 
protein sequences. Nature. 1984 Feb;307(5951):521–7.  
744. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express 
increased epidermal growth factor receptors. J Clin Invest. 1984 
Aug;74(2):647–51.  
745. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. 
Expression of epidermal growth factor receptors in human brain tumors. 
Cancer Research. 1984 Feb;44(2):753–60.  
746. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, et al. 
Amplification, enhanced expression and possible rearrangement of EGF 
receptor gene in primary human brain tumours of glial origin. Nature. 1985 
Jan;313(5998):144–7.  
747. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of 
aberrant epidermal growth factor receptor transcripts from amplified 
rearranged genes in human glioblastomas. Proceedings of the National 
Academy of Sciences. 1990 Nov 1;87(21):8602–6.  
748. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-
targeted therapies in cancer. Nat Med. 2013 Nov;19(11):1389–400.  
749. Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann 
N, Mazur PK, et al. EGF receptor is required for KRAS-induced pancreatic 
tumorigenesis. Cancer Cell. 2012 Sep 11;22(3):304–17.  
750. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, et al. 
PTEN loss of expression predicts cetuximab efficacy in metastatic 
colorectal cancer patients. Br J Cancer. 2007 Oct 22;97(8):1139–45.  
751. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. 
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N 
Engl J Med. 2008 Sep 11;359(11):1116–27.  
752. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. 
Targeted therapy for chordoma   
 359 
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head 
and neck. N Engl J Med. 2006 Feb 9;354(6):567–78.  
753. Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, et 
al. A receptor tyrosine kinase network composed of fibroblast growth factor 
receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor 
drives growth and survival of head and neck squamous carcinoma cell 
lines. Mol Pharmacol. 2013 Apr;83(4):882–93.  
754. Morrison G, Fu X, Shea M, Nanda S, Giuliano M, Wang T, et al. 
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in 
circumventing endocrine resistance. Breast Cancer Res Treat. 2014 
Apr;144(2):263–72.  
755. O'Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, 
et al. High concordance of drug-induced human hepatotoxicity with in vitro 
cytotoxicity measured in a novel cell-based model using high content 
screening. Arch Toxicol. 2006 Sep;80(9):580–604.  
756. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, 
et al. Clinical relevance of KRAS mutation detection in metastatic 
colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 
2007 Apr 23;96(8):1166–9.  
757. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, 
Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway 
impairs the response of metastatic colorectal cancers to anti-epidermal 
growth factor receptor antibody therapies. Cancer Research. 2007 Mar 
15;67(6):2643–8.  
758. Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, et al. Expression of 
PTEN and mTOR in sacral chordoma and association with poor prognosis. 
Med Oncol. Springer US; 2014 Feb 18;31(4):886–5.  
759. Lee D-H, Zhang Y, Kassam AB, Park M-J, Gardner P, Prevedello D, et al. 
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in 
Chordoma. PLoS ONE. 2015;10(8):e0134426.  
760. Capozzi M, Caterina I, De Divitiis C, Arx von C, Maiolino P, Tatangelo F, et 
al. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, 
resistance and how to overcome it. Int J Surg. 2015 Sep;21 Suppl 1:S89–
94.  
761. Timpe LC, Li D, Yen T-Y, Wong J, Yen R, Macher BA, et al. Mining the 
Breast Cancer Proteome for Predictors of Drug Sensitivity. J Proteomics 
Bioinform. 2015;8(9):204–11.  
762. Dabney R, Devine R, Sein N, George B. New agents in renal cell 
carcinoma. Target Oncol. 2014 Sep;9(3):183–93.  
763. Hasskarl J. Everolimus. Recent Results Cancer Res. 2014;201:373–92.  
764. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in 
Targeted therapy for chordoma 
360 
metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014 
Mar;15(3):155–62.  
765. Ehrhardt MJ, Karst J, Donohoue PA, Maheshwari M, McClain KL, Bingen 
K, et al. Recognition and treatment of concurrent active and 
neurodegenerative langerhans cell histiocytosis: a case report. J Pediatr 
Hematol Oncol. 2015 Jan;37(1):e37–40.  
766. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-in-
human phase I study of pictilisib (GDC-0941), a potent pan-class I 
phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced 
solid tumors. Clin Cancer Res. 2015 Jan 1;21(1):77–86.  
767. Trucco MM, Awad O, Wilky BA, Goldstein SD, Huang R, Walker RL, et al. 
A Novel Chordoma Xenograft Allows In Vivo Drug Testing and Reveals the 
Importance of NF-κB Signaling in Chordoma Biology. PLoS ONE. 
2013;8(11):e79950.  
768. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel J-F, 
Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years 
later. Blood. 2012 Aug 2;120(5):947–59.  
769. Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, et al. 
A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With 
Advanced Biliary Tract Cancers. Clin Colorectal Cancer. 2014 
Jun;13(2):81–6.  
770. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, et al. 
Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des. 
2007;13(5):471–85.  
771. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern 
RM, et al. A phase I trial of vorinostat and bortezomib in children with 
refractory or recurrent solid tumors: A Children's Oncology Group phase I 
consortium study (ADVL0916). Pediatr Blood Cancer. 2012 Aug 
9;60(3):390–5.  
772. Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, et al. A 
Phase I study of intermittently dosed vorinostat in combination with 
bortezomib in patients with advanced solid tumors. Invest New Drugs. 
2014 Apr;32(2):323–9.  
773. Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, et 
al. Frontline bortezomib and rituximab for the treatment of newly 
diagnosed high tumour burden indolent non-hodgkin lymphoma: a 
multicentre phase II study. Br J Haematol. 2014 Apr 25.  
774. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus 
DD, et al. Proteasome inhibitors: a novel class of potent and effective 
antitumor agents. Cancer Research. 1999 Jun 1;59(11):2615–22.  
775. Zavrski I, Jakob C, Kaiser M, Fleissner C, Heider U, Sezer O. Molecular 
and clinical aspects of proteasome inhibition in the treatment of cancer. 
Recent Results Cancer Res. 2007;176:165–76.  
Targeted therapy for chordoma   
 361 
776. Chen K-F, Yeh P-Y, Yeh K-H, Lu Y-S, Huang S-Y, Cheng A-L. Down-
regulation of phospho-Akt is a major molecular determinant of bortezomib-
induced apoptosis in hepatocellular carcinoma cells. Cancer Research. 
2008 Aug 15;68(16):6698–707.  
777. Chen K-F, Liu C-Y, Lin Y-C, Yu H-C, Liu T-H, Hou D-R, et al. CIP2A 
mediates effects of bortezomib on phospho-Akt and apoptosis in 
hepatocellular carcinoma cells. Oncogene. 2010 Nov 25;29(47):6257–66.  
778. Lin Y-C, Chen K-C, Chen C-C, Cheng A-L, Chen K-F. CIP2A-mediated Akt 
activation plays a role in bortezomib-induced apoptosis in head and neck 
squamous cell carcinoma cells. Oral Oncol. 2012 Jul;48(7):585–93.  
779. Lin L, Gaut D, Hu K, Yan H, Yin D, Koeffler HP. Dual targeting of 
glioblastoma multiforme with a proteasome inhibitor (Velcade) and a 
phosphatidylinositol 3-kinase inhibitor (ZSTK474). Int J Oncol. 2014 
Feb;44(2):557–62.  
780. Demel H-R, Feuerecker B, Piontek G, Seidl C, Blechert B, Pickhard A, et 
al. Effects of topoisomerase inhibitors that induce DNA damage response 
on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma 
cells. Am J Cancer Res. 2015;5(5):1649–64.  
781. Kim A, Park S, Lee J-E, Jang W-S, Lee S-J, Kang HJ, et al. The dual PI3K 
and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and 
overcomes bortezomib resistance in mantle cell lymphoma cells. Leuk 
Res. 2012 Jul;36(7):912–20.  
782. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of 
the in vitro cell line, human xenograft, and mouse allograft preclinical 
cancer models. Clin Cancer Res. 2003 Sep 15;9(11):4227–39.  
783. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz 
S, et al. Relationships between drug activity in NCI preclinical in vitro and 
in vivo models and early clinical trials. Br J Cancer. 2001 May 
18;84(10):1424–31.  
784. Benson JD, Chen Y-NP, Cornell-Kennon SA, Dorsch M, Kim S, 
Leszczyniecka M, et al. Validating cancer drug targets. Nature. 2006 May 
25;441(7092):451–6.  
785. Zheng W, Thorne N, McKew JC. Phenotypic screens as a renewed 
approach for drug discovery. Drug Discovery Today. 2013 Nov;18(21-
22):1067–73.  
786. Crockford A, Jamal-Hanjani M, Hicks J, Swanton C. Implications of 
intratumour heterogeneity for treatment stratification. J Pathol. 2013 Dec 
10;232(2):264–73.  
787. Burger A. A zebrafish model of chordoma initiated by notochord-driven 
expression of HRAS12 [Internet]. 2013 [cited 2015 Jul 19]. Available from: 
http://dmm.biologists.org.libproxy.ucl.ac.uk/content/7/7/907.full.pdf+html 
788. Peterson RT, Link BA, Dowling JE, Schreiber SL. Small molecule 
Targeted therapy for chordoma 
362 
developmental screens reveal the logic and timing of vertebrate 
development. Proc Natl Acad Sci USA. 2000 Nov 21;97(24):12965–9.  
789. Rennekamp AJ, Peterson RT. 15 years of zebrafish chemical screening. 
Curr Opin Chem Biol. 2015 Feb;24:58–70.  
790. Kopetz S, Lemos R, Powis G. The promise of patient-derived xenografts: 
the best laid plans of mice and men. Clin Cancer Res. 2012 Oct 
1;18(19):5160–2.  
791. Decaudin D. Primary human tumor xenografted models (“tumorgrafts”) for 
good management of patients with cancer. Anticancer Drugs. 2011 
Oct;22(9):827–41.  
792. Stewart EL, Mascaux C, Pham N-A, Sakashita S, Sykes J, Kim L, et al. 
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of 
Prognosis and Map Resistance Pathways in EGFR-Mutant Lung 
Adenocarcinoma. Journal of Clinical Oncology. 2015 Aug 1;33(22):2472–
80.  
793. Garralda E, Paz K, Lopez-Casas PP, Jones S, Katz A, Kann LM, et al. 
Integrated Next-Generation Sequencing and Avatar Mouse Models for 
Personalized Cancer Treatment. Clinical Cancer Research. 2014 Apr 
30;20(9):2476–84.  
794. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome 
remodelling in a basal-like breast cancer metastasis and xenograft. 
Nature. 2010 Apr 15;464(7291):999–1005.  
795. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, Mariani P, et al. 
Characterization of a large panel of patient-derived tumor xenografts 
representing the clinical heterogeneity of human colorectal cancer. Clin 
Cancer Res. 2012 Oct 1;18(19):5314–28.  
796. Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, 
Karikari C, et al. Tumor engraftment in nude mice and enrichment in 
stroma- related gene pathways predict poor survival and resistance to 
gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011 Sep 
1;17(17):5793–800.  
797. Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET/CT imaging in 
oncology. Ann Saudi Med. 2011 Jan;31(1):3–13.  
798. Maguire CA, Bovenberg MS, Crommentuijn MH, Niers JM, Kerami M, 
Teng J, et al. Triple bioluminescence imaging for in vivo monitoring of 
cellular processes. Mol Ther Nucleic Acids. 2013;2:e99.  
799. Kim J-B, Urban K, Cochran E, Lee S, Ang A, Rice B, et al. Non-invasive 
detection of a small number of bioluminescent cancer cells in vivo. PLoS 
ONE. 2010;5(2):e9364.  
800. Barranco SC, Ho DH, Drewinko B, Romsdahl MM, Humphrey RM. 
Differential sensitivites of human melanoma cells grown in vitro to 
arabinosylcytosine. Cancer Research. 1972 Dec;32(12):2733–6.  
Targeted therapy for chordoma   
 363 
801. Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P. Heterogeneity 
in drug sensitivity among tumor cell subpopulations of a single mammary 
tumor. Cancer Research. 1978 Nov;38(11 Pt 1):3758–63.  
802. Wang J, Li L, Zhang K, Yu Y, Li B, Li J, et al. Characterization of two novel 
cell lines with distinct heterogeneity derived from a single human bile duct 
carcinoma. PLoS ONE. 2013;8(1):e54377.  
803. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, 
Jones S, Maitra A, et al. Personalizing cancer treatment in the age of 
global genomic analyses: PALB2 gene mutations and the response to 
DNA damaging agents in pancreatic cancer. Molecular Cancer 
Therapeutics. 2011 Jan;10(1):3–8.  
804. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, 
et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated 
with histologic subtypes and are predictive of sensitivity to PI3K inhibitors 
in lung cancer preclinical models. Clin Cancer Res. 2012 Dec 
15;18(24):6771–83.  
805. Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez 
V, Diez-Gonzalez L, et al. Activation of the PI3K/mTOR/AKT pathway and 
survival in solid tumors: systematic review and meta-analysis. PLoS ONE. 
2014;9(4):e95219.  
806. Desilet N, Campbell TN, Choy FYM. p53-based anti-cancer therapies: An 
empty promise? Curr Issues Mol Biol. 2010;12(3):143–6.  
807. Razzak M. Targeted therapies: One step closer to drugging p53. Nat Rev 
Clin Oncol. 2013 Mar 19;10(5):246–6.  
808. Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler 
L, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-
mediated peptide inhibitor of p53 ubiquitination in patients with advanced 
solid tumours. Br J Cancer. 2013 Mar 19;108(5):1061–70.  
809. Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, 
Zwaenepoel K, et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin 
to induce p53 dependent tumor cell apoptosis in non-small cell lung 
cancer. Oncotarget. 2015 Jun 10.  
810. Pallini R, Maira G, Pierconti F, Falchetti ML, Alvino E, Cimino-Reale G, et 
al. Chordoma of the skull base: predictors of tumor recurrence. Journal of 
Neurosurgery. 2003 Apr;98(4):812–22.  
811. Fischer C, Scheipl S, Zopf A, Niklas N, Deutsch A, Jorgensen M, et al. 
Mutation Analysis of Nine Chordoma Specimens by Targeted Next-
Generation Cancer Panel Sequencing. Journal of Cancer. 
2015;6(10):984–9.  
812. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment 
heterogeneity on therapeutic response. Nature. 2013 Sep 
19;501(7467):346–54.  
Targeted therapy for chordoma 
364 
813. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, et al. The 
exomes of the NCI-60 panel: a genomic resource for cancer biology and 
systems pharmacology. Cancer Research. 2013 Jul 15;73(14):4372–82.  
814. Leary RJ, Kinde I, Diehl F, Schmidt K, Clouser C, Duncan C, et al. 
Development of Personalized Tumor Biomarkers Using Massively Parallel 
Sequencing. Science Translational Medicine 2010 Feb 24;2(20):20ra14–4.  
815. Mcbride DJ, Orpana AK, Sotiriou C, Joensuu H, Stephens PJ, Mudie LJ, et 
al. Use of cancer-specific genomic rearrangements to quantify disease 
burden in plasma from patients with solid tumors. Genes Chromosom 
Cancer. 2010 Nov;49(11):1062–9.  
816. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. 
Detection of chromosomal alterations in the circulation of cancer patients 
with whole-genome sequencing. Science Translational Medicine. 2012 
Nov 28;4(162):162ra154.  
817. Vora A, Goulden N, Wade R, Mitchell C, Hancock J. Treatment reduction 
for children and young adults with low-risk acute lymphoblastic leukaemia 
defined by minimal residual disease (UKALL 2003): a randomised 
controlled trial. Lancet Oncol. 2013.  
818. Moorman AV, Robinson H, Schwab C, Richards SM, Hancock J, Mitchell 
CD, et al. Risk-Directed Treatment Intensification Significantly Reduces 
the Risk of Relapse Among Children and Adolescents With Acute 
Lymphoblastic Leukemia and Intrachromosomal Amplification of 
Chromosome 21: A Comparison of the MRC ALL97/99 and UKALL2003 
Trials. J Clin Oncol. 2013 Sep 17;31(27):3389–96.  
819. Radich JP, Gooley T, Bryant E, Chauncey T, Clift R, Beppu L, et al. The 
significance of bcr-abl molecular detection in chronic myeloid leukemia 
patients “late,” 18 months or more after transplantation. Blood. 2001 Sep 
15;98(6):1701–7.  
820. Mahon F-X, Etienne G. Deep molecular response in chronic myeloid 
leukemia: the new goal of therapy? Clin Cancer Res. 2014 Jan 
15;20(2):310–22.  
821. Egan DN, Beppu L, Radich JP. Patients with Philadelphia-positive 
leukemia with BCR-ABL kinase mutations before allogeneic 
transplantation predominantly relapse with the same mutation. Biol Blood 
Marrow Transplant. 2015 Jan;21(1):184–9.  
822. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. 
Quantitation of targets for PCR by use of limiting dilution. Biotech. 1992 
Sep;13(3):444–9.  
823. Wan JH, Sykes PJ, Orell SR, Morley AA. Rapid method for detecting 
monoclonality in B cell lymphoma in lymph node aspirates using the 
polymerase chain reaction. J Clin Pathol. 1992 May;45(5):420–3.  
824. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. 
COSMIC: mining complete cancer genomes in the Catalogue of Somatic 
Targeted therapy for chordoma   
 365 
Mutations in Cancer. Nucleic acids …. 2010.  
825. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et 
al. COSMIC: exploring the world's knowledge of somatic mutations in 
human cancer. Nucleic Acids Research. 2015 Jan;43(Database 
issue):D805–11.  
826. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, et al. Utility of 
circulating B-RAF DNA mutation in serum for monitoring melanoma 
patients receiving biochemotherapy. Clin Cancer Res. 2007 Apr 
1;13(7):2068–74.  
827. Olsson L, Paulsson K, Bovée JVMG, Nord KH. Clonal Evolution through 
Loss of Chromosomes and Subsequent Polyploidization in 
Chondrosarcoma. Katoh M, editor. PLoS ONE. 2011 Sep 20;6(9):e24977.  
828. Dorner AJ, Badola S, Niu H. Characterization of circulating tumor DNA for 
genetic assessment of solid tumors. Clin Pharmacol Ther. 2015 Apr 7.  
829. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and 
treatment selection. Nat Rev Cancer. 2005 Nov;5(11):845–56.  
830. Füzéry AK, Levin J, Chan MM, Chan DW. Translation of proteomic 
biomarkers into FDA approved cancer diagnostics: issues and challenges. 
Clin Proteomics. 2013;10(1):13.  
831. Martinez SJ, Moreno CC, Vinson EN, Dodd LG, Brigman BE. Angiomatoid 
fibrous histiocytoma: novel MR imaging findings. Skeletal Radiol. 2016 Feb 
27.  
832. Mäbert K, Cojoc M, Peitzsch C, Kurth I, Souchelnytskyi S, Dubrovska A. 
Cancer biomarker discovery: current status and future perspectives. Int J 
Radiat Biol. 2014 Aug;90(8):659–77.  
833. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012 Apr;6(2):140–
6.  
834. Cao D, Fan ST, Chung SS. Identification and characterization of a novel 
human aldose reductase-like gene. J Biol Chem. 1998 May 
8;273(19):11429–35.  
835. Gallego O, Ruiz FX, Ardèvol A, Domínguez M, Alvarez R, de Lera AR, et 
al. Structural basis for the high all-trans-retinaldehyde reductase activity of 
the tumor marker AKR1B10. Proceedings of the National Academy of 
Sciences. 2007 Dec 26;104(52):20764–9.  
836. Kumar R, Son M, Bavi R, Lee Y, Park C, Arulalapperumal V, et al. Novel 
chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 
3D QSAR pharmacophore modeling. Acta Pharmacol Sin. 2015 Jun 8.  
837. Ruiz FX, Gallego O, Ardèvol A, Moro A, Domínguez M, Alvarez S, et al. 
Aldo-keto reductases from the AKR1B subfamily: retinoid specificity and 
control of cellular retinoic acid levels. Chem Biol Interact. 2009 Mar 
16;178(1-3):171–7.  
Targeted therapy for chordoma 
366 
838. Balendiran GK, Martin H-J, El-Hawari Y, Maser E. Cancer biomarker 
AKR1B10 and carbonyl metabolism. Chem Biol Interact. 2009 Mar 
16;178(1-3):134–7.  
839. Matsunaga T. Aldo–keto reductase 1B10 and its role in proliferation 
capacity of drug-resistant cancers. 2012 Jan 27;:1–11.  
840. Morikawa Y, Kezuka C, Endo S, Ikari A, Soda M, Yamamura K, et al. 
Acquisition of doxorubicin resistance facilitates migrating and invasive 
potentials of gastric cancer MKN45 cells through up-regulating aldo-keto 
reductase 1B10. Chem Biol Interact. 2015 Mar 25;230:30–9.  
841. Zhong L, Shen H, Huang C, Jing H, Cao D. AKR1B10 induces cell 
resistance to daunorubicin and idarubicin by reducing C13 ketonic group. 
Toxicol Appl Pharmacol. 2011 Aug 15;255(1):40–7.  
842. Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose 
reductase family proteins overexpressed in human hepatocellular 
carcinoma. Hepatology. 1998 Apr;27(4):943–50.  
843. Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, et 
al. AKR1B10 expression is associated with less aggressive hepatocellular 
carcinoma: a clinicopathological study of 168 cases. Liver Int. 2011 
Jul;31(6):810–6.  
844. Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, 
Tannapfel A. Identification and expression analysis of the aldo-
ketoreductase1-B10 gene in primary malignant liver tumours. J Hepatol. 
2010 Feb;52(2):220–7.  
845. Semmo N, Weber T, Idle JR, Beyoğlu D. Metabolomics reveals that aldose 
reductase activity due to AKR1B10 is upregulated in hepatitis C virus 
infection. J Viral Hepat. 2015 Jul;22(7):617–24.  
846. Tsuzura H, Genda T, Sato S, Murata A, Kanemitsu Y, Narita Y, et al. 
Expression of aldo-keto reductase family 1 member b10 in the early stages 
of human hepatocarcinogenesis. Int J Mol Sci. 2014;15(4):6556–68.  
847. Ma J, Yan R, Zu X, Cheng J-M, Rao K, Liao D-F, et al. Aldo-keto 
reductase family 1 B10 affects fatty acid synthesis by regulating the 
stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol 
Chem. 2008 Feb 8;283(6):3418–23.  
848. Hashimoto Y, Imanishi K, Tokui N, Okamoto T, Okamoto A, Hatakeyama 
S, et al. Carboplatin-gemcitabine combination chemotherapy upregulates 
AKR1B10 expression in bladder cancer. Int J Clin Oncol. 2013 
Feb;18(1):177–82.  
849. Wang R, Wang G, Ricard MJ, Ferris B, Strulovici-Barel Y, Salit J, et al. 
Smoking-induced upregulation of AKR1B10 expression in the airway 
epithelium of healthy individuals. Chest. 2010 Dec;138(6):1402–10.  
850. Fukumoto S-I, Yamauchi N, Moriguchi H, Hippo Y, Watanabe A, 
Shibahara J, et al. Overexpression of the aldo-keto reductase family 
Targeted therapy for chordoma   
 367 
protein AKR1B10 is highly correlated with smokers' non-small cell lung 
carcinomas. Clin Cancer Res. 2005 Mar 1;11(5):1776–85.  
851. Hevir N, Sinkovec J, Lanišnik Rižner T. Decreased levels of AKR1B1 and 
AKR1B10 in cancerous endometrium compared to adjacent non-
cancerous tissue. Chem Biol Interact. 2013 Feb 25;202(1-3):226–33.  
852. Zhang W, Li H, Yang Y, Liao J, Yang G-Y. Knockdown or inhibition of aldo-
keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating 
Kras-E-cadherin pathway. Cancer Letters. 2014 Dec 28;355(2):273–80.  
853. Ma J, Luo D-X, Huang C, Shen Y, Bu Y, Markwell S, et al. AKR1B10 
overexpression in breast cancer: association with tumor size, lymph node 
metastasis and patient survival and its potential as a novel serum marker. 
Int J Cancer. 2012 Sep 15;131(6):E862–71.  
854. Tirabosco R. Aldoketoreductasis 1 B10 (AKR1B10) Expression in Tissues 
and Tumours Showing Notochordal Differentiation. A Role as a Neoplastic 
Biomarker and a Potential Therapeutic Target.  
855. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. 
Clinical implications of genomic alterations in the tumour and circulation of 
pancreatic cancer patients. Nat Commun. 2015;6:7686.  
856. Patel KM, Tsui DWY. The translational potential of circulating tumour DNA 
in oncology. Clin Biochem. 2015 Apr 15.  
857. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, et al. 
TP53 and KRAS2 mutations in plasma DNA of healthy subjects and 
subsequent cancer occurrence: a prospective study. Cancer Research. 
2006 Jul 1;66(13):6871–6.  
858. Chan KCA, Hung ECW, Woo JKS, Chan PKS, Leung S-F, Lai FPT, et al. 
Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus 
DNA analysis in a surveillance program. Cancer. 2013 May 
15;119(10):1838–44.  
859. Milbury CA, Zhong Q, Lin J, Williams M, Olson J. Determining lower limits 
of detection of digital PCR assays for cancer-related gene mutations. 
Biomolecular Detection …. 2014.  
860. McInerney P, Adams P, Hadi MZ. Error Rate Comparison during 
Polymerase Chain Reaction by DNA Polymerase. Mol Biol Int. 
2014;2014:287430.  
861. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of 
cancer patients and the effect of therapy. Cancer Research. 1977 
Mar;37(3):646–50.  
862. Barrett AN, Zimmermann BG, Wang D, Holloway A, Chitty LS. 
Implementing Prenatal Diagnosis Based on Cell-Free Fetal DNA: Accurate 
Identification of Factors Affecting Fetal DNA Yield. Novelli G, editor. PLoS 
ONE. 2011 Oct 4;6(10):e25202.  
Targeted therapy for chordoma 
368 
863. Wong D, Moturi S, Angkachatchai V, Mueller R, DeSantis G, van den 
Boom D, et al. Optimizing blood collection, transport and storage 
conditions for cell free DNA increases access to prenatal testing. Clin 
Biochem. 2013 Aug;46(12):1099–104.  
864. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA 
in plasma and serum samples: higher concentrations of genomic DNA 
found in serum than in plasma. Transfusion. 2001 Feb;41(2):276–82.  
865. Angert RM, LeShane ES, Lo YMD, Chan LYS, Delli-Bovi LC, Bianchi DW. 
Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 
hours after collection: analysis of first- and third-trimester samples. Clin 
Chem. 2003 Jan;49(1):195–8.  
866. Toro PV, Erlanger B, Beaver JA, Cochran RL, VanDenBerg DA, Yakim E, 
et al. Comparison of cell stabilizing blood collection tubes for circulating 
plasma tumor DNA. Clin Biochem. 2015 Oct;48(15):993–8.  
867. Barrett AN, Zimmermann BG, Wang D, Holloway A, Chitty LS. 
Implementing prenatal diagnosis based on cell-free fetal DNA: accurate 
identification of factors affecting fetal DNA yield. PLoS ONE. 
2011;6(10):e25202.  
868. Fleischhacker M, Schmidt B, Weickmann S, Fersching DMI, Leszinski GS, 
Siegele B, et al. Methods for isolation of cell-free plasma DNA strongly 
affect DNA yield. Clin Chim Acta. 2011 Nov 20;412(23-24):2085–8.  
869. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler 
KW. Cancer genome landscapes. Science. 2013 Mar 29;339(6127):1546–
58.  
870. Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et 
al. Analysis of circulating tumour DNA to monitor disease burden following 
colorectal cancer surgery. Gut. 2015 Feb 4.  
871. Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A, et al. 
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal 
cancer patients with a novel, high-sensitivity multiplexed mutation 
detection platform. Oncotarget. 2015 Feb 10;6(4):2549–61.  
872. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et 
al. Detection of epidermal growth factor receptor mutations in serum as a 
predictor of the response to gefitinib in patients with non-small-cell lung 
cancer. Clin Cancer Res. 2006 Jul 1;12(13):3915–21.  
873. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell 
lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. 
Oncogene. 2009 Aug;28 Suppl 1:S24–31.  
874. Davies JM, Robinson AE, Cowdrey C, Mummaneni PV, Ducker GS, 
Shokat KM, et al. Generation of a patient-derived chordoma xenograft and 
characterization of the phosphoproteome in a recurrent chordoma. Journal 
of Neurosurgery. 2013 Nov 29.  
Targeted therapy for chordoma   
 369 
875. Gorges TM, Schiller J, Schmitz A, Schuetzmann D, Schatz C, Zollner TM, 
et al. Cancer therapy monitoring in xenografts by quantitative analysis of 
circulating tumor DNA. Biomarkers. 2012 Sep;17(6):498–506.  
876. Dokmanovic M, Wu WJ. Monitoring Trastuzumab Resistance and 
Cardiotoxicity: A Tale of Personalized Medicine. Adv Clin Chem. 
2015;70:95–130.  
  
Targeted therapy for chordoma 
370 
 
  
Targeted therapy for chordoma   
 371 
 
9 APPENDIX 
  
Targeted therapy for chordoma 
372 
 
 
  
Targeted therapy for chordoma 
373 
9.1 Supplement data 
 
Table 9.1 Luciferase raw data expression data from Living image software 
 
Crude data from living image software, CR number is the label for the individual images (identifiable at the top of the pictures in the figures above), Region of 
interest (ROI) is assigned in grouped images identifying each mouse – further identified by mouse id number and treatment given. The luciferase expression 
is measured by photons, max/min/average and with standard deviation. The different time points have been added far right column. 
Image Number ROI Image Layer Total Flux (p/s) Avg Radiance 
(p/s/cm2/sr)
Stdev Radiance Min Radiance Max Radiance Mouse # Treatment Time point
CR20140821113107 ROI 1 Overlay 6.63E+08 2.89E+07 2.05E+07 2.27E+06 7.02E+07 Mouse 1 KD day 0
CR20140821113107 ROI 2 Overlay 4.05E+08 2.91E+07 1.96E+07 2.24E+06 6.86E+07 Mouse 2 GFP day 0
CR20140821113107 ROI 3 Overlay 2.36E+09 7.53E+07 7.39E+07 3.03E+06 2.06E+08 Mouse 6 KD day 0
CR20140828154620 ROI 1 Overlay 1.87E+08 6.54E+06 6.70E+06 2.64E+05 2.81E+07 Mouse 1 KD day 7
CR20140828154620 ROI 2 Overlay 1.70E+07 6.66E+05 4.99E+05 3.07E+04 1.68E+06 Mouse 2 GFP day 7
CR20140828154620 ROI 3 Overlay 1.28E+08 5.88E+06 5.22E+06 3.72E+05 1.87E+07 Mouse 6 KD day 7
CR20140904144739 ROI 1 Overlay 9.62E+07 7.12E+06 3.51E+06 1.21E+06 1.70E+07 Mouse 1 KD day 14
CR20140904144739 ROI 2 Overlay 8.85E+08 3.02E+07 2.61E+07 1.24E+06 9.79E+07 Mouse 2 GFP day 14
CR20140904144739 ROI 3 Overlay 3.80E+08 1.88E+07 1.49E+07 1.23E+06 5.07E+07 Mouse 6 KD day 14
CR20140910141854 ROI 1 Overlay 4.33E+07 2.11E+06 1.29E+06 1.67E+05 6.04E+06 Mouse 1 KD day 21
CR20140910141854 ROI 2 Overlay 9.40E+08 2.70E+07 2.35E+07 1.32E+06 8.32E+07 Mouse 2 GFP day 21
CR20140910141854 ROI 3 Overlay 6.31E+08 2.43E+07 2.24E+07 1.34E+06 7.48E+07 Mouse 6 KD day 21
CR20140828160617 ROI 1 Overlay 3.79E+07 2.04E+06 2.15E+06 1.13E+05 7.65E+06 Mouse 4 PBS day 7
CR20140904143425 ROI 1 Overlay 5.11E+08 1.95E+07 1.99E+07 8.22E+05 7.74E+07 Mouse 4 PBS day 14
CR20140904143425 ROI 2 Overlay 2.22E+08 1.47E+07 1.18E+07 1.11E+06 3.94E+07 Mouse 5 PBS day 14
CR20140910142927 ROI 1 Overlay 5.43E+08 2.03E+07 2.03E+07 7.35E+05 7.63E+07 Mouse 4 PBS day 21
CR20140910142927 ROI 2 Overlay 2.87E+08 1.44E+07 1.33E+07 4.37E+05 4.45E+07 Mouse 5 PBS day 21
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9.2 Drug screening appendix 
9.2.1 Cancer hot spot mutation screen 
 1 2 3 4 5 6 
A BRAF IDH1 132 FGFR1_K656 FGFR4_V510 SF3B1_E622 GNAS1_Q227 
B KRAS G12 IDH2 140 FGFR2_S252 FGFR3_R428 SF3B1_G742 GNAS1_K233 
C EGFR 
L858R / L861 
IDH2 172 FGFR2_N549 FGFR3_A391 JAK2_v617 NRAS_1 (Q61) 
D EGFR G719X H3F3B_K37 FGRF2_660 FGFR3_G370-2 JAK2_N542_E5 NRAS_2 (12-13) 
E EGFR Exon 19 
del 
H3F3A_K37 FGFR3_T435 NOTCH1_L1574 JAK2_R683 NRAS_K117 
F EGFR Exon 20 
ins 
H3F3A_K27 FGFR3_K650 NOTCH1_L1600 GNAS1_K876 NRAS_A146 
G EGFR T790M FGFR1_T141 FGFR3_G697 
 
NOTCH1_L1678 GNAS1_R844 CTNNB1_34-45 
(b catenin 1) 
H KRAS K61 FGFR1_N546 FGFR3_K717 NOTCH1_R1598 GNAS1_R201 CTNNB1_15_22 
(b catenin 2) 
 
 1 2 3 4 5 6 
A BRAF EGFR T790M KIT-9 GNAS1_K876 H3F3A_K37 P53-6 
B KRAS 12 
 
IDH1 132 KIT-10 NRAS_G12 PTEN-7 
PDGFRA-5 
P53-7 
C EGFR 
L858R / L861 
KIT-3 NRAS-1 CTNNB1_34-45 
(b catenin 1) 
H3F3A_K27 P53-8 
D EGFR G719X KIT-4 NRAS-2 PTEN-1 
PDGFRA-4 
P53-1 P53-9 
E EGFR Exon 
19 del 
KIT-5 GNAS1_R201 NRAS_K117 P53-2 P53-10 
F EGFR Exon 
20 ins 
KIT-6 GNAS1_Q227 NRAS_A146 P53-3 P53-11 
G KRAS K61 
 
IDH2 140 GNAS1_K233 CTNNB1_15_22 
(b catenin 2) 
P53-4 P53-12 
H PDGFRA 1 IDH2  
172 
GNAS1_R844 H3F3B_K37 P53-5 P53-13 
Primer map for Fluidigm hot spot mutation
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9.2.2 Optimisation of WST-1 assay  
Comparison of WST-1 with “gold standard” method Cell titre Glo (CTG) assay 
 
 
Figure 9.1 Optimisation of WST1 
WST-1 assay was compared with Cell titre glow (CTG) as this is the gold standard for 
assessing viability in compound treated cells. As the initial screen on the GSK PKIS1 library 
was done using WST-1 the comparability and stability between the two assays was assessed. 
Similar graphical plots for WST-1 and CTG assays at a 3-hour end point read. Potency 
measured using WST-1 Assay shows slight variability over time. The data supports the 
recommendation to read plates @ 3 hours. IC50 of SSP at 3 hours is ~ 1.3µM. 
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9.2.3 DMSO tolerance - optimisation 
 
Figure 9.2 Optimisation of DMSO tolerance in U-CH1 cells 
Example of the DMSO tolerance for U-CH1 cells. No data has been corrected for background. 
DMSO titration range from 0% (medium) to 10%. WST-1 data indicates cells can tolerate up to 
0.625% DMSO, any increase in concentration causes a decrease in signal. Cell titre glow (CTG) 
data shows toleration up to 0.315% DMSO only, an increase in concentration leads to loss of 
signal (e.g. Cell death). This data was generated at 3 hours incubations with the WST-1 
reagent. UCH1 Cells are fairly sensitive to DMSO compared to other cell types (e.g. Up to 1% 
DMSO). DMSO tolerance of U-CH1 cells in line with the MUG Chor and U-CH2 cell lines and 
therefore 0.315% will be used for all. 
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9.2.4 Anti-cancer library compounds 
 
 
 
SelleckChem ID/Name SelleckChem Target Class Information
ABT-869(Linifanib) CSF-1R
Potent ATP-competitive VEGFR/PDGFR Inhibitor for KDR, CSF-1R, Flt-1/3 and 
PDGFRβ. Mostly Effective in Mutant Kinase-Dependent Cancer Cells (i.e. 
FLT3). Phase 3.
ABT-888 (Veliparib) PARP PARP1/2 
BEZ235(NVP-BEZ235) (Dactolisib) ATM/ATR Dual ATP-competitive Inhibitor PI3K and mTOR
BIBF1120 (Nintedanib) FGFR Triple Angiokinase Inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β
Bortezomib Proteasome 20S proteasome Inhibitor
CHIR-258(Dovitinib) c-Kit
 Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit), Class IV 
(FGFR1/3) and class V (VEGFR1-4) RTKs. Less potent to InsR, EGFR, c-Met, 
EphA2, Tie2, IGF-1R and HER2. Phase 4.
Dasatinib Bcr-Abl Multi-targeted Inhibitor Abl, Src and c-Kit
Deforolimus(MK-8669) 
(Ridaforolimus) mTOR
Selective mTOR Inhibitor. Not classified as a prodrug, mTOR inhibition and 
FKBP12 binding is similar to rapamycin.
Imatinib Mesylate Bcr-Abl Multi-target Inhibitor of v-Abl, c-Kit and PDGFR
Lapatinib Ditosylate EGFR (GW572016, GW2016) Potent EGFR and ErbB2 Inhibitor
Pazopanib Hydrochloride PDGR/EGFR/c-Kit/FGFR (GW786034) Multi-target Inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, 
FGFR, c-Kit and c-Fms.
SelleckChem ID/Name SelleckChem Target Class Information
Perifosine AKT Akt Inhibitor. Targets Pleckstrin Homology Domain of Akt. Phase 2.
Sorafenib Tosylate PDGFR Multikinase Inhibitor of Raf-1, B-Raf and VEGFR-2.
Temsirolimus mTOR mTOR Inhibitor
AZD2281(Olaparib) PARP Selective Inhibitor of PARP1/2. Less Effective Against tankyrase-1. Phase 1/2.
GDC-0941 PI3K Potent Inhibitor of PI3Kα/δ, with Modest Selectivity Against p110β (11-fold) and p110γ 
(25-fold).
GDC-0449(Vismodegib) Hedgehog Hedgehog Inhibitor and P-gp
Brivanib(BMS-540215) FGFR ATP-competitive Inhibitor Against VEGFR2. Moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.
Belinostat(PXD101) HDAC HDAC Inhibitor with Activity Demonstrated in Ciisplatin-Resistant Tumors. Phase 1/2.
XL147 PI3K Selective and Reversible Class I PI3K inhibitor for PI3Kα/δ/γ. Less potent to PI3Kβ. Phase 1/2.
Everolimus(RAD001) mTOR mTOR Inhibitor of FKBP12
YM155 (Sepantronium Bromide) E3 Ligase 
Potent Survivin Suppressant by Inhibiting Survivin Promoter Activity. Does not 
Significantly Inhibit SV40 Promoter Activity, but is Observed to Slightly Inhibit the 
Interaction of Survivin with XIAP. Phase 1/2.
SelleckChem ID/Name SelleckChem Target Class Information
17-AAG (Tanespimycin) HSP (e.g. HSP90) HSP90 Inhibitor
17-DMAG(Alvespimycin) HSP (e.g. HSP90) HSP90 Inhibitor
Docetaxel (Taxotere) Microtubule Associated Inhibitor of Depolymerisation of Microtubules by Binding to Stabilized Microtubules.
Ritonavir Antiretroviral Antiretroviral Drug which Inhibits a particular Liver Enzyme that normally 
Metabolizes Protease Inhibitors, Cytochrome P450-3A4 (CYP3A4).
CUDC-101 EGFR Potent Multi-targeted Inhibitor Against HDAC, EGFR and HER2  and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1.
Decitabine DNA Methyltransferase Potent Inhibitor of DNA Methylation 
Adriamycin (Doxorubicin) Autophagy Antibiotic Agent that Inhibits DNA Topoisomerase II and Induces DNA Damage and Apoptosis.
Carboplatin DNA/RNA Synthesis DNA Synthesis Inhibitor by Binding to DNA and Interfering with the Cell's 
Repair Mechanism.
OSI-930 c-Kit  Inhibitor of Kit, KDR and CSF-1R. Also Potent to Flt-1, c-Raf and Lck and low 
activity against PDGFRα/β, Flt-3 and Abl. Phase 1.
Ellence Topoisomerase Semisynthetic L-arabino Derivative of Doxorubicin, is an Antineoplastic Agent by Inhibiting Topoisomerase.
Etoposide(Etopophos) Topoisomerase Semisynthetic Derivative of Podophyllotoxin, which Inhibits DNA Synthesis 
via Topoisomerase II Inhibition Activity.
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SelleckChem ID/Name SelleckChem Target Class Information
Flavopiridol(Alvocidib) CDK
Competes with ATP to Inhibit CDKs including CDK1, CDK2, CDK4 and CDK6. 7.5-
fold more selective for CDK1, 2, 4, 6 versus CDK7. Flavopiridol is initially found to 
inhibit EGFR and PKA. Phase 1/2.
Leucovorin Calcium Other Reduced Folic Acid
Celecoxib COX Selective COX-2 Inhibitor
GSK1059615 mTOR/PI3K Dual Inhibitor of PI3Kα/β/δ/γ (Reversible) and mTOR. Phase 1
MGCD-265 c-Met/VEGFR Multi-target and ATP-competitive Inhibitor of c-Met and VEGFR1/2/3. Also Inhibits Ron 
and Tie2. Phase 1/2.
PHA-793887 CDK Inhibitor of CDK2, CDK5 and CDK7.  It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. Phase 1.
AP24534 (Ponatinib) Bcr-Abl Potent Multi-target Inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src.
AZD8055 mTOR ATP-competitive mTOR inhibitor with excellent selectivity (
∼
1,000-fold) against PI3K 
isoforms and ATM/DNA-PK. Phase 1.
SB939 (Pracinostat) HDAC Pan-HDAC Inhibitor with exception for HDAC6. It has no activity against the class III 
isoenzyme SIRT I. Phase 2.
Ibuprofen NSAID NSAID
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9.2.5 Protein expression in chordoma cell lines 
 
Protein expression in chordoma cell lines +/- EGF spiking indicates hetero-dimerisation of 
EGFR:ErbB2 / EGFR:ErbB4 and a homodimer of EGFR:EGFR across all lines to varying 
degrees. Kindly provided by Dr Susanne Scheipl. 
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9.3 Dose response and DPE IC50 profiling 
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Compound ID 
GSK 
ID/Compound 
Name
Library Pathway UCH1 Caspase-Glo 3/7 UCH1 CellTiter-Glo UCH2 Caspase-Glo 3/7 UCH2 CellTiter-Glo MUG.Chor1 Caspase-Glo 3/7 
MUG.Chor1 CellTiter-
Glo
CRT0047607:05 AG1478 Calbiochem EGFR 
CRT0103071:02 Compound 56 Calbiochem EGFR 
CRT0103079:02 EGFR/ErbB2/ErbB4 Inhibitor Calbiochem 
EGFR/ErbB-
2/ErbB-4 
CRT0103123:02 PD 174780 Calbiochem EGFR 
CRT0103124:02 PD 174265 Calbiochem EGFR  
CRT0159097:02 GDC-0941 Anticancer Class 1A PI3K Inhibitor 
CRT0363358:02 GW461104A PKIS1 ErbB-1/ErbB2
CRT0363377:02 GW410563A PKIS1 VEGFR2, EFGR
CRT0363431:01 GW282449A PKIS1 EGFR/ErbB2 
CRT0363479:02 GW576609A PKIS1 ErbB-1/ErbB2
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CRT0363484:02 GW616030X PKIS1 ErbB-1/ErbB2
CRT0363568:02 GW680191X PKIS1 EGFR/ErbB2
CRT0423387:01 GI230329A PKIS2 EGFR
CRT0423403:01 GSK1307810A PKIS2
ROCK1, AKT, 
PKA, 
P70S6K, 
Aurora A
CRT0423493:01 GSK1660437A PKIS2 BRAF, SRC, LCK, LYN
CRT0423504:01 GSK198271A PKIS2 ErbB family, BRAF
CRT0423580:01 GSK299495A PKIS2 Src, ErbB family, BRAF
CRT0423587:01 GSK326180A PKIS2 ErbB family, BRAF
CRT0423593:01 GSK357952A PKIS2 Src, ErbB family, BRAF
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Figure 9.3 Differential phenotypic effect, induction of apoptosis and cell death 
Caspase-Glo-3/7 and CellTiter-Glo output as curves for U-CH1, U-CH2 and MUG Chor cell lines at 6 hours (Blue), 24 hours (Green), 48 hour 
(Brown) and 72 hours (Grey) demonstrating differential phenotypic effect following treatment with 22 EGFR inhibitors. Induction of apoptosis 
and percentage inhibition (cell death)
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9.4 Optimisation of methods for ctDNA  
9.4.1 Extraction efficiency of DNA from plasma 
 
!
Figure 9.4 Extraction efficiency of DNA from plasma 
Extraction efficiency was assessed by spiking frog DNA (XenT) approximately 20,000 
molecules into the plasma prior to extraction to assess recovery. The percentage of XenT 
recovered was compared to a reference dPCR result of spike diluted in 50µL water (to emulate 
the final concentration of the spike in plasma at the end of extraction). Results are within one 
standard deviation of the mean, n=23.  
 
  
Mutation
#)FAM,
positive)
droplets*
Mutant)
copies/mL)
plasma
Total)
copies/mL)
plasma
XenT)
efficiency
Expt)of)XenT
Pooled)plasma)
ID
0 0 1243 79% 48 B
1 1 1172 85% 48 B
0 0 925 71% 48 B
1 1 1200 81% 48 B
2 5 1220 72% 48 B
2 4 1143 73% 48 B
0 0 1004 79% 48 B
1 2 857 81% 48 B
0 0 1141 85% 31 A
0 0 747 67% 31 A
0 0 624 70% 48 B
0 0 489 59% 48 B
Mean: 75%
SD: 8%
PIK3CA(1)
LYST(2)
PIK3CA(2)
Pooled&plasma&results
Pooled&plasma&
ID
XenT&
efficiency
Expt&of&XenT
Copies&
RPP30/mL
Expt&of&RPP30
A 64% 31 1391 31
B 81% 48 1357 48
Mean: 1498
SD: 195
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9.4.2 Overcoming DNA crosslinking on PPFE samples 
9.4.2.1 DNA Enzyme digest and/or dilution of DNA 
 
 
 
Figure 9.5 PIK3CA(1) assay optimisation for tumour DNA  
Image on the top shows neat tumour DNA assay for PIK3CA(1), it is not possible to separate 
the different molecules making the result unreliable. For optimisation we diluted DNA and used 
restriction digest to overcome cross-linking caused by formalin from FFPE samples, and dilution 
to dilute inhibitors in the sample. Tumour DNA was diluted (1:18) (middle image), and bottom 
image: dilution 1:9 and the DNA had undergone restriction digest using HindIII restriction 
enzyme. With the optimisation we achieved to establish the optimal temperature, the dilution 
factor, and that restriction digest was not required if the sample was diluted (data below). 
 
 
 
 
Exp020 (2 µL neat, 60'C)
Exp024 (2 µL diluted 1 in 18, 57'C)
Exp024 (2 µL diluted 1 in 9, 59'C, HindIII digest)
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Figure 9.6 PIK3CA(2) assay optimisation for tumour DNA  
Image on the top shows neat tumour DNA assay for PIK3CA(2), it is not possible to separate 
the different molecules making the result unreliable. For optimisation we diluted DNA and used 
restriction digest to overcome cross-linking caused by formalin from FFPE samples, and dilution 
to dilute inhibitors in the sample. Tumour DNA was diluted (1:18) (middle image), and bottom 
image: dilution 1:9 and the DNA had undergone restriction digest using HindIII restriction 
enzyme. With the optimisation we achieved to establish the optimal temperature, the dilution 
factor, and that restriction digest was not required if the sample was diluted.  
 
 
 
Exp020 (2 µL neat, 60'C)
Exp024 (2 µL diluted 1 in 15, 57'C)
Exp024 (2 µL diluted 1 in 8, 59'C, HindIII digest)
Targeted therapy for chordoma   
 387 
9.4.3 Optimisation of PCR and primers  
9.4.3.1 PCR run with temperature gradient for optimisation of primers   
!
Figure 9.7 Optimisation of PCR PIK3CA(1) 
PCR run with temperature gradient for primer optimisation. Imaging generated from QX200 
droplet reader (analysis), optimising primer for PIK3CA(1) mutation on tumour DNA. A: 60°C, B: 
59°C, C: 57°C. The optimal temperature: 59°C. FFPE tumour sample.  
 
 
A 
B 
C 
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Figure 9.8 Optimisation of PCR PIK3CA(2) 
Analysis from QX200 droplet reader. Optimisation of the temperature for the primer for 
PIK3CA(2) mutation on tumour DNA. A: 60°C, B: 59°C; C: 57°C. The optimal temperature: 57-
59°C, FFPE tumour sample.  
 
A 
B 
C 
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Figure 9.9 Optimisation of PCR GENE X(2)  
Optimisation of the temperature for the primer for GENE X2 mutation on tumour DNA. Analysis 
by QX200 droplet reader; GENE X(2) insertion frame shift mutation run at (A) 60°C; (B) 57°C; 
(C) 55°C the assay worked best at 60°C, FFPE tumour sample. 
A 
B 
C 
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9.4.4 Failed primers and probe 
 
Figure 9.10 Results of ddPCR for GENE X(1) mutation in tumour sample 
Analysis by QX200 droplet reader; GENE X(1) deletion frame shift mutation run at a temperature 
gradient; assay did not work at any temperature (A: 61-63°C B: 59°C, C: 57°C). The GENE X(1) probe 
was not specific for mutant/wild-type, and we were unable to design primers and probe for this mutation. 
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